{"37abbc87696bd267316fd415dee2445fc00b4734": [["I. INTRODUCTIONOne of the central questions in theoretical epidemiology [1] [2] [3] is how to identify individuals that are important for an infection to spread [4, 5] .", [["infection", "DISEASE", 141, 150], ["an infection", "PROBLEM", 138, 150], ["infection", "OBSERVATION", 141, 150]]], ["What \"important\" means depends on the particular scenario-what kind of disease spreads and what can be done about it.", [["disease spreads", "PROBLEM", 71, 86], ["disease", "OBSERVATION", 71, 78]]], ["First, influence maximization is aimed at identifying the nodes that, if they are sources of the outbreak, would maximize the expected outbreak size (the number of nodes infected at least once) [6, 7] .", [["influence maximization", "TREATMENT", 7, 29], ["the outbreak", "PROBLEM", 93, 105], ["nodes", "OBSERVATION", 58, 63], ["outbreak", "OBSERVATION_MODIFIER", 135, 143], ["size", "OBSERVATION_MODIFIER", 144, 148], ["nodes", "OBSERVATION", 164, 169]]], ["Second, vaccination is aimed at finding the nodes that, if vaccinated (or, in practice, deleted from the network), would reduce the expected outbreak size the most [5] .", [["vaccination", "TREATMENT", 8, 19], ["nodes", "OBSERVATION", 44, 49], ["size", "OBSERVATION_MODIFIER", 150, 154]]], ["Third, sentinel surveillance is aimed at finding the nodes that are likely to get infected early [8, 9] .", [["nodes", "ANATOMY", 53, 58], ["sentinel surveillance", "TEST", 7, 28], ["nodes", "OBSERVATION", 53, 58]]], ["These three notions of importance do not necessarily yield the same answer as to which node is most important.", [["node", "ANATOMY", 87, 91], ["node", "MULTI-TISSUE_STRUCTURE", 87, 91], ["node", "OBSERVATION", 87, 91]]], ["In this work, we investigate how the ranking of important nodes for these three aspects differs and why (see Fig. 1 ).I. INTRODUCTIONIn this paper, we evaluate the three aspects of importance with respect to the susceptible-infectious-removed (SIR) disease-spreading model [1] [2] [3] 10] on small connected graphs (all connected graphs from three up to seven nodes).", [["nodes", "MULTI-TISSUE_STRUCTURE", 58, 63], ["spreading model", "TEST", 257, 272], ["small connected graphs", "TEST", 292, 314], ["all connected graphs", "TEST", 316, 336], ["nodes", "OBSERVATION", 58, 63], ["infectious", "OBSERVATION", 224, 234], ["nodes", "OBSERVATION", 360, 365]]], ["The main reason we restrict ourselves to small graphs is that it allows us to use symbolic algebra, and thus exact calculations [11] .", [["symbolic algebra", "TREATMENT", 82, 98], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In this way we can discover, e.g., the smallest graph where the three aspects of importance disagree about which node is most important; cf. Ref.", [["node", "ANATOMY", 113, 117], ["node", "MULTI-TISSUE_STRUCTURE", 113, 117], ["node", "OBSERVATION", 113, 117]]], ["We argue that graphs of seven nodes are still large enough to illustrate the effects of distance.I. INTRODUCTIONNevertheless, large networks are important to study.", [["seven nodes", "PROBLEM", 24, 35], ["seven", "OBSERVATION_MODIFIER", 24, 29], ["nodes", "OBSERVATION", 30, 35], ["large", "OBSERVATION_MODIFIER", 46, 51], ["large", "OBSERVATION_MODIFIER", 126, 131]]], ["A possible future extension of this work will be to address the relationship between the three importance measures for larger networks.", [["possible", "UNCERTAINTY", 2, 10]]], ["[13] , the difference between influence maximization and vaccination problems on (some rather large) empirical networks is studied.", [["influence maximization", "TREATMENT", 30, 52], ["vaccination problems", "PROBLEM", 57, 77]]], ["The authors compare the top results of heuristic algorithms to identify influential single nodes, whereas in this paper we will consider the influence of all nodes, and also all sets of two and three nodes.", [["single nodes", "MULTI-TISSUE_STRUCTURE", 84, 96], ["heuristic algorithms", "TEST", 39, 59], ["influential single nodes", "PROBLEM", 72, 96], ["nodes", "OBSERVATION", 91, 96], ["nodes", "OBSERVATION", 158, 163], ["nodes", "OBSERVATION", 200, 205]]], ["[13] is a bit different from ours-they call important nodes for vaccination \"blockers\" and important nodes for influence maximization \"spreaders\".) * holme@cns.pi.titech.ac.jp We will proceed by discussing our setup in greater detail: our implementation of the SIR model, how to analyze the three aspects of importance, network centrality measures that we need for our analysis, and our results, including the smallest networks where different nodes come out as most important.II. PRELIMINARIESIn this section, we provide the background to our analysis.", [["nodes", "MULTI-TISSUE_STRUCTURE", 101, 106], ["nodes", "MULTI-TISSUE_STRUCTURE", 444, 449], ["a bit different", "PROBLEM", 8, 23], ["vaccination \"blockers", "TREATMENT", 64, 85], ["important nodes", "PROBLEM", 91, 106], ["our analysis", "TEST", 365, 377], ["different nodes", "PROBLEM", 434, 449], ["our analysis", "TEST", 540, 552], ["nodes", "OBSERVATION", 54, 59], ["nodes", "OBSERVATION", 101, 106], ["nodes", "OBSERVATION", 444, 449]]], ["The basis of our analysis is graphs G(V ,E) consisting of N nodes V and M links E.A. ImportanceAs mentioned earlier, there are three ways to think of importance in theoretical infectious disease epidemiology.", [["our analysis", "TEST", 13, 25], ["nodes V", "OBSERVATION", 60, 67], ["infectious", "OBSERVATION", 176, 186]]], ["Influence maximization was first studied in computer science with viral marketing in mind [6, 7] .", [["Influence maximization", "TREATMENT", 0, 22]]], ["As was mentioned, a node is important for influence maximization if it is a seed of an infection that could cause a large outbreak.", [["node", "ANATOMY", 20, 24], ["infection", "DISEASE", 87, 96], ["node", "MULTI-TISSUE_STRUCTURE", 20, 24], ["a node", "PROBLEM", 18, 24], ["influence maximization", "TREATMENT", 42, 64], ["an infection", "PROBLEM", 84, 96], ["a large outbreak", "PROBLEM", 114, 130], ["node", "OBSERVATION", 20, 24], ["infection", "OBSERVATION", 87, 96], ["large", "OBSERVATION_MODIFIER", 116, 121], ["outbreak", "OBSERVATION", 122, 130]]], ["For epidemiological applications, therefore, it might be interesting if one could immunize people against a disease before an outbreak happens.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["a disease", "PROBLEM", 106, 115]]], ["We will simply measure the expected outbreak size (S) (the expected number of nodes to catch the disease), with S as the set of source nodes, and we will rank the set of nodes according to their .A. ImportanceFor vaccination, we will use the average outbreak size from one random seed node to estimate the importance of a node [1, 2, 14, 15] .", [["seed node", "ANATOMY", 280, 289], ["node", "ANATOMY", 322, 326], ["seed node", "MULTI-TISSUE_STRUCTURE", 280, 289], ["vaccination", "TREATMENT", 213, 224], ["outbreak", "OBSERVATION_MODIFIER", 36, 44], ["size", "OBSERVATION_MODIFIER", 45, 49], ["nodes", "OBSERVATION", 78, 83], ["nodes", "OBSERVATION", 135, 140], ["nodes", "OBSERVATION", 170, 175], ["size", "OBSERVATION_MODIFIER", 259, 263], ["node", "OBSERVATION", 285, 289], ["node", "OBSERVATION", 322, 326]]], ["We assume the vaccinees are deleted from the network before the outbreak starts.", [["vaccinees", "ORGANISM", 14, 23]]], ["The node with the smallest is the one that is most important for the vaccination problem.A. ImportanceSentinel surveillance assumes a response after the outbreak already started (compared to influence maximization and vaccination, where the action affecting the nodes in question is assumed to take place before the outbreak happens).", [["node", "ANATOMY", 4, 8], ["node", "MULTI-TISSUE_STRUCTURE", 4, 8], ["nodes", "MULTI-TISSUE_STRUCTURE", 262, 267], ["the vaccination problem", "TREATMENT", 65, 88], ["vaccination", "TREATMENT", 218, 229], ["node", "OBSERVATION", 4, 8], ["smallest", "OBSERVATION_MODIFIER", 18, 26], ["most important", "UNCERTAINTY", 46, 60], ["nodes", "OBSERVATION", 262, 267]]], ["A node is important for sentinel surveillance if it gets infected early so that the health authorities can activate their countermeasures.", [["node", "ANATOMY", 2, 6], ["node", "MULTI-TISSUE_STRUCTURE", 2, 6], ["sentinel surveillance", "TEST", 24, 45], ["node", "OBSERVATION", 2, 6]]], ["This is usually determined by the lead time-the expected difference between the time a sentinel node gets infected, or the outbreaks dies out, and the infection time of any node in the graph [8] .", [["node", "ANATOMY", 96, 100], ["node", "ANATOMY", 173, 177], ["infection", "DISEASE", 151, 160], ["sentinel node", "MULTI-TISSUE_STRUCTURE", 87, 100], ["infected", "PROBLEM", 106, 114], ["the infection", "PROBLEM", 147, 160], ["node", "OBSERVATION", 96, 100], ["infected", "OBSERVATION_MODIFIER", 106, 114], ["infection", "OBSERVATION", 151, 160], ["node", "OBSERVATION", 173, 177]]], ["We will instead measure the average discovery time time \u03c4 (i) from the beginning of the infection until a node i gets infected or the outbreak dies [9] .", [["node", "ANATOMY", 106, 110], ["infection", "DISEASE", 88, 97], ["the infection", "PROBLEM", 84, 97], ["infection", "OBSERVATION", 88, 97], ["node", "OBSERVATION", 106, 110]]], ["The node with the Illustration of the three different notions of importance we explore in this work.", [["node", "ANATOMY", 4, 8], ["node", "MULTI-TISSUE_STRUCTURE", 4, 8], ["node", "OBSERVATION", 4, 8]]], ["Panel (a) shows an example of an SIR outbreak in a seven-node network.", [["node network", "MULTI-TISSUE_STRUCTURE", 57, 69], ["node", "OBSERVATION", 57, 61]]], ["Panels (b)-(d) show how this outbreak influences maximization (a), vaccination (b), and sentinel surveillance, respectively.", [["Panels", "TEST", 0, 6], ["sentinel surveillance", "TEST", 88, 109]]], ["The idea of influence maximization (b) is that a node is important if the outbreak originating at it is expected to be large.", [["node", "ANATOMY", 49, 53], ["node", "MULTI-TISSUE_STRUCTURE", 49, 53], ["a node", "PROBLEM", 47, 53], ["node", "OBSERVATION", 49, 53], ["large", "OBSERVATION", 119, 124]]], ["The idea of vaccination (c) is that a node is important if removing it would reduce significantly the average outbreak size.", [["node", "ANATOMY", 38, 42], ["node", "MULTI-TISSUE_STRUCTURE", 38, 42], ["a node", "PROBLEM", 36, 42], ["node", "OBSERVATION", 38, 42], ["average", "OBSERVATION_MODIFIER", 102, 109], ["outbreak", "OBSERVATION_MODIFIER", 110, 118], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["The idea of sentinel surveillance (d) is that a node is important if a sensor on it would detect the outbreak early.", [["node", "ANATOMY", 48, 52], ["node", "MULTI-TISSUE_STRUCTURE", 48, 52], ["sentinel surveillance", "TEST", 12, 33], ["a node", "PROBLEM", 46, 52], ["node", "OBSERVATION", 48, 52]]], ["The shades of the nodes in (c) and (d) are proportional to their contribution.", [["nodes", "ANATOMY", 18, 23], ["shades", "OBSERVATION_MODIFIER", 4, 10], ["nodes", "OBSERVATION", 18, 23]]], ["In a stochastic simulation, one would average the values over many runs and, for (c) and (d), many seeds of the outbreak.", [["the outbreak", "PROBLEM", 108, 120]]], ["In this work, however, rather than running simulations, we calculate the exact expectation values of these quantities. smallest discovery time is then considered most important for sentinel surveillance.", [["sentinel surveillance", "TEST", 181, 202]]], ["We will briefly discuss such a conditioned \u03c4 and refer to it as \u03c4 .A. ImportanceFor all of the three problems mentioned above, one can consider sets of nodes rather than individuals.", [["nodes", "MULTI-TISSUE_STRUCTURE", 152, 157], ["nodes", "OBSERVATION", 152, 157]]], ["There can be more than one source (for influence maximization), vaccinee, or sentinel.", [["influence maximization", "TREATMENT", 39, 61], ["vaccinee", "TREATMENT", 64, 72]]], ["We will, in general, call these sets active nodes and denote their number as n.", [["nodes", "MULTI-TISSUE_STRUCTURE", 44, 49], ["nodes", "OBSERVATION", 44, 49]]], ["We will try to find the optimal sets of active nodes (and call them optimal nodes).", [["nodes", "MULTI-TISSUE_STRUCTURE", 47, 52], ["nodes", "MULTI-TISSUE_STRUCTURE", 76, 81], ["active nodes", "PROBLEM", 40, 52], ["active", "OBSERVATION_MODIFIER", 40, 46], ["nodes", "OBSERVATION", 47, 52], ["nodes", "OBSERVATION", 76, 81]]], ["Note that this is not the same as ranking the nodes in order of importance and taking the n most important ones-such a \"greedy\" approach can in many cases fail [7, 15] .A. ImportanceNote that for vaccination and sentinel surveillance, we use one source node of the infection.", [["infection", "DISEASE", 265, 274], ["node", "MULTI-TISSUE_STRUCTURE", 253, 257], ["vaccination", "TREATMENT", 196, 207], ["sentinel surveillance", "TEST", 212, 233], ["the infection", "PROBLEM", 261, 274], ["nodes", "OBSERVATION", 46, 51], ["node", "OBSERVATION", 253, 257], ["infection", "OBSERVATION", 265, 274]]], ["This is the standard approach in infectious disease epidemiology simply because most outbreaks are thought to start with one person [3, 17] .B. SIR modelWe will use the constant infection and recovery-rate version of the SIR model [17] .", [["infection", "DISEASE", 178, 187], ["person", "SPECIES", 125, 131], ["the constant infection", "PROBLEM", 165, 187], ["infectious", "OBSERVATION", 33, 43]]], ["In this formulation, if a susceptible node i is connected to an infectious node j , then i becomes infected at a rate \u03b2.", [["node", "ANATOMY", 38, 42], ["node", "ANATOMY", 75, 79], ["a susceptible node i", "PROBLEM", 24, 44], ["an infectious node j", "TREATMENT", 61, 81], ["infected", "PROBLEM", 99, 107], ["node", "OBSERVATION", 38, 42], ["infectious", "OBSERVATION_MODIFIER", 64, 74], ["node", "OBSERVATION", 75, 79], ["infected", "OBSERVATION", 99, 107]]], ["Infected nodes recover at a rate \u03bd.", [["nodes", "ANATOMY", 9, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 9, 14], ["Infected nodes", "PROBLEM", 0, 14], ["a rate", "TEST", 26, 32], ["nodes", "OBSERVATION", 9, 14]]], ["Without loss of generality, we can set \u03bd = 1 (equivalently, this means we are measuring time in units of 1/\u03bd).", [["loss of generality", "PROBLEM", 8, 26]]], ["Let C be a configuration (i.e., a specification of the state-S, I, or R-of every node), M SI is the number of links between S and I nodes, and N I is the number of infected nodes.", [["node", "ANATOMY", 81, 85], ["nodes", "ANATOMY", 173, 178], ["Let C", "GENE_OR_GENE_PRODUCT", 0, 5], ["N I", "GENE_OR_GENE_PRODUCT", 143, 146], ["nodes", "MULTI-TISSUE_STRUCTURE", 173, 178], ["N I", "PROTEIN", 143, 146], ["infected nodes", "PROBLEM", 164, 178], ["configuration", "OBSERVATION_MODIFIER", 11, 24], ["node", "OBSERVATION", 81, 85], ["nodes", "OBSERVATION", 132, 137], ["number", "OBSERVATION_MODIFIER", 154, 160], ["infected", "OBSERVATION_MODIFIER", 164, 172], ["nodes", "OBSERVATION", 173, 178]]], ["Then, the rate of events (either infections or recoveries) is \u03b2M SI + N I , which gives the expected duration of C asB.", [["infections", "DISEASE", 33, 43], ["C asB", "GENE_OR_GENE_PRODUCT", 113, 118], ["C asB", "PROTEIN", 113, 118]]], ["SIR modelProceeding in the spirit of the Gillespie algorithm, the probability of the next event being an infection event is \u03b2M SI t , and the probability of a recovery event is N I t [2, 18] .C. Exact calculations of and \u03c4Exactly calculating the outbreak size and time to discovery or extinction is, in principle, straightforward.", [["infection", "DISEASE", 105, 114], ["an infection event", "PROBLEM", 102, 120], ["Exact calculations", "TEST", 195, 213], ["infection", "OBSERVATION", 105, 114], ["outbreak", "OBSERVATION_MODIFIER", 246, 254], ["size", "OBSERVATION_MODIFIER", 255, 259]]], ["Consider the change from configuration C into C by an infection event (changing node i from susceptible to infectious).", [["node", "ANATOMY", 80, 84], ["infection", "DISEASE", 54, 63], ["node i", "MULTI-TISSUE_STRUCTURE", 80, 86], ["an infection event", "PROBLEM", 51, 69], ["infection", "OBSERVATION", 54, 63], ["node", "OBSERVATION", 80, 84], ["infectious", "OBSERVATION", 107, 117]]], ["This can happen in m i ways, where m i is the number of links between i and an infectious node.", [["node", "ANATOMY", 90, 94], ["node", "MULTI-TISSUE_STRUCTURE", 90, 94], ["an infectious node", "PROBLEM", 76, 94], ["infectious", "OBSERVATION_MODIFIER", 79, 89], ["node", "OBSERVATION", 90, 94]]], ["To compute the expected time for a chain of events, one sums the t for all configurations of the chain.C. Exact calculations of and \u03c4We will illustrate the description above with an example.", [["C.", "SPECIES", 103, 105], ["C.", "SPECIES", 103, 105], ["chain", "ANATOMY_MODIFIER", 97, 102]]], ["The probability of the outbreak chain 7 is (multiply the probabilities of the transitions)C. Exact calculations of and \u03c4The expected duration of the infection chain isC.", [["infection", "DISEASE", 149, 158], ["infection chain", "PROTEIN", 149, 164], ["isC", "PROTEIN", 165, 168], ["the infection chain isC", "PROBLEM", 145, 168], ["infection", "OBSERVATION", 149, 158], ["chain isC", "OBSERVATION", 159, 168]]], ["Exact calculations of and \u03c4of chain 7 to \u03c4 .", [["\u03c4", "GENE_OR_GENE_PRODUCT", 41, 42], ["\u03c4", "PROTEIN", 41, 42], ["Exact calculations", "TEST", 0, 18]]], ["Exact calculations of and \u03c4The expressions of and \u03c4 are fractions of polynomials.", [["\u03c4", "GENE_OR_GENE_PRODUCT", 50, 51], ["\u03c4", "PROTEIN", 50, 51]]], ["For the largest networks we study (seven nodes), these polynomials can be of order up to 43 with up to 54-digit integer coefficients.", [["these polynomials", "TEST", 49, 66], ["largest", "OBSERVATION_MODIFIER", 8, 15]]], ["Calculating for the influence maximization or vaccination problems follows the same path as the \u03c4 calculation above.", [["the influence maximization", "TREATMENT", 16, 42], ["vaccination problems", "TREATMENT", 46, 66]]], ["The difference is that instead of multiplying by the expected time of a chain, one would multiply by the number of recovered susceptible infectious recovered sentinel \u03b2/(2\u03b2+1) \u03b2 / ( 2 \u03b2 + 1 ) nodes in that branch.", [["2 \u03b2 + 1", "GENE_OR_GENE_PRODUCT", 182, 189], ["nodes in that branch", "PROBLEM", 192, 212], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["susceptible", "OBSERVATION_MODIFIER", 125, 136], ["infectious", "OBSERVATION_MODIFIER", 137, 147], ["nodes", "OBSERVATION", 192, 197], ["branch", "ANATOMY_MODIFIER", 206, 212]]], ["Furthermore, there are no sentinels to stop outbreaks, so trees (like Fig. 2 ) become larger.C. Exact calculations of and \u03c4In practice, our approach to analyzing network epidemiological models is time-consuming.", [["C.", "SPECIES", 93, 95], ["C.", "SPECIES", 93, 95], ["no", "UNCERTAINTY", 23, 25], ["larger", "OBSERVATION_MODIFIER", 86, 92]]], ["Because of this, we could not handle networks of more than seven nodes.", [["nodes", "ANATOMY", 65, 70], ["nodes", "OBSERVATION", 65, 70]]], ["The code was implemented in both Python (with the SymPy library [19] ) and C with the FLINT library [20] .", [["FLINT library", "DNA", 86, 99], ["the SymPy library", "TREATMENT", 46, 63]]], ["It also uses the subgraph isomorphism algorithm VF2 [21] as implemented in the igraph C library [22] .", [["the subgraph isomorphism algorithm VF2", "TREATMENT", 13, 51]]], ["Our code is available at http://github.com/pholme/exact-importance, which also includes code to calculate \u03c4 (mentioned above but not investigated in the paper).D. Centrality measuresTo better understand how the network structure determines what nodes are most important, we measure the average values of static importance predictors.", [["nodes", "ANATOMY", 245, 250], ["\u03c4", "PROTEIN", 106, 107], ["nodes", "OBSERVATION", 245, 250]]], ["In general, there are many ways to be the central means for a node-is it a node often passed by things traveling over the network, or is it a node for which short paths exist to other nodes?", [["node", "ANATOMY", 62, 66], ["node", "ANATOMY", 75, 79], ["node", "ANATOMY", 142, 146], ["node", "MULTI-TISSUE_STRUCTURE", 62, 66], ["a node", "PROBLEM", 60, 66], ["other nodes", "PROBLEM", 178, 189], ["node", "OBSERVATION", 62, 66], ["node", "OBSERVATION", 75, 79], ["node", "OBSERVATION", 142, 146], ["nodes", "OBSERVATION", 184, 189]]], ["Different rationales give different measures.", [["different measures", "TREATMENT", 26, 44]]], ["These are typically positively correlated, but they do not rank the nodes in the exact same way, and thus they can complement each other [23] .", [["nodes", "OBSERVATION", 68, 73]]], ["We focus on three measures: degree, closeness centrality, and vitality.D. Centrality measuresDegree centrality is simply the number of neighbors of a node.", [["node", "ANATOMY", 150, 154], ["node", "MULTI-TISSUE_STRUCTURE", 150, 154], ["a node", "PROBLEM", 148, 154], ["number", "OBSERVATION_MODIFIER", 125, 131], ["node", "OBSERVATION", 150, 154]]], ["If a node has twice the neighbors of another, it has twice as many nodes to which to spread an infection.", [["node", "ANATOMY", 5, 9], ["infection", "DISEASE", 95, 104], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["many nodes", "PROBLEM", 62, 72], ["an infection", "PROBLEM", 92, 104], ["node", "OBSERVATION", 5, 9], ["nodes", "OBSERVATION", 67, 72], ["infection", "OBSERVATION", 95, 104]]], ["This makes it more important for influence maximization and vaccination.", [["influence maximization", "TREATMENT", 33, 55], ["vaccination", "TREATMENT", 60, 71]]], ["It also has twice as many nodes from which to get the infections, which contributes to its importance for vaccination and sentinel surveillance.", [["infections", "DISEASE", 54, 64], ["many nodes", "PROBLEM", 21, 31], ["the infections", "PROBLEM", 50, 64], ["vaccination", "TREATMENT", 106, 117], ["sentinel surveillance", "TEST", 122, 143], ["nodes", "OBSERVATION", 26, 31], ["infections", "OBSERVATION", 54, 64]]], ["On the other hand, degree is not a global quantity-it could happen that the neighbors of a high-degree node are so peripheral that a disease could easily die out there.", [["high-degree node", "ANATOMY", 91, 107], ["node", "MULTI-TISSUE_STRUCTURE", 103, 107], ["a high-degree node", "PROBLEM", 89, 107], ["a disease", "PROBLEM", 131, 140], ["high-degree", "OBSERVATION_MODIFIER", 91, 102], ["node", "OBSERVATION", 103, 107], ["disease", "OBSERVATION", 133, 140]]], ["The simplest way of modifying the degree to become a global measure is to operationalize the idea that a node is central if it is the neighbor of many central nodes.D. Centrality measuresWith the simplest possible assumptions, this reasoning leads to eigenvector centrality, i.e., the centrality of node i can be estimated as the ith entry of the leading eigenvector of the adjacency matrix [10] .", [["node", "ANATOMY", 105, 109], ["central nodes", "ANATOMY", 151, 164], ["node", "MULTI-TISSUE_STRUCTURE", 105, 109], ["central nodes", "MULTI-TISSUE_STRUCTURE", 151, 164], ["matrix", "CELLULAR_COMPONENT", 384, 390], ["many central nodes", "PROBLEM", 146, 164], ["global", "OBSERVATION", 53, 59], ["node", "OBSERVATION", 105, 109], ["central", "OBSERVATION_MODIFIER", 113, 120], ["many", "OBSERVATION_MODIFIER", 146, 150], ["central nodes", "OBSERVATION", 151, 164], ["node", "OBSERVATION", 299, 303], ["adjacency matrix", "OBSERVATION", 374, 390]]], ["For the small graphs that we consider, however, the eigenvector centrality is so strongly correlated with degree (intuitively so, because \"everything is local\" in a very small graph) that it makes little sense to include it in the analysis.D. Centrality measuresMany centrality measures are based on the shortest paths.", [["the small graphs", "PROBLEM", 4, 20], ["the analysis", "TEST", 227, 239], ["small", "OBSERVATION_MODIFIER", 8, 13], ["centrality", "OBSERVATION", 267, 277]]], ["Perhaps the simplest of these measures is closeness centrality-using the idea that a node is central if it is on average close to other nodes [10, 23] .", [["node", "ANATOMY", 85, 89], ["node", "MULTI-TISSUE_STRUCTURE", 85, 89], ["node", "OBSERVATION", 85, 89], ["central", "OBSERVATION_MODIFIER", 93, 100], ["nodes", "OBSERVATION", 136, 141]]], ["This leads to a measure of the centrality of i as the reciprocal distance to all other nodes in the network:D. Centrality measuresThe main problem, in general, with closeness centrality may be that it is ill-defined on disconnected graphs.", [["nodes", "OBSERVATION", 87, 92], ["main", "OBSERVATION_MODIFIER", 134, 138], ["problem", "OBSERVATION", 139, 146]]], ["We chose the third centrality measure-vitality-with the vaccination problem in mind.", [["the vaccination problem", "TREATMENT", 52, 75]]], ["Vitality is, in general, a class of measures that estimate node centrality based on its impact on the network if it is deleted [23] .", [["node", "ANATOMY", 59, 63], ["node", "MULTI-TISSUE_STRUCTURE", 59, 63], ["node", "OBSERVATION", 59, 63]]], ["In our work, we let vitality denote the particular metricD.", [["metricD", "DNA", 51, 58]]], ["Centrality measureswhere s(G) is the number of nodes in the largest component of G. This measure is thus in the interval [1,N \u2212 1], and it increases with i's ability, if removed, to fragment the network.", [["number", "OBSERVATION_MODIFIER", 37, 43], ["nodes", "OBSERVATION", 47, 52], ["largest", "OBSERVATION_MODIFIER", 60, 67], ["component", "OBSERVATION_MODIFIER", 68, 77]]], ["Since vaccination is, in practice, like removing nodes from the network, we expect v to identify important nodes for \u03b2 close to 1.", [["\u03b2", "PROTEIN", 117, 118], ["vaccination", "TREATMENT", 6, 17], ["nodes", "OBSERVATION", 49, 54], ["nodes", "OBSERVATION", 107, 112]]], ["For large graphs, we expect v to be very close to 1, so we only recommend it for small graphs such as the ones we used here.", [["large graphs", "PROBLEM", 4, 16], ["small graphs", "PROBLEM", 81, 93]]], ["Another popular centrality measure-betweenness centrality (roughly how many shortest paths there are in the network that passes a node) [10]-is very strongly correlated with vitality for our set of small graphs, and it is thus omitted from the analysis.E. Small distinct graphsIn our work, we systematically evaluate small distinct (nonisomorphic) connected graphs.", [["E.", "SPECIES", 253, 255], ["small graphs", "TEST", 198, 210], ["the analysis", "TEST", 240, 252], ["Small distinct graphs", "PROBLEM", 256, 277], ["small distinct (nonisomorphic) connected graphs", "PROBLEM", 317, 364], ["node", "OBSERVATION", 130, 134], ["distinct", "OBSERVATION_MODIFIER", 262, 270], ["graphs", "OBSERVATION", 271, 277], ["small", "OBSERVATION_MODIFIER", 317, 322], ["distinct", "OBSERVATION_MODIFIER", 323, 331]]], ["We use all such graphs with 3 N 7.", [["all such graphs", "TREATMENT", 7, 22]]], ["There are two such graphs with N = 3, six with N = 4, 20 with N = 5, 112 with N = 6, and 853 with N = 7.", [["two such graphs", "TEST", 10, 25], ["N", "TEST", 31, 32], ["N", "TEST", 47, 48], ["N", "TEST", 62, 63], ["N", "TEST", 78, 79], ["N", "TEST", 98, 99]]], ["To generate these, we use the program GENG [24] .III. RESULTSIn our analysis, we will focus on when and why the three cases of node importance rank nodes differently.", [["node", "ANATOMY", 127, 131], ["node", "MULTI-TISSUE_STRUCTURE", 127, 131], ["our analysis", "TEST", 64, 76], ["node", "OBSERVATION", 127, 131]]], ["We will start with some extreme examples, and continue with general properties of all small graphs.A. Special casesInspired by Ref.", [["A.", "SPECIES", 99, 101]]], ["This is the smallest graph where the most important single node (n = 1) is different for influence maximization, vaccination, and sentinel surveillance.", [["node", "ANATOMY", 59, 63], ["single node", "MULTI-TISSUE_STRUCTURE", 52, 63], ["influence maximization", "TREATMENT", 89, 111], ["vaccination", "TREATMENT", 113, 124], ["sentinel surveillance", "TEST", 130, 151], ["smallest", "OBSERVATION_MODIFIER", 12, 20], ["node", "OBSERVATION", 59, 63]]], ["For [(1 + \u221a 5)/2,(3 + \u221a 17)/4] \u2248 (1.62,1.78), node 6 is the most important node for influence maximization, 5 is most important for vaccination, and 1 is most important for sentinel surveillance.", [["node", "ANATOMY", 75, 79], ["node", "MULTI-TISSUE_STRUCTURE", 75, 79], ["node", "TEST", 46, 50], ["sentinel surveillance", "TEST", 173, 194], ["node", "OBSERVATION", 46, 50], ["node", "OBSERVATION", 75, 79]]], ["For small \u03b2 values, 6 is most important for all three aspects of importance.", [["small \u03b2 values", "PROBLEM", 4, 18], ["small", "OBSERVATION_MODIFIER", 4, 9]]], ["The fact that 5 and 6 have a larger degree than the others is, of course, helpful for an outbreak to take hold in the population.", [["larger", "OBSERVATION_MODIFIER", 29, 35], ["degree", "OBSERVATION_MODIFIER", 36, 42]]], ["Node 6 is slightly more important as a seed node since the extra link in its neighborhood helps the outbreak to persist longer [there are the (6, 7, 4) and (6, 4, 7) infection paths that, although unlikely, do not exist for diseases starting at 5].", [["seed node", "ANATOMY", 39, 48], ["infection", "DISEASE", 166, 175], ["seed node", "MULTI-TISSUE_STRUCTURE", 39, 48], ["a seed node", "PROBLEM", 37, 48], ["infection paths", "PROBLEM", 166, 181], ["diseases", "PROBLEM", 224, 232], ["slightly", "OBSERVATION_MODIFIER", 10, 18], ["more important", "OBSERVATION_MODIFIER", 19, 33], ["node", "OBSERVATION", 44, 48]]], ["For sentinel surveillance and for low enough \u03b2, the outbreak would typically end by the outbreak becoming extinct rather than hitting a sentinel.", [["sentinel surveillance", "TEST", 4, 25]]], ["Thus, for low \u03b2, when an outbreak has the highest chance of surviving if it starts at 6, then putting in a sentinel is good because an outbreak is either instantly discovered or will likely soon be extinct.", [["extinct", "OBSERVATION", 198, 205]]], ["With a conditional discovery time \u03c4 , the curves are strictly decreasing (since the early die-off is omitted), so 1 is the most important node for all \u03b2.A. Special casesFor larger \u03b2, node 1 becomes, relatively speaking, more important for influence maximization and sentinel surveillance.", [["node", "ANATOMY", 138, 142], ["node", "MULTI-TISSUE_STRUCTURE", 138, 142], ["influence maximization", "TREATMENT", 239, 261], ["sentinel surveillance", "TEST", 266, 287], ["decreasing", "OBSERVATION_MODIFIER", 62, 72], ["node", "OBSERVATION", 138, 142], ["node", "OBSERVATION", 183, 187]]], ["This is the most central node in aspects other than degree.", [["node", "ANATOMY", 25, 29], ["central node", "MULTI-TISSUE_STRUCTURE", 17, 29], ["most", "OBSERVATION_MODIFIER", 12, 16], ["central", "OBSERVATION_MODIFIER", 17, 24], ["node", "OBSERVATION", 25, 29], ["than degree", "OBSERVATION_MODIFIER", 47, 58]]], ["For vaccination, however, node 5 is most important as it fragments the network most [the vitality is the same for both nodes v(5) = v(1) = 2, but the size of the second biggest component is larger if 1 is deleted].", [["vaccination", "TREATMENT", 4, 15], ["node", "OBSERVATION", 26, 30], ["nodes", "OBSERVATION", 119, 124], ["size", "OBSERVATION_MODIFIER", 150, 154], ["biggest", "OBSERVATION_MODIFIER", 169, 176], ["component", "OBSERVATION_MODIFIER", 177, 186], ["larger", "OBSERVATION_MODIFIER", 190, 196]]], ["So since 1 becomes more important than 6 at a larger \u03b2 value for influence maximization compared with sentinel surveillance, there is an interval of beta where the network of Fig. 3 has three distinct most important nodes for the three aspects of importance that we investigate.A. Special casesFor two active nodes (n = 2), the smallest network with no overlap between the optimal node sets is actually smaller than for n = 1.", [["node", "ANATOMY", 381, 385], ["beta", "GENE_OR_GENE_PRODUCT", 149, 153], ["Fig. 3", "GENE_OR_GENE_PRODUCT", 175, 181], ["nodes", "MULTI-TISSUE_STRUCTURE", 216, 221], ["node", "MULTI-TISSUE_STRUCTURE", 381, 385], ["A.", "SPECIES", 278, 280], ["influence maximization", "TREATMENT", 65, 87], ["sentinel surveillance", "TEST", 102, 123], ["two active nodes", "PROBLEM", 298, 314], ["distinct", "OBSERVATION_MODIFIER", 192, 200], ["most important", "OBSERVATION_MODIFIER", 201, 215], ["nodes", "OBSERVATION", 216, 221], ["active", "OBSERVATION_MODIFIER", 302, 308], ["nodes", "OBSERVATION", 309, 314], ["node", "OBSERVATION", 381, 385], ["smaller", "OBSERVATION_MODIFIER", 403, 410]]], ["This network, displayed in Fig. 4 , has six nodes and eight links.", [["six", "OBSERVATION_MODIFIER", 40, 43], ["nodes", "OBSERVATION", 44, 49]]], ["Note that N = 6 is the smallest number of nodes to make three distinct sets of two nodes, so in that sense the n = 2 example seems more extreme than the n = 1 counterpart, Fig. 3 .A. Special casesFor large \u03b2 values, 1 and 2 are the most important nodes for influence maximization, 5 and 6 are most important for vaccination, and 3 and 4 are most important for sentinel surveillance.", [["large \u03b2 values", "TEST", 200, 214], ["influence maximization", "TREATMENT", 257, 279], ["vaccination", "TREATMENT", 312, 323], ["sentinel surveillance", "TEST", 360, 381], ["smallest", "OBSERVATION_MODIFIER", 23, 31], ["number", "OBSERVATION_MODIFIER", 32, 38], ["nodes", "OBSERVATION", 42, 47], ["three distinct", "OBSERVATION_MODIFIER", 56, 70], ["two", "OBSERVATION_MODIFIER", 79, 82], ["nodes", "OBSERVATION", 83, 88], ["large", "OBSERVATION_MODIFIER", 200, 205], ["nodes", "OBSERVATION", 247, 252]]], ["5 and 6 are the nodes that, if deleted, break the network into the smallest components, which explains why they are most important for vaccination (at least for large \u03b2).", [["nodes", "OBSERVATION", 16, 21], ["smallest", "OBSERVATION_MODIFIER", 67, 75]]], ["In addition to 5 and 6, 1 and 2 are the only pair of nodes whose neighborhoods contain all other nodes.", [["nodes", "ANATOMY", 53, 58], ["nodes", "ANATOMY", 97, 102], ["nodes", "MULTI-TISSUE_STRUCTURE", 53, 58], ["nodes", "MULTI-TISSUE_STRUCTURE", 97, 102], ["5 and 6, 1 and 2", "DNA", 15, 31], ["all other nodes", "PROBLEM", 87, 102], ["nodes", "OBSERVATION", 53, 58], ["all", "OBSERVATION_MODIFIER", 87, 90], ["nodes", "OBSERVATION", 97, 102]]], ["Nodes 1 and 2 both have degree 3, as opposed to 5 and 6, which have degrees 4 and 2, respectively.", [["Nodes", "TEST", 0, 5]]], ["It is not clear whether that makes 1 and 2 better than 5 and 6 for influence maximization, or why.", [["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]], ["Similarly, it is hard to understand why 3 and 4 are the best nodes for sentinel surveillance.", [["nodes", "MULTI-TISSUE_STRUCTURE", 61, 66], ["sentinel surveillance", "TEST", 71, 92], ["nodes", "OBSERVATION", 61, 66]]], ["The neighborhoods of these nodes do not even contain the entire graph.A. Special casesWe can see that the optimal sets of nodes in Fig. 4 do not have links within themselves.", [["nodes", "ANATOMY", 122, 127], ["nodes", "MULTI-TISSUE_STRUCTURE", 122, 127], ["nodes", "OBSERVATION", 27, 32], ["nodes", "OBSERVATION", 122, 127]]], ["This means that as n grows, the distance between the optimal nodes will be larger than 1.", [["nodes", "ANATOMY", 61, 66], ["nodes", "MULTI-TISSUE_STRUCTURE", 61, 66], ["nodes", "OBSERVATION", 61, 66], ["larger", "OBSERVATION_MODIFIER", 75, 81]]], ["Another such observation is that for small \u03b2, the optimal nodes for the three importance aspects are overlapping.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 43, 44], ["small \u03b2, the optimal nodes", "PROBLEM", 37, 63], ["nodes", "OBSERVATION", 58, 63]]], ["In this parameter region, most outbreaks die out before they reach a sentinel.", [["sentinel", "OBSERVATION", 69, 77]]], ["If the outbreak starts at a high-degree node in a highly connected neighborhood, there is a larger chance for it to survive.", [["node", "MULTI-TISSUE_STRUCTURE", 40, 44], ["the outbreak", "PROBLEM", 3, 15], ["node", "OBSERVATION", 40, 44], ["larger", "OBSERVATION_MODIFIER", 92, 98]]], ["For all three importance aspects, it is important to have active nodes where an outbreak would be likely to survive.", [["nodes", "MULTI-TISSUE_STRUCTURE", 65, 70], ["active nodes", "PROBLEM", 58, 70], ["active", "OBSERVATION_MODIFIER", 58, 64], ["nodes", "OBSERVATION", 65, 70]]], ["Still, as evident from Fig. 4 , there are examples where the optimal nodes are not overlapping.B. \u03b2 dependenceWe will now move to a more statistical evaluation of all graphs with 3-7 nodes.", [["nodes", "ANATOMY", 69, 74], ["nodes", "MULTI-TISSUE_STRUCTURE", 69, 74], ["the optimal nodes", "PROBLEM", 57, 74], ["a more statistical evaluation", "TEST", 130, 159], ["all graphs", "TEST", 163, 173], ["Fig", "OBSERVATION", 23, 26], ["optimal", "OBSERVATION_MODIFIER", 61, 68], ["nodes", "OBSERVATION", 69, 74], ["not", "UNCERTAINTY", 79, 82], ["overlapping", "OBSERVATION_MODIFIER", 83, 94], ["nodes", "OBSERVATION", 183, 188]]], ["Other summary statistics, including grouping the graphs according to size, give the same conclusions.B. \u03b2 dependenceLet u a,b i be the optimal sets for a given network, \u03b2, and importance classes a and b.", [["grouping the graphs", "TEST", 36, 55], ["dependence", "OBSERVATION_MODIFIER", 106, 116]]], ["The first quantity we look at is the pairwise overlap of sets of optimal nodes as measured by the Jaccard overlap,B. \u03b2 dependencewhereB. \u03b2 dependenceFor example, in Fig. 4 at \u03b2 = 2, we haveB. \u03b2 dependencewhere a is influence maximization and b represents sentinel surveillance, givingB. \u03b2 dependenceAs seen in Fig. 5 , for n = 1, the overlap between the optimal nodes for vaccination and sentinel surveillance has a minimum as a function of \u03b2.", [["nodes", "ANATOMY", 362, 367], ["\u03b2", "GENE_OR_GENE_PRODUCT", 117, 118], ["nodes", "MULTI-TISSUE_STRUCTURE", 362, 367], ["B. \u03b2 dependencewhereB", "DNA", 114, 135], ["optimal nodes", "PROBLEM", 65, 78], ["sentinel surveillance", "TEST", 255, 276], ["vaccination", "TREATMENT", 372, 383], ["sentinel surveillance", "TEST", 388, 409], ["optimal", "OBSERVATION_MODIFIER", 65, 72], ["nodes", "OBSERVATION", 73, 78], ["nodes", "OBSERVATION", 362, 367]]], ["The same is true for sentinel surveillance versus influence maximization when n = 3.", [["sentinel surveillance", "TEST", 21, 42], ["influence maximization", "TREATMENT", 50, 72]]], ["It is hard to say why, beyond that, for individual graphs the J (a,b,\u03b2) curves can of course be nonmonotonous as different aspects of the graph structure determine the role of the nodes.", [["nodes", "ANATOMY", 180, 185], ["nodes", "OBSERVATION", 180, 185]]], ["We note that (for a different spreading model and much larger networks), Ref.", [["a different spreading model", "TREATMENT", 18, 45]]], ["[13] finds the Jaccard similarity between influence maximization and vaccination to have a minimum as a function of \u03b2.C. Structural predictorsNext, we investigate the structural properties of the most influential nodes and how they depend on \u03b2.", [["nodes", "ANATOMY", 213, 218], ["nodes", "MULTI-TISSUE_STRUCTURE", 213, 218], ["influence maximization", "TREATMENT", 42, 64], ["vaccination", "TREATMENT", 69, 80], ["nodes", "OBSERVATION", 213, 218]]], ["In Fig. 6 , we plot the degree, closeness centrality, and vitality as a function of \u03b2 for all aspects of importance and n \u2208 {1,2,3}.", [["\u03b2", "PROTEIN", 84, 85]]], ["The first thing to notice is the general impression that centralities of the optimal nodes decrease with \u03b2.", [["nodes", "ANATOMY", 85, 90], ["nodes", "MULTI-TISSUE_STRUCTURE", 85, 90], ["the optimal nodes", "PROBLEM", 73, 90], ["optimal", "OBSERVATION_MODIFIER", 77, 84], ["nodes", "OBSERVATION", 85, 90], ["decrease", "OBSERVATION_MODIFIER", 91, 99]]], ["The only case with an opposite trend is vitality [ Fig. 6(c) ], where the curves are increasing monotonically.", [["increasing", "OBSERVATION_MODIFIER", 85, 95]]], ["If we first focus on the case with one active node, this could be understood as the ability of nodes to (if removed) fragment the network.", [["node", "ANATOMY", 46, 50], ["node", "MULTI-TISSUE_STRUCTURE", 46, 50], ["active", "OBSERVATION_MODIFIER", 39, 45], ["node", "OBSERVATION", 46, 50], ["nodes", "OBSERVATION", 95, 100]]], ["This ability is captured by vitality and becomes more important as \u03b2 increases.C. Structural predictorsContinuing the analysis for n = 1, when \u03b2 is low the most important thing is for the outbreak to persist in the population.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 67, 68], ["C", "GENE_OR_GENE_PRODUCT", 79, 80], ["\u03b2", "PROTEIN", 67, 68], ["the analysis", "TEST", 114, 126], ["the outbreak", "PROBLEM", 184, 196]]], ["If an active node has a high degree, it is likely to be the source of a large outbreak, meaning it is important for influence maximization (which was also concluded by Ref.", [["node", "ANATOMY", 13, 17], ["node", "MULTI-TISSUE_STRUCTURE", 13, 17], ["an active node", "PROBLEM", 3, 17], ["a large outbreak", "PROBLEM", 70, 86], ["influence maximization", "TREATMENT", 116, 138], ["active", "OBSERVATION_MODIFIER", 6, 12], ["node", "OBSERVATION", 13, 17], ["high degree", "OBSERVATION_MODIFIER", 24, 35], ["likely to be", "UNCERTAINTY", 43, 55], ["large", "OBSERVATION_MODIFIER", 72, 77], ["outbreak", "OBSERVATION", 78, 86]]], ["If a high-degree node is deleted, it would remove many links that could spread the disease and thus be important for vaccination [25] .", [["node", "ANATOMY", 17, 21], ["a high-degree node", "PROBLEM", 3, 21], ["the disease", "PROBLEM", 79, 90], ["high-degree", "OBSERVATION_MODIFIER", 5, 16], ["node", "OBSERVATION", 17, 21], ["disease", "OBSERVATION", 83, 90]]], ["It would also be important not to put a sentinel on a low-degree node for sentinel surveillance and low \u03b2 as diseases reaching low-degree nodes would likely die out.", [["node", "MULTI-TISSUE_STRUCTURE", 65, 69], ["a low-degree node", "TREATMENT", 52, 69], ["sentinel surveillance", "TEST", 74, 95], ["low \u03b2 as diseases", "PROBLEM", 100, 117], ["low-degree nodes", "PROBLEM", 127, 143], ["node", "OBSERVATION", 65, 69], ["low-degree", "OBSERVATION_MODIFIER", 127, 137], ["nodes", "OBSERVATION", 138, 143]]], ["So panels Figs.", [["Figs", "OBSERVATION_MODIFIER", 10, 14]]], ["6(a) and 6(c) can be understood as a shift from nodes of high degree to nodes of high vitality.", [["high degree to nodes of high vitality", "PROBLEM", 57, 94], ["nodes", "OBSERVATION", 48, 53], ["high degree", "OBSERVATION_MODIFIER", 57, 68], ["nodes", "OBSERVATION", 72, 77], ["high vitality", "OBSERVATION_MODIFIER", 81, 94]]], ["Closeness centrality-seen in Fig. 6 (b)-is harder to explain.", [["Closeness centrality", "PROBLEM", 0, 20]]], ["Values of c increase with \u03b2 for influence maximization but decrease for vaccination.", [["Values", "TEST", 0, 6], ["influence maximization", "TREATMENT", 32, 54], ["vaccination", "TREATMENT", 72, 83]]], ["One way of understanding this is from the observation that vitality is most important for vaccination [as evident from Fig. 6(c) ], and degree is most important for influence maximization [as seen in Fig. 6(a) ].", [["vaccination", "TREATMENT", 90, 101], ["influence maximization", "TREATMENT", 165, 187]]], ["The results of Fig. 6 (b) then suggest that the high vitality nodes optimizing the solution of the vaccination problem have a lower closeness centrality.", [["the high vitality nodes", "PROBLEM", 44, 67], ["the vaccination problem", "TREATMENT", 95, 118], ["a lower closeness centrality", "PROBLEM", 124, 152]]], ["Indeed, for many of the graphs we study, the highest vitality node has many degree-1 neighbors-cf. node 5 in Fig. 3 -which does not necessarily contribute to the closeness centrality.", [["the graphs we study", "TEST", 20, 39]]], ["For influence maximization, it seems that the optimal nodes are central in the closeness sense-the closer to average the seed node is to the rest of the network, the higher is the chance for the outbreak to reach the entire network.C. Structural predictorsFor n = 2 and 3, the picture is somewhat different than for n = 1.", [["seed node", "ANATOMY", 121, 130], ["nodes", "MULTI-TISSUE_STRUCTURE", 54, 59], ["seed node", "MULTI-TISSUE_STRUCTURE", 121, 130], ["influence maximization", "TREATMENT", 4, 26], ["the optimal nodes", "PROBLEM", 42, 59], ["nodes", "OBSERVATION", 54, 59], ["central", "OBSERVATION_MODIFIER", 64, 71], ["node", "OBSERVATION", 126, 130]]], ["In these cases, all centrality measures are decreasing monotonically.", [["all", "OBSERVATION_MODIFIER", 16, 19], ["centrality", "OBSERVATION_MODIFIER", 20, 30], ["decreasing", "OBSERVATION_MODIFIER", 44, 54], ["monotonically", "OBSERVATION_MODIFIER", 55, 68]]], ["The order of importance measures are all the same, with vaccination having the largest values, and influence maximization the smallest.", [["importance measures", "TREATMENT", 13, 32], ["vaccination", "TREATMENT", 56, 67], ["largest", "OBSERVATION_MODIFIER", 79, 86], ["smallest", "OBSERVATION_MODIFIER", 126, 134]]], ["It is no longer the case for vaccination that the optimizing nodes have high vitality and low closeness centrality (as it was for n = 1).", [["nodes", "ANATOMY", 61, 66], ["nodes", "MULTI-TISSUE_STRUCTURE", 61, 66], ["vaccination", "TREATMENT", 29, 40], ["high vitality", "PROBLEM", 72, 85], ["low closeness centrality", "PROBLEM", 90, 114], ["no longer", "UNCERTAINTY", 6, 15], ["nodes", "OBSERVATION", 61, 66], ["high vitality", "OBSERVATION_MODIFIER", 72, 85]]], ["Indeed, for the vaccination case, the optimal nodes are usually independent of \u03b2, which is why the curves for vaccination in Figs.", [["nodes", "ANATOMY", 46, 51], ["nodes", "MULTI-TISSUE_STRUCTURE", 46, 51], ["\u03b2", "GENE_OR_GENE_PRODUCT", 79, 80], ["the vaccination case", "TREATMENT", 12, 32], ["vaccination in Figs", "TREATMENT", 110, 129], ["nodes", "OBSERVATION", 46, 51]]], ["However, as we will argue further below, the optimal nodes would usually not be close to each other.", [["nodes", "MULTI-TISSUE_STRUCTURE", 53, 58], ["nodes", "OBSERVATION", 53, 58]]], ["One could think of each node being responsible for (and centrally situated within) a region of the network, and that that tendency is so strong that it overrides all simple centrality measures.", [["node", "ANATOMY", 24, 28], ["node", "MULTI-TISSUE_STRUCTURE", 24, 28], ["each node", "PROBLEM", 19, 28], ["node", "OBSERVATION", 24, 28]]], ["On the other hand, there are group centrality measures that could perhaps increase with \u03b2 [26] (that could be a theme for another paper).D. Distance between optimal nodesThe fact that all the curves of Figs.", [["nodes", "ANATOMY", 165, 170], ["nodes", "MULTI-TISSUE_STRUCTURE", 165, 170], ["group centrality measures", "TREATMENT", 29, 54], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["nodes", "OBSERVATION", 165, 170]]], ["6(d)-6(i) are nonincreasing could be explained by the fact that the separation of the optimal nodes increases with \u03b2.", [["nodes", "ANATOMY", 94, 99], ["nodes", "MULTI-TISSUE_STRUCTURE", 94, 99], ["could be explained", "UNCERTAINTY", 28, 46], ["separation", "OBSERVATION_MODIFIER", 68, 78], ["optimal", "OBSERVATION_MODIFIER", 86, 93], ["nodes", "OBSERVATION", 94, 99]]], ["In Fig. 7 , we try to make this argument more quantitative by measuring the average (shortest path) distance d between the optimal nodes.", [["distance d between the optimal nodes", "PROBLEM", 100, 136], ["optimal", "OBSERVATION_MODIFIER", 123, 130], ["nodes", "OBSERVATION", 131, 136]]], ["In the limit of small \u03b2, these values come rather close to its minimum of 1, but as \u03b2 increases, so does d.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 22, 23], ["\u03b2", "PROTEIN", 84, 85], ["these values", "TEST", 25, 37], ["small", "OBSERVATION_MODIFIER", 16, 21]]], ["6(d)-6(i)-the vaccination curve is almost constant, sentinel surveillance increases moderately, but influence maximization increases much more.D. Distance between optimal nodesA larger separation gives the sentinels the ability on average to be closer to outbreaks anywhere in the network, while for influence maximization a larger separation means that there are more susceptible-infectious links (fewer infectious-infectious links) in the incipient outbreak.", [["nodes", "ANATOMY", 171, 176], ["D.", "SPECIES", 143, 145], ["D.", "SPECIES", 143, 145], ["the vaccination curve", "TEST", 10, 31], ["sentinel surveillance", "TEST", 52, 73], ["the incipient outbreak", "PROBLEM", 437, 459], ["nodes", "OBSERVATION", 171, 176], ["larger", "OBSERVATION_MODIFIER", 178, 184], ["separation", "OBSERVATION_MODIFIER", 185, 195], ["more", "OBSERVATION_MODIFIER", 364, 368], ["susceptible", "OBSERVATION_MODIFIER", 369, 380], ["infectious", "OBSERVATION_MODIFIER", 381, 391], ["fewer", "OBSERVATION_MODIFIER", 399, 404], ["infectious", "OBSERVATION_MODIFIER", 405, 415], ["incipient", "OBSERVATION_MODIFIER", 441, 450], ["outbreak", "OBSERVATION_MODIFIER", 451, 459]]], ["For vaccination there is no such positive effect of a larger separation that we can think of, which is a part of the explanation as to why the optimal sets are relatively independent of \u03b2 for n > 1.", [["vaccination", "TREATMENT", 4, 15], ["a larger separation", "TREATMENT", 52, 71], ["no", "UNCERTAINTY", 25, 27]]], ["The rest of the explanation, i.e., why the trends for n = 1 are so much weaker when n > 1, is not clear to us, and it is something we will investigate further in the future.IV. DISCUSSIONWe investigated the average properties of the optimal nodes for all our graphs.", [["nodes", "OBSERVATION", 241, 246]]], ["We found that the overlap between the optimal nodes of the different importance aspects are largest for small \u03b2.", [["optimal", "OBSERVATION_MODIFIER", 38, 45], ["nodes", "OBSERVATION", 46, 51], ["different", "OBSERVATION_MODIFIER", 59, 68], ["largest", "OBSERVATION_MODIFIER", 92, 99], ["small", "OBSERVATION_MODIFIER", 104, 109]]], ["In the small-\u03b2 region, a high degree seems most important for all importance aspects.", [["small", "OBSERVATION_MODIFIER", 7, 12], ["high degree", "OBSERVATION_MODIFIER", 25, 36]]], ["For larger \u03b2 nodes, it becomes more important for them to be positioned such that they would fragment the network if they were removed, particularly for the vaccination problem (slightly less for the sentinel surveillance problem, and much less for influence maximization).", [["\u03b2 nodes", "ANATOMY", 11, 18], ["\u03b2 nodes", "MULTI-TISSUE_STRUCTURE", 11, 18], ["larger \u03b2 nodes", "PROBLEM", 4, 18], ["the vaccination problem", "PROBLEM", 153, 176], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["\u03b2", "OBSERVATION_MODIFIER", 11, 12], ["nodes", "OBSERVATION", 13, 18]]], ["On the other hand, when the number of active nodes increases, it becomes important for the nodes to be spread out-the average distance between them increases.", [["nodes", "ANATOMY", 45, 50], ["nodes", "MULTI-TISSUE_STRUCTURE", 45, 50], ["active nodes", "PROBLEM", 38, 50], ["the nodes", "PROBLEM", 87, 96], ["active", "OBSERVATION_MODIFIER", 38, 44], ["nodes", "OBSERVATION", 45, 50], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["nodes", "OBSERVATION", 91, 96], ["increases", "OBSERVATION_MODIFIER", 148, 157]]], ["This effect is large for influence maximization, intermediate for sentinel surveillance, and very small for vaccination.", [["influence maximization", "TREATMENT", 25, 47], ["sentinel surveillance", "TEST", 66, 87], ["large", "OBSERVATION_MODIFIER", 15, 20]]], ["The small effect for vaccination can be understood since all that matters is to fragment the network, and for that purpose the vaccine does not necessarily have to be distant.IV. DISCUSSIONMost of the behavior discussed above seems quite natural.", [["vaccination", "TREATMENT", 21, 32], ["the vaccine", "TREATMENT", 123, 134], ["IV", "TREATMENT", 175, 177], ["small", "OBSERVATION_MODIFIER", 4, 9], ["effect", "OBSERVATION_MODIFIER", 10, 16]]], ["For small \u03b2, the dominant aspect of the dynamics is how fast an outbreak will die out.", [["small \u03b2", "GENE_OR_GENE_PRODUCT", 4, 11], ["small", "OBSERVATION_MODIFIER", 4, 9], ["dominant", "OBSERVATION_MODIFIER", 17, 25]]], ["For large \u03b2, the outbreak will almost certainly reach all nodes.", [["large \u03b2, the outbreak", "PROBLEM", 4, 25], ["large", "OBSERVATION_MODIFIER", 4, 9], ["nodes", "OBSERVATION", 58, 63]]], ["For vaccination and sentinel surveillance, this leads to a question of deleting nodes that would break the network into the smallest components.", [["vaccination", "TREATMENT", 4, 15], ["sentinel surveillance", "TEST", 20, 41], ["deleting nodes", "PROBLEM", 71, 85], ["nodes", "OBSERVATION", 80, 85], ["smallest", "OBSERVATION_MODIFIER", 124, 132], ["components", "OBSERVATION_MODIFIER", 133, 143]]], ["(In the former case, this is trivial since the size of the outbreak is almost surely the size of the connected component to which the seed node belongs.", [["seed node", "ANATOMY", 134, 143], ["seed node", "MULTI-TISSUE_STRUCTURE", 134, 143], ["trivial", "OBSERVATION", 29, 36], ["size", "OBSERVATION_MODIFIER", 47, 51], ["outbreak", "OBSERVATION", 59, 67], ["size", "OBSERVATION_MODIFIER", 89, 93], ["seed node", "OBSERVATION", 134, 143]]], ["In the latter, we conclude this from the monotonically increasing vitality).IV. DISCUSSIONAs an extension, it would be interesting to confirm this work in larger networks using stochastic simulations.", [["stochastic simulations", "TREATMENT", 177, 199]]], ["This would not allow for the discoveries of special graphs such as those in Figs.", [["special graphs", "TEST", 44, 58]]], ["[13] (comparing the vaccination and influence maximization for n = 1 in large empirical networks).", [["the vaccination", "TREATMENT", 16, 31], ["influence maximization", "TREATMENT", 36, 58]]]], "PMC7492064": [["As Choy correctly points out, pulsatility could affect cortisol levels.", [["cortisol", "CHEMICAL", 55, 63], ["cortisol", "CHEMICAL", 55, 63], ["cortisol", "SIMPLE_CHEMICAL", 55, 63], ["Choy", "PROTEIN", 3, 7], ["pulsatility", "TEST", 30, 41], ["cortisol levels", "TEST", 55, 70]]], ["Gibbison and colleagues2 showed concordance of adrenocorticotropic hormone and cortisol pulses, crucially with significantly less pulsatility in critical illness compared with healthy volunteers.", [["Gibbison", "CHEMICAL", 0, 8], ["cortisol", "CHEMICAL", 79, 87], ["cortisol", "CHEMICAL", 79, 87], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 47, 74], ["cortisol", "SIMPLE_CHEMICAL", 79, 87], ["volunteers", "ORGANISM", 184, 194], ["colleagues2", "TEST", 13, 24], ["adrenocorticotropic hormone", "TEST", 47, 74], ["cortisol pulses", "TEST", 79, 94], ["significantly less pulsatility in critical illness", "PROBLEM", 111, 161], ["adrenocorticotropic hormone", "OBSERVATION", 47, 74], ["illness", "OBSERVATION", 154, 161]]], ["This finding suggests that pulsatility might not have as great an effect on cortisol levels in critically ill patients as they would in healthy patients.", [["cortisol", "CHEMICAL", 76, 84], ["critically ill", "DISEASE", 95, 109], ["cortisol", "CHEMICAL", 76, 84], ["cortisol", "SIMPLE_CHEMICAL", 76, 84], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 144, 152], ["pulsatility", "PROBLEM", 27, 38], ["cortisol levels", "TEST", 76, 91], ["pulsatility", "OBSERVATION", 27, 38]]]], "a42ff48d50aa3a0ebfe840d46ed2204c49955442": [["In addition to the impact of the COVID-19 on people's emotions, people's coping strategies will also change as a result.", [["people", "ORGANISM", 45, 51], ["people", "ORGANISM", 64, 70], ["COVID-19", "DNA", 33, 41], ["people", "SPECIES", 45, 51], ["people", "SPECIES", 64, 70], ["the COVID", "TREATMENT", 29, 38], ["people's coping strategies", "TREATMENT", 64, 90]]], ["People have identified two general coping strategies: one is a problem-focused coping, the purpose is to solve the problem or take action to change the status quo; the other is an emotion-focused coping, which aims to reduce the emotional distress associated with stressful situations [12] .", [["emotional distress", "DISEASE", 229, 247], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["the emotional distress", "PROBLEM", 225, 247]]], ["Studies have found that emotions lead to specific coping strategies [13] , and vice versa.", [["Studies", "TEST", 0, 7]]]], "8cbc79e63c08258edef9ed362498b779a592977a": [["Traditional pathogen detection methods in public health infectious disease surveillance rely upon the identification of agents that are already known to be associated with a particular clinical syndrome.", [["infectious disease", "DISEASE", 56, 74], ["agents", "TREATMENT", 120, 126], ["a particular clinical syndrome", "PROBLEM", 172, 202]]], ["The emerging field of metagenomics has the potential to revolutionize pathogen detection in public health laboratories by allowing the simultaneous detection of all microorganisms in a clinical sample, without a priori knowledge of their identities, through the use of next-generation DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 285, 288], ["the simultaneous detection", "TEST", 131, 157], ["all microorganisms", "PROBLEM", 161, 179], ["next-generation DNA sequencing", "TREATMENT", 269, 299]]], ["A single metagenomics analysis has the potential to detect rare and novel pathogens, and to uncover the role of dysbiotic microbiomes in infectious and chronic human disease.", [["infectious and chronic human disease", "DISEASE", 137, 173], ["human", "ORGANISM", 160, 165], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["A single metagenomics analysis", "TEST", 0, 30], ["rare and novel pathogens", "PROBLEM", 59, 83], ["dysbiotic microbiomes", "PROBLEM", 112, 133], ["chronic human disease", "PROBLEM", 152, 173], ["pathogens", "OBSERVATION", 74, 83], ["infectious", "OBSERVATION", 137, 147], ["chronic human disease", "OBSERVATION", 152, 173]]], ["Making use of advances in sequencing platforms and bioinformatics tools, recent studies have shown that metagenomics can even determine the whole-genome sequences of pathogens, allowing inferences about antibiotic resistance, virulence, evolution and transmission to be made.", [["whole-genome sequences", "DNA", 140, 162], ["sequencing platforms", "TEST", 26, 46], ["bioinformatics tools", "TEST", 51, 71], ["recent studies", "TEST", 73, 87], ["pathogens", "PROBLEM", 166, 175], ["antibiotic resistance", "TREATMENT", 203, 224], ["virulence", "PROBLEM", 226, 235]]], ["We are entering an era in which more novel infectious diseases will be identified through metagenomics-based methods than through traditional laboratory methods.", [["infectious diseases", "DISEASE", 43, 62], ["novel infectious diseases", "PROBLEM", 37, 62], ["infectious", "OBSERVATION", 43, 53]]], ["The impetus is now on public health laboratories to integrate metagenomics techniques into their diagnostic arsenals.How do we detect infectious diseases?", [["infectious diseases", "DISEASE", 134, 153], ["infectious diseases", "PROBLEM", 134, 153], ["infectious", "OBSERVATION", 134, 144]]], ["An introduction to public health laboratory surveillancePublic health infectious disease surveillance employs two strategies to detect cases and outbreaks of communicable diseases: laboratory-based surveillance and syndromic surveillance, which relies on non-laboratory data.", [["infectious disease", "DISEASE", 70, 88], ["communicable diseases", "DISEASE", 158, 179], ["syndromic surveillance", "TEST", 215, 237], ["non-laboratory data", "TEST", 255, 274]]], ["Although syndromic surveillance is sometimes the only viable option for population-level monitoring of certain diseases, laboratory-based surveillance is usually more accurate, as the definitive diagnosis of most infectious diseases requires laboratory confirmation.", [["infectious diseases", "DISEASE", 213, 232], ["syndromic surveillance", "TEST", 9, 31], ["certain diseases", "PROBLEM", 103, 119], ["most infectious diseases", "PROBLEM", 208, 232], ["laboratory confirmation", "TEST", 242, 265]]], ["A range of methods are available in public health laboratories: traditional assays include microscopy and culture-based analyses, as well as immunoassays that detect antigens from the pathogen or immune responses from the host; modern techniques include nucleic acid amplification tests.", [["nucleic acid", "CHEMICAL", 254, 266], ["antigens", "PROTEIN", 166, 174], ["traditional assays", "TEST", 64, 82], ["microscopy", "TEST", 91, 101], ["culture", "TEST", 106, 113], ["based analyses", "TEST", 114, 128], ["immunoassays", "TEST", 141, 153], ["the pathogen", "PROBLEM", 180, 192], ["modern techniques", "TREATMENT", 228, 245], ["nucleic acid amplification tests", "TEST", 254, 286]]], ["Nevertheless, many samples entering a public health laboratory remain undiagnosed despite being subjected to a battery of conventional laboratory tests.How do we detect infectious diseases?", [["samples", "ANATOMY", 19, 26], ["infectious diseases", "DISEASE", 169, 188], ["conventional laboratory tests", "TEST", 122, 151], ["infectious diseases", "PROBLEM", 169, 188], ["infectious", "OBSERVATION", 169, 179]]], ["An introduction to public health laboratory surveillanceConventional laboratory assays fail to detect a causative agent in approximately 40% of gastroenteritis [1] and as many as 60% of encephalitis cases [2] , complicating surveillance of these diseases.", [["gastroenteritis", "DISEASE", 144, 159], ["encephalitis", "DISEASE", 186, 198], ["Conventional laboratory assays", "TEST", 56, 86], ["a causative agent", "PROBLEM", 102, 119], ["gastroenteritis", "PROBLEM", 144, 159], ["encephalitis cases", "PROBLEM", 186, 204], ["these diseases", "PROBLEM", 240, 254], ["diseases", "OBSERVATION", 246, 254]]], ["Presuming a pathogenic agent is present in the sample, the undetected disease agents in these cases may simply be known species that are not targeted by a laboratory's testing algorithm or they may be truly novel pathogens.", [["sample", "ANATOMY", 47, 53], ["a pathogenic agent", "PROBLEM", 10, 28], ["the undetected disease agents", "PROBLEM", 55, 84], ["known species", "PROBLEM", 114, 127], ["a laboratory's testing algorithm", "TEST", 153, 185], ["novel pathogens", "PROBLEM", 207, 222], ["pathogenic agent", "OBSERVATION", 12, 28], ["disease", "OBSERVATION", 70, 77]]], ["The emergence of novel microorganisms challenges laboratory surveillance efforts, which must constantly evolve to identify new pathogens, such as the Middle East respiratory syndrome coronavirus (MERS-CoV) [3, 4] and H7N9 influenza [5] .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 150, 194], ["influenza", "DISEASE", 222, 231], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 150, 194], ["MERS-CoV", "ORGANISM", 196, 204], ["H7N9 influenza", "ORGANISM", 217, 231], ["MERS-CoV", "SPECIES", 196, 204], ["H7N9 influenza", "SPECIES", 217, 231], ["Middle East respiratory syndrome coronavirus", "SPECIES", 150, 194], ["MERS-CoV", "SPECIES", 196, 204], ["new pathogens", "PROBLEM", 123, 136], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 146, 194], ["H7N9 influenza", "PROBLEM", 217, 231], ["Middle", "ANATOMY_MODIFIER", 150, 156], ["respiratory syndrome", "OBSERVATION", 162, 182]]], ["Over 60% of these emerging pathogens are zoonotic in origin [6] , with their entry into human populations facilitated by both human encroachment into previously uninhabited regions and vector redistribution resulting from habitat loss and climate change [7] .How do we detect infectious diseases?", [["habitat loss", "DISEASE", 222, 234], ["infectious diseases", "DISEASE", 276, 295], ["human", "ORGANISM", 88, 93], ["human", "ORGANISM", 126, 131], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 126, 131], ["vector redistribution", "PROBLEM", 185, 206], ["habitat loss", "PROBLEM", 222, 234], ["infectious diseases", "PROBLEM", 276, 295], ["pathogens", "OBSERVATION", 27, 36], ["zoonotic", "OBSERVATION_MODIFIER", 41, 49], ["encroachment", "OBSERVATION", 132, 144], ["vector redistribution", "OBSERVATION", 185, 206], ["habitat loss", "OBSERVATION", 222, 234], ["infectious", "OBSERVATION", 276, 286]]], ["An introduction to public health laboratory surveillanceOne potential way to improve laboratory surveillance would be to employ molecular methods and analytical algorithms that are pathogen-agnostic.", [["laboratory surveillance", "TEST", 85, 108], ["molecular methods", "TEST", 128, 145], ["analytical algorithms", "TEST", 150, 171], ["pathogen", "PROBLEM", 181, 189]]], ["Metagenomics, the culture-independent sequencing and analysis of all nucleic acids recovered from a sample, has the potential to revolutionize the detection of both known and novel microorganisms.", [["sample", "ANATOMY", 100, 106], ["nucleic acids", "CHEMICAL", 69, 82], ["Metagenomics", "TEST", 0, 12], ["the culture", "TEST", 14, 25], ["analysis", "TEST", 53, 61], ["all nucleic acids", "TEST", 65, 82], ["the detection", "TEST", 143, 156], ["novel microorganisms", "PROBLEM", 175, 195]]], ["Its holistic nature means that instead of performing multiple targeted assays, each looking for a specific pathogen, laboratories can use a single sequencingbased test that is capable of identifying most, if not all, microorganisms in a sample without the need for culture.", [["sample", "ANATOMY", 237, 243], ["multiple targeted assays", "TEST", 53, 77], ["a specific pathogen", "PROBLEM", 96, 115], ["a single sequencingbased test", "TEST", 138, 167], ["microorganisms", "PROBLEM", 217, 231], ["culture", "TEST", 265, 272]]], ["Furthermore, the use of sequencing technology permits the assembly of the complete, or near-complete, genomes of pathogens from a sample.", [["sequencing technology", "TEST", 24, 45], ["a sample", "TEST", 128, 136]]], ["These sequence data can then be used to predict antibiotic resistance phenotypes, to identify virulence genes and to inform enhanced outbreak investigations [8] .How do we detect infectious diseases?", [["infectious diseases", "DISEASE", 179, 198], ["virulence genes", "DNA", 94, 109], ["These sequence data", "TEST", 0, 19], ["antibiotic resistance phenotypes", "PROBLEM", 48, 80], ["infectious diseases", "PROBLEM", 179, 198], ["infectious", "OBSERVATION", 179, 189]]], ["An introduction to public health laboratory surveillanceIn recent years, metagenomics has proven useful in investigating novel species and strains [9] [10] [11] , outbreaks [12, 13] and complex diseases [14, 15] .", [["strains", "PROBLEM", 139, 146], ["complex diseases", "PROBLEM", 186, 202]]], ["As next-generation sequencing technologies improve and costs continue to drop, we anticipate that metagenomic approaches to infectious disease investigations will become increasingly common in public health laboratories, particularly given recent technical improvements that mean that metagenomics can detect pathogens at very low abundance and be can performed directly from clinical samples [16] or even single cells [17] .How do we detect infectious diseases?", [["cells", "ANATOMY", 413, 418], ["infectious disease", "DISEASE", 124, 142], ["infectious diseases", "DISEASE", 442, 461], ["cells", "CELL", 413, 418], ["infectious disease investigations", "TEST", 124, 157], ["pathogens", "PROBLEM", 309, 318], ["infectious diseases", "PROBLEM", 442, 461], ["infectious", "OBSERVATION", 442, 452]]], ["An introduction to public health laboratory surveillanceThis review explores metagenomics approaches from the public health laboratory perspective, beginning with a description of two metagenomics approaches and their utility in pathogen detection.", [["pathogen detection", "TEST", 229, 247]]], ["We then discuss the implementation of metagenomics approaches in the public health setting, covering challenges that still need to be addressed, such as diagnostic sensitivities, computational resources, and ascertainment of causation.How do we detect infectious diseases?", [["infectious diseases", "DISEASE", 252, 271], ["metagenomics approaches", "TREATMENT", 38, 61], ["diagnostic sensitivities", "TEST", 153, 177], ["infectious diseases", "PROBLEM", 252, 271], ["infectious", "OBSERVATION", 252, 262]]], ["Traditional laboratory methods for pathogen detection The traditional paradigm in diagnostic microbiology relies upon tests tailored to etiological agents that are definitively associated with a specific syndrome.", [["pathogen detection", "TEST", 35, 53], ["tests", "TEST", 118, 123], ["etiological agents", "TREATMENT", 136, 154], ["a specific syndrome", "PROBLEM", 193, 212]]], ["Most reference laboratories currently employ a panel of laboratory assays, including culture, microscopy, serology, and PCR.", [["a panel", "TEST", 45, 52], ["laboratory assays", "TEST", 56, 73], ["culture", "TEST", 85, 92], ["microscopy", "TEST", 94, 104], ["serology", "TEST", 106, 114], ["PCR", "TEST", 120, 123]]], ["These tools can be powerful methods for identifying microbes, but only if the respective culture conditions, microscope sensitivity, serologic reagents, and PCR primers are compatible with the microbial target and specimen type.How do we detect infectious diseases?", [["infectious diseases", "DISEASE", 245, 264], ["PCR primers", "DNA", 157, 168], ["the respective culture conditions", "TEST", 74, 107], ["microscope sensitivity", "TEST", 109, 131], ["serologic reagents", "TEST", 133, 151], ["PCR primers", "TEST", 157, 168], ["infectious diseases", "PROBLEM", 245, 264], ["infectious", "OBSERVATION", 245, 255]]], ["An introduction to public health laboratory surveillanceWhen conventional tests fail to identify microbial pathogens in a sample, an enhanced molecular approach can be used in which PCR-based analyses designed to capture a wider array of targets are employed.", [["sample", "ANATOMY", 122, 128], ["conventional tests", "TEST", 61, 79], ["microbial pathogens", "PROBLEM", 97, 116], ["an enhanced molecular approach", "TREATMENT", 130, 160], ["PCR", "TEST", 182, 185]]], ["These include single or multiplexed PCR assays for conserved regions within a species or genus [18, 19] , differentially labeled nucleic acid probes, and direct sequencing of PCR products [20] [21] [22] .", [["nucleic acid", "CHEMICAL", 129, 141], ["nucleic acid", "SIMPLE_CHEMICAL", 129, 141], ["multiplexed PCR assays", "TEST", 24, 46], ["nucleic acid probes", "TEST", 129, 148], ["direct sequencing of PCR products", "TREATMENT", 154, 187]]], ["Computational analyses are used to identify conserved regions in the genomes of known species or genus members; these regions are chosen as primer or probe targets.", [["primer or probe targets", "DNA", 140, 163], ["Computational analyses", "TEST", 0, 22]]], ["In multiplexed assays, regions from multiple targets can be selected to detect the most common pathogens known to be associated with a clinical syndrome.", [["multiplexed assays", "TEST", 3, 21], ["the most common pathogens", "PROBLEM", 79, 104], ["a clinical syndrome", "PROBLEM", 133, 152]]], ["Consensus PCR using degenerate primers has also been used successfully to identify a large variety of bacteria and viruses from various hosts and environments, including the recently emerged MERS-CoV [23] .How do we detect infectious diseases?", [["infectious diseases", "DISEASE", 223, 242], ["MERS-CoV", "ORGANISM", 191, 199], ["MERS-CoV", "SPECIES", 191, 199], ["Consensus PCR", "TEST", 0, 13], ["degenerate primers", "PROBLEM", 20, 38], ["a large variety of bacteria", "PROBLEM", 83, 110], ["viruses", "PROBLEM", 115, 122], ["infectious diseases", "PROBLEM", 223, 242], ["large", "OBSERVATION_MODIFIER", 85, 90], ["variety", "OBSERVATION_MODIFIER", 91, 98], ["bacteria", "OBSERVATION", 102, 110], ["infectious", "OBSERVATION", 223, 233]]], ["Metagenomics approaches for pathogen detection When both conventional and enhanced molecular testing fail to identify a causative agent in a sample, the culture-free, holistic metagenomics approach might provide an answer.", [["pathogen detection", "TEST", 28, 46], ["enhanced molecular testing", "TEST", 74, 100], ["a causative agent", "PROBLEM", 118, 135], ["a sample", "TEST", 139, 147], ["the culture", "TEST", 149, 160], ["holistic metagenomics approach", "TREATMENT", 167, 197]]], ["As with metagenomics studies in human and environmental microbiology [24] [25] [26] , public health metagenomics can take one of two forms.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["metagenomics studies", "TEST", 8, 28]]], ["The first is a targeted strategy called deep amplicon sequencing (DAS), which employs a pre-sequencing PCR amplification step to amplify selectively a taxonomic marker such as a rRNA gene.", [["rRNA", "CELLULAR_COMPONENT", 178, 182], ["rRNA gene", "DNA", 178, 187], ["deep amplicon sequencing", "PROBLEM", 40, 64], ["a pre-sequencing PCR amplification step", "TREATMENT", 86, 125], ["a rRNA gene", "TREATMENT", 176, 187]]], ["The second is a broader strategy known as shotgun metagenomics, in which the total nucleic acid content of a sample is sequenced either directly or after applying an enrichment step, which might be a capture-based approach or subtraction prior to sequencing (Table 1 ).", [["sample", "ANATOMY", 109, 115], ["nucleic acid", "CHEMICAL", 83, 95], ["the total nucleic acid content", "PROBLEM", 73, 103], ["subtraction", "TREATMENT", 226, 237]]], ["There are benefits and disadvantages to both methods, with some groups adopting a parallel approach in which both techniques are applied to a sample of interest [27] .Deep amplicon sequencingWithin a given taxonomic group, certain gene families occur in every known member species.", [["a parallel approach", "TREATMENT", 80, 99], ["Deep amplicon sequencing", "TREATMENT", 167, 191]]], ["The Human Microbiome Project (HMP), along with many environmental microbiome studies investigating various microbial communities, have used PCR primers to target conserved gene families.", [["Human", "ORGANISM", 4, 9], ["PCR primers", "DNA", 140, 151], ["conserved gene families", "DNA", 162, 185], ["Human", "SPECIES", 4, 9], ["PCR primers", "TREATMENT", 140, 151]]], ["By designing PCR primers to amplify regions within these genes, researchers generate PCR products called amplicons.", [["PCR primers", "DNA", 13, 24], ["PCR products", "DNA", 85, 97], ["PCR primers", "TEST", 13, 24], ["PCR products", "TREATMENT", 85, 97]]], ["The DNA sequences of these amplicons are specific to different microbial species, allowing the identification of the various members of the microbial community.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequences", "DNA", 4, 17], ["The DNA sequences", "TEST", 0, 17], ["these amplicons", "PROBLEM", 21, 36], ["different microbial species", "PROBLEM", 53, 80], ["microbial species", "OBSERVATION", 63, 80]]], ["Using next-generation-based 'deep sequencing' , the many different amplicons in a sample can all be sequenced.", [["sample", "ANATOMY", 82, 88], ["next-generation-based 'deep sequencing'", "TREATMENT", 6, 45], ["the many different amplicons", "TREATMENT", 48, 76]]], ["The DAS technique is capable of identifying novel microorganisms, describing the microbiome of a specimen, and quantifying the abundance of various taxa in a sample (Table 1) .Deep amplicon sequencingBacterial DAS strategies typically utilize primers that are specific to conserved genes, such as 16S rRNA, chaperonin-60 (cpn-60; also named heat shock protein-90 (hsp-90) or groEL) [41] , or the RNA polymerase (rpoB) [42] .", [["specimen", "ANATOMY", 97, 105], ["16S", "GENE_OR_GENE_PRODUCT", 297, 300], ["rRNA", "CELLULAR_COMPONENT", 301, 305], ["chaperonin-60", "GENE_OR_GENE_PRODUCT", 307, 320], ["cpn-60", "GENE_OR_GENE_PRODUCT", 322, 328], ["heat shock protein-90", "GENE_OR_GENE_PRODUCT", 341, 362], ["hsp-90", "GENE_OR_GENE_PRODUCT", 364, 370], ["groEL) [41]", "GENE_OR_GENE_PRODUCT", 375, 386], ["conserved genes", "DNA", 272, 287], ["16S rRNA", "DNA", 297, 305], ["chaperonin-60", "DNA", 307, 320], ["cpn-60", "DNA", 322, 328], ["heat shock protein-90", "DNA", 341, 362], ["hsp-90", "DNA", 364, 370], ["groEL", "DNA", 375, 380], ["RNA polymerase (rpoB) [42]", "DNA", 396, 422], ["The DAS technique", "TEST", 0, 17], ["novel microorganisms", "PROBLEM", 44, 64], ["a specimen", "TEST", 95, 105], ["Deep amplicon sequencingBacterial DAS strategies", "TREATMENT", 176, 224], ["primers", "TREATMENT", 243, 250], ["16S rRNA", "TEST", 297, 305], ["chaperonin", "TEST", 307, 317], ["heat shock protein", "TEST", 341, 359], ["hsp", "TEST", 364, 367], ["the RNA polymerase", "TEST", 392, 410]]], ["Similarly, protozoan [43, 44] and fungal [45] DAS studies often target conserved 18S rRNA gene regions.", [["fungal [45] DAS", "SIMPLE_CHEMICAL", 34, 49], ["18S rRNA gene regions", "DNA", 81, 102], ["fungal", "TEST", 34, 40], ["DAS studies", "TEST", 46, 57]]], ["The extraordinary genomic diversity of viruses precludes the amplification of universally conserved genes and the ability to take a complete viral census of a sample; however, primers that are specific to large phylogenetic groups, such as the picorna-like virus superfamily, have enabled largescale viral DAS studies of previously uncharacterized viral populations (Table 1 ) [33] .Deep amplicon sequencingWith respect to pathogen detection, the PCR amplification step inherent in the DAS protocol increases the assay's sensitivity for the microorganisms being targeted, potentially allowing higher resolution and more confident identification of strains or species.", [["picorna-like virus", "ORGANISM", 244, 262], ["universally conserved genes", "DNA", 78, 105], ["picorna-like virus superfamily", "PROTEIN", 244, 274], ["The extraordinary genomic diversity of viruses", "PROBLEM", 0, 46], ["a sample", "TEST", 157, 165], ["the picorna-like virus superfamily", "PROBLEM", 240, 274], ["pathogen detection", "TEST", 423, 441], ["the PCR amplification", "TEST", 443, 464], ["the DAS protocol", "TEST", 482, 498], ["the assay's sensitivity", "TEST", 509, 532], ["the microorganisms", "PROBLEM", 537, 555], ["strains", "PROBLEM", 648, 655], ["species", "PROBLEM", 659, 666], ["extraordinary", "OBSERVATION_MODIFIER", 4, 17], ["genomic", "OBSERVATION_MODIFIER", 18, 25], ["diversity", "OBSERVATION_MODIFIER", 26, 35], ["viruses", "OBSERVATION", 39, 46]]], ["Despite its utility in detecting otherwise unidentifiable organisms, however, potential biases in PCR amplification or variable copy numbers of the targeted genes can cause DAS to generate artificially inflated counts of certain taxa in a sample [46, 47] .", [["targeted genes", "DNA", 148, 162], ["otherwise unidentifiable organisms", "PROBLEM", 33, 67], ["potential biases in PCR amplification", "PROBLEM", 78, 115], ["DAS", "PROBLEM", 173, 176]]], ["Furthermore, the 'universal' primers used in DAS might not be truly universal, potentially causing certain species, or even groups of species, to be missed [48] .", [["the 'universal' primers", "TREATMENT", 13, 36], ["certain species", "PROBLEM", 99, 114]]], ["Thus, DAS can give an inaccurate estimation of the microbial community composition.", [["community", "ANATOMY", 61, 70]]], ["Given that DAS introduces an inherent bias into pathogen detection and requires some a priori knowledge of the potential pathogenic agent of interest in order to select the appropriate gene for amplification, an unbiased sequence-independent shotgun metagenomics approach is better suited to the task of identifying unknown organisms in a sample of interest. \u2022 Characterization of the healthy human gut microbiome (HMP) [28] \u2022 Potentially higher sensitivityDeep amplicon sequencing\u2022 Targeted gene may not be truly universalDeep amplicon sequencing\u2022 Determination of taxonomic relationshipsDeep amplicon sequencing\u2022 Ancient gut microbiomes found to be more similar to modern rural than modern cosmopolitan microbiomes [29] \u2022 Less expensive as fewer reads are required for taxonomic classificationDeep amplicon sequencing\u2022 Primer bias may alter population structureDeep amplicon sequencing\u2022 rpoB \u2022 Archaeal and bacterial identificationSpecific primers need to be made to discriminate between each group.", [["gut microbiome", "ANATOMY", 399, 413], ["gut", "ANATOMY", 623, 626], ["human", "ORGANISM", 393, 398], ["gut", "ORGANISM_SUBDIVISION", 399, 402], ["gut", "ORGANISM_SUBDIVISION", 623, 626], ["rpoB", "DNA", 889, 893], ["human", "SPECIES", 393, 398], ["human", "SPECIES", 393, 398], ["pathogen detection", "TEST", 48, 66], ["an unbiased sequence", "TEST", 209, 229], ["independent shotgun metagenomics approach", "TREATMENT", 230, 271], ["higher sensitivityDeep amplicon sequencing", "PROBLEM", 439, 481], ["Deep amplicon sequencing", "TREATMENT", 523, 547], ["Deep amplicon sequencing", "TREATMENT", 589, 613], ["Deep amplicon sequencing", "TREATMENT", 795, 819], ["Deep amplicon sequencing", "TREATMENT", 863, 887], ["rpoB", "PROBLEM", 889, 893], ["Archaeal and bacterial identificationSpecific primers", "TREATMENT", 896, 949], ["may not be", "UNCERTAINTY", 497, 507], ["taxonomic relationships", "OBSERVATION", 566, 589]]], ["RdRP, RNA-dependent RNA polymerase.MetagenomicsIn contrast to the approach taken by DAS of leveraging conserved gene families across bacteria, fungi, protists or viruses, shotgun metagenomics can potentially catalogue all of the microbes present in a sample, irrespective of their kingdom of origin, by sequencing all the nucleic acid extracted from a specimen.", [["sample", "ANATOMY", 251, 257], ["specimen", "ANATOMY", 352, 360], ["nucleic acid", "CHEMICAL", 322, 334], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 6, 34], ["RdRP, RNA-dependent RNA polymerase", "PROTEIN", 0, 34], ["RdRP", "PROBLEM", 0, 4], ["RNA-dependent RNA polymerase", "PROBLEM", 6, 34], ["MetagenomicsIn contrast", "TREATMENT", 35, 58], ["gene families across bacteria", "PROBLEM", 112, 141], ["fungi", "PROBLEM", 143, 148], ["viruses", "PROBLEM", 162, 169], ["shotgun metagenomics", "PROBLEM", 171, 191], ["the nucleic acid", "TEST", 318, 334], ["a specimen", "TEST", 350, 360], ["dependent", "OBSERVATION_MODIFIER", 10, 19], ["RNA polymerase", "OBSERVATION", 20, 34], ["microbes", "OBSERVATION", 229, 237]]], ["Extracted material is sequenced on a next-generation sequencing platform, and the resulting reads compared to a reference database.", [["Extracted material", "PROBLEM", 0, 18], ["a reference database", "TEST", 110, 130]]], ["These databases are much larger than those used in DAS, as they must contain all known sequences from all organisms rather than a set of sequences from a single gene family.", [["single gene family", "DNA", 154, 172], ["These databases", "TEST", 0, 15], ["larger", "OBSERVATION_MODIFIER", 25, 31]]], ["Although this makes the analytical part of a shotgun study computationally intensive, the advantages over DAS are numerous.", [["a shotgun study", "TEST", 43, 58]]], ["Shotgun methods are less biased and generate data that better reflect the sample's true population structure, as recently shown by the HMP team [39] .", [["HMP", "CHEMICAL", 135, 138], ["Shotgun methods", "TREATMENT", 0, 15]]], ["Furthermore, only shotgun methods can interrogate the accessory genome, that is, the non-core set of genes that often differentiate pathogenic bacteria within a genus or species from closely related commensal strains.", [["strains", "ANATOMY", 209, 216], ["accessory genome", "DNA", 54, 70], ["shotgun methods", "TREATMENT", 18, 33], ["pathogenic bacteria", "PROBLEM", 132, 151], ["a genus or species", "PROBLEM", 159, 177], ["commensal strains", "PROBLEM", 199, 216], ["accessory genome", "OBSERVATION", 54, 70]]], ["For example, Escherichia coli strains K12 and O157:H7 are identical by 16S rRNA DAS analysis, yet the latter strain is considerably more virulent [13] .MetagenomicsShotgun metagenomics studies, which are sometimes followed by Sanger sequencing to generate complete, finished genomes of novel viruses, have identified several novel pathogens from clinical samples (Table 1) [49] [50] [51] [52] [53] [54] [55] .", [["Escherichia coli", "ORGANISM", 13, 29], ["strains K12", "ORGANISM", 30, 41], ["O157:H7", "ORGANISM", 46, 53], ["[49] [50] [51] [52] [53] [54] [55]", "SIMPLE_CHEMICAL", 373, 407], ["Escherichia coli", "SPECIES", 13, 29], ["Escherichia coli", "SPECIES", 13, 29], ["K12", "SPECIES", 38, 41], ["O157:H7", "SPECIES", 46, 53], ["Escherichia coli strains K12", "PROBLEM", 13, 41], ["16S rRNA DAS analysis", "TEST", 71, 92], ["the latter strain", "PROBLEM", 98, 115], ["MetagenomicsShotgun metagenomics studies", "TEST", 152, 192], ["novel viruses", "PROBLEM", 286, 299], ["several novel pathogens", "PROBLEM", 317, 340], ["clinical samples", "TEST", 346, 362], ["Escherichia coli", "OBSERVATION", 13, 29]]], ["A recent notable discovery is the Bas-Congo virus, a rhabdovirus that was associated with a 2009 hemorrhagic fever outbreak in the African Congo [37] .", [["hemorrhagic fever", "DISEASE", 97, 114], ["Bas-Congo virus", "ORGANISM", 34, 49], ["Bas-Congo virus", "SPECIES", 34, 49], ["the Bas-Congo virus", "PROBLEM", 30, 49], ["a rhabdovirus", "PROBLEM", 51, 64], ["a 2009 hemorrhagic fever", "PROBLEM", 90, 114], ["rhabdovirus", "OBSERVATION", 53, 64], ["hemorrhagic", "OBSERVATION_MODIFIER", 97, 108], ["fever", "OBSERVATION", 109, 114]]], ["After metagenome-based detection and subsequent de novo assembly of the full-length virus genome, this novel rhabdovirus was shown to share only 25% amino acid identity with its closest known relative.", [["amino acid", "CHEMICAL", 149, 159], ["amino acid", "CHEMICAL", 149, 159], ["rhabdovirus", "CANCER", 109, 120], ["amino acid", "AMINO_ACID", 149, 159], ["full-length virus genome", "DNA", 72, 96], ["rhabdovirus", "DNA", 109, 120], ["the full-length virus genome", "TREATMENT", 68, 96], ["this novel rhabdovirus", "PROBLEM", 98, 120], ["25% amino acid identity", "PROBLEM", 145, 168]]], ["Other examples of novel pathogens that have been discovered through metagenomics include previously unknown cycloviruses found in the cerebrospinal fluid of patients with paraplegia of unknown etiology [56] and a unique hybrid circo/parvovirus (NIH-CQV) in seronegative hepatitis patients [57] .How does it work?", [["cerebrospinal fluid", "ANATOMY", 134, 153], ["paraplegia", "DISEASE", 171, 181], ["circo/parvovirus", "DISEASE", 227, 243], ["hepatitis", "DISEASE", 270, 279], ["cycloviruses", "CANCER", 108, 120], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 134, 153], ["patients", "ORGANISM", 157, 165], ["parvovirus", "ORGANISM", 233, 243], ["NIH-CQV", "ORGANISM", 245, 252], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 280, 288], ["novel pathogens", "PROBLEM", 18, 33], ["previously unknown cycloviruses", "PROBLEM", 89, 120], ["the cerebrospinal fluid", "TEST", 130, 153], ["paraplegia", "PROBLEM", 171, 181], ["a unique hybrid circo", "TEST", 211, 232], ["parvovirus", "PROBLEM", 233, 243], ["seronegative hepatitis patients", "PROBLEM", 257, 288], ["pathogens", "OBSERVATION", 24, 33], ["cerebrospinal", "ANATOMY", 134, 147], ["fluid", "OBSERVATION", 148, 153], ["paraplegia", "OBSERVATION", 171, 181], ["seronegative hepatitis", "OBSERVATION", 257, 279]]], ["Technical and computational aspects of shotgun metagenomicsGiven the advantages of shotgun metagenomics over DAS for pathogen detection, the former is becoming increasingly prominent in the public health laboratory setting.", [["shotgun metagenomics", "TREATMENT", 39, 59], ["pathogen detection", "TEST", 117, 135], ["increasingly", "OBSERVATION_MODIFIER", 160, 172], ["prominent", "OBSERVATION", 173, 182]]], ["Laboratories must adapt to the new technical challenges presented by this technique, including the preparation of samples and sequencing libraries, sequencing, and bioinformatics analysis.Sample and library preparationAlthough some metagenomics studies opt to sequence all of the nucleic acid extracted from a sample regardless of its origin, others adopt a focused strategy in which only a select population of microorganisms (bacteria or viruses) or a specific nucleic acid population (DNA or RNA) is targeted.", [["nucleic acid", "CHEMICAL", 280, 292], ["nucleic acid", "CHEMICAL", 463, 475], ["DNA", "CELLULAR_COMPONENT", 488, 491], ["sequencing libraries", "TEST", 126, 146], ["sequencing", "TEST", 148, 158], ["bioinformatics analysis", "TEST", 164, 187], ["Sample", "TEST", 188, 194], ["library preparation", "TREATMENT", 199, 218], ["some metagenomics studies", "TEST", 227, 252], ["the nucleic acid", "TEST", 276, 292], ["microorganisms", "PROBLEM", 412, 426], ["bacteria", "PROBLEM", 428, 436], ["viruses", "PROBLEM", 440, 447], ["a specific nucleic acid population (DNA or RNA", "PROBLEM", 452, 498]]], ["In these cases, sample preparation pipelines must be modified to target specifically the group of interest.", [["sample preparation pipelines", "TREATMENT", 16, 44]]], ["In a virus-specific metagenomics study, cellular material is first removed using filtration or centrifugation to maximize the recovery of virions [58, 59] .", [["cellular", "ANATOMY", 40, 48], ["cellular material", "CELL", 40, 57], ["a virus", "PROBLEM", 3, 10], ["specific metagenomics study", "TEST", 11, 38], ["filtration", "TREATMENT", 81, 91], ["centrifugation", "TREATMENT", 95, 109], ["virus", "OBSERVATION", 5, 10]]], ["Enzymatic treatment of the sample with nucleases can further enrich for viral nucleic acids by removing non-viral nucleic acids while viral nucleic acids remain protected within the nucleocapsid (Figure 1 ) [60] .Sample and library preparationA second technical issue is that the microbial fraction of nucleic acid in a clinical sample can be extremely small, as most of the DNA present is often of human origin.", [["sample", "ANATOMY", 27, 33], ["sample", "ANATOMY", 329, 335], ["nucleic acids", "CHEMICAL", 78, 91], ["nucleic acids", "CHEMICAL", 114, 127], ["nucleic acids", "CHEMICAL", 140, 153], ["nucleic acid", "CHEMICAL", 302, 314], ["nucleic acid", "SIMPLE_CHEMICAL", 302, 314], ["DNA", "CELLULAR_COMPONENT", 375, 378], ["human", "ORGANISM", 399, 404], ["nucleases", "PROTEIN", 39, 48], ["human", "SPECIES", 399, 404], ["human", "SPECIES", 399, 404], ["Enzymatic treatment", "TREATMENT", 0, 19], ["nucleases", "TREATMENT", 39, 48], ["viral nucleic acids", "TREATMENT", 72, 91], ["non-viral nucleic acids", "TREATMENT", 104, 127], ["viral nucleic acids", "TEST", 134, 153], ["Sample", "TEST", 213, 219], ["library preparation", "TREATMENT", 224, 243], ["the microbial fraction", "TEST", 276, 298], ["nucleic acid", "PROBLEM", 302, 314], ["the DNA", "PROBLEM", 371, 378], ["nucleic acid", "OBSERVATION", 302, 314], ["small", "OBSERVATION_MODIFIER", 353, 358], ["DNA", "OBSERVATION", 375, 378]]], ["Human DNA can be removed prior to and post-DNA sequencing, using laboratory and bioinformatics methods, respectively.", [["Human", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["Human DNA", "DNA", 0, 9], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human DNA", "TREATMENT", 0, 9], ["post-DNA sequencing", "TEST", 38, 57]]], ["If human DNA is removed using laboratory methods, the small amount of microbial nucleic acid remaining will require newer techniques in sequence library construction to generate usable DNA libraries.", [["nucleic acid", "CHEMICAL", 80, 92], ["human", "ORGANISM", 3, 8], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["human DNA", "DNA", 3, 12], ["DNA libraries", "DNA", 185, 198], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human DNA", "TREATMENT", 3, 12], ["laboratory methods", "TEST", 30, 48], ["microbial nucleic acid remaining", "PROBLEM", 70, 102], ["newer techniques", "TREATMENT", 116, 132], ["sequence library construction", "TREATMENT", 136, 165], ["small", "OBSERVATION_MODIFIER", 54, 59], ["amount", "OBSERVATION_MODIFIER", 60, 66]]], ["Library preparation kits such as Nextera XT (Illumina, San Diego, CA, USA) now require just one nanogram of input DNA.", [["DNA", "CELLULAR_COMPONENT", 114, 117], ["Library preparation kits", "TREATMENT", 0, 24]]], ["Nextera XT was recently used in a metagenomics characterization of the pathogen in the 2011 German Shiga-Toxigenic E. coli outbreak [12] .", [["Shiga", "CHEMICAL", 99, 104], ["E. coli", "ORGANISM", 115, 122], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 115, 122], ["Nextera XT", "TREATMENT", 0, 10], ["the pathogen", "PROBLEM", 67, 79], ["Toxigenic E. coli outbreak", "PROBLEM", 105, 131], ["E. coli", "OBSERVATION_MODIFIER", 115, 122]]], ["To further aid in the detection of microorganisms in samples with very low levels of nucleic acid, or nucleic acid present at very low concentrations, higher sequencing depth might also be necessary to uncover rare sequences [61] .Sample and library preparationOther laboratory protocols can be implemented to sequence directly from a clinical sample with low nucleic acid concentration, including random PCR as well as multiple displacement amplification (MDA).", [["samples", "ANATOMY", 53, 60], ["nucleic acid", "CHEMICAL", 85, 97], ["nucleic acid", "CHEMICAL", 102, 114], ["nucleic acid", "CHEMICAL", 360, 372], ["nucleic acid", "SIMPLE_CHEMICAL", 85, 97], ["nucleic acid", "SIMPLE_CHEMICAL", 102, 114], ["nucleic acid", "SIMPLE_CHEMICAL", 360, 372], ["microorganisms in samples", "PROBLEM", 35, 60], ["very low levels of nucleic acid", "PROBLEM", 66, 97], ["nucleic acid", "TEST", 102, 114], ["very low concentrations", "PROBLEM", 126, 149], ["a clinical sample", "TEST", 333, 350], ["low nucleic acid concentration", "TREATMENT", 356, 386], ["random PCR", "TEST", 398, 408], ["multiple displacement amplification (MDA)", "TREATMENT", 420, 461]]], ["A recent example by McLean et al. [17] coupled fluorescenceactivated cell sorting (FACS) and MDA for single-cell genomic analyses of microbial communities in the biofilm from a hospital sink.", [["cell", "ANATOMY", 69, 73], ["communities", "ANATOMY", 143, 154], ["biofilm", "ANATOMY", 162, 169], ["MDA", "CHEMICAL", 93, 96], ["MDA", "CHEMICAL", 93, 96], ["fluorescenceactivated cell", "CELL", 47, 73], ["MDA", "SIMPLE_CHEMICAL", 93, 96], ["MDA", "TEST", 93, 96], ["microbial communities", "OBSERVATION", 133, 154]]], ["The incorporation of MDA also avoids the introduction of mutations in the single cell approach, which may result from culturing the individually sorted bacterial cells [62] [63] [64] .DNA sequencingFollowing nucleic acid extraction and library preparation (Figure 1 ), DNA sequencing is performed.", [["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 162, 167], ["MDA", "CHEMICAL", 21, 24], ["nucleic acid", "CHEMICAL", 208, 220], ["MDA", "CHEMICAL", 21, 24], ["MDA", "SIMPLE_CHEMICAL", 21, 24], ["cell", "CELL", 81, 85], ["cells", "CELL", 162, 167], ["nucleic acid", "SIMPLE_CHEMICAL", 208, 220], ["DNA", "CELLULAR_COMPONENT", 269, 272], ["mutations", "PROBLEM", 57, 66], ["the single cell approach", "TREATMENT", 70, 94], ["culturing", "TEST", 118, 127], ["bacterial cells", "TEST", 152, 167], ["nucleic acid extraction", "TREATMENT", 208, 231], ["library preparation", "TREATMENT", 236, 255], ["DNA sequencing", "TEST", 269, 283]]], ["Multiple next-generation sequencing platforms are available ( platform is dependent on the sample being sequenced, the questions being asked, and the laboratory's budget and capacity.", [["Multiple next-generation sequencing platforms", "TEST", 0, 45]]], ["An increasing number of public health laboratories are acquiring their own 'bench-top' sequencing machines, such as the Illumina MiSeq and Ion Torrent PGM, which are small, affordable and ideally suited for microbial work, but other laboratories outsource samples to a larger sequencing center.BioinformaticsFollowing sequencing, the hundreds of thousands to millions of short reads generated must be computationally transformed into meaningful data reflective of the presence and abundance of the microbes of interest.", [["Illumina MiSeq", "DNA", 120, 134], ["top' sequencing machines", "TREATMENT", 82, 106], ["the Illumina MiSeq", "TREATMENT", 116, 134], ["Ion Torrent PGM", "TREATMENT", 139, 154], ["sequencing", "TEST", 318, 328], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["small", "OBSERVATION_MODIFIER", 166, 171]]], ["Bioinformatics analysis is often performed using a staged approach, as outlined in Figure 1 .", [["Bioinformatics analysis", "TEST", 0, 23], ["a staged approach", "TREATMENT", 49, 66]]], ["A public health laboratory working in metagenomics must have sufficient computational power and analytic expertise to execute these steps, which may require hiring an experienced bioinformatician to design an in-house data analysis pipeline.BioinformaticsComputational pipelines typically begin with the removal of sequencing library adapters and filtering of low-quality sequences, although this step is sometimes handled by software embedded in the DNA sequencer itself.", [["DNA", "CELLULAR_COMPONENT", 451, 454], ["the removal of sequencing library adapters", "TREATMENT", 300, 342], ["filtering of low-quality sequences", "TREATMENT", 347, 381]]], ["For clinical samples of human origin, in which human-derived sequence reads comprise the majority of data generated by the sequencer, it is necessary to remove the human reads, often by comparing all of the reads to a human reference genome and discarding those that map to the human genome [68, 69] .BioinformaticsReads that remain after filtering can then be directly compared to microbial reference sequence databases or assembled de novo into larger clusters of contiguous sequence reads (contigs), which are then compared to reference sequence databases.", [["samples", "ANATOMY", 13, 20], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 47, 52], ["human", "ORGANISM", 164, 169], ["human", "ORGANISM", 218, 223], ["human", "ORGANISM", 278, 283], ["human-derived sequence reads", "DNA", 47, 75], ["human reference genome", "DNA", 218, 240], ["human genome", "DNA", 278, 290], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 278, 283], ["microbial reference sequence databases", "TEST", 382, 420], ["human origin", "OBSERVATION_MODIFIER", 24, 36]]], ["First, individual reads are compared to a reference database in order to assign as many reads as possible to their species, genus, or phylum of origin.", [["origin", "ANATOMY_MODIFIER", 144, 150]]], ["The database used for reference-based assembly, as well as the parameters used to call a match, must be chosen carefully because they have a large impact on the assembly generated and on the time taken to generate it.", [["large", "OBSERVATION_MODIFIER", 141, 146]]], ["Large databases increase the chance of finding a match but significantly increase the analysis time.", [["Large databases", "PROBLEM", 0, 15], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["Similarly, more permissive parameters might enable the identification of species that are divergent from the reference organism, but may also lead to incorrect taxonomic assignments.", [["species", "PROBLEM", 73, 80], ["more permissive", "OBSERVATION_MODIFIER", 11, 26]]], ["Thus, reference-based assembly can also be performed in stages, with increasing database size and decreasing stringency.BioinformaticsNext, remaining reads that did not map to any microbial sequence can be assembled de novo, often using specific algorithms that have been developed for metagenomic assemblies [70] .", [["increasing database size", "PROBLEM", 69, 93], ["decreasing stringency", "PROBLEM", 98, 119], ["metagenomic assemblies", "PROBLEM", 286, 308], ["size", "OBSERVATION_MODIFIER", 89, 93], ["decreasing", "OBSERVATION_MODIFIER", 98, 108], ["stringency", "OBSERVATION", 109, 119]]], ["For taxonomic assignment of the contigs generated, algorithms that are capable of identifying more distant taxonomic matches must be used [71] .", [["algorithms", "TEST", 51, 61]]], ["Alternatively, a strategy to identify novel sequence reads by using paired-end information to increase iteratively the size of contigs of known classification has recently been developed and successfully implemented to identify two novel arenaviruses in snakes [72] .What can it do?", [["arenaviruses", "DISEASE", 238, 250], ["arenaviruses", "ORGANISM", 238, 250], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["Applications of metagenomics in public health infectious disease surveillanceCurrently, public health infectious disease surveillance requires a priori knowledge of the pathogen of interest, in that there must be a validated test for the pathogen, and it must be included in the laboratory's test portfolio.", [["infectious disease", "DISEASE", 46, 64], ["infectious disease", "DISEASE", 102, 120], ["a validated test", "TEST", 213, 229], ["the pathogen", "PROBLEM", 234, 246]]], ["This approach often cannot detect the emergence of completely novel pathogens or pathogens that are not known to be present in a given region.", [["completely novel pathogens", "PROBLEM", 51, 77], ["pathogens", "PROBLEM", 81, 90], ["pathogens", "OBSERVATION", 68, 77]]], ["When such an unknown or unusual infectious disease syndrome is encountered, patient specimens will be serially tested against a list of known and suspected pathogens ( Figure 2 ).", [["specimens", "ANATOMY", 84, 93], ["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["unusual infectious disease syndrome", "PROBLEM", 24, 59], ["patient specimens", "TEST", 76, 93], ["infectious", "OBSERVATION_MODIFIER", 32, 42]]], ["Nevertheless, conventional laboratory testing might remain negative even after multiple samples are collected and multiple tests are conducted.", [["samples", "ANATOMY", 88, 95], ["conventional laboratory testing", "TEST", 14, 45], ["multiple samples", "TEST", 79, 95], ["multiple tests", "TEST", 114, 128]]], ["It is at this point that an investigational pathogen-agnostic method such as metagenomics should be deployed, with the results helping both to uncover unknown etiological agents and to inform the development of new laboratory diagnostic tests or the testing of algorithms to detect future instances of the pathogen in question.What can it do?", [["new laboratory diagnostic tests", "TEST", 211, 242], ["the testing of algorithms", "TEST", 246, 271], ["the pathogen", "PROBLEM", 302, 314]]], ["Applications of metagenomics in public health infectious disease surveillanceThere are several examples of instances in which a metagenomic approach was able to detect pathogens missed by traditional techniques (Table 3 ).", [["infectious disease", "DISEASE", 46, 64], ["a metagenomic approach", "TREATMENT", 126, 148], ["pathogens", "PROBLEM", 168, 177]]], ["These include scenarios in which the pathogen was present at very low levels in the sample [73] , where the suspected pathogen was not the true cause and was not detected by the tests used [12, 53, 73] , and where the causal agent was either a distantly related variant of the suspect pathogen or an (See figure on previous page.)", [["the suspected pathogen", "PROBLEM", 104, 126], ["the tests", "TEST", 174, 183], ["pathogen", "PROBLEM", 285, 293], ["pathogen", "OBSERVATION", 118, 126]]], ["Figure 1 Workflow outlining a pipeline of laboratory and bioinformatics methods required for metagenomic pathogen detection.", [["bioinformatics methods", "TEST", 57, 79], ["metagenomic pathogen detection", "TEST", 93, 123]]], ["The left side (pale blue) lists each step in the metagenomics workflow and the right side lists the tools used for each stage.", [["left side", "ANATOMY", 4, 13], ["left", "ANATOMY_MODIFIER", 4, 8], ["right", "ANATOMY_MODIFIER", 79, 84]]], ["Boxes on the right are color-coded to indicate the type of tool used: dark blue, laboratory method; gray, data format; green, computer software; maroon, database.", [["dark blue", "PROBLEM", 70, 79], ["laboratory method", "TEST", 81, 98], ["data format", "TEST", 106, 117], ["right", "ANATOMY_MODIFIER", 13, 18]]], ["BWA, Burrows-Wheeler Aligner; BLAST, Basic Local Alignment Search Tool; IMG, integrated microbial genomics; MG-RAST, Metagenomics Rapid Annotation Server.What can it do?", [["MG", "TEST", 108, 110]]], ["Applications of metagenomics in public health infectious disease surveillanceentirely new species [9] [10] [11] .", [["infectious disease", "DISEASE", 46, 64], ["new species", "PROBLEM", 86, 97]]], ["For example, metagenomics was able to detect pathogens that were missed because of each of the above reasons in a study of condyloma samples that were negative for human papillomavirus (HPV) by PCR.", [["condyloma samples", "ANATOMY", 123, 140], ["human papillomavirus (HPV)", "DISEASE", 164, 190], ["condyloma samples", "CANCER", 123, 140], ["human", "ORGANISM", 164, 169], ["papillomavirus", "ORGANISM", 170, 184], ["HPV", "ORGANISM", 186, 189], ["human", "SPECIES", 164, 169], ["human papillomavirus", "SPECIES", 164, 184], ["HPV", "SPECIES", 186, 189], ["metagenomics", "PROBLEM", 13, 25], ["pathogens", "PROBLEM", 45, 54], ["a study", "TEST", 112, 119], ["condyloma samples", "TEST", 123, 140], ["human papillomavirus", "PROBLEM", 164, 184], ["PCR", "TEST", 194, 197], ["condyloma", "OBSERVATION", 123, 132]]], ["Metagenomics detected both HPV type 6 and putative novel HPV types, as well as the molluscum contagiosum virus (MCV), all of which would have gone undetected using conventional techniques [73] .", [["molluscum contagiosum", "DISEASE", 83, 104], ["HPV", "ORGANISM", 57, 60], ["molluscum contagiosum virus", "ORGANISM", 83, 110], ["molluscum contagiosum virus", "SPECIES", 83, 110], ["molluscum contagiosum virus", "SPECIES", 83, 110], ["MCV", "SPECIES", 112, 115], ["Metagenomics", "TEST", 0, 12], ["putative novel HPV types", "PROBLEM", 42, 66], ["the molluscum contagiosum virus", "PROBLEM", 79, 110], ["MCV", "TEST", 112, 115]]], ["Beyond pathogen detection, many shotgun metagenomics studies have successfully generated complete or nearly complete pathogen genome assemblies from a sample [16, 17, 40] , allowing a comprehensive characterization of the microbe in question at multiple levels.", [["pathogen detection", "TEST", 7, 25], ["many shotgun metagenomics studies", "TEST", 27, 60], ["a comprehensive characterization", "TEST", 182, 214]]], ["Such assemblies might allow prediction of the microbial phenotype, as indicated by the presence or absence of antimicrobial resistance or virulence genes.", [["virulence genes", "DNA", 138, 153], ["antimicrobial resistance or virulence genes", "PROBLEM", 110, 153], ["antimicrobial resistance", "OBSERVATION", 110, 134]]], ["They can also be used to calculate the microbial genotype by using in silico techniques in concert with epidemiological information to identify person-to-person transmission events and outbreak or epidemic dynamics [74, 79] .", [["person", "SPECIES", 144, 150]]], ["In the case of functional profiling, metagenomics offers the significant advantage of replacing multiple tests with a single analysis (Figure 2 ), although it must be noted that it is not always possible to detect which species within a metagenome a particular gene comes from [78] .What can it do?", [["multiple tests", "TEST", 96, 110], ["a single analysis", "TEST", 116, 133]]], ["Applications of metagenomics in public health infectious disease surveillanceRather than a single etiological agent, a particular combination of species within an individual can sometimes cause a disease.", [["infectious disease", "DISEASE", 46, 64], ["species", "PROBLEM", 145, 152], ["a disease", "PROBLEM", 194, 203], ["disease", "OBSERVATION", 196, 203]]], ["Through a mixture of DAS and shotgun metagenomics, the HMP has characterized the healthy microbiomes of 242 individuals, collecting microbial nucleic acids from 18 body habitats from five sites (oral, nasal, skin, gut, and urogenital) [81] .", [["body habitats", "ANATOMY", 164, 177], ["sites", "ANATOMY", 188, 193], ["oral", "ANATOMY", 195, 199], ["nasal", "ANATOMY", 201, 206], ["skin", "ANATOMY", 208, 212], ["gut", "ANATOMY", 214, 217], ["urogenital", "ANATOMY", 223, 233], ["HMP", "CHEMICAL", 55, 58], ["nucleic acids", "CHEMICAL", 142, 155], ["HMP", "CHEMICAL", 55, 58], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["oral", "ORGANISM_SUBDIVISION", 195, 199], ["nasal", "ORGANISM_SUBDIVISION", 201, 206], ["skin", "ORGAN", 208, 212], ["gut", "ORGANISM_SUBDIVISION", 214, 217], ["urogenital", "ORGAN", 223, 233], ["collecting microbial nucleic acids", "TEST", 121, 155], ["nasal", "ANATOMY", 201, 206], ["skin", "ANATOMY", 208, 212], ["gut", "ANATOMY", 214, 217], ["urogenital", "ANATOMY", 223, 233]]], ["By comparing the microbial diversity of these sites across individuals, the HMP demonstrated that the healthy human microbiome differs significantly in taxonomic composition between individuals and between body sites, while the microbial metabolic pathways at each site remain stable [28, 82] .", [["body sites", "ANATOMY", 206, 216], ["HMP", "CHEMICAL", 76, 79], ["human", "ORGANISM", 110, 115], ["body sites", "MULTI-TISSUE_STRUCTURE", 206, 216], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["stable", "OBSERVATION_MODIFIER", 277, 283]]], ["Through a public-health lens, metagenomics thus provides the opportunity to compare taxonomic and functional differences between the microbes present in healthy individuals and those with a range of conditions, from acute infections to chronic diseases of both known and unknown etiology.What can it do?", [["infections", "DISEASE", 222, 232], ["chronic diseases", "DISEASE", 236, 252], ["acute infections", "PROBLEM", 216, 232], ["chronic diseases", "PROBLEM", 236, 252], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["infections", "OBSERVATION", 222, 232], ["chronic", "OBSERVATION_MODIFIER", 236, 243], ["diseases", "OBSERVATION", 244, 252]]], ["Applications of metagenomics in public health infectious disease surveillanceMetagenomic studies employing a case-control association discovery approach have identified associations between inflammatory bowel disease and Enterobacteriaceae [83] , colorectal carcinoma and Fusobacterium [35] , and type 2 diabetes and butyrate-producing bacteria [14, 84] .", [["bowel", "ANATOMY", 203, 208], ["colorectal carcinoma", "ANATOMY", 247, 267], ["infectious disease", "DISEASE", 46, 64], ["inflammatory bowel disease", "DISEASE", 190, 216], ["colorectal carcinoma", "DISEASE", 247, 267], ["type 2 diabetes", "DISEASE", 297, 312], ["butyrate", "CHEMICAL", 317, 325], ["butyrate", "CHEMICAL", 317, 325], ["bowel", "ORGAN", 203, 208], ["colorectal carcinoma", "CANCER", 247, 267], ["butyrate", "SIMPLE_CHEMICAL", 317, 325], ["Metagenomic studies", "TEST", 77, 96], ["inflammatory bowel disease", "PROBLEM", 190, 216], ["Enterobacteriaceae", "PROBLEM", 221, 239], ["colorectal carcinoma", "PROBLEM", 247, 267], ["Fusobacterium", "PROBLEM", 272, 285], ["type 2 diabetes", "PROBLEM", 297, 312], ["butyrate-producing bacteria", "PROBLEM", 317, 344], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["bowel", "ANATOMY", 203, 208], ["disease", "OBSERVATION", 209, 216], ["colorectal", "ANATOMY", 247, 257], ["carcinoma", "OBSERVATION", 258, 267]]], ["However, this study design requires careful matching of characteristics, including age, gender, ethnicity and underlying co-morbidities across cases and controls, and any associations identified must be verified in additional samples.", [["this study", "TEST", 9, 19], ["underlying co-morbidities across cases and controls", "PROBLEM", 110, 161]]], ["Two recent studies investigating metagenomic associations with type 2 diabetes highlight such difficulties.", [["type 2 diabetes", "DISEASE", 63, 78], ["Two recent studies", "TEST", 0, 18], ["type 2 diabetes", "PROBLEM", 63, 78], ["such difficulties", "PROBLEM", 89, 106]]], ["The studies used two populations, one of mixed gender from China and the other of elderly European females.", [["The studies", "TEST", 0, 11]]], ["Although both populations demonstrated an association between butyrateproducing bacteria and type 2 diabetes, other discriminatory characteristics differed between the two groups; when the classification generated from one sample set was used on the other, its predictive power was much reduced [14, 84, 85] .What can it do?", [["type 2 diabetes", "DISEASE", 93, 108], ["butyrateproducing bacteria", "PROBLEM", 62, 88], ["type 2 diabetes", "PROBLEM", 93, 108], ["diabetes", "OBSERVATION", 100, 108]]], ["Applications of metagenomics in public health infectious disease surveillanceDespite these difficulties, association studies provide valuable information about the nature of dysbiotic microbiomes, that is, the disruption in the membership or functional capacity of the healthy microbiome [80] .", [["infectious disease", "DISEASE", 46, 64], ["these difficulties", "PROBLEM", 85, 103], ["association studies", "TEST", 105, 124], ["dysbiotic microbiomes", "PROBLEM", 174, 195], ["the disruption", "PROBLEM", 206, 220]]], ["This altered state could result from a pathogenic species changing the abundance and distribution of other microbial community members, or could be caused by iatrogenic interventions such as antibiotic treatment.", [["a pathogenic species", "PROBLEM", 37, 57], ["iatrogenic interventions", "TREATMENT", 158, 182], ["antibiotic treatment", "TREATMENT", 191, 211], ["pathogenic species", "OBSERVATION", 39, 57], ["abundance", "OBSERVATION_MODIFIER", 71, 80], ["distribution", "OBSERVATION_MODIFIER", 85, 97], ["iatrogenic", "OBSERVATION", 158, 168]]], ["Understanding dysbiosis and its role in disease opens the door to the development of alternative forms of treatment, such as probiotics and stool transplants [82] , which have been effective in treating Clostridium difficile infections [86] .What can it do?", [["Clostridium difficile infections", "DISEASE", 203, 235], ["Clostridium difficile", "ORGANISM", 203, 224], ["Clostridium difficile", "SPECIES", 203, 224], ["Clostridium difficile", "SPECIES", 203, 224], ["Understanding dysbiosis", "PROBLEM", 0, 23], ["disease", "PROBLEM", 40, 47], ["treatment", "TREATMENT", 106, 115], ["probiotics", "TREATMENT", 125, 135], ["stool transplants", "TREATMENT", 140, 157], ["Clostridium difficile infections", "PROBLEM", 203, 235], ["dysbiosis", "OBSERVATION", 14, 23]]], ["Applications of metagenomics in public health infectious disease surveillanceBeyond profiling of bacterial and viral microbiomes, the fungal component of the human microbiome, the 'mycobiome' , is an emerging field.", [["mycobiome", "ANATOMY", 181, 190], ["infectious disease", "DISEASE", 46, 64], ["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["bacterial and viral microbiomes", "PROBLEM", 97, 128], ["the 'mycobiome'", "TREATMENT", 176, 191], ["bacterial", "OBSERVATION_MODIFIER", 97, 106], ["viral microbiomes", "OBSERVATION", 111, 128], ["fungal", "OBSERVATION_MODIFIER", 134, 140]]], ["Akin to early bacteriological DAS studies, only culturable fungal species associated with illnesses have been studied in detail.", [["early bacteriological DAS studies", "TEST", 8, 41], ["culturable fungal species", "PROBLEM", 48, 73], ["illnesses", "PROBLEM", 90, 99], ["fungal species", "OBSERVATION", 59, 73]]], ["Recently, targeted DAS of 18S rRNA revealed that the species diversity of the endogenous fungal community is richer than previously assumed [87] .", [["18S", "GENE_OR_GENE_PRODUCT", 26, 29], ["rRNA", "CELLULAR_COMPONENT", 30, 34], ["18S rRNA", "DNA", 26, 34], ["18S rRNA", "TEST", 26, 34], ["the species diversity", "PROBLEM", 49, 70], ["species", "OBSERVATION_MODIFIER", 53, 60], ["diversity", "OBSERVATION_MODIFIER", 61, 70], ["endogenous", "OBSERVATION_MODIFIER", 78, 88], ["fungal", "OBSERVATION_MODIFIER", 89, 95]]], ["Furthermore, the mycobiome is not unique to humans: diverse fungal populations have also been recovered from a variety of mammals [45] .", [["humans", "ORGANISM", 44, 50], ["fungal populations", "CELL", 60, 78], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["diverse fungal populations", "PROBLEM", 52, 78]]], ["The impact that the mycobiome has on human health and disease is currently unknown, and additional investigations using metagenomics approaches are required to further characterize the mycobiome and its potential public health impacts.", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["disease", "PROBLEM", 54, 61], ["metagenomics approaches", "TREATMENT", 120, 143]]], ["Currently, specimens are sent for conventional laboratory tests.", [["specimens", "ANATOMY", 11, 20], ["specimens", "CANCER", 11, 20], ["specimens", "TEST", 11, 20], ["conventional laboratory tests", "TEST", 34, 63]]], ["If one of these tests is positive (dashed arrows), then an actionable result is generated.", [["these tests", "TEST", 10, 21]]], ["With advances in metagenomics, these methods may be performed earlier in the diagnostic algorithm in the future (black arrows) instead of following multiple traditional laboratory tests.What can it do?", [["these methods", "TEST", 31, 44], ["the diagnostic algorithm", "TEST", 73, 97], ["multiple traditional laboratory tests", "TEST", 148, 185]]], ["Applications of metagenomics in public health infectious disease surveillanceIn addition to identifying unknown or novel pathogens and characterization of normal and disease-associated microbial communities, metagenomics can also be advantageous in the characterization of the microbiomes of environments that are relevant to public health, such as hospitals and healthcare facilities.", [["communities", "ANATOMY", 195, 206], ["infectious disease", "DISEASE", 46, 64], ["novel pathogens", "PROBLEM", 115, 130], ["normal", "OBSERVATION", 155, 161]]], ["Previous nonmetagenomic studies have looked for the presence of specific pathogens in healthcare environments [88, 89] , but metagenomic profiling of these environments allows the simultaneous detection of multiple pathogens.", [["Previous nonmetagenomic studies", "TEST", 0, 31], ["multiple pathogens", "PROBLEM", 206, 224], ["multiple", "OBSERVATION_MODIFIER", 206, 214], ["pathogens", "OBSERVATION", 215, 224]]], ["For example, a single metagenomics study was able to identify 78 candidate species from a biofilm in a hospital sink [17] , including the identification of a new bacterial phylum [90] .", [["biofilm", "ANATOMY", 90, 97], ["a single metagenomics study", "TEST", 13, 40], ["a new bacterial phylum", "PROBLEM", 156, 178], ["new", "OBSERVATION_MODIFIER", 158, 161], ["bacterial phylum", "OBSERVATION", 162, 178]]], ["This is the focus of the recent Hospital Microbiome Project [91] , which aims to investigate interactions between the microbiomes of patients and their surrounding hospital environment.What can it do?", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141]]], ["Applications of metagenomics in public health infectious disease surveillanceWhat stands in our way?", [["infectious disease", "DISEASE", 46, 64]]], ["A recent study using metagenomics to investigate diarrhea samples that were positive for Shiga-Toxigenic E. coli showed a sensitivity of only 67% compared to culture [12, 78] , implying that further advances are necessary if metagenomics is to replace traditional culture-based and molecular diagnostics.", [["samples", "ANATOMY", 58, 65], ["diarrhea", "DISEASE", 49, 57], ["Shiga-Toxigenic E. coli", "ORGANISM", 89, 112], ["E. coli", "SPECIES", 105, 112], ["E. coli", "SPECIES", 105, 112], ["A recent study", "TEST", 0, 14], ["diarrhea samples", "PROBLEM", 49, 65], ["Shiga", "PROBLEM", 89, 94], ["Toxigenic E. coli", "TEST", 95, 112], ["a sensitivity", "TEST", 120, 133], ["culture", "TEST", 158, 165], ["traditional culture", "TEST", 252, 271], ["molecular diagnostics", "TEST", 282, 303]]], ["However, the same study demonstrated metagenomics' utility in identifying 'unknown unknowns' , with the authors able to identify co-infections that were not detected by conventional testing.What can it do?", [["the same study", "TEST", 9, 23], ["co-infections", "PROBLEM", 129, 142], ["conventional testing", "TEST", 169, 189]]], ["Applications of metagenomics in public health infectious disease surveillanceAt the moment, metagenomics has proven most useful in the detection of novel microorganisms.", [["infectious disease", "DISEASE", 46, 64], ["novel microorganisms", "PROBLEM", 148, 168]]], ["Discovering a novel pathogen or an unusual collection of microorganisms within a clinical sample is, however, merely the first step in the process of determining its role in a disease.", [["a novel pathogen", "PROBLEM", 12, 28], ["an unusual collection of microorganisms", "PROBLEM", 32, 71], ["a disease", "PROBLEM", 174, 183], ["unusual", "OBSERVATION_MODIFIER", 35, 42], ["collection", "OBSERVATION", 43, 53], ["microorganisms", "OBSERVATION_MODIFIER", 57, 71], ["disease", "OBSERVATION", 176, 183]]], ["The identification of a microbial species through its genome alone does not establish causation.", [["a microbial species", "PROBLEM", 22, 41], ["microbial species", "OBSERVATION", 24, 41]]], ["In fact, many of the pathogens that have been discovered through this approach fail to meet Koch's postulates for causality as it is sometimes not possible to culture the pathogen or to identify a suitable animal model for further studies [99] .", [["the pathogens", "PROBLEM", 17, 30], ["the pathogen", "PROBLEM", 167, 179], ["further studies", "TEST", 223, 238], ["pathogens", "OBSERVATION", 21, 30]]], ["After the introduction of PCR-and DNA-based identification methods, Fredericks and Relman [99] suggested modified postulates, but even these might not be adequate for recognizing complex diseases in which a combination of multiple It is now possible to perform metagenomic studies from a single cell [16, 73, 78] Biases in culturing and other methods may point to the wrong pathogenWhat can it do?", [["cell", "ANATOMY", 295, 299], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["cell", "CELL", 295, 299], ["PCR", "TEST", 26, 29], ["DNA", "TEST", 34, 37], ["recognizing complex diseases", "PROBLEM", 167, 195], ["metagenomic studies", "TEST", 261, 280], ["Biases in culturing", "TEST", 313, 332], ["other methods", "TREATMENT", 337, 350], ["the wrong pathogen", "PROBLEM", 364, 382], ["diseases", "OBSERVATION", 187, 195]]], ["Applications of metagenomics in public health infectious disease surveillanceGenomes have been assembled from organisms with relative nucleic acid abundances as low as 0.1%Identification of novel or variant pathogensEarly identification of novel pathogens is vital to prevent potential outbreaksIdentification of novel or variant pathogensMay not identify pathogens that are unknown or too divergent from known organismsIdentification of novel or variant pathogensDe novo assembly allows generation of genome sequences from novel pathogens [9] [10] [11] Detection of transmission [79, 80] microorganisms and/or environmental factors are required to cause disease.", [["infectious disease", "DISEASE", 46, 64], ["nucleic acid", "CHEMICAL", 134, 146], ["genome sequences", "DNA", 502, 518], ["relative nucleic acid abundances", "PROBLEM", 125, 157], ["variant pathogens", "PROBLEM", 199, 216], ["novel pathogens", "PROBLEM", 240, 255], ["variant pathogens", "PROBLEM", 322, 339], ["pathogens", "PROBLEM", 356, 365], ["known organisms", "PROBLEM", 405, 420], ["variant pathogens", "PROBLEM", 447, 464], ["genome sequences", "TEST", 502, 518], ["novel pathogens", "TEST", 524, 539], ["Detection of transmission", "TEST", 554, 579], ["microorganisms", "PROBLEM", 589, 603], ["environmental factors", "PROBLEM", 611, 632], ["disease", "PROBLEM", 655, 662], ["pathogens", "OBSERVATION_MODIFIER", 455, 464]]], ["More recently, a set of postulates that are applicable to metagenomics has been suggested [96] ; but even these require inoculation into a host, which may not be possible for all pathogens.Identification of novel or variant pathogensOther evidence, such as serological and epidemiological analyses, or the ability to stop the disease with microorganism-specific drugs or antibodies, have also been used to address difficulties in meeting Koch's postulates [11, 75, 100] .", [["antibodies", "PROTEIN", 371, 381], ["all pathogens", "PROBLEM", 175, 188], ["variant pathogens", "PROBLEM", 216, 233], ["serological and epidemiological analyses", "TEST", 257, 297], ["the disease", "PROBLEM", 322, 333], ["microorganism", "PROBLEM", 339, 352], ["specific drugs", "TREATMENT", 353, 367], ["antibodies", "TREATMENT", 371, 381], ["may not be possible", "UNCERTAINTY", 151, 170], ["pathogens", "OBSERVATION_MODIFIER", 224, 233]]], ["For ubiquitous viruses (for example, Epstein-Barr virus, human herpes virus 6 and torque teno virus) or for diseases for which additional variables such as host genetics and environmental factors play a significant role, however, proof of causality can be exceedingly difficult [14, 15] .", [["Epstein-Barr virus", "ORGANISM", 37, 55], ["human herpes virus 6", "ORGANISM", 57, 77], ["torque teno virus", "ORGANISM", 82, 99], ["human", "SPECIES", 57, 62], ["herpes virus", "SPECIES", 63, 75], ["Epstein-Barr virus", "SPECIES", 37, 55], ["human herpes virus", "SPECIES", 57, 75], ["torque teno virus", "SPECIES", 82, 99], ["ubiquitous viruses", "PROBLEM", 4, 22], ["Epstein-Barr virus", "PROBLEM", 37, 55], ["human herpes virus", "PROBLEM", 57, 75], ["torque teno virus", "PROBLEM", 82, 99], ["diseases", "PROBLEM", 108, 116], ["viruses", "OBSERVATION", 15, 22]]], ["In such circumstances, care must be taken not to create spurious links between infectious agents and disease, since such false associations could lead to potentially dangerous treatments and might be harder to disprove than to generate initially [75] .", [["infectious agents", "TREATMENT", 79, 96], ["disease", "PROBLEM", 101, 108], ["dangerous treatments", "TREATMENT", 166, 186]]], ["For other complex diseases with a polymicrobial etiology, metagenomics can provide a foundation for more targeted quantitative analyses on larger cohorts in order to differentiate between the microorganism(s) driving the disease and non-pathogenic commensals [101] .Identification of novel or variant pathogensWhen interpreting results from metagenomic studies, it is also important to balance scientific plausibility with Research findings are more likely to be true when the prior probability of the finding is high [102] ; thus, for unusual metagenomics results, additional lines of evidence are required for confirmation.", [["other complex diseases", "PROBLEM", 4, 26], ["a polymicrobial etiology", "PROBLEM", 32, 56], ["the microorganism", "PROBLEM", 188, 205], ["the disease", "PROBLEM", 217, 228], ["variant pathogens", "PROBLEM", 293, 310], ["metagenomic studies", "TEST", 341, 360], ["confirmation", "TEST", 612, 624], ["complex", "OBSERVATION_MODIFIER", 10, 17], ["diseases", "OBSERVATION", 18, 26], ["polymicrobial", "OBSERVATION_MODIFIER", 34, 47], ["pathogens", "OBSERVATION_MODIFIER", 301, 310]]], ["For example, in a study of nasopharyngeal swabs taken from individuals in the 2009 H1N1 pandemic, one sample contained a pair of reads that mapped with 97% nucleotide identity to Ebola virus, but after further investigation, this finding was concluded to be contamination [13] .", [["nasopharyngeal swabs", "ANATOMY", 27, 47], ["nucleotide", "CHEMICAL", 156, 166], ["Ebola virus", "DISEASE", 179, 190], ["nucleotide", "CHEMICAL", 156, 166], ["nasopharyngeal swabs", "CANCER", 27, 47], ["Ebola virus", "ORGANISM", 179, 190], ["Ebola virus", "SPECIES", 179, 190], ["Ebola virus", "SPECIES", 179, 190], ["a study", "TEST", 16, 23], ["nasopharyngeal swabs", "TEST", 27, 47], ["Ebola virus", "PROBLEM", 179, 190], ["further investigation", "TEST", 202, 223], ["nasopharyngeal", "ANATOMY", 27, 41], ["Ebola virus", "OBSERVATION", 179, 190]]], ["Since shotgun metagenomics is a relatively new field, all the possible causes of contamination are not yet known, but they can include experimental reagents, DNA extraction columns [103, 104] , cross-contamination during sample processing, and carry-over between sequencing runs [97] .", [["sample", "ANATOMY", 221, 227], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["contamination", "PROBLEM", 81, 94], ["experimental reagents", "TREATMENT", 135, 156], ["DNA extraction columns", "TEST", 158, 180], ["sequencing runs", "TEST", 263, 278], ["contamination", "OBSERVATION", 81, 94]]], ["Despite these caveats, all new discoveries must initially arise from novel and unexpected findings, but they must be followed up with the appropriate control samples and experiments.Conclusions and future perspectivesAlthough metagenomics pre-dates next-generation sequencing, current sequencing technology has transformed this emerging field, enabling the comprehensive characterization of all of the microbes in a sample.", [["the comprehensive characterization", "TEST", 353, 387]]], ["As metagenomic approaches mature and the methods are clinically validated, metagenomics-based approaches might become front-line diagnostic tests for infectious diseases in the public health setting.", [["infectious diseases", "DISEASE", 150, 169], ["diagnostic tests", "TEST", 129, 145], ["infectious diseases", "PROBLEM", 150, 169]]], ["When faced with an unknown or complex infectious disease, multiple conventional diagnostic tests are often used, potentially leading to unnecessary costs and delays in diagnosis.", [["an unknown or complex infectious disease", "PROBLEM", 16, 56], ["multiple conventional diagnostic tests", "TEST", 58, 96], ["complex", "OBSERVATION_MODIFIER", 30, 37], ["infectious", "OBSERVATION", 38, 48]]], ["Instead, metagenomics might be used as a single comprehensive screening test for potential pathogens, both known and novel, as well as to assess the state of an individual's microbiome ( Figure 2 ).", [["a single comprehensive screening test", "TEST", 39, 76], ["potential pathogens", "PROBLEM", 81, 100]]], ["Additional targeted diagnostic tests could then be used to further understand the clinical disease and determine management options.", [["Additional targeted diagnostic tests", "TEST", 0, 36], ["the clinical disease", "PROBLEM", 78, 98], ["management options", "TREATMENT", 113, 131]]], ["As sequencing becomes cheaper and faster, it will become possible to serially characterize human microbiomes to investigate changes over time.", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96]]], ["This could lead to personalized medicine for infectious diseases that accounts for the host genome and microbiome, and to personalized treatments such as the use of narrow-spectrum antibiotics to reduce disruption of the microbiome or specific probiotics to restore an individual's microbiome to a healthy state [82] .", [["infectious diseases", "DISEASE", 45, 64], ["infectious diseases", "PROBLEM", 45, 64], ["personalized treatments", "TREATMENT", 122, 145], ["narrow-spectrum antibiotics", "TREATMENT", 165, 192], ["disruption of the microbiome", "TREATMENT", 203, 231], ["specific probiotics", "TREATMENT", 235, 254]]], ["Similar procedures could also be applied to environmental microbiomes in healthcare settings; for example, urinary catheters could be treated with prebiotics to reduce the risk of colonization by harmful bacteria [105] .", [["urinary", "ANATOMY", 107, 114], ["urinary", "ORGANISM_SUBSTANCE", 107, 114], ["Similar procedures", "TREATMENT", 0, 18], ["urinary catheters", "TREATMENT", 107, 124], ["prebiotics", "TREATMENT", 147, 157], ["colonization", "PROBLEM", 180, 192], ["harmful bacteria", "PROBLEM", 196, 212], ["urinary", "ANATOMY", 107, 114], ["catheters", "OBSERVATION", 115, 124]]], ["In fact, it has been suggested that metagenomic investigations of the microbiome could become so standard that DNA sequencers could be used in household toilets to monitor changes in stool microbiome content, which could then be used to guide interventions to maintain health [106] .Conclusions and future perspectivesWhen a pathogen of interest is known, current metagenomic approaches have limited sensitivity compared to traditional techniques for pathogen detection.", [["DNA", "CELLULAR_COMPONENT", 111, 114], ["metagenomic investigations", "TEST", 36, 62], ["DNA sequencers", "TREATMENT", 111, 125], ["changes in stool microbiome content", "PROBLEM", 172, 207], ["traditional techniques", "TEST", 424, 446], ["pathogen detection", "TEST", 451, 469]]], ["Thus, although metagenomics might one day be used for screening clinical samples, it is currently best positioned as a complementary technique to be used alongside culture and other traditional methods.", [["samples", "ANATOMY", 73, 80], ["screening clinical samples", "TEST", 54, 80], ["a complementary technique", "TREATMENT", 117, 142], ["culture", "TEST", 164, 171]]], ["The greatest value of metagenomics is in clinical cases where conventional techniques fail to find a microbial cause.", [["conventional techniques", "TEST", 62, 85], ["a microbial cause", "PROBLEM", 99, 116], ["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["To be considered a bona fide clinical test for pathogen detection in a public health laboratory, standard metagenomic protocols are necessary both for testing and analyzing samples and for inter-laboratory comparison of results.", [["samples", "ANATOMY", 173, 180], ["pathogen detection", "TEST", 47, 65], ["testing", "TEST", 151, 158], ["analyzing samples", "TEST", 163, 180]]], ["As whole-genome sequencing technologies decrease in price and increase in speed and simplicity, however, it is expected that metagenomics approaches will be applied more often in public health emergencies, and routine pipelines are likely to evolve from ongoing collaborations between researchers and clinicians.", [["metagenomics approaches", "TREATMENT", 125, 148], ["routine pipelines", "TREATMENT", 210, 227], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["Such forward steps will be crucial for increasing our arsenal of tools in public health, thus allowing us to rapidly detect and to manage novel and emerging infectious diseases.", [["infectious diseases", "DISEASE", 157, 176], ["emerging infectious diseases", "PROBLEM", 148, 176]]]], "18c8acf67b1858bc3b60bd0ac35a01ecd176d817": [["For example, in a spatial context, these approaches have attempted to identify geographic areas with similar taxa, areas that have been variously called \"biogeographical regions\" (Gonzales-Orozco, Thornhill, Knerr, Laffan, & Miller, 2014) , \"bioregions\" (Bloomfield et al., 2017) , or \"biogeographical modules\" (Carstensen et al., 2012) .", [["similar", "OBSERVATION_MODIFIER", 101, 108], ["taxa", "OBSERVATION_MODIFIER", 109, 113]]]], "714370d75af9d91c8812733f732d98ddfff8074a": [["IntroductionThe 2013-2016 Ebola virus (EBOV) outbreak resulted in over 28 500 con\ue103rmed cases across three continents with an overall mortality rate of 39.5% (http://www.who.int/mediacentre/news/ releases/2016/ebola-zero-liberia/en/).", [["Ebola virus (EBOV) outbreak", "DISEASE", 26, 53], ["Ebola virus", "ORGANISM", 26, 37], ["EBOV", "ORGANISM", 39, 43], ["Ebola virus", "SPECIES", 26, 37], ["Ebola virus", "SPECIES", 26, 37], ["EBOV", "SPECIES", 39, 43], ["an overall mortality rate", "TEST", 122, 147]]], ["Unlike previous outbreaks, lack of preparedness in West Africa, local customs that facilitated transmission, and the generally poor healthcare infrastructure were key to the unprecedented size of the outbreak.", [["outbreaks", "OBSERVATION", 16, 25], ["size", "OBSERVATION_MODIFIER", 188, 192], ["outbreak", "OBSERVATION", 200, 208]]], ["It quickly became clear that success in containing the outbreak would pivot on three actions: (1) reliable diagnosis of suspected/probable cases i.e. symptomatic individuals; (2) quick isolation of patients con\ue103rmed as infected with EBOV, and; (3) effective contact tracing.", [["EBOV", "DISEASE", 233, 237], ["patients", "ORGANISM", 198, 206], ["EBOV", "ORGANISM", 233, 237], ["patients", "SPECIES", 198, 206], ["EBOV", "SPECIES", 233, 237], ["symptomatic individuals", "PROBLEM", 150, 173], ["EBOV", "PROBLEM", 233, 237]]], ["1 Unfortunately, symptomatic, suspected cases were difficult to differentially diagnose against other causative agents of hemorrhagic fever, as symptoms were generally non-speci\ue103c and common to other endemic, high incidence infections such as malaria, yellow fever, and Lassa fever.", [["hemorrhagic fever", "DISEASE", 122, 139], ["infections", "DISEASE", 224, 234], ["malaria", "DISEASE", 243, 250], ["yellow fever", "DISEASE", 252, 264], ["Lassa fever", "DISEASE", 270, 281], ["Lassa fever", "SPECIES", 270, 281], ["symptomatic", "PROBLEM", 17, 28], ["hemorrhagic fever", "PROBLEM", 122, 139], ["symptoms", "PROBLEM", 144, 152], ["high incidence infections", "PROBLEM", 209, 234], ["malaria", "PROBLEM", 243, 250], ["yellow fever", "PROBLEM", 252, 264], ["Lassa fever", "PROBLEM", 270, 281], ["hemorrhagic", "OBSERVATION_MODIFIER", 122, 133], ["fever", "OBSERVATION", 134, 139], ["malaria", "OBSERVATION", 243, 250], ["yellow", "OBSERVATION_MODIFIER", 252, 258], ["fever", "OBSERVATION", 259, 264], ["Lassa", "OBSERVATION_MODIFIER", 270, 275]]], ["Furthermore, epidemiological information, where available, only marginally contributed to patient triage by increasing EBOV disease risk potential from 'suspected' to 'probable'.", [["patient", "ORGANISM", 90, 97], ["EBOV", "ORGANISM", 119, 123], ["patient", "SPECIES", 90, 97], ["EBOV", "SPECIES", 119, 123], ["increasing EBOV disease risk", "PROBLEM", 108, 136]]], ["Thus, it became essential to obtain explicit, clinical diagnostic grade evidence of active EBOV infection as quickly as possible a\ue09der patient presentation.", [["EBOV infection", "DISEASE", 91, 105], ["EBOV", "ORGANISM", 91, 95], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["EBOV", "SPECIES", 91, 95], ["active EBOV infection", "PROBLEM", 84, 105], ["evidence of", "UNCERTAINTY", 72, 83], ["active", "OBSERVATION_MODIFIER", 84, 90], ["EBOV", "OBSERVATION_MODIFIER", 91, 95], ["infection", "OBSERVATION", 96, 105]]], ["Nucleic acid ampli\ue103cation testing (NAAT) using thermal cycling, \ue104uorescent probes and real time, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was quickly recognized as the most reliable clinical diagnostic solution for symptomatic EBOV patients.", [["EBOV", "DISEASE", 257, 261], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["EBOV", "ORGANISM", 257, 261], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["EBOV", "SPECIES", 257, 261], ["Nucleic acid ampli\ue103cation testing", "TEST", 0, 33], ["thermal cycling", "TREATMENT", 47, 62], ["\ue104uorescent probes", "TREATMENT", 64, 81], ["quantitative reverse transcription polymerase chain reaction", "PROBLEM", 97, 157], ["RT-qPCR", "TEST", 159, 166], ["symptomatic EBOV patients", "PROBLEM", 245, 270]]], ["2 Thus, studies during previous outbreaks [3] [4] [5] and data emerging from West Africa 4 reaffirmed that patients would present to triage only when symptoms became intense, corresponding to high viraemia levels ranging 10 5 -10 10 genome equivalents per ml (GE per ml) of whole blood.IntroductionImportantly, RT-qPCR is an internationally adopted in vitro diagnostic (IVD) technology considered robust, sensitive, and highly speci\ue103c.", [["whole blood", "ANATOMY", 274, 285], ["viraemia", "DISEASE", 197, 205], ["patients", "ORGANISM", 107, 115], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["patients", "SPECIES", 107, 115], ["symptoms", "PROBLEM", 150, 158], ["high viraemia levels", "PROBLEM", 192, 212], ["whole blood", "PROBLEM", 274, 285]]], ["Unlike most other territories, in the USA the Food and Drug Administration (FDA) presently regulates stringently both IVD thermal cycler instruments and associated IVD assay kits through extensive clinical trials before issuing marketing authorization.", [["Drug Administration (FDA", "TREATMENT", 55, 79], ["IVD thermal cycler instruments", "TREATMENT", 118, 148], ["associated IVD assay kits", "TREATMENT", 153, 178], ["extensive clinical trials", "TREATMENT", 187, 212]]], ["Furthermore, diagnostic services based on NAAT are provided only through FDA-regulated laboratories; the services also cover infectious disease agent diagnostics, including a multitude of RNA viruses.", [["NAAT", "TEST", 42, 46], ["RNA viruses", "PROBLEM", 188, 199], ["RNA viruses", "OBSERVATION", 188, 199]]], ["6 This regulatory framework applies whether the diagnostic test is available as an independently marketed IVD kit or an assay developed in-house in the regulated laboratory using regulated reagents.", [["the diagnostic test", "TEST", 44, 63], ["an assay", "TEST", 117, 125]]], ["Such measures enhance diagnostic service reliability, a requirement important in the context of highly infectious disease such as hazard group 3 and 4 pathogens.IntroductionImplementation of NAAT diagnostics for EBOV disease was spearheaded by the August 2014 FDA Emergency Use Authorization (EUA) of the EZ1 Taqman\u00ae assay which uses FAMlabelled \ue104uorescent probes for RT-qPCR undertaken on one of several FDA-approved thermal cyclers (http://www.fda. gov/downloads/MedicalDevices/Safety/EmergencySituations/ UCM418799.pdf).", [["infectious disease", "DISEASE", 103, 121], ["EBOV disease", "DISEASE", 212, 224], ["EBOV", "ORGANISM", 212, 216], ["EBOV", "SPECIES", 212, 216], ["highly infectious disease", "PROBLEM", 96, 121], ["hazard group 3 and 4 pathogens", "PROBLEM", 130, 160], ["NAAT diagnostics", "TEST", 191, 207], ["EBOV disease", "PROBLEM", 212, 224], ["the EZ1 Taqman\u00ae assay", "TEST", 301, 322], ["FAMlabelled \ue104uorescent probes", "TREATMENT", 334, 363], ["RT-qPCR", "TEST", 368, 375], ["thermal cyclers", "TREATMENT", 418, 433], ["downloads", "TREATMENT", 455, 464], ["MedicalDevices", "TREATMENT", 465, 479], ["infectious", "OBSERVATION", 103, 113]]], ["This molecular test involves the quantitative detection of two RNA substrates: the EBOV glycoprotein (GP) 7 gene encoded in the negative RNA genome of EBOV, and the human ribonuclease P (RP) transcript which is found at high levels in human bio\ue104uid samples, as an endogenous/process control.", [["bio\ue104uid samples", "ANATOMY", 241, 256], ["EBOV glycoprotein (GP) 7", "GENE_OR_GENE_PRODUCT", 83, 107], ["EBOV", "ORGANISM", 151, 155], ["human", "ORGANISM", 165, 170], ["ribonuclease P", "GENE_OR_GENE_PRODUCT", 171, 185], ["RP", "GENE_OR_GENE_PRODUCT", 187, 189], ["human", "ORGANISM", 235, 240], ["bio\ue104uid samples", "TISSUE", 241, 256], ["RNA substrates", "RNA", 63, 77], ["EBOV glycoprotein (GP) 7 gene", "DNA", 83, 112], ["negative RNA genome", "DNA", 128, 147], ["human ribonuclease P (RP) transcript", "RNA", 165, 201], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 235, 240], ["EBOV", "SPECIES", 151, 155], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 235, 240], ["This molecular test", "TEST", 0, 19], ["the EBOV glycoprotein (GP)", "TREATMENT", 79, 105], ["the human ribonuclease P (RP) transcript", "TREATMENT", 161, 201], ["an endogenous/process control", "TREATMENT", 261, 290]]], ["8 To date, this so-called Trombley assay 7 remains the gold standard of diagnostic care 7, 9, 10 used by public health agencies worldwide and is reported to be the most sensitive and speci\ue103c for semi-quantitative EBOV diagnosis in viraemic, i.e. symptomatic patients.", [["EBOV", "ORGANISM", 213, 217], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["EBOV", "SPECIES", 213, 217], ["viraemic", "PROBLEM", 231, 239]]], ["10 Thus, the Trombley assay features a 0.0001 plaque forming unit per reaction (PFU per reaction) lower limit of detection (LLOD), across a 5 log-linear dynamic range (LDR), 7, 9 and analytical speci\ue103city against human RNA, and 75 other pathogens (http://www.fda.gov/downloads/ MedicalDevices/Safety/EmergencySituations/UCM408334.pdf).", [["human", "ORGANISM", 213, 218], ["human RNA", "RNA", 213, 222], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["the Trombley assay", "TEST", 9, 27], ["analytical speci\ue103city", "TEST", 183, 204], ["human RNA", "PROBLEM", 213, 222]]], ["Of note, the quali\ue103cation and performance data of this assay do not pertain to the reaction substrate, the EBOV RNA genome, but rather the amount of live virus in the sample.", [["sample", "ANATOMY", 167, 173], ["EBOV", "ORGANISM", 107, 111], ["EBOV RNA genome", "DNA", 107, 122], ["EBOV", "SPECIES", 107, 111], ["this assay", "TEST", 50, 60], ["the reaction substrate", "PROBLEM", 79, 101], ["the EBOV RNA genome", "PROBLEM", 103, 122], ["live virus", "PROBLEM", 149, 159]]], ["This relates to the use of infectious virus quanti\ue103cation methods in classical virology (PFU quanti\ue103cation assays), 11 which are medically valuable in informing the risk of infection/transmission, rather than the biochemically relevant assay substrate concentration reported by NAAT.", [["infection", "DISEASE", 173, 182], ["NAAT", "PROTEIN", 278, 282], ["infectious virus quanti\ue103cation methods", "TREATMENT", 27, 65], ["infection/transmission", "PROBLEM", 173, 195], ["infection", "OBSERVATION", 173, 182]]], ["Yet studies with in vitro produced virus 9, 12 and macaque infection models 13 indicate the viral genomes might be 10-fold 12 to 10 000-fold 9 higher than infectious virions in a given sample.", [["virions", "ANATOMY", 166, 173], ["sample", "ANATOMY", 185, 191], ["infection", "DISEASE", 59, 68], ["macaque", "ORGANISM", 51, 58], ["viral genomes", "DNA", 92, 105], ["Yet studies", "TEST", 0, 11], ["virus", "TEST", 35, 40], ["macaque infection models", "TEST", 51, 75], ["the viral genomes", "PROBLEM", 88, 105], ["infectious virions", "PROBLEM", 155, 173], ["viral genomes", "OBSERVATION", 92, 105]]], ["This has been evidenced across many hazard group 3 and 4 viruses, and has been associated to the extent of virus passage in vitro.", [["many hazard group 3 and 4 viruses", "PROBLEM", 31, 64], ["virus passage", "PROBLEM", 107, 120], ["virus", "OBSERVATION", 107, 112]]], ["13 Clinical data remains limited given the preference for immediate virus inactivation for health and safety reasons.IntroductionUnfortunately, the entire Trombley procedure is slow, laboratory-based, and has considerable safety implications.", [["Clinical data", "TEST", 3, 16], ["immediate virus inactivation", "TREATMENT", 58, 86], ["the entire Trombley procedure", "TREATMENT", 144, 173]]], ["Thus, venous blood is the biological sample of choice, but the large volumes needed (3.5 ml) increase the risk of uncontrolled bleeding for patients exhibiting hemorrhagic symptoms.", [["venous blood", "ANATOMY", 6, 18], ["bleeding", "DISEASE", 127, 135], ["hemorrhagic", "DISEASE", 160, 171], ["venous blood", "ORGANISM_SUBSTANCE", 6, 18], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["venous blood", "TEST", 6, 18], ["uncontrolled bleeding", "PROBLEM", 114, 135], ["hemorrhagic symptoms", "PROBLEM", 160, 180], ["venous", "ANATOMY", 6, 12], ["large", "OBSERVATION_MODIFIER", 63, 68], ["uncontrolled", "OBSERVATION_MODIFIER", 114, 126], ["bleeding", "OBSERVATION", 127, 135], ["hemorrhagic", "OBSERVATION_MODIFIER", 160, 171]]], ["The samples also present a risk of infection to the healthcare staff collecting them and the diagnostic laboratory personnel analyzing them, making extensive safety training essential in reducing transmission.", [["samples", "ANATOMY", 4, 11], ["infection", "DISEASE", 35, 44], ["The samples", "TEST", 0, 11], ["infection", "PROBLEM", 35, 44], ["extensive safety training", "TREATMENT", 148, 173], ["infection", "OBSERVATION", 35, 44]]], ["Notwithstanding safety concerns, the Trombley assay procedure further necessitates considerable technical expertise involving multiple manual steps operating expensive laboratory infrastructure and mains-powered instrumentation, using expensive consumables stored constantly at 4 C. Appropriately equipped facilities were scant in West Africa and the technology was not suited to laboratory-free \ue103eld deployment in rural regions where need was at its highest.", [["the Trombley assay procedure", "TREATMENT", 33, 61], ["mains-powered instrumentation", "TREATMENT", 198, 227], ["expensive consumables", "TREATMENT", 235, 256]]], ["2 In addition, at $US$100, the cost per patient 14 exceeded by up to tenfold the annual, per capita healthcare expenditure in the region.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["region", "ANATOMY_MODIFIER", 130, 136]]], ["15 Moreover, the time-to-results, at best 5-8 hours from sample receipt, restricted throughput capacity and presented additional infection risks to EBOV-free patients awaiting results whilst in triage.", [["infection", "DISEASE", 129, 138], ["EBOV", "ORGANISM", 148, 152], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["EBOV", "SPECIES", 148, 152], ["restricted throughput capacity", "PROBLEM", 73, 103], ["additional infection", "PROBLEM", 118, 138], ["infection", "OBSERVATION", 129, 138]]], ["Thus, the ideal diagnostic test should be affordable, sensitive, speci\ue103c, user-friendly, robust, rapid, equipment-free and deliverable to those in needi.e. usable in the \ue103eld with minimal requirements for additional resources.", [["the ideal diagnostic test", "TEST", 6, 31], ["additional resources", "TREATMENT", 205, 225]]], ["Ideally, this would also involve minimal bio\ue104uid volumes, such as microliter drops of blood analysed in situ by digital venipuncture, not dissimilar to over-the-counter, point-of-need glucometers.", [["blood", "ANATOMY", 86, 91], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["minimal bio\ue104uid volumes", "PROBLEM", 33, 56], ["microliter drops of blood", "TREATMENT", 66, 91], ["digital venipuncture", "TEST", 112, 132], ["glucometers", "TREATMENT", 184, 195], ["minimal", "OBSERVATION_MODIFIER", 33, 40]]], ["To date, the most clinically advanced, close-to-patient NAAT IVDs still require powered instrumentation, a fully equipped laboratory setting (\ue103xed or mobile), training associated to multiple handling steps starting with 3.5 ml of venous blood, and consumables still far too costly for the countries most affected by such tropical disease.", [["venous blood", "ANATOMY", 230, 242], ["patient", "ORGANISM", 48, 55], ["venous", "ORGANISM_SUBSTANCE", 230, 236], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["patient", "SPECIES", 48, 55], ["patient NAAT IVDs", "PROBLEM", 48, 65], ["powered instrumentation", "TREATMENT", 80, 103], ["venous blood", "TREATMENT", 230, 242], ["such tropical disease", "PROBLEM", 316, 337], ["venous", "ANATOMY", 230, 236], ["tropical disease", "OBSERVATION", 321, 337]]], ["2, 10, 17 Here, we report our efforts to address the need for quantitative, rapid and reliable, molecular diagnosis of EBOV disease in symptomatic patients arriving at triage, under the 12 month Emergency Call Research for Health in Humanitarian Crisis (r2hc) program of the Enhancing Learning and Research for Humanitarian Assistance (ELRHA) organization.", [["EBOV disease", "DISEASE", 119, 131], ["2, 10, 17", "CHEMICAL", 0, 9], ["EBOV", "ORGANISM", 119, 123], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["EBOV", "SPECIES", 119, 123], ["EBOV disease", "PROBLEM", 119, 131], ["Humanitarian Assistance (ELRHA)", "TREATMENT", 311, 342], ["EBOV disease", "OBSERVATION", 119, 131], ["symptomatic", "OBSERVATION_MODIFIER", 135, 146]]], ["Taking into account reports that quantitative PCR (qPCR) is possible in reactions containing blood, 18, 19 we present evidence that this extends to RT-qPCR retaining quantitative diagnostic value without the need for substantial formulation/enzyme modi\ue103cations, provided far-red dyes are used to overcome the \ue104uorogenic inhibition effect of blood and the minimal impact on sensitivity remains clinically acceptable.", [["blood", "ANATOMY", 93, 98], ["blood", "ANATOMY", 341, 346], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["red dyes", "SIMPLE_CHEMICAL", 275, 283], ["blood", "ORGANISM_SUBSTANCE", 341, 346], ["quantitative PCR (qPCR", "TEST", 33, 55], ["blood", "TEST", 93, 98], ["substantial formulation/enzyme modi\ue103cations", "TREATMENT", 217, 260], ["far-red dyes", "TREATMENT", 271, 283], ["the \ue104uorogenic inhibition effect of blood", "PROBLEM", 305, 346], ["sensitivity", "TEST", 373, 384], ["minimal", "OBSERVATION_MODIFIER", 355, 362]]], ["We further evaluate the utility of controlled freezing and thawing cycles in disrupting virion structures to release viral genomes directly in blood samples as an energy and engineering-efficient means of eliminating manual or automated RNA extraction and puri\ue103cation.", [["blood samples", "ANATOMY", 143, 156], ["blood samples", "ORGANISM_SUBSTANCE", 143, 156], ["viral genomes", "DNA", 117, 130], ["controlled freezing", "TREATMENT", 35, 54], ["thawing cycles", "TREATMENT", 59, 73], ["disrupting virion structures", "PROBLEM", 77, 105], ["viral genomes", "PROBLEM", 117, 130], ["blood samples", "TEST", 143, 156], ["automated RNA extraction", "TREATMENT", 227, 251], ["puri\ue103cation", "TREATMENT", 256, 267], ["viral genomes", "OBSERVATION", 117, 130]]], ["We further present the development of an instrument and computational approach compatible with parallel detection of multiple far-red dyes, engineered for \ue103eld deployment at the point of need, in a laboratory infrastructure-free manner, and with minimal end-user training requirements.", [["multiple far-red dyes", "PROBLEM", 117, 138], ["\ue103eld deployment", "TREATMENT", 155, 170], ["minimal end-user training requirements", "TREATMENT", 246, 284], ["instrument", "OBSERVATION", 41, 51], ["multiple", "OBSERVATION_MODIFIER", 117, 125], ["red dyes", "OBSERVATION", 130, 138]]], ["Finally, we determine the performance of this approach in detecting and quantifying EBOV against the gold standard, laboratory-based Trombley assay, within the context of screening symptomatic patients in a triage setting.Benchmark assay system performanceGiven the emerging evidence that the Trombley GP assay performed better against a number of other RT-qPCR assays for EBOV, 7, 9, 10 and to focus our efforts, we adopted the Trombley assays for the EBOV GP and NP genes in our work.", [["EBOV", "ORGANISM", 84, 88], ["patients", "ORGANISM", 193, 201], ["EBOV", "ORGANISM", 373, 377], ["EBOV", "ORGANISM", 453, 457], ["EBOV GP and NP genes", "DNA", 453, 473], ["patients", "SPECIES", 193, 201], ["EBOV", "SPECIES", 84, 88], ["EBOV", "SPECIES", 373, 377], ["EBOV", "SPECIES", 453, 457], ["this approach", "TREATMENT", 41, 54], ["the Trombley GP assay", "TEST", 289, 310], ["qPCR assays", "TEST", 357, 368], ["EBOV", "TEST", 373, 377]]], ["Moreover, to overcome limited biosafety level 4 (BSL4) facility and staff availability due to increased screening services demand, we used surrogate EBOV templates.", [["EBOV", "ORGANISM", 149, 153], ["EBOV", "SPECIES", 149, 153], ["surrogate EBOV templates", "TREATMENT", 139, 163]]], ["We reasoned against chemically synthesized RNA as a template because blood nucleases rapidly degrade such biomaterials at ambient temperatures, 20 which could prove problematic with minimal assay formulations.", [["blood", "ANATOMY", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["blood nucleases", "PROTEIN", 69, 84], ["chemically synthesized RNA", "TREATMENT", 20, 46], ["blood nucleases", "PROBLEM", 69, 84], ["ambient temperatures", "TEST", 122, 142], ["minimal assay formulations", "TREATMENT", 182, 208]]], ["On the other hand, de novo construction of in vitro produced, non-infectious, and/or replication-de\ue103cient EBOV virions, 21 an approach common for many well-studied species of mammalian viruses, was actively discouraged outside high containment for reasons of health, safety, and biosecurity.", [["EBOV", "ORGANISM", 106, 110], ["mammalian viruses", "ORGANISM", 175, 192], ["EBOV", "SPECIES", 106, 110], ["non-infectious", "PROBLEM", 62, 76], ["EBOV virions", "TREATMENT", 106, 118], ["mammalian viruses", "PROBLEM", 175, 192], ["non-infectious", "OBSERVATION", 62, 76], ["mammalian viruses", "OBSERVATION", 175, 192]]], ["We thus elected to use commercially available recombinant MS2 coliphage as our primary surrogate template (AR14), despite the robustness of this virion compared to the easily fragmentable nature of \ue103lovirus particles, 22 and pseudotyped lentivirus (PV) based on HIV manufactured in-house as a fallback template (see ESI, Fig. S1 \u2020).", [["\ue103lovirus", "GENE_OR_GENE_PRODUCT", 198, 206], ["pseudotyped", "ORGANISM", 225, 236], ["lentivirus", "ORGANISM", 237, 247], ["HIV", "ORGANISM", 262, 265], ["HIV", "SPECIES", 262, 265], ["PV", "SPECIES", 249, 251], ["HIV", "SPECIES", 262, 265], ["recombinant MS2 coliphage", "TREATMENT", 46, 71], ["this virion", "PROBLEM", 140, 151], ["\ue103lovirus particles", "PROBLEM", 198, 216], ["pseudotyped lentivirus", "PROBLEM", 225, 247], ["a fallback template", "TREATMENT", 291, 310]]], ["23 To benchmark Trombley assay performance with these standards, we performed the plate-based EZ1 kit standard operating procedure (SOP) on an ABI7500 real time thermal cycler.", [["EZ1", "PROTEIN", 94, 97], ["the plate-based EZ1 kit standard operating procedure", "TREATMENT", 78, 130], ["an ABI7500 real time thermal cycler", "TREATMENT", 140, 175]]], ["7 We thus used healthy volunteer blood freshly collected by super\ue103cial venipuncture, spiked with AR14 to a \ue103nal concentration of 1.67 \u00c2 10 11 GE per ml of blood.", [["blood", "ANATOMY", 33, 38], ["blood", "ANATOMY", 155, 160], ["AR14", "CHEMICAL", 97, 101], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["AR14", "SIMPLE_CHEMICAL", 97, 101], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["AR14", "TREATMENT", 97, 101], ["a \ue103nal concentration", "TEST", 105, 125], ["blood", "TEST", 155, 160]]], ["Viral RNA was then extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Manchester, UK), puri\ue103ed extracts were serially diluted with nuclease-free water and 5 ml volumes were assayed in triplicate.", [["extracts", "ANATOMY", 99, 107], ["Viral", "ORGANISM", 0, 5], ["extracts", "ORGANISM_SUBSTANCE", 99, 107], ["Viral RNA", "RNA", 0, 9], ["nuclease", "PROTEIN", 135, 143], ["Viral RNA", "PROBLEM", 0, 9], ["puri\ue103ed extracts", "TREATMENT", 91, 107], ["nuclease-free water and 5 ml volumes", "TREATMENT", 135, 171]]], ["The results demonstrated independent ampli\ue103cation efficiencies for the GP and NP assays (98.0% and 102%, respectively) despite the use of the same template, resulting in distinct curve \ue103ts as determined by Akaike's informative criteria test (Fig. 1) .", [["independent ampli\ue103cation efficiencies", "PROBLEM", 25, 62], ["the GP", "TEST", 67, 73], ["NP assays", "TEST", 78, 87], ["the same template", "TREATMENT", 138, 155], ["ampli\ue103cation efficiencies", "OBSERVATION", 37, 62]]], ["The high concentration of AR14, however, allowed us to demonstrate a linear dynamic range (LDR) for both assays 3 logs higher than that reported previously.", [["AR14", "CHEMICAL", 26, 30], ["AR14", "SIMPLE_CHEMICAL", 26, 30], ["both assays", "TEST", 100, 111], ["high", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22]]], ["7 Moreover, the 6.67 genome equivalent per reaction (GE per reaction) lower limit of detection (LLOD) and low variability between technical replicates, as demonstrated through 95% con\ue103dence bands across the dilution series (% CV < 2.09% for GP and < 3.41% for NP), set performance standards for forward work.", [["low variability", "PROBLEM", 106, 121], ["the dilution series", "TEST", 203, 222], ["CV", "TEST", 226, 228], ["GP", "TEST", 241, 243], ["low variability", "OBSERVATION_MODIFIER", 106, 121]]], ["Furthermore, a\ue09der generating PV constructs containing the Trombley assay target sequences corresponding to the 1976 EBOV Yambuka-Ecran reference genome (PV76) and the 2014 EBOV Guinea Makona reference genome (PV14), we con\ue103rmed that the single nucleotide polymorphisms identi\ue103ed within the West African outbreak isolate 24 had limited impact on diagnostic assay reliability (see ESI, Fig. S1 , Tables S1 and S2 \u2020).RT-qPCR proceeds but is \ue104uorogenically inhibited by blood not treated with anticoagulantsPrevious reports 18, 19, 25 indicated that PCR containing whole blood may proceed in the context of enabling mutations in the Taq DNA polymerase (OmniTaq mutant) 18, 19 or with at least one commercially available, research-grade polymerase supplemented with reaction enhancers.", [["blood", "ANATOMY", 466, 471], ["whole blood", "ANATOMY", 561, 572], ["nucleotide", "CHEMICAL", 244, 254], ["S2", "GENE_OR_GENE_PRODUCT", 408, 410], ["blood", "ORGANISM_SUBSTANCE", 466, 471], ["blood", "ORGANISM_SUBSTANCE", 567, 572], ["Taq", "GENE_OR_GENE_PRODUCT", 629, 632], ["DNA", "CELLULAR_COMPONENT", 633, 636], ["PV constructs", "DNA", 29, 42], ["Trombley assay target sequences", "DNA", 58, 89], ["1976 EBOV Yambuka-Ecran reference genome", "DNA", 111, 151], ["PV76", "DNA", 153, 157], ["2014 EBOV Guinea Makona reference genome", "DNA", 167, 207], ["PV14", "DNA", 209, 213], ["S1", "PROTEIN", 389, 391], ["S1", "PROTEIN", 401, 403], ["S2", "PROTEIN", 408, 410], ["Taq DNA polymerase", "PROTEIN", 629, 647], ["OmniTaq mutant) 18, 19", "PROTEIN", 649, 671], ["research-grade polymerase", "PROTEIN", 717, 742], ["reaction enhancers", "DNA", 761, 779], ["EBOV Guinea Makona", "SPECIES", 172, 190], ["PV", "SPECIES", 29, 31], ["PV constructs", "TREATMENT", 29, 42], ["the Trombley assay target sequences", "TEST", 54, 89], ["the single nucleotide polymorphisms", "PROBLEM", 233, 268], ["diagnostic assay reliability", "TEST", 345, 373], ["anticoagulants", "TREATMENT", 489, 503], ["PCR", "TEST", 546, 549], ["whole blood", "TEST", 561, 572], ["enabling mutations", "PROBLEM", 603, 621], ["the Taq DNA polymerase", "TREATMENT", 625, 647], ["reaction enhancers", "PROBLEM", 761, 779], ["S1", "ANATOMY", 401, 403]]], ["25 Importantly, qPCR with SYBR Green I nucleic acid stain (520 nm emission peak) was only achieved with their OmniTaq enzyme 18 and by overcoming the inhibitory effect of blood on \ue104uorogenicity dose-dependently, e.g. by using 64\u00c2 higher concentrations of dye for a reaction spiked with 10% v/v blood.", [["blood", "ANATOMY", 171, 176], ["blood", "ANATOMY", 294, 299], ["nucleic acid", "CHEMICAL", 39, 51], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 26, 38], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["\ue104uorogenicity", "SIMPLE_CHEMICAL", 180, 193], ["dye", "SIMPLE_CHEMICAL", 255, 258], ["blood", "ORGANISM_SUBSTANCE", 294, 299], ["OmniTaq enzyme 18", "PROTEIN", 110, 127], ["qPCR", "TEST", 16, 20], ["SYBR Green I nucleic acid stain", "TEST", 26, 57], ["nm emission peak", "TEST", 63, 79], ["their OmniTaq enzyme", "TEST", 104, 124], ["dye", "TREATMENT", 255, 258], ["a reaction", "PROBLEM", 263, 273], ["10% v/v blood", "TREATMENT", 286, 299]]], ["Notably, this work involved blood and plasma treated with anticoagulants which are known PCR inhibitors, and samples were freeze-thawed up to \ue103ve times.", [["blood", "ANATOMY", 28, 33], ["plasma", "ANATOMY", 38, 44], ["samples", "ANATOMY", 109, 116], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["anticoagulants", "TREATMENT", 58, 72], ["PCR inhibitors", "TREATMENT", 89, 103]]], ["Use of green dye-labelled Taqman\u00ae probes (CAL Fluor 540 nm) was later shown by the same group to require a complex PCR enhancer cocktail to achieve detection of as little as 7 genome equivalents per microliter (GE per ml) of DNA template with their OmniTaq polymerase in the presence of blood.", [["blood", "ANATOMY", 287, 292], ["DNA", "CELLULAR_COMPONENT", 225, 228], ["OmniTaq polymerase", "GENE_OR_GENE_PRODUCT", 249, 267], ["blood", "ORGANISM_SUBSTANCE", 287, 292], ["green dye-labelled Taqman\u00ae probes", "DNA", 7, 40], ["OmniTaq polymerase", "PROTEIN", 249, 267], ["green dye-labelled Taqman\u00ae probes", "TREATMENT", 7, 40], ["a complex PCR enhancer cocktail", "TREATMENT", 105, 136], ["DNA template", "TREATMENT", 225, 237], ["their OmniTaq polymerase", "TEST", 243, 267], ["blood", "OBSERVATION", 287, 292]]], ["Although the authors demonstrated that the cocktail could be useful for other polymerases in end-point PCR assays, they did not discuss its' use in RT-qPCR.", [["the cocktail", "TREATMENT", 39, 51], ["other polymerases", "PROBLEM", 72, 89], ["PCR assays", "TEST", 103, 113]]], ["Encouraged by these reports, and working in parallel to constructing the PV standards, we investigated whether the blood compatibility of PCR could be extended to RNA templates and RT-PCR using similar, well-characterized assays.", [["blood", "ANATOMY", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["the blood compatibility of PCR", "PROBLEM", 111, 141], ["RNA templates", "TEST", 163, 176], ["RT-PCR", "TEST", 181, 187]]], ["6, 27 However, in line with our projected application of analyzing patient blood immediately upon collection, we dispensed with anticoagulants and blood storage altogether.", [["blood", "ANATOMY", 75, 80], ["blood", "ANATOMY", 147, 152], ["patient", "ORGANISM", 67, 74], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["patient", "SPECIES", 67, 74], ["anticoagulants", "TREATMENT", 128, 142], ["blood storage", "TREATMENT", 147, 160]]], ["Instead, we spiked fresh human blood directly into reactions by obtaining it through digital venipuncture ad hoc.", [["blood", "ANATOMY", 31, 36], ["human", "ORGANISM", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30]]], ["We thus assembled onestep RT-qPCR reactions with a commercially available Taq polymerase (GoTaq\u00ae G2 Flex; Promega, Inc) or the bloodtolerant OmniTaq 2 (DNA Polymerase Technology, Inc.), using the manufacturer's mastermix, respectively, and 5 U per reaction of GoScript\u00ae Moloney Murine Leukemia virus reverse transcriptase (Promega).", [["DNA", "CELLULAR_COMPONENT", 152, 155], ["GoScript\u00ae", "ORGANISM", 260, 269], ["Moloney Murine Leukemia virus", "ORGANISM", 270, 299], ["Promega", "ORGANISM", 323, 330], ["Taq polymerase", "PROTEIN", 74, 88], ["bloodtolerant OmniTaq 2", "DNA", 127, 150], ["reverse transcriptase", "PROTEIN", 300, 321], ["Murine", "SPECIES", 278, 284], ["Murine Leukemia virus", "SPECIES", 278, 299], ["qPCR reactions", "PROBLEM", 29, 43], ["a commercially available Taq polymerase", "TREATMENT", 49, 88], ["GoTaq\u00ae G2 Flex", "TREATMENT", 90, 104], ["Promega", "TREATMENT", 106, 113], ["the bloodtolerant OmniTaq", "TREATMENT", 123, 148], ["the manufacturer's mastermix", "TREATMENT", 192, 220], ["GoScript\u00ae Moloney Murine Leukemia virus", "TREATMENT", 260, 299], ["transcriptase (Promega)", "TREATMENT", 308, 331]]], ["Importantly, although these mastermix formulations remained proprietary, both suppliers con\ue103rmed that neither formulation featured additives to overcome PCR inhibitors.", [["these mastermix formulations", "TREATMENT", 22, 50], ["PCR inhibitors", "TREATMENT", 153, 167]]], ["Working on wet ice, these reactions were spiked with 4 \u00c2 10 8 copies of Escherichia coli MS2 phage RNA, a FAM-labelled Taqman\u00ae probe (518 nm emission peak), and increasing concentrations of fresh blood (Fig. 2 ).", [["blood", "ANATOMY", 196, 201], ["FAM", "CHEMICAL", 106, 109], ["Escherichia coli", "ORGANISM", 72, 88], ["FAM", "SIMPLE_CHEMICAL", 106, 109], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["Escherichia coli MS2 phage RNA", "RNA", 72, 102], ["Escherichia coli", "SPECIES", 72, 88], ["Escherichia coli", "SPECIES", 72, 88], ["these reactions", "PROBLEM", 20, 35], ["Escherichia coli", "TREATMENT", 72, 88], ["a FAM", "TEST", 104, 109], ["nm emission peak", "TEST", 138, 154], ["increasing concentrations of fresh blood", "PROBLEM", 161, 201], ["increasing", "OBSERVATION_MODIFIER", 161, 171], ["concentrations", "OBSERVATION_MODIFIER", 172, 186], ["fresh blood", "OBSERVATION", 190, 201]]], ["To our surprise, our results indicated that RT-PCR successfully proceeded in the presence of blood with no obvious differences between the hot-start, wild type Taq polymerase (Fig. 2a) and the blood-adapted OmniTaq mutant (Fig. 2b) .", [["blood", "ANATOMY", 93, 98], ["blood", "ANATOMY", 193, 198], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 160, 174], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["OmniTaq", "GENE_OR_GENE_PRODUCT", 207, 214], ["hot-start", "DNA", 139, 148], ["wild type Taq polymerase", "PROTEIN", 150, 174], ["OmniTaq mutant", "PROTEIN", 207, 221], ["Fig. 2b", "PROTEIN", 223, 230], ["RT-PCR", "TEST", 44, 50], ["blood", "PROBLEM", 93, 98], ["obvious differences", "PROBLEM", 107, 126], ["wild type Taq polymerase", "PROBLEM", 150, 174], ["the blood", "TEST", 189, 198], ["OmniTaq mutant", "TREATMENT", 207, 221], ["no obvious", "UNCERTAINTY", 104, 114]]], ["However, in both cases, blood inhibited the \ue104uorogenic signal of the probe in a concentration-dependent manner.RT-qPCR proceeds but is \ue104uorogenically inhibited by blood not treated with anticoagulantsTo determine whether this was a limitation of using \ue104uorescently labelled probe detection chemistry, we evaluated qPCR output with OmniTaq 2 against 5.5 \u00c2 10 3 copies of lambda phage DNA, with a 10\u00c2 higher Sybr Green I concentration and up to 5% v/v blood, in line with the stain/blood ratios indicated by Kermekchiev et al. As with the FAMlabelled probe, this reaction format also exhibited blood concentration-dependent inhibition of \ue104uorogenic signal (Fig. S2 \u2020) .", [["blood", "ANATOMY", 24, 29], ["blood", "ANATOMY", 163, 168], ["blood", "ANATOMY", 450, 455], ["blood", "ANATOMY", 480, 485], ["blood", "ANATOMY", 592, 597], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["DNA", "CELLULAR_COMPONENT", 383, 386], ["Sybr Green I", "GENE_OR_GENE_PRODUCT", 406, 418], ["blood", "ORGANISM_SUBSTANCE", 450, 455], ["blood", "ORGANISM_SUBSTANCE", 480, 485], ["blood", "ORGANISM_SUBSTANCE", 592, 597], ["lambda phage DNA", "DNA", 370, 386], ["FAMlabelled probe", "DNA", 537, 554], ["anticoagulants", "TREATMENT", 186, 200], ["qPCR output", "TEST", 314, 325], ["OmniTaq", "TREATMENT", 331, 338], ["lambda phage DNA", "TREATMENT", 370, 386], ["the stain", "TEST", 470, 479], ["blood ratios", "TEST", 480, 492], ["the FAMlabelled probe", "TREATMENT", 533, 554], ["this reaction", "PROBLEM", 556, 569], ["blood concentration", "PROBLEM", 592, 611], ["dependent inhibition of \ue104uorogenic signal", "PROBLEM", 612, 653]]], ["Taken together, these results suggested that qPCR and RT-qPCR might be achievable in the presence of blood despite the inhibitory effect of heme, 25 with wild type DNA polymerases in minimal mastermix formulations, provided no anticoagulants were used during blood sampling, and the inhibitory effect of blood on dye \ue104uorogenicity could be overcome.Far-red probe dyes and DNA stains enable RT-qPCR in bloodGiven the spectral properties of blood and the better signal-tonoise ratio of far-red dyes in other optical platforms such as confocal microscopy and in vivo bioimaging, 26 we hypothesized far red/infrared \ue104uorophores might resolve the \ue104uorogenic inhibition effect of blood.", [["blood", "ANATOMY", 101, 106], ["blood", "ANATOMY", 259, 264], ["blood", "ANATOMY", 304, 309], ["blood", "ANATOMY", 401, 406], ["blood", "ANATOMY", 439, 444], ["blood", "ANATOMY", 674, 679], ["heme", "CHEMICAL", 140, 144], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["heme", "SIMPLE_CHEMICAL", 140, 144], ["DNA", "CELLULAR_COMPONENT", 164, 167], ["blood", "ORGANISM_SUBSTANCE", 259, 264], ["blood", "ORGANISM_SUBSTANCE", 304, 309], ["dye", "SIMPLE_CHEMICAL", 313, 316], ["DNA", "CELLULAR_COMPONENT", 372, 375], ["blood", "ORGANISM_SUBSTANCE", 401, 406], ["blood", "ORGANISM_SUBSTANCE", 439, 444], ["\ue104uorophores", "SIMPLE_CHEMICAL", 612, 623], ["blood", "ORGANISM_SUBSTANCE", 674, 679], ["heme", "PROTEIN", 140, 144], ["wild type DNA polymerases", "PROTEIN", 154, 179], ["qPCR", "TEST", 45, 49], ["RT-qPCR", "TEST", 54, 61], ["wild type DNA polymerases", "TREATMENT", 154, 179], ["minimal mastermix formulations", "TREATMENT", 183, 213], ["anticoagulants", "TREATMENT", 227, 241], ["blood sampling", "TEST", 259, 273], ["blood on dye \ue104uorogenicity", "PROBLEM", 304, 330], ["Far-red probe dyes", "TEST", 349, 367], ["DNA stains", "TEST", 372, 382], ["RT", "TEST", 390, 392], ["qPCR", "TEST", 393, 397], ["blood", "TEST", 401, 406], ["red dyes", "PROBLEM", 488, 496], ["confocal microscopy", "TEST", 532, 551], ["vivo bioimaging", "TEST", 559, 574], ["red/infrared \ue104uorophores", "PROBLEM", 599, 623], ["the \ue104uorogenic inhibition effect of blood", "PROBLEM", 638, 679], ["blood", "ANATOMY", 401, 406]]], ["To examine this hypothesis, the emission spectra of a gamut of commercially available, far-red nucleic acid stains (SYTO\u00ae family) and \ue104uorescent dyes (CAL635, Quasar 670, Quasar 705) was assessed in the presence or absence of fresh human blood (Fig. 2c) .", [["blood", "ANATOMY", 238, 243], ["nucleic acid", "CHEMICAL", 95, 107], ["CAL635", "CHEMICAL", 151, 157], ["Quasar 670, Quasar 705", "CHEMICAL", 159, 181], ["CAL635", "CHEMICAL", 151, 157], ["\ue104uorescent dyes", "SIMPLE_CHEMICAL", 134, 149], ["CAL635", "SIMPLE_CHEMICAL", 151, 157], ["human", "ORGANISM", 232, 237], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["red nucleic acid stains", "TEST", 91, 114]]], ["Using an Ocean Optics Maya LSL \ue104uorimeter, we also took the opportunity in these experiments to evaluate a variety of light sources: light emitting diodes (Luxeon Phillips and Dragon Osram), \ue103ltered white light sources and laser diodes.", [["light emitting diodes", "TREATMENT", 133, 154], ["Luxeon Phillips", "TREATMENT", 156, 171], ["laser diodes", "TREATMENT", 223, 235]]], ["In these studies, use of a laser diode source provided power output advantages that were paralleled by several reduced engineering problems, such as optical \ue103ber coupling and structural stability, and dispensation of wavelength \ue103ltering requirements because lasers are a discrete wavelength light source.", [["these studies", "TEST", 3, 16], ["a laser diode source", "TREATMENT", 25, 45], ["power output advantages", "TREATMENT", 55, 78], ["several reduced engineering problems", "PROBLEM", 103, 139], ["optical \ue103ber coupling", "TREATMENT", 149, 170], ["wavelength \ue103ltering requirements", "TREATMENT", 217, 249], ["lasers", "TREATMENT", 258, 264], ["stability", "OBSERVATION_MODIFIER", 186, 195]]], ["Thus, use of this source provided more excitation power to the vessel and, with temperature stabilization, a more stable power and wavelength that any of the power LEDs tested. and (b, d) nucleoprotein (NP) assays were subjected to one-step qRT-PCR on an ABI7500 using the EZ1 SOP.", [["vessel", "ANATOMY", 63, 69], ["vessel", "MULTI-TISSUE_STRUCTURE", 63, 69], ["EZ1 SOP", "DNA", 273, 280], ["temperature stabilization", "TREATMENT", 80, 105], ["the power LEDs", "TEST", 154, 168], ["b, d) nucleoprotein (NP) assays", "TEST", 182, 213], ["PCR", "TEST", 245, 248], ["vessel", "ANATOMY", 63, 69]]], ["These tests were repeated on RNA extracts of the AR14 template (d) to demonstrate an 8 log LDR with independent curve fits per assay (<0.01% probability of single curve fit, Akaike's Informative Criteria test).", [["extracts", "ANATOMY", 33, 41], ["These tests", "TEST", 0, 11], ["RNA extracts", "TEST", 29, 41], ["assay", "TEST", 127, 132], ["single curve fit", "TEST", 156, 172]]], ["Means AE 95% confidence bands are shown.Far-red probe dyes and DNA stains enable RT-qPCR in bloodThese studies also suggested that the emission peaks of far red DNA stains were not consistently affected, with some exhibiting minimal inhibition (e.g. 13% for SYTO-17), and others over resulting in 700% signal increase (SYTO-63), probably on account of the differential cell permeability and individual binding properties of these stains to extracellular/ intracellular DNA and RNA ( and -64 might be more selective for DNA over RNA.", [["blood", "ANATOMY", 92, 97], ["cell", "ANATOMY", 369, 373], ["extracellular", "ANATOMY", 440, 453], ["intracellular", "ANATOMY", 455, 468], ["SYTO-17", "CHEMICAL", 258, 265], ["SYTO-17", "CHEMICAL", 258, 265], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["cell", "CELL", 369, 373], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 440, 453], ["intracellular DNA", "CELLULAR_COMPONENT", 455, 472], ["DNA", "CELLULAR_COMPONENT", 519, 522], ["Means AE", "TEST", 0, 8], ["confidence bands", "TEST", 13, 29], ["Far-red probe dyes", "TEST", 40, 58], ["DNA stains", "TEST", 63, 73], ["RT", "TEST", 81, 83], ["qPCR", "TEST", 84, 88], ["blood", "TEST", 92, 97], ["These studies", "TEST", 97, 110], ["the emission peaks", "PROBLEM", 131, 149], ["red DNA stains", "TEST", 157, 171], ["SYTO", "TEST", 258, 262], ["SYTO", "TEST", 319, 323], ["the differential cell permeability", "PROBLEM", 352, 386], ["these stains", "TEST", 424, 436], ["extracellular/ intracellular DNA", "PROBLEM", 440, 472], ["RNA", "TEST", 477, 480], ["DNA over RNA", "PROBLEM", 519, 531], ["blood", "ANATOMY", 92, 97], ["minimal", "OBSERVATION_MODIFIER", 225, 232], ["increase", "OBSERVATION_MODIFIER", 309, 317], ["differential cell permeability", "OBSERVATION", 356, 386], ["intracellular DNA", "OBSERVATION", 455, 472]]], ["In our whole blood assay format, however, SYTO-17 and SYTO-61 showed comparable levels of peak signal loss, with SYTO-60, -62, and -63 exhibiting a substantial increase in peak signal levels, followed by SYTO-59 and SYTO-64 (<20% peak signal increase).", [["whole blood", "ANATOMY", 7, 18], ["SYTO-61", "CHEMICAL", 54, 61], ["SYTO-17", "CHEMICAL", 42, 49], ["SYTO-61", "CHEMICAL", 54, 61], ["SYTO-59", "CHEMICAL", 204, 211], ["SYTO-64", "CHEMICAL", 216, 223], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["SYTO-17", "GENE_OR_GENE_PRODUCT", 42, 49], ["SYTO-61", "SIMPLE_CHEMICAL", 54, 61], ["SYTO-59", "GENE_OR_GENE_PRODUCT", 204, 211], ["SYTO-64", "GENE_OR_GENE_PRODUCT", 216, 223], ["our whole blood assay", "TEST", 3, 24], ["SYTO", "TEST", 42, 46], ["SYTO", "TEST", 54, 58], ["peak signal loss", "PROBLEM", 90, 106], ["SYTO", "TEST", 113, 117], ["a substantial increase in peak signal levels", "PROBLEM", 146, 190], ["SYTO", "TEST", 204, 208], ["SYTO", "TEST", 216, 220], ["peak signal loss", "OBSERVATION", 90, 106], ["substantial", "OBSERVATION_MODIFIER", 148, 159], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["peak signal", "OBSERVATION", 172, 183]]], ["These reports and our results therefore indicate SYTO-59, and -64 might have direct utility in substituting SYBR Green I on whole blood qPCR and RT-qPCR, especially since SYTO-64 has been previously demonstrated to have no impact on PCR efficiency.", [["whole blood", "ANATOMY", 124, 135], ["SYTO-64", "CHEMICAL", 171, 178], ["SYTO-59", "CHEMICAL", 49, 56], ["SYTO-59", "GENE_OR_GENE_PRODUCT", 49, 56], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 108, 120], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["SYTO-64", "GENE_OR_GENE_PRODUCT", 171, 178], ["SYBR Green I", "PROTEIN", 108, 120], ["SYTO", "PROTEIN", 171, 175], ["SYTO", "TEST", 49, 53], ["whole blood qPCR", "TEST", 124, 140], ["RT-qPCR", "TEST", 145, 152], ["SYTO", "TEST", 171, 175], ["PCR efficiency", "PROBLEM", 233, 247]]], ["33 In stark contrast to the nucleic acid stains, the probecompatible Quasar 670, Quasar 705 and CAL635 dyes consistently exhibited some 30-50% signal inhibition (Fig. 2c) .", [["nucleic acid", "CHEMICAL", 28, 40], ["Quasar 670", "CHEMICAL", 69, 79], ["Quasar 670", "CHEMICAL", 69, 79], ["CAL635", "CHEMICAL", 96, 102], ["the nucleic acid stains", "TEST", 24, 47], ["CAL635 dyes", "TREATMENT", 96, 107]]], ["However, all three allowed for 15.2 dB, 9.98 dB and 15.9 dB signal-to-noise ratios at their corresponding emission peaks ( Fig. S3A -C \u2020), respectively, relative to background blood emission spectra (Fig. S3L \u2020) .", [["blood", "ANATOMY", 176, 181], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["S3A", "PROTEIN", 128, 131], ["dB", "TEST", 36, 38], ["dB", "TEST", 45, 47], ["dB signal", "TEST", 57, 66], ["noise ratios", "TEST", 70, 82]]], ["Taken together, these results indicated that the \ue104uorogenic inhibition effect of blood might be restricted to green dyes and perhaps even yellow-orange dyes, making far red \ue104uorophores in general appropriate substitutes for qPCR and RT-qPCR.Far-red probe dyes and DNA stains enable RT-qPCR in bloodWe proceeded to investigate this by procuring the EZ1 assay GP probe conjugated to an array of far-red dye/quencher combinations, in the presence of 8% v/v fresh human blood ( Fig. 2d and S4 \u2020).", [["blood", "ANATOMY", 81, 86], ["blood", "ANATOMY", 293, 298], ["blood", "ANATOMY", 466, 471], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["green dyes", "SIMPLE_CHEMICAL", 110, 120], ["yellow-orange dyes", "SIMPLE_CHEMICAL", 138, 156], ["DNA", "CELLULAR_COMPONENT", 264, 267], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["human", "ORGANISM", 460, 465], ["blood", "ORGANISM_SUBSTANCE", 466, 471], ["EZ1", "PROTEIN", 348, 351], ["human", "SPECIES", 460, 465], ["human", "SPECIES", 460, 465], ["the \ue104uorogenic inhibition effect of blood", "PROBLEM", 45, 86], ["green dyes", "PROBLEM", 110, 120], ["yellow-orange dyes", "PROBLEM", 138, 156], ["far red \ue104uorophores", "PROBLEM", 165, 184], ["qPCR", "TEST", 224, 228], ["RT-qPCR", "TEST", 233, 240], ["Far-red probe dyes", "TEST", 241, 259], ["DNA stains", "TEST", 264, 274], ["RT", "TEST", 282, 284], ["qPCR", "TEST", 285, 289], ["blood", "TEST", 293, 298], ["the EZ1 assay GP probe", "TREATMENT", 344, 366], ["red dye/quencher combinations", "TREATMENT", 397, 426], ["blood", "ANATOMY", 293, 298]]], ["Using a custom optics array we con\ue103rmed adequately detectable signal emission with all dye/quencher combinations, although some data suggested quencher-speci\ue103c interactions with the biological matrix similar to other reports involving cell 34 and animal 35 assays (see ESI \u2020).", [["cell", "ANATOMY", 235, 239], ["matrix", "CELLULAR_COMPONENT", 193, 199], ["cell 34", "CELL", 235, 242], ["all dye/quencher combinations", "TREATMENT", 83, 112], ["some data", "TEST", 123, 132], ["quencher-speci\ue103c interactions", "PROBLEM", 143, 172]]], ["With signal nonetheless detected with all dyes, we triaged dye/ quencher pairs based on manufacturing cost, probe yield/ puri\ue103cation, and signal strength to arrive at Quasar 670/BHQ2 as the optimal substitute chemistry, particularly since stability issues were also experienced with BHQ3 probes between batches.Far-red probe dyes and DNA stains enable RT-qPCR in bloodWe thus proceeded to examine whether use of this \ue104uorophore/quencher combination with the Trombley GP assay (henceforth referred to as Trombley+ or GP+ assay; Table S3 \u2020) would affect RT-qPCR reaction performance.", [["blood", "ANATOMY", 363, 368], ["BHQ3", "CHEMICAL", 283, 287], ["BHQ3", "SIMPLE_CHEMICAL", 283, 287], ["DNA", "CELLULAR_COMPONENT", 334, 337], ["blood", "ORGANISM_SUBSTANCE", 363, 368], ["\ue104uorophore", "SIMPLE_CHEMICAL", 417, 427], ["Trombley", "PROTEIN", 503, 511], ["GP", "PROTEIN", 516, 518], ["dye/ quencher pairs", "TREATMENT", 59, 78], ["manufacturing cost", "TREATMENT", 88, 106], ["puri\ue103cation", "TREATMENT", 121, 132], ["stability issues", "PROBLEM", 239, 255], ["BHQ3 probes", "TREATMENT", 283, 294], ["Far-red probe dyes", "TEST", 311, 329], ["DNA stains", "TEST", 334, 344], ["RT", "TEST", 352, 354], ["qPCR", "TEST", 355, 359], ["blood", "TEST", 363, 368], ["this \ue104uorophore/quencher", "TREATMENT", 412, 436], ["the Trombley GP assay", "TEST", 454, 475], ["Trombley", "TEST", 503, 511], ["GP+ assay", "TEST", 516, 525], ["RT", "TEST", 552, 554], ["blood", "ANATOMY", 363, 368]]], ["Using RNA extracts of AR14 (Fig. 3a) , an analytical LLOD of 2 GE/reaction, an 8 log LDR and a % CV < 2.73% was determined for the GP+ assay, with an 103% reaction efficiency and 91.6% probability of single curve \ue103t against the FAM-labelled GP assay ( Fig. 1 ) using Akaike's Informative Criterion test.", [["extracts", "ANATOMY", 10, 18], ["FAM", "CHEMICAL", 228, 231], ["FAM", "SIMPLE_CHEMICAL", 228, 231], ["RNA extracts", "TEST", 6, 18], ["an analytical LLOD", "TEST", 39, 57], ["an 8 log LDR", "TEST", 76, 88], ["a % CV", "TEST", 93, 99], ["the GP+ assay", "TEST", 127, 140], ["an 103% reaction efficiency", "PROBLEM", 147, 174], ["single curve", "TEST", 200, 212], ["the FAM", "TEST", 224, 231], ["Akaike's Informative Criterion test", "TEST", 267, 302]]], ["Importantly, these \ue103ndings were reaffirmed by extending this analysis to PV14 (5.76 \u00c2 10 3 GE per ml LLOD; % CV < 1.26; 107% efficiency; 93.0% probability of single curve \ue103t; Fig. 3b ) and external surrogate standards for EBOV NAATs 36 (1.46 \u00c2 10 3 GE per ml LLOD; % CV < 2.81; 97.4% reaction efficiency; 94.9% probability of single curve \ue103t Fig. 3c ).", [["EBOV", "ORGANISM", 222, 226], ["EBOV", "SPECIES", 222, 226], ["PV14", "TEST", 73, 77], ["LLOD", "TEST", 101, 105], ["CV", "TEST", 109, 111], ["efficiency", "TEST", 125, 135], ["single curve \ue103t", "TEST", 158, 173], ["Fig.", "TEST", 175, 179], ["external surrogate standards", "TEST", 189, 217], ["EBOV NAATs", "TEST", 222, 232], ["LLOD", "TEST", 259, 263], ["CV", "TEST", 267, 269], ["reaction efficiency", "TEST", 284, 303], ["single curve", "TEST", 326, 338]]], ["Together, these results indicated that substitution of green probe chemistries with blood compatible, farred dye/quencher pairs such as Quasar670/BHQ2 may facilitate rapid transition of pre-validated, probe-based assays to whole blood-compatible RT-qPCR.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsIndividual assay performance notwithstanding, clinical diagnostic reliability pivots on the elimination, if possible, of false positive/negative results.", [["blood", "ANATOMY", 84, 89], ["blood", "ANATOMY", 229, 234], ["blood", "ANATOMY", 294, 299], ["BHQ2", "CHEMICAL", 146, 150], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["blood", "ORGANISM_SUBSTANCE", 294, 299], ["green probe chemistries", "TEST", 55, 78], ["farred dye/quencher pairs", "PROBLEM", 102, 127], ["whole blood", "TEST", 223, 234], ["Spectrophotometric signal detection", "TEST", 254, 289], ["blood", "TEST", 294, 299], ["qPCR", "TEST", 311, 315], ["RT-qPCR reactions", "TEST", 320, 337], ["Individual assay performance", "TEST", 337, 365], ["false positive/negative results", "PROBLEM", 458, 489]]], ["Plate-based NAATs such as the EZ1 assay minimize this risk by performing diagnostic reactions parallel to sample control reactions; separate positive and negative control reactions serve as process controls.", [["Plate-based NAATs", "TREATMENT", 0, 17], ["the EZ1 assay", "TEST", 26, 39], ["diagnostic reactions", "TEST", 73, 93], ["sample control reactions", "TEST", 106, 130], ["based", "ANATOMY_MODIFIER", 6, 11], ["NAATs", "OBSERVATION", 12, 17]]], ["Ensuring comparable levels of diagnostic reliability with point of care systems requires either multiplexed analysis for appropriate controls within a single reaction chamber, or micro\ue104uidic/ multiple reaction chamber detection of distinct templates.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsWe reasoned that a single reaction chamber solution would maintain minimal consumable costs for an ASSUREDcompatible point of need system.", [["blood", "ANATOMY", 290, 295], ["blood", "ORGANISM_SUBSTANCE", 290, 295], ["diagnostic reliability", "TEST", 30, 52], ["care systems", "TREATMENT", 67, 79], ["multiplexed analysis", "TEST", 96, 116], ["a single reaction chamber", "TREATMENT", 149, 174], ["micro\ue104uidic/ multiple reaction chamber", "TREATMENT", 179, 217], ["Spectrophotometric signal detection", "TEST", 250, 285], ["blood", "TEST", 290, 295], ["qPCR", "TEST", 307, 311], ["RT-qPCR reactions", "TEST", 316, 333], ["a single reaction chamber solution", "TREATMENT", 350, 384], ["multiple", "OBSERVATION_MODIFIER", 192, 200], ["reaction chamber", "OBSERVATION", 201, 217], ["distinct templates", "OBSERVATION", 231, 249]]], ["Where DNA intercalator stains such as SYBR Green I or SYTO-64 are used in a multiplexed assay approach, high resolution melting curve analysis can report individual amplicon generation.", [["SYTO-64", "CHEMICAL", 54, 61], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 38, 50], ["SYTO-64", "GENE_OR_GENE_PRODUCT", 54, 61], ["SYBR Green I or SYTO-64", "DNA", 38, 61], ["DNA intercalator stains", "TEST", 6, 29], ["SYTO", "TEST", 54, 58], ["a multiplexed assay approach", "TREATMENT", 74, 102], ["high resolution melting curve analysis", "TEST", 104, 142]]], ["37 On the other hand, implementation of this methodology requires either substantial, expert end-user input, 38 signi\ue103cant algorithm training 39, 40 and/or high complexity, costly instrumentation.", [["signi\ue103cant algorithm training", "TEST", 112, 141], ["costly instrumentation", "TREATMENT", 173, 195]]], ["40 Moreover, our immediately relevant EBOV GP and RP assays in the EZ1 kit involved probe-based detection.", [["EBOV", "ORGANISM", 38, 42], ["EZ1", "DNA", 67, 70], ["EBOV", "SPECIES", 38, 42], ["RP assays", "TEST", 50, 59]]], ["In these cases, existing assays can be readily multiplexed if no competitive PCR inhibition is experimentally evidenced, and \ue104uorophores with spectrally distinct emission peaks are used.", [["\ue104uorophores", "SIMPLE_CHEMICAL", 125, 136], ["existing assays", "TEST", 16, 31], ["competitive PCR inhibition", "PROBLEM", 65, 91], ["spectrally distinct emission peaks", "PROBLEM", 142, 176], ["emission peaks", "OBSERVATION", 162, 176]]], ["41 From an instrument perspective, probe multiplexing requires either multiple detectors, each equipped with its own detection range \ue103lter, or a single detector mounted with a moving \ue103lter wheel equipped with the relevant wavelength \ue103lters.", [["a moving \ue103lter wheel", "TREATMENT", 174, 194]]], ["Both solutions, however, bear manufacturing cost and instrument reliability implications due to the requirement for multiple and/or moving parts, which are ill-suited to \ue103eld deployment in resource-limited countries.", [["multiple and/or moving parts", "TREATMENT", 116, 144]]], ["This makes a single detector approach lacking \ue103ltering requirements, such as that proposed herein, a valuable Fig. 3 Assay migration to the blood-compatible Trombley+ chemistry has no impact on assay performance.", [["blood", "ANATOMY", 140, 145], ["Trombley", "CHEMICAL", 157, 165], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["Trombley+", "SIMPLE_CHEMICAL", 157, 166], ["the blood", "TEST", 136, 145], ["assay performance", "TEST", 194, 211]]], ["Triplicate ABI7500 reactions with the Trombley+ GP assay chemistry (GP+) on 10-fold serial dilutions of RNA extracted from AR14 EBOV surrogate (a), PV14 EBOV surrogate (b) and National Institute of Biological Standards and Controls (NIBSC) Ebola virus NAAT standard (c) suggest retention of the template concentration-dependent 8 log-linear dynamic range and <10 genome equivalent per reaction LLOD.", [["AR14 EBOV", "ORGANISM", 123, 132], ["Ebola virus", "ORGANISM", 240, 251], ["Ebola virus", "SPECIES", 240, 251], ["Ebola virus", "SPECIES", 240, 251], ["the Trombley", "TEST", 34, 46], ["GP assay chemistry", "TEST", 48, 66], ["GP", "TEST", 68, 70], ["serial dilutions of RNA", "TREATMENT", 84, 107], ["Biological Standards", "TREATMENT", 198, 218], ["Ebola virus NAAT", "TEST", 240, 256], ["the template concentration", "TEST", 291, 317]]], ["To compare instrument performance (d), bloodfree 20 ml (ABI7500) and 62.5 ml reactions (QuRapID) on AR14 RNA extracts were carried out in parallel, demonstrating comparable reaction kinetics and Ct (exponential onset) values.", [["extracts", "ANATOMY", 109, 117], ["extracts", "ORGANISM_SUBSTANCE", 109, 117], ["AR14", "SPECIES", 100, 104], ["AR14 RNA extracts", "TREATMENT", 100, 117], ["comparable reaction kinetics", "PROBLEM", 162, 190], ["Ct", "TEST", 195, 197], ["reaction kinetics", "OBSERVATION", 173, 190]]], ["Means AE 95% confidence bands are shown in (a-c).", [["Means AE", "TEST", 0, 8], ["confidence bands", "TEST", 13, 29]]], ["Individual replicates are shown in (d), with the inset spectrophotometric traces demonstrating example amplification spectra (Y axis, 5500-10 500 AFU) obtained across 665-675 nm (X axis) at each cycle (Z axis; depth) in the QuRapID reactions, with coloured lines corresponding to spectra across cycles 10-22. solution.", [["the inset spectrophotometric traces", "TEST", 45, 80], ["the QuRapID reactions", "PROBLEM", 220, 241], ["coloured lines", "TREATMENT", 248, 262], ["spectra across cycles", "TEST", 280, 301], ["solution", "TREATMENT", 309, 317], ["coloured lines", "OBSERVATION", 248, 262]]], ["Although our modelling efforts con\ue103rmed that mathematical 42,43 spectral unmixing allowed for concomitant use of Quasar 670, Quasar 705 (duplex) and CAL635 (triplex; see ESI \u2020), multiplexing of the GP, NP and RP assays resulted in loss of sensitivity.", [["Quasar 705", "CHEMICAL", 125, 135], ["spectral unmixing", "TEST", 64, 81], ["NP and RP assays", "TEST", 202, 218], ["loss of sensitivity", "PROBLEM", 231, 250]]], ["We therefore focused on demonstrating robust proof of principle for the platform on a singleplex format and opted for de\ue103ning key multiplexing parameters through computational modelling based on the highly reliable 44 kinetic spectral ratiometry 45 method and the principles of the 2 \u00c0DDC t approach 46 (see ESI, Fig. S5 \u2020) .Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsThese modelling results justi\ue103ed the use of spectrophotometry in data acquisition for a blood-compatible point of care instrument, as it would support both DNA stain high resolution melting analysis assays and quantitative, multiplexed probebased assays.", [["blood", "ANATOMY", 365, 370], ["blood", "ANATOMY", 496, 501], ["blood", "ORGANISM_SUBSTANCE", 365, 370], ["blood", "ORGANISM_SUBSTANCE", 496, 501], ["DNA", "CELLULAR_COMPONENT", 564, 567], ["a singleplex format", "TREATMENT", 84, 103], ["Spectrophotometric signal detection", "TEST", 325, 360], ["blood", "TEST", 365, 370], ["qPCR", "TEST", 382, 386], ["RT-qPCR reactions", "TEST", 391, 408], ["spectrophotometry in data acquisition", "TEST", 452, 489], ["a blood", "TEST", 494, 501], ["care instrument", "TREATMENT", 522, 537], ["DNA stain", "TEST", 564, 573], ["multiplexed probebased assays", "TEST", 632, 661]]], ["Consequently, our \ue103nal excitation/emission detection array was determined to involve an Ocean Optics Maya LSL tuned to detect all light in the range 600-800 nm.", [["our \ue103nal excitation/emission detection array", "TEST", 14, 58]]], ["To offer the capacity for parallel, independent sample testing, the instrument was also con\ue103gured to offer 8 independent sample wells; this necessitated a custom octofurcated \ue103ber (Fig. 4a ) with a shared spectrophotometer end consisting of 8 \u00c2 0.22 NA, low OH, 200 mm cored \ue103ber terminating in a single keyed SMA connector attached to the spectrophotometer.", [["OH", "CHEMICAL", 258, 260], ["OH", "CHEMICAL", 258, 260], ["SMA connector", "PROTEIN", 310, 323], ["independent sample testing", "TEST", 36, 62], ["a custom octofurcated \ue103ber", "TREATMENT", 153, 179], ["a shared spectrophotometer end", "TREATMENT", 196, 226], ["low OH, 200 mm cored \ue103ber", "TREATMENT", 254, 279], ["a single keyed SMA connector", "TREATMENT", 295, 323], ["SMA", "ANATOMY", 310, 313]]], ["In order to allow random access and to facilitate the use of a single shared spectrophotometer, each well was illuminated individually so that any spectra observed could be attributed to a speci\ue103c sample.", [["a single shared spectrophotometer", "TREATMENT", 61, 94], ["a speci\ue103c sample", "TEST", 187, 203]]], ["The emission/collection legs of the \ue103bers terminated at one end at an individual 635 nm laser diode per reaction position and the other located above the reaction vessel itself, into a barrel lens for focusing and collimating the excitation emission ( Fig. 4b and c ).", [["vessel", "ANATOMY", 163, 169], ["legs", "ORGANISM_SUBDIVISION", 24, 28], ["vessel", "MULTI-TISSUE_STRUCTURE", 163, 169], ["\ue103bers", "PROTEIN", 36, 41], ["nm laser diode per reaction position", "TREATMENT", 85, 121], ["collimating the excitation emission", "TREATMENT", 214, 249], ["collection", "ANATOMY_MODIFIER", 13, 23], ["legs", "ANATOMY", 24, 28], ["reaction position", "OBSERVATION", 104, 121], ["reaction vessel", "OBSERVATION", 154, 169], ["barrel lens", "OBSERVATION", 185, 196]]], ["The laser diode was built into a housing with an SMA connector and 650 nm bandpass built in to remove any excitation outside of the 635 nm laser line (FB650-40, Thorlabs).", [["635 nm laser line", "CELL_LINE", 132, 149], ["FB650", "CELL_LINE", 151, 156], ["Thorlabs", "CELL_LINE", 161, 169], ["The laser diode", "TREATMENT", 0, 15], ["an SMA connector", "TREATMENT", 46, 62], ["nm laser line", "TREATMENT", 136, 149], ["FB650", "TEST", 151, 156], ["SMA", "ANATOMY", 49, 52]]], ["A 650 nm longpass \ue103lter was built into the entrance of the MAYA LSL to further \ue103lter unwanted laser light from the resulting emission spectra.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsTo con\ue103rm that implementation of this emission/detection chemistry and optics array would perform as expected, we \ue103rst built a single well, Peltier-based thermal cycling testing rig (Fig. 4b ) around our spectrophotometric testing array.", [["blood", "ANATOMY", 182, 187], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["650 nm longpass \ue103lter", "DNA", 2, 23], ["MAYA LSL", "PROTEIN", 59, 67], ["A 650 nm longpass \ue103lter", "TREATMENT", 0, 23], ["laser light", "TREATMENT", 94, 105], ["Spectrophotometric signal detection", "TEST", 142, 177], ["blood", "TEST", 182, 187], ["qPCR", "TEST", 199, 203], ["RT-qPCR reactions", "TEST", 208, 225], ["this emission/detection chemistry", "TEST", 258, 291], ["thermal cycling testing rig", "TREATMENT", 379, 406], ["our spectrophotometric testing array", "TEST", 425, 461], ["650 nm", "OBSERVATION_MODIFIER", 2, 8], ["MAYA LSL", "OBSERVATION", 59, 67]]], ["We also mold-manufactured a custom designed reaction consumable, molded from a thermally conductive (15 W m \u00c01 K \u00c01 ) carbon loaded polypropylene compound consisting of 56% carbon (Lati SpA, Vedano Olona, Italy) with an easy handling puck and corresponding clear optical lid (Fig. 4d ) that reduced the thermal energy requirements for freezing and rapid thermal cycling.", [["carbon", "CHEMICAL", 173, 179], ["carbon", "CHEMICAL", 118, 124], ["polypropylene", "CHEMICAL", 132, 145], ["carbon", "CHEMICAL", 173, 179], ["carbon", "SIMPLE_CHEMICAL", 173, 179], ["a custom designed reaction", "PROBLEM", 26, 52], ["a thermally conductive (15 W m \u00c01 K \u00c01 ) carbon loaded polypropylene compound", "TREATMENT", 77, 154], ["56% carbon (Lati SpA, Vedano Olona", "TREATMENT", 169, 203], ["an easy handling puck", "TREATMENT", 217, 238], ["the thermal energy requirements", "PROBLEM", 299, 330], ["freezing", "PROBLEM", 335, 343], ["rapid thermal cycling", "TREATMENT", 348, 369]]], ["The vessel had an optically clear cap and top-down excitation/ emission measurement using the previously described re\ue104ectance probe.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsWe next proceeded to test the ampli\ue103cation efficiency for the blood-compatible Trombley+ assay (Quasar 670/BHQ2 GP probe) on AR14 RNA extracts across the diagnostic laboratory standard ABI7500 instrument and consumables, vs. our testing rig (Fig. 4b) .", [["vessel", "ANATOMY", 4, 10], ["blood", "ANATOMY", 172, 177], ["blood", "ANATOMY", 277, 282], ["extracts", "ANATOMY", 349, 357], ["vessel", "MULTI-TISSUE_STRUCTURE", 4, 10], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["blood", "ORGANISM_SUBSTANCE", 277, 282], ["re\ue104ectance probe", "DNA", 115, 131], ["emission measurement", "TEST", 63, 83], ["the previously described re\ue104ectance probe", "TREATMENT", 90, 131], ["Spectrophotometric signal detection", "TEST", 132, 167], ["blood", "TEST", 172, 177], ["qPCR", "TEST", 189, 193], ["RT-qPCR reactions", "TEST", 198, 215], ["the blood", "TEST", 273, 282], ["our testing rig", "TEST", 440, 455], ["vessel", "ANATOMY", 4, 10], ["optically", "OBSERVATION_MODIFIER", 18, 27], ["clear", "OBSERVATION", 28, 33], ["cap", "OBSERVATION_MODIFIER", 34, 37], ["top", "OBSERVATION_MODIFIER", 42, 45]]], ["As the ABI7500 uses onset of ampli\ue103cation threshold cycle (Ct) calling as well as curve smoothening algorithms, 47 we developed a live Ct calling protocol based on real time data processing using the raw \ue104uorescence values obtained during the run.", [["ABI7500", "CHEMICAL", 7, 14], ["ABI7500", "DNA", 7, 14], ["ampli\ue103cation threshold cycle", "TREATMENT", 29, 57], ["Ct", "TEST", 59, 61], ["a live Ct calling protocol", "TREATMENT", 128, 154], ["the raw \ue104uorescence values", "TEST", 196, 222]]], ["Data was \ue103rst baselined by averaging the \ue104uorescence values observed in the 5 cycles prior to any \ue104uorescence rise.", [["any \ue104uorescence rise", "PROBLEM", 94, 114]]], ["These new values were then screened to determine the highest \ue104uorescence observed in each channel and a relative \ue104uorescence value for each well was determined by dividing each cycles' observed \ue104uorescence values by this maximum value and a graph of cycle against relative \ue104uorescence on a 0-100 scale was plotted.", [["These new values", "TEST", 0, 16], ["relative \ue104uorescence", "PROBLEM", 264, 284]]], ["The cycle number at which a 10% increase in \ue104uorescence over baseline was taken as the Ct.", [["the Ct", "TEST", 83, 89], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["The results indicated comparable reaction rates and Ct values across the two platforms (Ct 9.50 and 10.5, respectively; Fig. 3d ), despite the markedly different reaction volumes, consumable thermal properties, ramping rates, instrument optics and signal processing algorithms, supporting further use of this real time thermal cycling system.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsSingle chamber, phase transition, blood-compatible RT-qPCR with no pre-processingSpectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsPhase transition, such as ice crystal formation during freezing, can release intracellular contents by disrupting cytosolic and nuclear membranes.", [["blood", "ANATOMY", 382, 387], ["blood", "ANATOMY", 459, 464], ["blood", "ANATOMY", 546, 551], ["intracellular", "ANATOMY", 666, 679], ["cytosolic", "ANATOMY", 703, 712], ["nuclear membranes", "ANATOMY", 717, 734], ["blood", "ORGANISM_SUBSTANCE", 382, 387], ["blood", "ORGANISM_SUBSTANCE", 459, 464], ["blood", "ORGANISM_SUBSTANCE", 546, 551], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 666, 679], ["cytosolic", "CELLULAR_COMPONENT", 703, 712], ["nuclear membranes", "CELLULAR_COMPONENT", 717, 734], ["reaction rates", "TEST", 33, 47], ["Ct values", "TEST", 52, 61], ["the two platforms", "TEST", 69, 86], ["Ct", "TEST", 88, 90], ["the markedly different reaction volumes", "PROBLEM", 139, 178], ["consumable thermal properties", "TREATMENT", 180, 209], ["ramping rates", "TEST", 211, 224], ["instrument optics", "TEST", 226, 243], ["signal processing algorithms", "TEST", 248, 276], ["this real time thermal cycling system", "TREATMENT", 304, 341], ["Spectrophotometric signal detection", "TEST", 342, 377], ["blood", "TEST", 382, 387], ["qPCR", "TEST", 399, 403], ["RT-qPCR reactions", "TEST", 408, 425], ["Single chamber, phase transition", "TEST", 425, 457], ["blood", "TEST", 459, 464], ["RT-qPCR", "TEST", 476, 483], ["pre-processingSpectrophotometric signal detection", "TEST", 492, 541], ["blood", "TEST", 546, 551], ["qPCR", "TEST", 563, 567], ["RT-qPCR reactions", "TEST", 572, 589], ["Phase transition", "PROBLEM", 589, 605], ["ice crystal formation", "PROBLEM", 615, 636], ["disrupting cytosolic and nuclear membranes", "PROBLEM", 692, 734], ["markedly", "OBSERVATION_MODIFIER", 143, 151], ["different", "OBSERVATION_MODIFIER", 152, 161], ["reaction volumes", "OBSERVATION", 162, 178], ["intracellular contents", "OBSERVATION", 666, 688], ["nuclear membranes", "OBSERVATION", 717, 734]]], ["Protein denaturation at high temperatures can also disrupt ribonucleoprotein complexes, thereby releasing nucleic acids for analytical assays.", [["nucleic acids", "CHEMICAL", 106, 119], ["nucleic acids", "SIMPLE_CHEMICAL", 106, 119], ["ribonucleoprotein complexes", "PROTEIN", 59, 86], ["Protein denaturation", "PROBLEM", 0, 20], ["high temperatures", "PROBLEM", 24, 41], ["releasing nucleic acids", "TREATMENT", 96, 119], ["analytical assays", "TEST", 124, 141], ["denaturation", "OBSERVATION", 8, 20], ["ribonucleoprotein complexes", "OBSERVATION", 59, 86]]], ["Used together, it has been proposed that the two processes might enable access to bacterial DNA templates for real time PCR in a single chamber system without the need for any biological sample preprocessing (WO/2011/157989).", [["DNA", "CELLULAR_COMPONENT", 92, 95], ["bacterial DNA templates", "DNA", 82, 105], ["bacterial DNA templates", "TREATMENT", 82, 105], ["real time PCR", "TEST", 110, 123]]], ["We hypothesized that these processes would also stress viral particle structures adequately to allow for RT-PCR detection of viral RNA in a single reaction chamber.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsWe sought to test the hypothesis with MS2 coliphage virions (Armored RNA\u00ae), reasoning that proof of principle on such a robust template would likely extend to lipid-enveloped viruses and the more fragile Filoviruses.", [["blood", "ANATOMY", 204, 209], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["viral RNA", "RNA", 125, 134], ["stress viral particle structures", "PROBLEM", 48, 80], ["RT-PCR detection", "TEST", 105, 121], ["viral RNA", "PROBLEM", 125, 134], ["a single reaction chamber", "TREATMENT", 138, 163], ["Spectrophotometric signal detection", "TEST", 164, 199], ["blood", "TEST", 204, 209], ["qPCR", "TEST", 221, 225], ["RT-qPCR reactions", "TEST", 230, 247], ["MS2 coliphage virions", "TREATMENT", 285, 306], ["a robust template", "TREATMENT", 365, 382], ["lipid", "TREATMENT", 406, 411], ["enveloped viruses", "PROBLEM", 412, 429], ["the more fragile Filoviruses", "PROBLEM", 434, 462], ["viral particle", "OBSERVATION", 55, 69], ["viral RNA", "OBSERVATION", 125, 134], ["viruses", "OBSERVATION", 422, 429], ["more fragile", "OBSERVATION_MODIFIER", 438, 450], ["Filoviruses", "OBSERVATION", 451, 462]]], ["22 Manual preliminary experiments suggested $10 cycles of freezing and 95 C denaturation were optimal for releasing RNA from MS2 virions, but that the high levels of RNase activity in bio\ue104uids between ambient temperatures and 85 C (ref.", [["RNase", "GENE_OR_GENE_PRODUCT", 166, 171], ["RNase", "PROTEIN", 166, 171], ["freezing and 95 C denaturation", "TREATMENT", 58, 88], ["releasing RNA from MS2 virions", "PROBLEM", 106, 136], ["ambient temperatures", "TEST", 201, 221]]], ["We therefore decided to carry out further experiments using automated thermal cycling capable of reaching \u00c020 C, and replaced 95 C denaturation with simple thawing.", [["\u00c020 C", "CELL_LINE", 106, 111], ["simple thawing", "TREATMENT", 149, 163]]], ["This would also allow us to further examine whether denaturation was indeed essential in releasing viral RNA genomes from MS2 virions, for them to be accessed by reverse transcriptase.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsThus, we assembled a Peltier thermal cycling rig around the custom blood-compatible spectrophotometric emission/ detection array used in our earlier experiments, modi\ue103ed through use of a heat removal module (HRM).", [["blood", "ANATOMY", 224, 229], ["blood", "ANATOMY", 334, 339], ["MS2 virions", "ORGANISM", 122, 133], ["blood", "ORGANISM_SUBSTANCE", 224, 229], ["blood", "ORGANISM_SUBSTANCE", 334, 339], ["viral RNA genomes", "DNA", 99, 116], ["reverse transcriptase", "PROTEIN", 162, 183], ["denaturation", "PROBLEM", 52, 64], ["releasing viral RNA genomes from MS2 virions", "PROBLEM", 89, 133], ["Spectrophotometric signal detection", "TEST", 184, 219], ["blood", "TEST", 224, 229], ["qPCR", "TEST", 241, 245], ["RT-qPCR reactions", "TEST", 250, 267], ["a Peltier thermal cycling rig", "TREATMENT", 286, 315], ["spectrophotometric emission/ detection array", "TEST", 351, 395], ["a heat removal module", "TREATMENT", 452, 473]]], ["This is a \ue104uid cooled heatsink whereby the \ue104uid, in this case at 35 C, is held at a temperature intermediate of the PCR extension temperature and the freezing point (WO2010010361) to enable rapid \u00c020 C cooling.", [["rapid \u00c020 C cooling", "TREATMENT", 190, 209]]], ["This relies on high levels of thermal isolation of the heatsink from the sample such that the DT of the Peltier can be relied upon to drive the reaction \ue104uid to in excess of 50 C below that of the HRM and hence make possible freezing in higher temperature environments.", [["thermal isolation", "TREATMENT", 30, 47], ["freezing in higher temperature environments", "PROBLEM", 225, 268]]], ["In these tests, we also used the Trombley+ assay and 10 5 GE of our custom-manufactured AR14 EBOV Armored RNA\u00ae MS2 coliphage construct.", [["AR14", "ORGANISM", 88, 92], ["EBOV", "ORGANISM", 93, 97], ["AR14 EBOV Armored RNA\u00ae", "DNA", 88, 110], ["MS2 coliphage construct", "DNA", 111, 134], ["these tests", "TEST", 3, 14], ["the Trombley+ assay", "TREATMENT", 29, 48], ["our custom", "TREATMENT", 64, 74], ["coliphage construct", "OBSERVATION", 115, 134]]], ["Finally, given our results on RT-PCR enzyme tolerance for blood, we performed this test with the ABI Fast virus master mix, which is used in the EZ1 diagnostic assay.", [["blood", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["RT-PCR enzyme tolerance", "TEST", 30, 53], ["this test", "TEST", 78, 87], ["the ABI", "TEST", 93, 100]]], ["With the device achieving overall sample-to-answer in 70 minutes ahead of any additional RT-PCR thermal cycling timing optimization beyond the standard Taqman\u00ae cycling timings used in the EZ1 assay, these results reproduced the outcome of the manual study, identifying 8-10 freeze-thaw cycles as the optimal viral particle disruption range (Fig. 5a, S7A and B \u2020) .", [["Taqman\u00ae", "SIMPLE_CHEMICAL", 152, 159], ["S7A", "PROTEIN", 350, 353], ["the device", "TREATMENT", 5, 15], ["any additional RT-PCR thermal cycling timing optimization", "TREATMENT", 74, 131], ["the standard Taqman\u00ae cycling timings", "TREATMENT", 139, 175], ["the EZ1 assay", "TEST", 184, 197], ["the manual study", "TEST", 239, 255], ["freeze-thaw cycles", "TREATMENT", 274, 292], ["viral particle", "OBSERVATION", 308, 322]]], ["Moreover, the experiment con\ue103rmed that denaturation was not necessary for Fig. 4 The QuRapID platform.", [["denaturation", "PROBLEM", 39, 51], ["Fig", "PROBLEM", 74, 77], ["The QuRapID platform", "TREATMENT", 81, 101]]], ["A custom octofurcated fibre shares a single spectrophotometer end across 8 separate laser diodes and 8 separate optical heads (a) to allow for medium throughput through 8 independently operated, random access workstations (b).", [["A custom octofurcated fibre", "TREATMENT", 0, 27], ["a single spectrophotometer end across 8 separate laser diodes", "TREATMENT", 35, 96]]], ["The workstation contains the Peltier assay station connected to a temperature controller operated by a Raspberry Pi, which is connected to the laser diodes for light emission and the spectrophotometer for data acquisition and processing, whilst being operated by a touch screen compatible with personal protective gloves (c).", [["Raspberry Pi", "CHEMICAL", 103, 115], ["a temperature controller", "TREATMENT", 64, 88], ["the laser diodes", "TREATMENT", 139, 155], ["light emission", "TEST", 160, 174], ["data acquisition", "TEST", 205, 221], ["a touch screen", "TEST", 263, 277], ["personal protective gloves", "TREATMENT", 294, 320], ["Raspberry Pi", "OBSERVATION", 103, 115]]], ["Each assay station accepts a single, custom fabricated, disposable puck sealed with a custom optical lid designed for easy handling (d).", [["a single, custom fabricated, disposable puck", "TREATMENT", 27, 71], ["a custom optical lid", "TREATMENT", 84, 104]]], ["The resulting 20 kg, QuRapID instrument is a tabletop-sized device powered by a car alternator, car battery or mains electricity featuring eight independently operated assay stations, with software designed for simple (video online) end-user interaction in full personal protective equipment, suited for field deployment in a ruggedized case and medium throughput testing in a laboratory infrastructure-free manner (e).Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsaccessing viral nucleic acids for this form of viral particle disruption, even for the highly robust MS2 coliphage virions.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsWe therefore proceeded next to examine Trombley+ assay tolerance for blood by progressively increasing blood input from 0% to 10% v/v in reactions containing 6.6 \u00c2 10 8 GE per reaction AR14 (Fig. 5b, S7C and D \u2020).", [["blood", "ANATOMY", 459, 464], ["blood", "ANATOMY", 665, 670], ["blood", "ANATOMY", 777, 782], ["blood", "ANATOMY", 811, 816], ["nucleic acids", "CHEMICAL", 518, 531], ["blood", "ORGANISM_SUBSTANCE", 459, 464], ["blood", "ORGANISM_SUBSTANCE", 665, 670], ["blood", "ORGANISM_SUBSTANCE", 777, 782], ["blood", "ORGANISM_SUBSTANCE", 811, 816], ["QuRapID instrument", "TREATMENT", 21, 39], ["a tabletop-sized device", "TREATMENT", 43, 66], ["full personal protective equipment", "TREATMENT", 257, 291], ["medium throughput testing", "TEST", 346, 371], ["Spectrophotometric signal detection", "TEST", 419, 454], ["blood", "TEST", 459, 464], ["qPCR", "TEST", 476, 480], ["RT-qPCR", "TEST", 485, 492], ["viral nucleic acids", "TREATMENT", 512, 531], ["viral particle disruption", "PROBLEM", 549, 574], ["Spectrophotometric signal detection", "TEST", 625, 660], ["blood", "TEST", 665, 670], ["qPCR", "TEST", 682, 686], ["RT-qPCR reactions", "TEST", 691, 708], ["blood", "TEST", 777, 782], ["progressively increasing blood input", "PROBLEM", 786, 822], ["v/v in reactions", "PROBLEM", 838, 854], ["Fig.", "TEST", 899, 903], ["viral particle disruption", "OBSERVATION", 549, 574], ["MS2", "OBSERVATION", 603, 606], ["coliphage virions", "OBSERVATION", 607, 624]]], ["Thus, with the blood-free reactions returning a Ct of 15, an <128\u00c2 loss of signal (Ct of 22) was observed at low blood concentrations; however, the trend was reversed to peak at 8% v/v blood with only a 4\u00c2 signal loss (i.e. Ct 17).", [["blood", "ANATOMY", 15, 20], ["blood", "ANATOMY", 113, 118], ["blood", "ANATOMY", 185, 190], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["the blood-free reactions", "PROBLEM", 11, 35], ["a Ct", "TEST", 46, 50], ["an <128\u00c2 loss of signal", "PROBLEM", 58, 81], ["Ct", "TEST", 83, 85], ["low blood concentrations", "PROBLEM", 109, 133], ["peak", "TEST", 170, 174], ["a 4\u00c2 signal loss", "PROBLEM", 201, 217], ["Ct", "TEST", 224, 226]]], ["Crucially, this small signal loss only affected the assay lower limit of quanti\ue103cation (LLOQ; Fig. 5c ), as 66, and 6 GE of AR14 were successfully discriminated from a no template, 8% v/v blood-containing reaction, but the two positive samples were indistinguishable between them.", [["blood", "ANATOMY", 188, 193], ["samples", "ANATOMY", 236, 243], ["AR14", "GENE_OR_GENE_PRODUCT", 124, 128], ["blood", "ORGANISM_SUBSTANCE", 188, 193], ["AR14", "PROTEIN", 124, 128], ["this small signal loss", "PROBLEM", 11, 33], ["the assay", "TEST", 48, 57], ["LLOQ", "TEST", 88, 92], ["template", "TEST", 171, 179], ["8% v/v blood-containing reaction", "PROBLEM", 181, 213], ["the two positive samples", "PROBLEM", 219, 243], ["small", "OBSERVATION_MODIFIER", 16, 21], ["signal loss", "OBSERVATION", 22, 33], ["lower limit", "OBSERVATION_MODIFIER", 58, 69], ["no", "UNCERTAINTY", 168, 170]]], ["These results indicated that, although quanti\ue103cation at the lower end of the Trombley+ assay could be compromised in the presence of blood, detection could still be reliably achieved.", [["blood", "ANATOMY", 133, 138], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["the Trombley+ assay", "TEST", 73, 92], ["lower", "ANATOMY_MODIFIER", 60, 65]]], ["On the basis of the 1.4 \u00c2 10 4 PFU per ml whole blood detection limit for the laboratory-based Trombley assay, 9 we reasoned that use of 5 microliters of whole blood in our method, i.e. 70 PFUs per reaction in a volume compatible with digital venipuncture, would match the performance of the laboratory method whilst remaining above the Fig. 5 Optimised, controlled freeze-thawing of RNA viruses in probe-based qRT-PCR containing blood or serum. (a) Optimal freeze-thaw extraction of RNA from viruses within qRT-PCR master mixes in the same reaction vessel is achieved with 8-10 freeze-thaw cycles as determined through threshold cycle (Ct) detection of template amplification using the Trombley+ GP assay against 10 5 GE per reaction of AR14 templates.", [["blood", "ANATOMY", 48, 53], ["whole blood", "ANATOMY", 154, 165], ["blood", "ANATOMY", 430, 435], ["serum", "ANATOMY", 439, 444], ["vessel", "ANATOMY", 550, 556], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["blood", "ORGANISM_SUBSTANCE", 430, 435], ["serum", "ORGANISM_SUBSTANCE", 439, 444], ["vessel", "MULTI-TISSUE_STRUCTURE", 550, 556], ["AR14", "SIMPLE_CHEMICAL", 738, 742], ["qRT-PCR master mixes", "DNA", 508, 528], ["whole blood detection", "TEST", 42, 63], ["the laboratory", "TEST", 74, 88], ["Trombley assay", "TEST", 95, 109], ["digital venipuncture", "TREATMENT", 235, 255], ["the laboratory method", "TEST", 288, 309], ["RNA viruses", "PROBLEM", 384, 395], ["probe-based qRT", "TEST", 399, 414], ["PCR", "TEST", 415, 418], ["blood or serum", "TEST", 430, 444], ["Optimal freeze", "TREATMENT", 450, 464], ["thaw extraction", "TREATMENT", 465, 480], ["RNA from viruses", "PROBLEM", 484, 500], ["qRT", "TEST", 508, 511], ["template amplification", "TREATMENT", 654, 676], ["the Trombley+ GP assay", "TEST", 683, 705], ["AR14 templates", "TREATMENT", 738, 752], ["vessel", "ANATOMY", 550, 556]]], ["No blood was used in these reactions. (b) Increasing amounts of blood spiked into reactions containing 6.6 \u00c2 10 8 GE per reaction AR14 subjected to 10 automated freeze-thaw cycles results in a 2 Ct drop in GP Trombley+ assay performance (4\u00c2) against reactions containing no blood.", [["blood", "ANATOMY", 3, 8], ["blood", "ANATOMY", 64, 69], ["blood", "ANATOMY", 274, 279], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 274, 279], ["blood", "PROBLEM", 3, 8], ["Increasing amounts of blood spiked into reactions", "PROBLEM", 42, 91], ["a 2 Ct drop", "TEST", 191, 202], ["GP Trombley", "TEST", 206, 217], ["assay performance", "TEST", 219, 236], ["blood", "PROBLEM", 274, 279], ["blood", "ANATOMY", 3, 8]]], ["The Ct call in the absence of blood in the reaction (0% v/v final blood concentration) is used as an optimal performance reference. (c) Amplification discrimination for the Trombley+ assay between no template control (NTC) reactions, and reactions containing 66 GE of AR14.", [["blood", "ANATOMY", 30, 35], ["blood", "ANATOMY", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["AR14", "GENE_OR_GENE_PRODUCT", 268, 272], ["AR14", "PROTEIN", 268, 272], ["The Ct", "TEST", 0, 6], ["the reaction", "TEST", 39, 51], ["Amplification discrimination", "TEST", 136, 164], ["the Trombley+ assay", "TEST", 169, 188], ["template control (NTC) reactions", "PROBLEM", 200, 232]]], ["Reactions were spiked with 5 microliters of human blood (8% v/v final blood concentration in the reaction) and viral genomes were extracted in the qRT-PCR blood-containing mix using 8 freeze-thaw cycles. (d) Ten-fold serial dilutions in tissue culture media of tissue cultured derived, 700 PFU per ml Ebola virus were tested in three independent reactions using the Trombley+ GP assay.", [["blood", "ANATOMY", 50, 55], ["blood", "ANATOMY", 70, 75], ["blood", "ANATOMY", 155, 160], ["tissue", "ANATOMY", 237, 243], ["tissue", "ANATOMY", 261, 267], ["human", "ORGANISM", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["tissue", "TISSUE", 237, 243], ["tissue", "TISSUE", 261, 267], ["Ebola virus", "ORGANISM", 301, 312], ["viral genomes", "DNA", 111, 124], ["human", "SPECIES", 44, 49], ["Ebola virus", "SPECIES", 301, 312], ["human", "SPECIES", 44, 49], ["Ebola virus", "SPECIES", 301, 312], ["human blood", "TREATMENT", 44, 55], ["8% v/v final blood concentration", "TREATMENT", 57, 89], ["viral genomes", "PROBLEM", 111, 124], ["the qRT", "TEST", 143, 150], ["PCR blood", "TEST", 151, 160], ["Ten-fold serial dilutions", "TREATMENT", 208, 233], ["tissue culture", "TEST", 237, 251], ["Ebola virus", "PROBLEM", 301, 312], ["GP assay", "TEST", 376, 384]]], ["Fetal bovine serum was spiked into these reactions as a fresh patient sample matrix surrogate, to an 8% v/v final concentration. (e) Calibration of Ebola virus sample PFUs against GE content, as independently determined on the QuRapID under BSL4 testing using AR14 pre-qualification runs, reveals strong linear concordance between two Ebola virus strains diluted in FBS and the ArmoredRNA surrogate template (99.96% probability of single curve fit, Akaike's Informative Criteria test; individual replicates and 95% confidence bands shown). limit of quanti\ue103cation exhibited experimentally.", [["serum", "ANATOMY", 13, 18], ["FBS", "ANATOMY", 366, 369], ["Fetal", "ORGANISM_SUBSTANCE", 0, 5], ["bovine", "ORGANISM", 6, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["patient", "ORGANISM", 62, 69], ["Ebola virus", "ORGANISM", 148, 159], ["Ebola virus", "ORGANISM", 335, 346], ["FBS", "ORGANISM_SUBSTANCE", 366, 369], ["QuRapID", "DNA", 227, 234], ["BSL4", "DNA", 241, 245], ["bovine", "SPECIES", 6, 12], ["patient", "SPECIES", 62, 69], ["Ebola virus", "SPECIES", 148, 159], ["Ebola virus", "SPECIES", 335, 346], ["bovine", "SPECIES", 6, 12], ["Ebola virus", "SPECIES", 148, 159], ["Ebola virus", "SPECIES", 335, 346], ["Fetal bovine serum", "TEST", 0, 18], ["a fresh patient sample matrix surrogate", "TREATMENT", 54, 93], ["an 8% v/v final concentration", "TREATMENT", 98, 127], ["Ebola virus sample", "TEST", 148, 166], ["BSL4 testing", "TEST", 241, 253], ["strong linear concordance", "PROBLEM", 297, 322], ["two Ebola virus strains", "PROBLEM", 331, 354], ["FBS", "TEST", 366, 369], ["the ArmoredRNA surrogate template", "TREATMENT", 374, 407], ["single curve fit", "TEST", 431, 447], ["Akaike's", "TEST", 449, 457], ["Criteria test", "TEST", 470, 483], ["confidence bands", "TEST", 515, 531], ["Ebola virus", "OBSERVATION", 335, 346]]], ["Thus, the total reaction volume for our method was \ue103nalized at 62.5 ml containing a 5 ml blood sample (8% v/v).", [["blood sample", "ANATOMY", 89, 101], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["the total reaction volume", "TEST", 6, 31], ["our method", "TEST", 36, 46], ["blood sample", "TEST", 89, 101]]], ["To determine whether accurate sampling at this scale could take in the place in the \ue103eld we evaluated a range of IVD-grade, graduated plastic capillary samplers to observe a <3% standard deviation in 5 ml collection with the Pasteur pipette-like MicroSafe\u00ae capillaries (n \u00bc 20).", [["capillaries", "ANATOMY", 257, 268], ["capillary", "TISSUE", 142, 151], ["capillaries", "TISSUE", 257, 268], ["graduated plastic capillary samplers", "TREATMENT", 124, 160], ["a <3% standard deviation in 5 ml collection", "PROBLEM", 172, 215], ["the Pasteur pipette", "TEST", 221, 240]]], ["This was conducted by operators wearing BSL4 personal protective equipment comparable to that used by frontline healthcare workers in triage centers.Spectrophotometric signal detection for blood-containing qPCR and RT-qPCR reactionsHaving achieved an assay chemistry, detection system and sample volume predicted to match the diagnostic reliability of the laboratory-based Trombley assay, we proceeded to construct a prototype point-of-care instrument (Fig. 4d) .", [["blood", "ANATOMY", 189, 194], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["BSL4 personal protective equipment", "TREATMENT", 40, 74], ["Spectrophotometric signal detection", "TEST", 149, 184], ["blood", "TEST", 189, 194], ["qPCR", "TEST", 206, 210], ["RT-qPCR reactions", "TEST", 215, 232], ["an assay chemistry", "TEST", 248, 266]]], ["Importantly, this was designed for use in triage scenarios e.g. in emergency response primary care centers or in the vehicles of mobile outbreak response teams seeking to Quantitatively, Rapidly Identify (QuRapID) EBOV disease in symptomatic patients either off mains power or a car alternator power source.", [["EBOV disease", "DISEASE", 214, 226], ["EBOV", "ORGANISM", 214, 218], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["EBOV disease", "PROBLEM", 214, 226]]], ["Initially designed as a lightweight, A4-foot print format, the \ue103nal, 20 kg tabletop prototype sought to reduce the risk of unauthorized removal from triage centres and ensure robustness during transportation in e.g. off-road settings.", [["a lightweight", "TEST", 22, 35], ["unauthorized removal", "TREATMENT", 123, 143], ["triage centres", "TREATMENT", 149, 163], ["foot", "ANATOMY", 40, 44]]], ["In addition, this tabletop instrument featured 8 random access assay stations to allow for independent, parallel operation and a touch screen interface compatible with gloves.", [["this tabletop instrument", "TREATMENT", 13, 37], ["parallel operation", "TREATMENT", 104, 122], ["a touch screen interface", "TEST", 127, 151], ["gloves", "TREATMENT", 168, 174]]], ["A SOP was also devised (ESI video online and Fig. S8 \u2020) in line with the simplicity necessary for minimally trained frontline staff focusing on patient care in a high stress environment whilst in full personal protective equipment.", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["patient care", "TREATMENT", 144, 156]]], ["This included consumables design, automated buffer dispensing and secured thermal cycling that would minimize risk of environmental contamination, operator error or accidental sample release.Analytical sensitivity and speci\ue103city testing with live Ebola virusWith the outbreak ending by this time (November 2015) and the very limited number of new cases, the means for delivering evidence of clinical relevance with live EBOV were restricted to either stored samples or culture-derived EBOV tested in simulated patient samples.", [["sample", "ANATOMY", 176, 182], ["samples", "ANATOMY", 458, 465], ["samples", "ANATOMY", 518, 525], ["Ebola virusWith", "DISEASE", 247, 262], ["Ebola", "ORGANISM", 247, 252], ["EBOV", "ORGANISM", 420, 424], ["EBOV", "ORGANISM", 485, 489], ["patient", "ORGANISM", 510, 517], ["patient", "SPECIES", 510, 517], ["EBOV", "SPECIES", 420, 424], ["EBOV", "SPECIES", 485, 489], ["automated buffer dispensing", "TREATMENT", 34, 61], ["secured thermal cycling", "TREATMENT", 66, 89], ["environmental contamination", "PROBLEM", 118, 145], ["accidental sample release", "TREATMENT", 165, 190], ["Analytical sensitivity", "TEST", 191, 213], ["speci\ue103city testing", "TEST", 218, 236], ["live EBOV", "PROBLEM", 415, 424], ["culture", "TEST", 469, 476], ["EBOV", "PROBLEM", 485, 489]]], ["Previous reports indicated stored blood samples impacted efficient completion of PCR, 18,25 which motivated us to seek samples stored in the absence of additives known to impact PCR.", [["blood samples", "ANATOMY", 34, 47], ["samples", "ANATOMY", 119, 126], ["blood samples", "ORGANISM_SUBSTANCE", 34, 47], ["blood samples", "TEST", 34, 47], ["PCR", "TEST", 81, 84], ["impact PCR", "PROBLEM", 171, 181]]], ["However, anecdotal evidence indicated substantial operator variability in sampling and storage procedures throughout the West African outbreak.", [["substantial operator variability", "PROBLEM", 38, 70], ["storage procedures", "TREATMENT", 87, 105], ["substantial", "OBSERVATION_MODIFIER", 38, 49], ["variability", "OBSERVATION_MODIFIER", 59, 70]]], ["Therefore, to minimize the impact of such variability inherent to stored samples vs. what should be a minimal, direct sample analysis process, we elected to proceed with BSL4 laboratory testing with a range of live, culture-derived Filoviruses.", [["samples", "ANATOMY", 73, 80], ["Filoviruses", "CELL", 232, 243], ["BSL4 laboratory testing", "TEST", 170, 193], ["culture", "TEST", 216, 223], ["Filoviruses", "PROBLEM", 232, 243]]], ["On the other hand, collection of fresh human blood by digital venipuncture was prohibited in BSL4 for health and safety reasons.", [["blood", "ANATOMY", 45, 50], ["BSL4", "CHEMICAL", 93, 97], ["human", "ORGANISM", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["BSL4", "SIMPLE_CHEMICAL", 93, 97], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["fresh human blood", "PROBLEM", 33, 50], ["digital venipuncture", "TEST", 54, 74]]], ["As a result, fetal bovine serum (FBS) obtained without the use of anticoagulants or preservatives was used as a surrogate biological matrix to human blood.", [["fetal bovine serum", "ANATOMY", 13, 31], ["FBS", "ANATOMY", 33, 36], ["blood", "ANATOMY", 149, 154], ["fetal", "ORGANISM_SUBSTANCE", 13, 18], ["bovine", "ORGANISM", 19, 25], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["FBS", "ORGANISM_SUBSTANCE", 33, 36], ["matrix", "CELLULAR_COMPONENT", 133, 139], ["human", "ORGANISM", 143, 148], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["bovine", "SPECIES", 19, 25], ["human", "SPECIES", 143, 148], ["bovine", "SPECIES", 19, 25], ["human", "SPECIES", 143, 148], ["fetal bovine serum (FBS", "TEST", 13, 36], ["anticoagulants", "TREATMENT", 66, 80], ["preservatives", "TREATMENT", 84, 97]]], ["In doing so, we also acknowledged that direct volume substitution of blood with serum would double the \ue103nal concentration of serum components in our reactions, doubling in parallel their PCR inhibitory effects.Analytical sensitivity and speci\ue103city testing with live Ebola virusThus, the performance of the blood-compatible Trombley+ GP assay (Quasar 670/BHQ2) in ABI Fast virus master mix and our QuRapID prototype was evaluated against the Trombley/ ABI7500 FAST gold standard SOP with the same mastermix, the FAM-labelled GP assay, and a variety of Filoviruses (Table S2 \u2020) .", [["blood", "ANATOMY", 69, 74], ["serum", "ANATOMY", 80, 85], ["serum", "ANATOMY", 125, 130], ["blood", "ANATOMY", 306, 311], ["Ebola virus", "DISEASE", 266, 277], ["FAM", "CHEMICAL", 511, 514], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["Ebola virus", "ORGANISM", 266, 277], ["blood", "ORGANISM_SUBSTANCE", 306, 311], ["FAM", "SIMPLE_CHEMICAL", 511, 514], ["Ebola virus", "SPECIES", 266, 277], ["Ebola virus", "SPECIES", 266, 277], ["direct volume substitution of blood", "PROBLEM", 39, 74], ["serum", "TREATMENT", 80, 85], ["serum components", "PROBLEM", 125, 141], ["our reactions", "PROBLEM", 145, 158], ["Analytical sensitivity", "TEST", 210, 232], ["speci\ue103city testing", "TEST", 237, 255], ["live Ebola virus", "PROBLEM", 261, 277], ["the blood", "TEST", 302, 311], ["GP assay", "TEST", 333, 341], ["Quasar", "TEST", 343, 349], ["ABI Fast virus master mix", "TREATMENT", 363, 388], ["the FAM-labelled GP assay", "TEST", 507, 532], ["serum components", "OBSERVATION_MODIFIER", 125, 141]]], ["A\ue09der undertaking assay transfer to BSL4 and pre-quali\ue103cation with our AR14 standards ( Fig. 5d and S7E \u2020) , infectious, culture-propagated Filoviruses were serially diluted and tested at each resulting concentration on the QuRapID.", [["BSL4", "GENE_OR_GENE_PRODUCT", 35, 39], ["Filoviruses", "CELL", 139, 150], ["BSL4", "DNA", 35, 39], ["infectious", "PROBLEM", 108, 118], ["culture", "TEST", 120, 127], ["propagated Filoviruses", "TREATMENT", 128, 150], ["the QuRapID", "TREATMENT", 219, 230], ["infectious", "OBSERVATION", 108, 118]]], ["Alternatively, the serially diluted viruses were extracted, puri\ue103ed and assayed according to the EZ1 assay SOP.", [["EZ1", "PROTEIN", 97, 100], ["the serially diluted viruses", "PROBLEM", 15, 43]]], ["The results indicated the Trombley+/QuRapID system could detect as little as a 1.4 \u00c2 10 3 PFU per ml whole bloodequivalent of live EBOV Yambuka Ecran (Fig. 5d and S7F \u2020) , with a LLOQ of 1.4 \u00c2 10 4 PFU per ml whole blood-equivalent.", [["blood", "ANATOMY", 215, 220], ["Trombley+", "SIMPLE_CHEMICAL", 26, 35], ["EBOV", "ORGANISM", 131, 135], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["EBOV", "SPECIES", 131, 135], ["the Trombley+/QuRapID system", "PROBLEM", 22, 50], ["a LLOQ", "TEST", 177, 183]]], ["More importantly, however, performance across capsid surrogate viruses, EBOV Yambuka-Ecran and EBOV Makona Guinea was consistent in terms of the analyte that is quanti-\ue103ed by RT-qPCR i.e. genome equivalents, rather than the number of viable virions (Fig. 5e) .", [["virions", "ANATOMY", 241, 248], ["EBOV Yambuka-Ecran", "ORGANISM", 72, 90], ["EBOV Makona Guinea", "ORGANISM", 95, 113], ["EBOV Makona Guinea", "SPECIES", 95, 113], ["EBOV", "SPECIES", 95, 99], ["capsid surrogate viruses", "PROBLEM", 46, 70], ["EBOV Yambuka", "TEST", 72, 84], ["the analyte", "TREATMENT", 141, 152], ["quanti", "TEST", 161, 167], ["genome equivalents", "OBSERVATION", 188, 206]]], ["Crucially, no false positives were encountered across template-free controls or any of the genetically related viruses, con\ue103rming that the analytical speci\ue103city of the assay 7,9 had not been compromised in the presence of FBS and \ue104uorophore migration to far red spectra.", [["FBS", "ANATOMY", 222, 225], ["\ue104uorophore", "CHEMICAL", 230, 240], ["FBS", "ORGANISM_SUBSTANCE", 222, 225], ["\ue104uorophore", "SIMPLE_CHEMICAL", 230, 240], ["false positives", "PROBLEM", 14, 29], ["the genetically related viruses", "PROBLEM", 87, 118], ["the assay", "TEST", 164, 173], ["FBS", "PROBLEM", 222, 225], ["\ue104uorophore migration", "PROBLEM", 230, 250], ["no", "UNCERTAINTY", 11, 13], ["false positives", "OBSERVATION", 14, 29], ["viruses", "OBSERVATION", 111, 118]]], ["Furthermore, these data were obtained through independent experiments carried out across seven days using multiple, separate virus types and batches.", [["these data", "TEST", 13, 23], ["multiple, separate virus types", "TREATMENT", 106, 136]]], ["Nevertheless, and despite the propensity of PCR technologies for manual error, the results followed a log-linear relationship of virus genome concentration to Ct call, with 99.96% probability of single curve \ue103t, at a linear regression R 2 of 0.9967.", [["virus genome", "DNA", 129, 141], ["PCR technologies", "TEST", 44, 60], ["manual error", "TEST", 65, 77], ["a linear regression", "TEST", 215, 234]]], ["These results indicated that assay performance and relative quanti\ue103cation could be pre-calibrated using MS2 Coliphage under BSL2 safety standards, with the inhibitory effect of FBS (and blood) not affecting assay linearity.Analytical sensitivity and speci\ue103city testing with live Ebola virusOn this basis, to further investigate the extent to which the data generated by the two platforms were indeed comparable, we independently calibrated each dataset against standard curves generated using AR14, and calculated the unknown \ue103lovirus stock concentration in GE per ml.", [["FBS", "ANATOMY", 177, 180], ["blood", "ANATOMY", 186, 191], ["BSL2", "SIMPLE_CHEMICAL", 124, 128], ["FBS", "ORGANISM_SUBSTANCE", 177, 180], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["Ebola", "ORGANISM", 279, 284], ["assay performance", "TEST", 29, 46], ["MS2 Coliphage", "TREATMENT", 104, 117], ["BSL2 safety standards", "TREATMENT", 124, 145], ["FBS", "TEST", 177, 180], ["Analytical sensitivity", "TEST", 223, 245], ["speci\ue103city testing", "TEST", 250, 268], ["standard curves", "TEST", 461, 476], ["AR14", "TREATMENT", 493, 497], ["the unknown \ue103lovirus stock concentration", "TREATMENT", 514, 554]]], ["This analysis further indicated that the QuRapID platform returned data comparable to the gold standard lab-based Trombley method (Table 1) .", [["QuRapID", "DNA", 41, 48], ["This analysis", "TEST", 0, 13], ["the QuRapID platform", "TEST", 37, 57]]], ["However, it also highlighted that where use of manual extraction/puri\ue103cation might be more sensitive to non-infectious viral genomes through analyte stabilisation, the QuRapID whole blood assay might be less so.", [["blood", "ANATOMY", 182, 187], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["manual extraction/puri\ue103cation", "TREATMENT", 47, 76], ["non-infectious viral genomes", "PROBLEM", 104, 132], ["analyte stabilisation", "TREATMENT", 141, 162], ["the QuRapID whole blood assay", "TEST", 164, 193]]], ["Thus, the number of viral genomes to viable virions (log 10 GE/log 10 PFU ratio) for EBOV Yambuka-Ecran was higher than that of the younger EBOV Guinea Makona isolate irrespective of the platform used, but consistently lower on the QuRapID.", [["virions", "ANATOMY", 44, 51], ["EBOV", "ORGANISM", 85, 89], ["Yambuka-Ecran", "ORGANISM", 90, 103], ["EBOV", "ORGANISM", 140, 144], ["Guinea Makona", "ORGANISM", 145, 158], ["viral genomes", "DNA", 20, 33], ["QuRapID", "PROTEIN", 232, 239], ["EBOV Guinea Makona", "SPECIES", 140, 158], ["EBOV", "SPECIES", 85, 89], ["Guinea Makona", "SPECIES", 145, 158], ["PFU ratio", "TEST", 70, 79], ["EBOV Yambuka", "TEST", 85, 97], ["viral genomes", "OBSERVATION", 20, 33], ["lower", "OBSERVATION_MODIFIER", 219, 224]]], ["These results were in line with separate reports 9,13,50 which have suggested virus more extensively passaged in vitro might produce fewer infectious virions vs. newer isolates, thereby increasing the ratio of genomes to infectious particles in a bio\ue104uid.DiscussionThe socioeconomic value of molecular diagnostics in containing highly infectious disease has been convincingly demonstrated in the West and concurrent Central/East African EBOV outbreaks, 51 and the South Korean Middle East Respiratory Syndrome Coronavirus (MERS-CoV) outbreak.", [["infectious disease", "DISEASE", 335, 353], ["EBOV outbreaks", "DISEASE", 437, 451], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 477, 521], ["EBOV", "ORGANISM", 437, 441], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 477, 521], ["MERS-CoV", "ORGANISM", 523, 531], ["African EBOV", "SPECIES", 429, 441], ["Korean Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 470, 531], ["virus", "PROBLEM", 78, 83], ["fewer infectious virions", "PROBLEM", 133, 157], ["newer isolates", "PROBLEM", 162, 176], ["highly infectious disease", "PROBLEM", 328, 353], ["Respiratory Syndrome Coronavirus", "PROBLEM", 489, 521], ["outbreak", "PROBLEM", 533, 541], ["fewer", "OBSERVATION_MODIFIER", 133, 138], ["infectious", "OBSERVATION", 139, 149], ["increasing", "OBSERVATION_MODIFIER", 186, 196], ["infectious", "OBSERVATION_MODIFIER", 221, 231], ["infectious", "OBSERVATION", 335, 345], ["Middle", "ANATOMY_MODIFIER", 477, 483], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 489, 521]]], ["52 Furthermore, historical data causally link international travel and mass attendance events with pandemic transmission.", [["pandemic", "DISEASE", 99, 107], ["pandemic transmission", "TREATMENT", 99, 120]]], ["Yet, to date, there exists no true point of need solution suitable for mass screening that can support effective containment at international ports of entry or outbreak triage centers etc., with minimal economic burden, transportation and international trade disruption.", [["need solution", "TREATMENT", 44, 57], ["mass screening", "TEST", 71, 85], ["minimal economic burden", "PROBLEM", 195, 218], ["minimal", "OBSERVATION_MODIFIER", 195, 202], ["economic", "OBSERVATION_MODIFIER", 203, 211], ["burden", "OBSERVATION", 212, 218], ["trade disruption", "OBSERVATION", 253, 269]]], ["Indeed, we expect no such single system to prove of universal utility given transmission, symptomatology and carrier status may differ vastly depending on the biology of each pathogen and thus be best detectable through use of distinct analytical procedures.", [["symptomatology", "PROBLEM", 90, 104], ["distinct analytical procedures", "TREATMENT", 227, 257]]], ["Rather, a \ue104exible approach needs to be adopted, centered on responding rapidly, implementing appropriate technologies and proportionate procedures relevant to key factors to patient presentation and disease dissemination.", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["a \ue104exible approach", "TREATMENT", 8, 26], ["proportionate procedures", "TREATMENT", 122, 146], ["disease dissemination", "PROBLEM", 199, 220]]], ["Thus, whilst many highly infectious viral diseases may disseminate through asymptomatic carriers, EBOV transmission requires viraemia whose levels correlate with symptom intensity and indeed survival potential.", [["viral diseases", "DISEASE", 36, 50], ["viraemia", "DISEASE", 125, 133], ["EBOV", "ORGANISM", 98, 102], ["EBOV", "SPECIES", 98, 102], ["highly infectious viral diseases", "PROBLEM", 18, 50], ["asymptomatic carriers", "PROBLEM", 75, 96], ["viraemia whose levels", "TEST", 125, 146], ["symptom intensity", "PROBLEM", 162, 179], ["highly", "OBSERVATION_MODIFIER", 18, 24], ["infectious", "OBSERVATION", 25, 35]]], ["9,10,54,55 As a result, many efforts have been made to detect pre-symptomatic levels of EBOV infection, 56 with several anecdotal reports of various NAATs detecting pre-symptomatic individuals in the course of their evaluation during the West African outbreak.", [["9,10,54,55", "CHEMICAL", 0, 10], ["EBOV infection", "DISEASE", 88, 102], ["EBOV", "ORGANISM", 88, 92], ["NAATs", "CANCER", 149, 154], ["EBOV", "SPECIES", 88, 92], ["EBOV infection", "PROBLEM", 88, 102], ["their evaluation", "TEST", 210, 226], ["EBOV infection", "OBSERVATION", 88, 102]]], ["At present, however, the most reliable evidence thereto pertains to an 8-plex host microRNA biomarker signature detectable by NAAT in blood plasma.", [["blood plasma", "ANATOMY", 134, 146], ["NAAT", "SIMPLE_CHEMICAL", 126, 130], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["NAAT", "PROTEIN", 126, 130], ["an 8-plex host microRNA biomarker signature", "PROBLEM", 68, 111], ["NAAT in blood plasma", "TEST", 126, 146]]], ["57 However, this has only a 50% pre-symptomatic, and a relatively low 86% infection status classi\ue103cation potential.", [["infection", "DISEASE", 74, 83], ["a relatively low 86% infection", "PROBLEM", 53, 83], ["relatively", "OBSERVATION_MODIFIER", 55, 65], ["low", "OBSERVATION_MODIFIER", 66, 69], ["infection", "OBSERVATION", 74, 83]]], ["Therefore, reliable containment of future EBOV outbreaks will pivot on effective detection and screening of symptomatic individuals.", [["EBOV", "ORGANISM", 42, 46], ["EBOV", "SPECIES", 42, 46], ["effective detection", "TEST", 71, 90], ["symptomatic individuals", "PROBLEM", 108, 131]]], ["Crucially, such EBOV positive patients typically present with viraemia levels well in excess of 10 5 GE per ml of whole blood, i.e. some 2-4 orders of magnitude above of the LLOD of the Trombley and other RT-qPCR assays, as demonstrated in multiple studies during the West African 4,55,58,59 as well as historical outbreaks.", [["whole blood", "ANATOMY", 114, 125], ["viraemia", "DISEASE", 62, 70], ["EBOV", "ORGANISM", 16, 20], ["patients", "ORGANISM", 30, 38], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["patients", "SPECIES", 30, 38], ["EBOV", "SPECIES", 16, 20], ["viraemia levels", "TEST", 62, 77], ["whole blood", "TEST", 114, 125], ["other RT-qPCR assays", "TEST", 199, 219]]], ["[3] [4] [5] 60 Of the diagnostic solutions proposed for EBOV and other infectious diseases, the most advanced, minimal end-user input technologies include antibody lateral \ue104ow tests 61 and semiautomated NAATs.", [["EBOV", "DISEASE", 56, 60], ["infectious diseases", "DISEASE", 71, 90], ["[3] [4] [5] 60", "SIMPLE_CHEMICAL", 0, 14], ["EBOV", "ORGANISM", 56, 60], ["antibody lateral \ue104ow tests 61 and semiautomated NAATs", "PROTEIN", 155, 208], ["EBOV", "SPECIES", 56, 60], ["EBOV", "PROBLEM", 56, 60], ["other infectious diseases", "PROBLEM", 65, 90], ["antibody lateral \ue104ow tests", "TEST", 155, 181], ["infectious", "OBSERVATION", 71, 81]]], ["10, 17 The latter, however, remain the most reliable and robust methods for diagnosing EBOV in viraemic patients, 9, 10, 54 with antibody systems suited to exclusion screening in cadavers or patients exhibiting intense symptoms.", [["cadavers", "ANATOMY", 179, 187], ["EBOV", "DISEASE", 87, 91], ["viraemic", "DISEASE", 95, 103], ["EBOV", "ORGANISM", 87, 91], ["patients", "ORGANISM", 104, 112], ["cadavers", "ORGANISM", 179, 187], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 191, 199], ["EBOV", "SPECIES", 87, 91], ["antibody systems", "TEST", 129, 145], ["exclusion screening", "TEST", 156, 175], ["intense symptoms", "PROBLEM", 211, 227]]], ["62 Yet both NAATs used for diagnostic purposes in West Africa 7,63 required mobile laboratory deployments.", [["mobile laboratory deployments", "TREATMENT", 76, 105]]], ["Both instruments require basic laboratory infrastructure, are semi-quantitative, multiplexing-compatible and up to eight times faster than the manual Trombley method.", [["basic laboratory infrastructure", "TEST", 25, 56], ["the manual Trombley method", "TREATMENT", 139, 165]]], ["Whilst BioFire\u00ae offers FDA-approved, differential diagnosis at a cost of $US$150 per test, GeneXpert\u00ae assays for single agents at $US$20 and offers medium throughput through scalable devices.", [["BioFire\u00ae", "CHEMICAL", 7, 15], ["scalable devices", "TREATMENT", 174, 190]]], ["In both cases, however, sample processing still requires \ue104exible-\ue103lm isolator containment, technical expertise pertaining to the manual steps involved, and know-how related to data interpretation.", [["\ue104exible-\ue103lm isolator containment", "TREATMENT", 57, 89]]], ["Nonetheless, together, these solutions allow for index case causal agent identi\ue103cation and provide some capacity for screening, albeit still in a laboratory setting and at considerable cost largely due to micro\ue104uidics and/or pumps which mechanise as many manual procedures as possible.", [["screening", "TEST", 117, 126], ["micro\ue104uidics", "PROBLEM", 205, 217], ["pumps", "TREATMENT", 225, 230], ["manual procedures", "TREATMENT", 255, 272]]], ["Thus, overall, BioFire\u00ae tests are comparably priced to laboratory-based Trombley assays, whereas the GeneXpert\u00ae EBOV test remains up to twice more expensive than the annual per capita healthcare spend in West Africa, despite charitable development funding and ex-works pricing as negotiated by FIND Diagnostics on behalf of the WHO, substantially reimbursed by the Gates Foundation.", [["GeneXpert\u00ae EBOV", "ORGANISM", 101, 116], ["EBOV", "SPECIES", 112, 116], ["BioFire\u00ae tests", "TEST", 15, 29], ["Trombley assays", "TEST", 72, 87], ["the GeneXpert\u00ae EBOV test", "TEST", 97, 121]]], ["Importantly, the recently announced, portable GeneXpert\u00ae Omni offers single sample analysis capacity albeit with no improvement in sample-to-data turnaround (2 hours), questioning its mass screening utility.", [["single sample analysis capacity", "TEST", 69, 100], ["sample", "TEST", 131, 137], ["its mass screening utility", "PROBLEM", 180, 206], ["mass", "OBSERVATION", 184, 188]]], ["Elsewhere, emerging alternative NAAT solutions focus on the energy efficiency of isothermal ampli\ue103cation technologies 64 as well as the agnostic, de novo analytical power of memory sticksized sequencing systems.", [["emerging alternative NAAT solutions", "TREATMENT", 11, 46], ["isothermal ampli\ue103cation technologies", "TREATMENT", 81, 117]]], ["65, 66 Whilst many of these have been successfully evaluated in resource-limited settings, 64,65 these solutions still require extensive and costly laboratory infrastructure for sample pre-processing 64-66 even onto genome extraction, 65, 66 are non-quantitative, 64 closed access, 64, 66 or require high bandwidth data transfer/computational power access 65, 66 to realize their potential.DiscussionIn this work, we have demonstrated that controlled, low temperature freeze-thawing of viruses as structurally diverse as MS2 coliphage (Armored RNA\u00ae) and EBOV can release virion genomes within a complex bio\ue104uid matrix such as serum or fresh blood.", [["bio\ue104uid matrix", "ANATOMY", 603, 617], ["serum", "ANATOMY", 626, 631], ["blood", "ANATOMY", 641, 646], ["EBOV", "ORGANISM", 554, 558], ["matrix", "CELLULAR_COMPONENT", 611, 617], ["serum", "ORGANISM_SUBSTANCE", 626, 631], ["blood", "ORGANISM_SUBSTANCE", 641, 646], ["virion genomes", "DNA", 571, 585], ["EBOV", "SPECIES", 554, 558], ["sample pre-processing", "TEST", 178, 199], ["genome extraction", "TEST", 216, 233], ["low temperature freeze", "PROBLEM", 452, 474], ["viruses", "PROBLEM", 486, 493], ["MS2 coliphage", "PROBLEM", 521, 534], ["EBOV", "PROBLEM", 554, 558], ["a complex bio\ue104uid matrix", "PROBLEM", 593, 617], ["serum or fresh blood", "PROBLEM", 626, 646], ["low temperature", "OBSERVATION_MODIFIER", 452, 467], ["virion genomes", "OBSERVATION", 571, 585]]], ["Furthermore, we have evidenced that simple substitution of commonly used green DNA stains and probe dyes with red/far red \ue104uorophores spectrally compatible with blood eliminates \ue104uorogenic inhibition in RT-qPCR.", [["blood", "ANATOMY", 161, 166], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["\ue104uorophores", "SIMPLE_CHEMICAL", 122, 133], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["simple substitution", "TREATMENT", 36, 55], ["green DNA stains", "TEST", 73, 89], ["probe dyes", "TEST", 94, 104], ["red/far red \ue104uorophores", "PROBLEM", 110, 133], ["blood", "PROBLEM", 161, 166], ["\ue104uorogenic inhibition", "PROBLEM", 178, 199]]], ["Unlike previous reports involving various formats of stabilized blood, 18, 19, 25 in our hands, use of freshly obtained blood, e.g. by digital venipuncture, did not appear to extensively or entirely inhibit PCR.", [["blood", "ANATOMY", 64, 69], ["blood", "ANATOMY", 120, 125], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["digital venipuncture", "TEST", 135, 155], ["hands", "ANATOMY", 89, 94]]], ["More importantly, combination of controlled freeze/thawing with far red \ue104uorophores and simple RT-qPCR enzyme formulations was found to be reliable enough to adequately and co-linearly detect speci\ue103c genetic targets across at least two classes of viruses, assayed on separate days.", [["controlled freeze/thawing", "TREATMENT", 33, 58], ["far red \ue104uorophores", "TREATMENT", 64, 83], ["simple RT-qPCR enzyme formulations", "TEST", 88, 122], ["viruses", "PROBLEM", 247, 254], ["viruses", "OBSERVATION", 247, 254]]], ["To our knowledge this is the \ue103rst use of pre-calibration standards for RT-qPCR-mediated sample quanti\ue103cation, directly in whole blood, across a wide dynamic range, with minimal impact on sensitivity and no impact on diagnostic speci\ue103city.", [["sample", "ANATOMY", 88, 94], ["whole blood", "ANATOMY", 122, 133], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["pre-calibration standards", "TREATMENT", 41, 66], ["RT-qPCR", "TEST", 71, 78], ["sensitivity", "TEST", 187, 198], ["diagnostic speci\ue103city", "TEST", 216, 237], ["wide", "OBSERVATION_MODIFIER", 144, 148], ["minimal", "OBSERVATION_MODIFIER", 169, 176]]], ["Thus, the 1.4 \u00c2 10 4 PFU per ml of whole blood equivalent detection limit for the Trombley+ assay on the QuRapID platform is approximately one order of magnitude higher than the detection limit of the gold standard laboratory-based Trombley/ABI7500 test.", [["blood", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["ABI7500", "PROTEIN", 241, 248], ["whole blood equivalent detection", "TEST", 35, 67], ["the Trombley+ assay", "TEST", 78, 97]]], ["At \ue103rst glance this might appear too great a difference between a novel and a gold standard platform.", [["a gold standard platform", "TREATMENT", 76, 100]]], ["However, the Trombley+/ QuRapID LLOD is comparable to the independently reported LLOQ of the Trombley/ABI7500 gold standard at 1.2 \u00c2 10 4 PFU per ml.", [["Trombley+", "SIMPLE_CHEMICAL", 13, 22], ["the Trombley+/ QuRapID LLOD", "PROBLEM", 9, 36]]], ["9 Nonetheless, this metric does not relate to viral genomes, the analyte detected by both assays.", [["viral genomes", "DNA", 46, 59], ["viral genomes", "PROBLEM", 46, 59], ["the analyte", "TEST", 61, 72], ["not relate to", "UNCERTAINTY", 32, 45], ["viral genomes", "OBSERVATION", 46, 59]]], ["Rather, performance quali\ue103cation is expressed relative to the concentration of viable, infectious viral particles, which are impossible to quantify by RT-qPCR.", [["viable, infectious viral particles", "PROBLEM", 79, 113], ["infectious", "OBSERVATION", 87, 97]]], ["However, both our data and the latest independent Trombley assay performance report, 9 present GE/ PFU ratios: this makes direct comparisons acceptable across the studies, laboratories and platforms.", [["the studies", "TEST", 159, 170]]], ["Thus, in the context of the 1 \u00c2 10 5 GE per ml or greater viraemia levels exhibited by symptomatic EBOV patients, 3-5,55,58-60 our results evidence clinical utility for our proposed approach to meet demand during future EBOV outbreaks, subject to completion of the necessary EUA quali\ue103cation studies.", [["viraemia", "DISEASE", 58, 66], ["EBOV", "DISEASE", 99, 103], ["EBOV", "ORGANISM", 99, 103], ["patients", "ORGANISM", 104, 112], ["EBOV", "ORGANISM", 220, 224], ["patients", "SPECIES", 104, 112], ["EBOV", "SPECIES", 99, 103], ["EBOV", "SPECIES", 220, 224], ["greater viraemia levels", "PROBLEM", 50, 73], ["our proposed approach", "TREATMENT", 169, 190], ["the necessary EUA quali\ue103cation studies", "TEST", 261, 299], ["symptomatic", "OBSERVATION_MODIFIER", 87, 98], ["EBOV", "OBSERVATION", 99, 103]]], ["Moreover, as EBOV caches in the cerebrospinal \ue104uid of survivors and may lead to meningoenchephalitis, 67 we have also brie\ue104y examined whether our method is compatible with this bio\ue104uid.", [["cerebrospinal \ue104uid", "ANATOMY", 32, 50], ["meningoenchephalitis", "DISEASE", 80, 100], ["EBOV", "ORGANISM", 13, 17], ["cerebrospinal \ue104uid", "MULTI-TISSUE_STRUCTURE", 32, 50], ["EBOV", "SPECIES", 13, 17], ["meningoenchephalitis", "PROBLEM", 80, 100], ["cerebrospinal \ue104uid", "ANATOMY", 32, 50]]], ["Thus, we observed no effect from blood contamination on Trombley+/QuRapID Ct calls a\ue09der spiking AR14 at 1 \u00c2 10 8 GE into reactions containing 10% v/v human cerebrospinal \ue104uid (Fig. S9 \u2020) .", [["blood", "ANATOMY", 33, 38], ["cerebrospinal", "ANATOMY", 156, 169], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["Trombley+", "SIMPLE_CHEMICAL", 56, 65], ["human", "ORGANISM", 150, 155], ["cerebrospinal", "ORGANISM_SUBSTANCE", 156, 169], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["blood contamination", "PROBLEM", 33, 52], ["Trombley", "TEST", 56, 64], ["cerebrospinal \ue104uid", "ANATOMY", 156, 174]]], ["The approach may therefore offer utility beyond symptomatic EBOV diagnosis, not only to other infectious viral disease with viraemia levels relevant to the detection limits of our methodology, but also to the rapid and economic detection of the causes of meningitis where time-to-diagnosis through 3 day-long, classical clinical microbiology might be disadvantageous.", [["viral disease", "DISEASE", 105, 118], ["viraemia", "DISEASE", 124, 132], ["meningitis", "DISEASE", 255, 265], ["EBOV", "ORGANISM", 60, 64], ["EBOV", "SPECIES", 60, 64], ["other infectious viral disease", "PROBLEM", 88, 118], ["viraemia levels", "PROBLEM", 124, 139], ["our methodology", "TEST", 176, 191], ["meningitis", "PROBLEM", 255, 265], ["meningitis", "OBSERVATION", 255, 265]]], ["Most importantly, however, unlike many other approaches, the performance we report with this novel platform is achieved with 700\u00c2 less blood volume than the standard 3.5 ml needed for the gold standard Trombley assay.", [["blood", "ANATOMY", 135, 140], ["blood", "ORGANISM_SUBSTANCE", 135, 140]]], ["Studies are therefore underway to explore whether large volume PCR 68 accommodating higher amounts of patient sample at the point of care might meet and even exceed the sensitivity of the EZ1 SOP.DiscussionBeyond sensitivity and speci\ue103city, in line with the ASSURED criteria, 16 key to disseminated use of novel technologies, and especially in resource limited settings, is test affordability.", [["patient", "ORGANISM", 102, 109], ["EZ1 SOP", "PROTEIN", 188, 195], ["patient", "SPECIES", 102, 109], ["large volume PCR", "TEST", 50, 66], ["novel technologies", "TREATMENT", 306, 324], ["disseminated", "OBSERVATION", 286, 298]]], ["In its present, diagnostically relevant, 62.5 ml reaction format, disposables for the Trombley+ assay on the QuRapID cost US$12.50 per test before scale up or subsidy, an amount relevant to developing nations and competitive to emerging electricity-free, 69 or disposable isothermal NAAT that rely on complex fabrication methods.", [["disposable isothermal NAAT", "PROBLEM", 261, 287], ["complex fabrication methods", "TREATMENT", 301, 328]]], ["70 Thus, in the context of powered point-of-need solutions, the 2 minute, 10 cycle freeze/thaw process implemented in our approach adds only an additional 24 watts of energy requirement per test.", [["cycle freeze/thaw process", "TREATMENT", 77, 102]]], ["This can be nonetheless additionally managed through smart thermal load sharing between active stations operating ad hoc, thereby reducing overall energy requirements during screening use.", [["energy requirements", "OBSERVATION", 147, 166]]], ["Moreover, the overhead is effectively compensated by the lack of any motorized, expensive consumables or instrument parts that could otherwise compromise instrument robustness.", [["instrument parts", "PROBLEM", 105, 121]]], ["Thus, the standard operating procedure we devised involves a disposable consumable, pre-loaded with lyophilized reagents and an automated, pre-calibrated 57.5 ml solvent dispenser to eliminate the need for refrigeration.", [["the standard operating procedure", "TREATMENT", 6, 38], ["lyophilized reagents", "TREATMENT", 100, 120]]], ["Although the ABI Fast RT-qPCR mastermix we tested against live EBOV is not in itself amenable to lyophilisation, refrigeration-free RT-qPCR mastermix production is possible 71 and commercially available for research and diagnostic purposes.", [["EBOV", "ORGANISM", 63, 67], ["EBOV", "SPECIES", 63, 67], ["the ABI", "TEST", 9, 16], ["qPCR mastermix", "TEST", 25, 39], ["lyophilisation", "TEST", 97, 111], ["refrigeration", "TEST", 113, 126], ["diagnostic purposes", "TEST", 220, 239]]], ["To this end, we have screened and identi\ue103ed a proprietary, lyophilisation-and bloodcompatible formulation, successfully dried and tested it as part of this work; this formulation is presently under development to match the wet assay performance characteristics reported herein.DiscussionAn essential requirement in any diagnostic technology, particularly for hazard group 4 pathogens, however, is safety: this takes the form of both operator safety and diagnostic reliability.", [["lyophilisation", "TREATMENT", 59, 73], ["bloodcompatible formulation", "TREATMENT", 78, 105], ["this formulation", "TREATMENT", 162, 178], ["the wet assay", "TEST", 219, 232], ["hazard group 4 pathogens", "PROBLEM", 359, 383], ["diagnostic reliability", "TEST", 453, 475]]], ["Although the use of a \ue104exible \ue103lm isolator for the QuRapID instrument would be subject to local health and safety requirements in an 'orange' or 'red' triage zone, IVD-marked, low operator risk, sheathed lancets for digital venipuncture are readily and cheaply available over the counter e.g. for use with point of care glucometers.", [["a \ue104exible \ue103lm isolator", "TREATMENT", 20, 42], ["the QuRapID instrument", "TREATMENT", 47, 69], ["IVD", "PROBLEM", 164, 167], ["digital venipuncture", "TREATMENT", 216, 236], ["care glucometers", "TREATMENT", 315, 331]]], ["In our hands, these can be safely handled in full personal protective equipment suitable for hazard group 4 pathogens.", [["full personal protective equipment", "TREATMENT", 45, 79], ["hazard group 4 pathogens", "PROBLEM", 93, 117], ["hands", "ANATOMY", 7, 12]]], ["Use of plastic capillaries, such as the low error rate 5 ml Microsafe\u00ae trialed herein, can also eliminate the risk of injury or instrument contamination beyond the puck consumable.", [["plastic capillaries", "ANATOMY", 7, 26], ["capillaries", "TISSUE", 15, 26], ["plastic capillaries", "TREATMENT", 7, 26], ["the low error rate", "TREATMENT", 36, 54], ["injury", "PROBLEM", 118, 124], ["instrument contamination", "PROBLEM", 128, 152], ["plastic capillaries", "OBSERVATION", 7, 26], ["injury", "OBSERVATION", 118, 124]]], ["Similarly, the optical lid is additionally secured in place on the QuRapID during thermal cycling by the weight of the top-down detector, which is itself magnetically held in place.", [["thermal cycling", "TREATMENT", 82, 97], ["secured", "OBSERVATION", 43, 50]]], ["Crucially, no instrument, electronics or optics damage or failure was observed a\ue09der fumigation and exit of our prototype QuRapID platform from BSL4 containment a\ue09der testing with live EBOV.", [["BSL4", "SIMPLE_CHEMICAL", 143, 147], ["EBOV", "ORGANISM", 183, 187], ["EBOV", "SPECIES", 183, 187], ["instrument", "PROBLEM", 14, 24], ["optics damage", "PROBLEM", 41, 54], ["failure", "PROBLEM", 58, 65], ["our prototype QuRapID platform", "TREATMENT", 107, 137], ["BSL4 containment", "TREATMENT", 143, 159], ["no", "UNCERTAINTY", 11, 13], ["instrument", "OBSERVATION", 14, 24], ["failure", "OBSERVATION", 58, 65]]], ["Therefore, the platform retains the mobility and repeated utility requirement pertinent to rapid response in outbreak scenarios.DiscussionOn the other hand, experimental evidence is required supporting accurate detection of multiplexed RT-qPCR to support safe calling of process and diagnostic success during use of this technology.", [["multiplexed RT-qPCR", "TREATMENT", 224, 243], ["this technology", "TREATMENT", 316, 331], ["mobility", "OBSERVATION_MODIFIER", 36, 44], ["outbreak scenarios", "OBSERVATION", 109, 127]]], ["Unfortunately, in our hands, the singleplex Trombley assays and the RP control assay exhibited competitive inhibition at the lower end of analyte concentration.", [["the singleplex Trombley assays", "TEST", 29, 59], ["the RP control assay", "TEST", 64, 84], ["competitive inhibition", "PROBLEM", 95, 117], ["hands", "ANATOMY", 22, 27]]], ["Reasoning that altering even primer and probe concentrations would require re-quali\ue103cation of assay speci\ue103city, we decided instead to con\ue103rm the utility of our approach against EBOV genome detection in singleplex mode.", [["EBOV", "ORGANISM", 177, 181], ["EBOV genome", "DNA", 177, 188], ["EBOV", "SPECIES", 177, 181], ["altering even primer", "PROBLEM", 15, 35], ["assay speci\ue103city", "TEST", 94, 110], ["our approach", "TREATMENT", 156, 168], ["EBOV genome detection", "TREATMENT", 177, 198]]], ["Nevertheless, the resulting \ue104uorimetric data were used to examine state of the art mathematical deconvolution approaches used in other optical platforms operating in the same spectral ranges.", [["the resulting \ue104uorimetric data", "TEST", 14, 44]]], ["This analysis indicated that separation of commercially available probe \ue104uorophores in the 600-750 nm range is adequately assayed spectrophotometrically, and that the signal to noise ratio of a \ue104uorophore might direct its use in a multiplexed fashion.", [["\ue104uorophores", "CHEMICAL", 72, 83], ["This analysis", "TEST", 0, 13], ["probe \ue104uorophores", "TEST", 66, 83], ["a \ue104uorophore", "TREATMENT", 192, 204]]], ["Thus, an example dye trio consisting of CAL635, Quasar 670 and Quasar 705 could enable migration of an established triplex assay to the far red, blood-compatible spectrum, but the signal to noise ratio of Quasar 705 in the context of blood would make this \ue104uorophore suitable only for the detection of a high copy number control.", [["blood", "ANATOMY", 145, 150], ["blood", "ANATOMY", 234, 239], ["CAL635", "CHEMICAL", 40, 46], ["Quasar 670", "CHEMICAL", 48, 58], ["Quasar 705", "CHEMICAL", 63, 73], ["Quasar 705", "CHEMICAL", 205, 215], ["CAL635", "CHEMICAL", 40, 46], ["Quasar 705", "CHEMICAL", 63, 73], ["CAL635", "SIMPLE_CHEMICAL", 40, 46], ["Quasar 670", "SIMPLE_CHEMICAL", 48, 58], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["an established triplex assay", "TEST", 100, 128], ["noise ratio", "TEST", 190, 201], ["a high copy number control", "TREATMENT", 302, 328]]], ["Encouragingly, the spectral data obtained throughout these studies with Quasar 670-labelled probes are in line with our predictive modelling efforts regarding peak ratiometry.", [["Quasar 670-labelled probes", "DNA", 72, 98], ["the spectral data", "TEST", 15, 32], ["these studies", "TEST", 53, 66], ["Quasar", "TEST", 72, 78]]], ["Thus, \ue104uorigenic data normalization clearly exhibits adequate assay window in reliably detecting emission peak changes as no deviation in ratiometric pro\ue103les was detected for Quasar 670 relative to other dye emission peaks.", [["Quasar 670", "CHEMICAL", 175, 185], ["Quasar 670", "CHEMICAL", 175, 185], ["\ue104uorigenic data normalization", "TEST", 6, 35], ["deviation in ratiometric pro\ue103les", "PROBLEM", 125, 157], ["other dye emission peaks", "PROBLEM", 198, 222], ["emission peak", "OBSERVATION", 97, 110], ["no", "UNCERTAINTY", 122, 124]]], ["Efforts are thus underway to implement automated Ct calling in multiplex mode as well as viral genome quanti\ue103cation through reagent pre-calibration based on our observations across AR14 and the two distinct EBOV strains we tested.", [["AR14", "GENE_OR_GENE_PRODUCT", 181, 185], ["EBOV", "ORGANISM", 207, 211], ["viral genome", "DNA", 89, 101], ["EBOV", "SPECIES", 207, 211], ["Ct", "TEST", 49, 51], ["reagent pre-calibration", "TREATMENT", 124, 147], ["our observations", "TEST", 157, 173], ["the two distinct EBOV strains", "PROBLEM", 190, 219], ["distinct", "OBSERVATION_MODIFIER", 198, 206], ["EBOV strains", "OBSERVATION", 207, 219]]], ["Overall, whether substitution of probebased detection chemistry with DNA stains and high-resolution melt will enable further cost reductions in the future will largely depend on the relative diagnostic reliability, computational, and energy requirements of the two approaches when used in the presence of blood vs. already available, highly reliable probe assays.DiscussionIn this context, in response to the 2015 MERS-CoV South Korean outbreak, time-to-transfer for an established probe chemistry assay onto the QuRapID platform and far red, bloodcompatible chemistries was calculated at six to eight weeks, with rate limiting steps being (a) surrogate BSL2 template production, and (b) reagent synthesis.", [["blood", "ANATOMY", 305, 310], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["blood", "ORGANISM_SUBSTANCE", 305, 310], ["BSL2", "SIMPLE_CHEMICAL", 654, 658], ["probebased detection chemistry", "TEST", 33, 63], ["DNA stains", "TEST", 69, 79], ["further cost reductions", "TREATMENT", 117, 140], ["an established probe chemistry assay", "TEST", 467, 503], ["the QuRapID platform", "TEST", 509, 529], ["bloodcompatible chemistries", "TEST", 543, 570], ["b) reagent synthesis", "TREATMENT", 685, 705]]], ["Thus, stockpiling notwithstanding, we estimate that BSL4 laboratories with robust reagent supply chains could independently deliver mass screening, mass production-ready assays within a fortnight.", [["BSL4 laboratories", "TEST", 52, 69], ["robust reagent supply chains", "TREATMENT", 75, 103], ["mass screening", "TEST", 132, 146], ["mass production", "PROBLEM", 148, 163]]], ["The limited impact of established assay migration to bloodcompatible chemistries observed herein, coupled to readily available, high con\ue103dence computational assay design capability and parallel screening capacity even suggests utility against pathogen genomic dri\ue09d, to enable rapid response for newly identi\ue103ed pathogens.Primers, probes and \ue104uorescent dyesWe focused on the Trombley primer and probe sets for the EBOV GP and NP genes, 7, 9, 10 considering the human RP assay as a control, 8 and an MS2 Escherichia coli phage-speci\ue103c assay set 72,73 for \ue104uorescent probe-or intercalator-based blood tolerance studies (SYBR Green I; Thermo Fischer Scienti\ue103c, Warrington, UK).", [["blood", "ANATOMY", 592, 597], ["EBOV", "ORGANISM", 413, 417], ["GP", "GENE_OR_GENE_PRODUCT", 418, 420], ["human", "ORGANISM", 460, 465], ["Escherichia coli", "ORGANISM", 502, 518], ["blood", "ORGANISM_SUBSTANCE", 592, 597], ["\ue104uorescent dyesWe", "DNA", 341, 358], ["Trombley primer", "DNA", 374, 389], ["EBOV GP and NP genes", "DNA", 413, 433], ["human", "SPECIES", 460, 465], ["Escherichia coli", "SPECIES", 502, 518], ["EBOV", "SPECIES", 413, 417], ["human", "SPECIES", 460, 465], ["Escherichia coli", "SPECIES", 502, 518], ["established assay migration", "TREATMENT", 22, 49], ["bloodcompatible chemistries", "TEST", 53, 80], ["parallel screening capacity", "TEST", 185, 212], ["pathogen genomic dri\ue09d", "PROBLEM", 243, 264], ["newly identi\ue103ed pathogens", "PROBLEM", 295, 320], ["the Trombley primer", "TREATMENT", 370, 389], ["the human RP assay", "TEST", 456, 474], ["an MS2 Escherichia coli phage", "TREATMENT", 495, 524], ["speci\ue103c assay", "TEST", 525, 538], ["\ue104uorescent probe", "TREATMENT", 553, 569], ["intercalator", "TREATMENT", 573, 585], ["blood tolerance studies", "TEST", 592, 615]]], ["Primers (Table S3 \u2020RT-qPCR blood tolerance experimentsTo determine the tolerance of commercially available RT and PCR enzymes to blood, one-step reaction master mixes were assembled on wet ice using GoTaq\u00ae G2 Hot Start polymerase (Promega; Southampton, UK) in GoTaq\u00ae G2 Hot Start Colorless Master Mix (Promega) supplemented with 5 units of GoScript\u00ae Moloney Murine Leukemia Virus reverse transcriptase (Promega), primers and probes/dyes at concentrations as previously published.", [["blood", "ANATOMY", 27, 32], ["blood", "ANATOMY", 129, 134], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["Moloney Murine Leukemia Virus", "ORGANISM", 350, 379], ["Promega", "ORGANISM", 403, 410], ["reverse transcriptase", "PROTEIN", 380, 401], ["Murine", "SPECIES", 358, 364], ["Primers", "TEST", 0, 7], ["blood tolerance experiments", "TEST", 27, 54], ["PCR enzymes", "TEST", 114, 125], ["blood", "TEST", 129, 134], ["Colorless Master Mix (Promega)", "TREATMENT", 280, 310], ["GoScript\u00ae Moloney Murine Leukemia Virus", "TREATMENT", 340, 379], ["transcriptase (Promega)", "TREATMENT", 388, 411], ["primers and probes/dyes", "TREATMENT", 413, 436]]], ["6, 27 Duplicate aliquots were dispensed, and supplemented with blood and nuclease-free water (Promega) to achieve the \ue103nal blood concentrations indicated.", [["blood", "ANATOMY", 63, 68], ["blood", "ANATOMY", 123, 128], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["nuclease", "PROTEIN", 73, 81], ["nuclease-free water (Promega)", "TREATMENT", 73, 102], ["the \ue103nal blood concentrations", "TEST", 114, 143]]], ["Template was added last in each aliquot to achieve a 50 ml \ue103nal reaction volume ahead of commencing thermal cycling on an Illumina Eco\u2122 running Eco\u2122 So\ue09dware v.4.0.7.0 (Illumina Inc., San Diego, CA, USA).Surrogate virus standards and biological matricesTo enable accelerated development under biosafety level 2 (BSL2) we used a Hepatitis C Virus 74 (HCV) Armored RNA Quant\u00ae (Asuragen, Inc., Austin, TX, USA; manual phase disruption studies) as an MS2 coliphage virion model and three EBOV surrogates (Table S2 \u2020 To generate these recombinant lentiviruses, assay targets \ue104anked by BamHI and NotI (Geneart plasmids, Thermo Fisher Scienti\ue103c) were sub-cloned 23 into the transfer plasmid pDUAL-eGFP (a gi\ue09d from David Escors, University College London).", [["Hepatitis C", "DISEASE", 327, 338], ["Hepatitis C Virus 74", "ORGANISM", 327, 347], ["HCV", "ORGANISM", 349, 352], ["EBOV", "ORGANISM", 483, 487], ["lentiviruses", "ORGANISM", 541, 553], ["BamHI", "GENE_OR_GENE_PRODUCT", 579, 584], ["NotI", "GENE_OR_GENE_PRODUCT", 589, 593], ["eGFP", "GENE_OR_GENE_PRODUCT", 689, 693], ["BamHI", "DNA", 579, 584], ["NotI", "DNA", 589, 593], ["Geneart plasmids", "DNA", 595, 611], ["Thermo Fisher Scienti\ue103c", "DNA", 613, 636], ["sub-cloned 23", "DNA", 643, 656], ["transfer plasmid", "DNA", 666, 682], ["pDUAL", "DNA", 683, 688], ["eGFP", "DNA", 689, 693], ["Hepatitis C Virus", "SPECIES", 327, 344], ["Hepatitis C Virus 74", "SPECIES", 327, 347], ["HCV", "SPECIES", 349, 352], ["EBOV", "SPECIES", 483, 487], ["Template", "TREATMENT", 0, 8], ["a 50 ml \ue103nal reaction volume", "TREATMENT", 51, 79], ["Surrogate virus standards", "TREATMENT", 203, 228], ["a Hepatitis C Virus", "TREATMENT", 325, 344], ["manual phase disruption studies", "TEST", 407, 438], ["an MS2 coliphage virion model", "TREATMENT", 443, 472], ["three EBOV surrogates", "TREATMENT", 477, 498], ["these recombinant lentiviruses", "TREATMENT", 523, 553], ["BamHI and NotI (Geneart plasmids", "TREATMENT", 579, 611], ["Thermo Fisher Scienti\ue103c)", "TREATMENT", 613, 637]]], ["Lentiviruses were assembled in HEK293T cells grown in 10% v/v fetal bovine serum (FBS)-supplemented Dulbecco's Modi\ue103ed Eagle Medium (DMEM; Thermo Fisher Scienti\ue103c), 5% v/v CO 2 , 37 C, using a second-generation method involving 1 mg per ml polyethylenimine (Sigma Aldrich, Dorset, UK) co-transfection with pMD2.G (a gi\ue09d from Didier Trono; Addgene plasmid #12259) carrying the envelope protein for vesicular stomatitis virus, and p8.91 encoding the lentiviral core genes, 75 at a plasmid ratio of 1 : 1 : 1.5, respectively.", [["HEK293T cells", "ANATOMY", 31, 44], ["fetal bovine serum", "ANATOMY", 62, 80], ["FBS", "ANATOMY", 82, 85], ["polyethylenimine", "CHEMICAL", 240, 256], ["vesicular stomatitis", "DISEASE", 397, 417], ["CO", "CHEMICAL", 172, 174], ["polyethylenimine", "CHEMICAL", 240, 256], ["HEK293T cells", "CELL", 31, 44], ["bovine", "ORGANISM", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["FBS", "ORGANISM_SUBSTANCE", 82, 85], ["polyethylenimine", "SIMPLE_CHEMICAL", 240, 256], ["pMD2", "GENE_OR_GENE_PRODUCT", 306, 310], ["vesicular stomatitis virus", "ORGANISM", 397, 423], ["lentiviral", "ORGANISM", 448, 458], ["HEK293T cells", "CELL_LINE", 31, 44], ["pMD2", "PROTEIN", 306, 310], ["envelope protein", "PROTEIN", 376, 392], ["lentiviral core genes", "DNA", 448, 469], ["bovine", "SPECIES", 68, 74], ["vesicular stomatitis virus", "SPECIES", 397, 423], ["bovine", "SPECIES", 68, 74], ["stomatitis virus", "SPECIES", 407, 423], ["Lentiviruses", "PROBLEM", 0, 12], ["HEK293T cells", "TEST", 31, 44], ["fetal bovine serum", "TEST", 62, 80], ["FBS", "TEST", 82, 85], ["a second-generation method", "TREATMENT", 191, 217], ["Addgene plasmid", "TREATMENT", 339, 354], ["vesicular stomatitis virus", "PROBLEM", 397, 423], ["a plasmid ratio", "TEST", 477, 492], ["vesicular stomatitis", "ANATOMY", 397, 417]]], ["Supernatants were replaced with 6 mL fresh media at 16 hours and 0.45 mm \ue103lterharvested at 40 hours for 4 C storage.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["6 mL fresh media", "TREATMENT", 32, 48]]], ["Cells were fed with fresh media (5 ml) and Lentivirus was \ue103lter-harvested again at 64 hours, pooled, concentrated (4000 \u00c2 g, 4 C, 16 hours), resuspended in 1.0 mL DMEM, re-centrifuged through a 5 ml, 20% w/v sucrose cushion and re-suspended in 1.0 ml DMEM for \u00c080 C storage.", [["Cells", "ANATOMY", 0, 5], ["sucrose", "CHEMICAL", 208, 215], ["sucrose", "CHEMICAL", 208, 215], ["Cells", "CELL", 0, 5], ["Lentivirus", "ORGANISM", 43, 53], ["Lentivirus", "SPECIES", 43, 53], ["fresh media", "TREATMENT", 20, 31], ["Lentivirus", "TREATMENT", 43, 53], ["v sucrose cushion", "TREATMENT", 206, 223]]], ["Yields (viral particle per ml (vp per ml) or genome equivalent per ml (GE per ml)) were derived using a Nanosight NS300 (Malvern Instruments, Malvern, UK) a\ue09der 1 : 10 dilution in 10% v/v FBS-supplemented DMEM or interpolation against standard curves of AR14 RNA extracts by Trombley assay for the PV76 and PV14 constructs, respectively.", [["extracts", "ANATOMY", 262, 270], ["FBS", "ORGANISM_SUBSTANCE", 187, 190], ["AR14", "ORGANISM", 253, 257], ["extracts", "ORGANISM_SUBSTANCE", 262, 270], ["PV76", "GENE_OR_GENE_PRODUCT", 297, 301], ["AR14 RNA", "RNA", 253, 261], ["PV76 and PV14 constructs", "DNA", 297, 321], ["AR14", "SPECIES", 253, 257], ["PV76", "SPECIES", 297, 301], ["Yields (viral particle", "TREATMENT", 0, 22], ["a Nanosight NS300 (Malvern Instruments", "TREATMENT", 102, 140], ["v FBS", "TREATMENT", 185, 190], ["supplemented DMEM", "TREATMENT", 191, 208], ["interpolation", "TREATMENT", 212, 225], ["Trombley assay", "TEST", 274, 288]]], ["RNA extracts were obtained using the QIAamp Viral RNA Mini Kit (Qiagen, Manchester, UK), according to the manufacturer's instructions, assuming 100% extraction efficiency.Surrogate virus standards and biological matricesFresh human blood was aseptically obtained by digital venupucture of healthy adult male volunteers (Vitrex\u00ae Sterilance\u00ae LiteII lancets, VWR, Lutterworth, UK), as approved under the University of Westminster Research Ethics Committee (application no. VRE1415-0171, 7th Nov. 2014).", [["extracts", "ANATOMY", 4, 12], ["blood", "ANATOMY", 232, 237], ["VRE1415-0171", "CHEMICAL", 470, 482], ["VRE1415-0171", "CHEMICAL", 470, 482], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["human", "ORGANISM", 226, 231], ["blood", "ORGANISM_SUBSTANCE", 232, 237], ["volunteers", "ORGANISM", 308, 318], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["RNA extracts", "TEST", 0, 12], ["Surrogate virus standards", "TREATMENT", 171, 196], ["Fresh human blood", "TEST", 220, 237], ["Vitrex\u00ae Sterilance\u00ae LiteII lancets", "TREATMENT", 320, 354]]], ["Informed consent was obtained for any experimentation with human subjects.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64]]], ["Cerebrospinal \ue104uid (CSF) was kindly provided by Prof. T. Solomon (University of Liverpool).", [["Cerebrospinal", "ANATOMY", 0, 13], ["Cerebrospinal \ue104uid", "ORGANISM_SUBSTANCE", 0, 18], ["CSF", "ORGANISM_SUBSTANCE", 20, 23]]], ["Patient samples were simulated under BSL4 using FBS (Thermo Fisher Scienti\ue103c).Trombley assay transferPlate-based RT-qPCR assays were carried out on an ABI7500 (Thermo Fisher Scienti\ue103c) in accordance with the manufacturer's SOP speci\ue103ed for the EZ1 assay.", [["samples", "ANATOMY", 8, 15], ["FBS", "ORGANISM_SUBSTANCE", 48, 51], ["EZ1", "PROTEIN", 244, 247], ["Patient", "SPECIES", 0, 7], ["Patient samples", "TEST", 0, 15], ["Plate", "TEST", 101, 106], ["qPCR assays", "TEST", 116, 127], ["the EZ1 assay", "TEST", 240, 253], ["RT", "ANATOMY_MODIFIER", 113, 115]]], ["Brie\ue104y, a\ue09der extraction/ puri\ue103cation using the QIAamp Viral RNA Mini Kit into 70 ml eluents, RNA was serially diluted using nuclease-free water (Qiagen, Manchester, UK).", [["a\ue09der", "SIMPLE_CHEMICAL", 8, 12], ["nuclease", "PROTEIN", 124, 132], ["a\ue09der extraction", "TREATMENT", 8, 23], ["puri\ue103cation", "TREATMENT", 25, 36], ["the QIAamp", "TREATMENT", 43, 53], ["RNA", "TEST", 93, 96]]], ["Trombley assay one-step RT-qPCR 7 was carried out on 5 ml samples in ABI Fast virus master mix (Thermo Fisher Scienti\ue103c) at 20 ml \ue103nal reaction volumes.", [["samples", "ANATOMY", 58, 65], ["Trombley assay", "TEST", 0, 14], ["qPCR", "TEST", 27, 31], ["ABI Fast virus master mix (Thermo Fisher Scienti\ue103c)", "TREATMENT", 69, 120]]], ["Factional threshold cycle (Ct) values were obtained using the 7500 ABI so\ue09dware (v.2.3), implementing onset of ampli\ue103cation Ct calls.", [["Ct) values", "TEST", 27, 37]]], ["Performance metrics were derived on technical triplicates using electronic pipettes: data were represented as means AE 95% con\ue103dence bands (LDR testing) or triplicate average AE standard deviation, unless otherwise speci\ue103ed.QuRapID instrumentationPre-prototype work on phase transition was carried out using manual acetone/dry ice bath to 105 C dry block cycling of standard 0.2 ml PCR tubes (Thermo Fisher Scienti\ue103c).", [["acetone", "CHEMICAL", 315, 322], ["acetone", "SIMPLE_CHEMICAL", 315, 322], ["AE", "TEST", 116, 118], ["bands", "TEST", 133, 138], ["LDR testing", "TEST", 140, 151], ["triplicate average AE standard deviation", "PROBLEM", 156, 196], ["QuRapID instrumentation", "TREATMENT", 224, 247], ["manual acetone/dry ice bath", "TREATMENT", 308, 335], ["dry block cycling", "TREATMENT", 345, 362], ["standard 0.2 ml PCR tubes", "TREATMENT", 366, 391], ["instrumentation", "OBSERVATION", 232, 247]]], ["Sample temperature was measured in separate tubes loaded with equal volume mock samples and an alcohol thermometer to monitor ramping and hold rates.", [["alcohol", "CHEMICAL", 95, 102], ["alcohol", "CHEMICAL", 95, 102], ["alcohol", "SIMPLE_CHEMICAL", 95, 102], ["Sample temperature", "TEST", 0, 18], ["an alcohol thermometer", "TREATMENT", 92, 114]]], ["Instrument and so\ue09dware development of the novel QuRapID (Fig. 4d) thermal cycler (WO/2011/157989) involved a Raspberry Pi (Raspberry Pi Foundation, Cambridge, UK)-controlled, single-well prototype (Fig. 4c) with customfabricated thermal control printed circuit boards, to evaluate the complete Luxeon Rebel range of light emitting diodes (Lumileds, Amsterdam, Holland), \ue103ltered white light sources and laser diodes (Osram, Regensburg, Germany).", [["Pi", "CHEMICAL", 119, 121], ["thermal cycler", "TREATMENT", 66, 80], ["single-well prototype (Fig. 4c", "TREATMENT", 175, 205], ["customfabricated thermal control printed circuit boards", "TREATMENT", 212, 267], ["light emitting diodes", "TREATMENT", 316, 337], ["laser diodes", "TREATMENT", 402, 414]]], ["Performance testing was carried out on two separate 8-well instruments in three separate laboratories (University of Westminster, BioGene Ltd. and Public Health England).", [["Performance testing", "TEST", 0, 19]]], ["Fluorophore and probe dye/ quencher compatibility with blood was assessed in duplicate by adding 4-5ml of blood directly into a reaction master mix (50 ml \ue103nal volume).", [["blood", "ANATOMY", 55, 60], ["blood", "ANATOMY", 106, 111], ["Fluorophore", "SIMPLE_CHEMICAL", 0, 11], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["Fluorophore", "TREATMENT", 0, 11], ["probe dye/ quencher compatibility", "TREATMENT", 16, 49], ["a reaction master mix", "TREATMENT", 126, 147]]], ["Results were expressed as the absolute \ue104uorescence, and summarized as the difference in \ue104uorescence (positive or negative) in the presence and absence of blood a\ue09der background-subtraction.", [["blood", "ANATOMY", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["\ue104uorescence", "TEST", 88, 99]]], ["Emission peaks were de\ue103ned as the wavelength with the highest emission intensity for each dye, with peak emission intensity de\ue103ned as the average intensity at AE1 nm from the speci\ue103c wavelength (11 values total).", [["AE1 nm", "PROTEIN", 159, 165], ["Emission peaks", "TEST", 0, 14], ["peak emission intensity", "PROBLEM", 100, 123], ["AE1 nm", "TEST", 159, 165], ["the speci\ue103c wavelength", "TEST", 171, 193]]], ["Signal to noise ratios were calculated against the blood sample readings within the same wavelength region as de\ue103ned by the dye measurements in the presence of blood.", [["blood sample", "ANATOMY", 51, 63], ["blood", "ANATOMY", 160, 165], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["Signal to noise ratios", "TEST", 0, 22], ["the blood sample", "TEST", 47, 63], ["the dye measurements", "TEST", 120, 140], ["blood", "OBSERVATION", 160, 165]]], ["Threshold values were calculated as 1.5 standard deviations above the emission peak average intensity in the dye-free, blood background samples.", [["blood", "ANATOMY", 119, 124], ["samples", "ANATOMY", 136, 143], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["Threshold values", "TEST", 0, 16], ["blood background samples", "TEST", 119, 143], ["peak", "OBSERVATION_MODIFIER", 79, 83], ["average", "OBSERVATION_MODIFIER", 84, 91], ["intensity", "OBSERVATION_MODIFIER", 92, 101]]], ["Data processing was carried out on Microso\ue09d Excel (v.15; Microso\ue09d, Reading, UK) and graphical representation was performed on Microso\ue09d Excel or GraphPad Prizm v.7.0a (San Diego, CA, USA).", [["Data processing", "TEST", 0, 15]]], ["The end-user-directed SOP (video online) based on a 62.5 ml \ue103nal reaction volume and 5 ml fresh blood samples (8% v/v \ue103nal blood concentration in the reaction) is summarized in Fig. S7 . \u2020Biosafety level 4 (BSL4) sensitivity and speci\ue103city testingThe infectious viruses evaluated in this study (Table S2 \u2020) were speci\ue103c stocks produced at the Porton Down BSL4 laboratory of Public Health England.", [["blood samples", "ANATOMY", 96, 109], ["blood", "ANATOMY", 123, 128], ["blood samples", "ORGANISM_SUBSTANCE", 96, 109], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["S7", "GENE_OR_GENE_PRODUCT", 182, 184], ["S7", "PROTEIN", 182, 184], ["a 62.5 ml \ue103nal reaction volume", "TREATMENT", 50, 80], ["blood samples", "TEST", 96, 109], ["8% v/v \ue103nal blood concentration", "TREATMENT", 111, 142], ["Biosafety level", "TEST", 188, 203], ["sensitivity", "TEST", 213, 224], ["speci\ue103city testing", "TEST", 229, 247], ["The infectious viruses", "PROBLEM", 247, 269], ["this study", "TEST", 283, 293], ["speci\ue103c stocks", "PROBLEM", 312, 326], ["infectious", "OBSERVATION_MODIFIER", 251, 261]]], ["Live viruses were quanti\ue103ed by titration to obtain 50% tissue culture infectious dose (TCID 50 ) in VeroE6 cells (European Collection of Cell Cultures, UK) and titers were converted to PFU per ml by multiplying the TCID 50 /ml values by 0.7 assuming Poisson distribution.", [["tissue", "ANATOMY", 55, 61], ["VeroE6 cells", "ANATOMY", 100, 112], ["Cell Cultures", "ANATOMY", 137, 150], ["tissue", "TISSUE", 55, 61], ["VeroE6 cells", "CELL", 100, 112], ["Cell Cultures", "CELL", 137, 150], ["VeroE6 cells", "CELL_LINE", 100, 112], ["Live viruses", "PROBLEM", 0, 12], ["VeroE6 cells", "PROBLEM", 100, 112], ["Cell Cultures", "TEST", 137, 150], ["titers", "TEST", 160, 166]]], ["11 All live virus manipulations and QuRapID analyses were performed under BSL4 across 7 separate days including instrument pre-calibration runs on AR14.", [["QuRapID", "DNA", 36, 43], ["All live virus manipulations", "TEST", 3, 31], ["QuRapID analyses", "TEST", 36, 52]]], ["Live viruses were serially diluted 10-fold in FBS or minimal essential medium plus GlutaMax\u2122-I (MEM; Thermo Fisher Scienti\ue103c) and used as templates for the QuRapID-migrated Trombley GP assay (Trombley+ assay).", [["FBS", "ANATOMY", 46, 49], ["FBS", "ORGANISM_SUBSTANCE", 46, 49], ["QuRapID", "SIMPLE_CHEMICAL", 156, 163], ["Live viruses", "PROBLEM", 0, 12], ["FBS", "TEST", 46, 49], ["Thermo Fisher Scienti\ue103c)", "TREATMENT", 101, 125], ["the QuRapID", "TREATMENT", 152, 163]]], ["Reactions comprised of 57.5 ml RT-qPCR master-mix (TaqMan\u00ae Fast Virus 1-Step Master Mix (Thermo Fisher Scienti\ue103c), primers, and probes (Table S3 \u2020)), to which 5 ml of FBS-diluted virus or 4 ml FBS and 1 ml of MEM-diluted virus were directly added.", [["FBS", "ANATOMY", 193, 196], ["MEM", "CHEMICAL", 209, 212], ["FBS", "ORGANISM_SUBSTANCE", 167, 170], ["FBS", "ORGANISM_SUBSTANCE", 193, 196], ["mix (TaqMan\u00ae Fast Virus", "TREATMENT", 46, 69], ["FBS", "TEST", 167, 170], ["diluted virus", "TREATMENT", 171, 184], ["4 ml FBS", "TREATMENT", 188, 196], ["MEM-diluted virus", "TREATMENT", 209, 226]]], ["Assay performance was expressed as Ct call against titration-derived infectious virus concentration in PFU per ml or genome content in GE per ml based on AR14 pre-calibration.Biosafety level 4 (BSL4) sensitivity and speci\ue103city testingIndependent samples across the two virus dilution series (140 ml per dilution) were chemically inactivated in accordance with PHE's hazard group 4 inactivation methods.", [["samples", "ANATOMY", 246, 253], ["PHE", "CHEMICAL", 360, 363], ["PHE", "CHEMICAL", 360, 363], ["Assay performance", "TEST", 0, 17], ["Ct", "TEST", 35, 37], ["titration", "TEST", 51, 60], ["infectious virus concentration", "TREATMENT", 69, 99], ["AR14 pre-calibration", "TREATMENT", 154, 174], ["Biosafety level", "TEST", 175, 190], ["sensitivity", "TEST", 200, 211], ["speci\ue103city", "TEST", 216, 226], ["the two virus dilution series", "TREATMENT", 261, 290]]], ["Sample tubes were disinfected with detergent in accordance with PHE's BSL4 disinfection policy for safe working of material at BSL2.", [["PHE", "CHEMICAL", 64, 67], ["BSL4", "CHEMICAL", 70, 74], ["PHE", "CHEMICAL", 64, 67], ["PHE", "SIMPLE_CHEMICAL", 64, 67], ["BSL4", "SIMPLE_CHEMICAL", 70, 74], ["BSL2", "SIMPLE_CHEMICAL", 127, 131], ["BSL2", "PROTEIN", 127, 131], ["Sample tubes", "TREATMENT", 0, 12], ["PHE's BSL4 disinfection policy", "TREATMENT", 64, 94], ["safe working of material at BSL2", "TREATMENT", 99, 131], ["tubes", "OBSERVATION", 7, 12]]], ["RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) and quanti\ue103ed against RNA extract standard curves from AR14 using an Applied Biosystems 7500 Fast (Thermo Fisher Scien-ti\ue103c).", [["RNA", "RNA", 0, 3], ["the QIAamp Viral RNA Mini Kit (Qiagen)", "TREATMENT", 24, 62]]], ["Primer and probe sets speci\ue103c to Filoviruses other than EBOV were used in speci\ue103city tests (Table S3 \u2020) .", [["EBOV", "ORGANISM", 56, 60], ["EBOV", "SPECIES", 56, 60], ["Primer and probe sets speci\ue103c", "TREATMENT", 0, 29], ["Filoviruses", "TREATMENT", 33, 44], ["EBOV", "TREATMENT", 56, 60], ["speci\ue103city tests", "TEST", 74, 90]]], ["Stock virion concentration in GE per ml was quanti\ue103ed as the titration range average, as calculated per analytical platform.Statistical methodsLinear regression analyses to de\ue103ne assay LDR were conducted on GraphPad Prizm on the means of technical triplicates, with 95% con\ue103dence bands graphically represented across the titration range tested.", [["Stock virion concentration", "TREATMENT", 0, 26], ["assay LDR", "TEST", 179, 188], ["95% con\ue103dence bands graphically", "PROBLEM", 266, 297], ["virion concentration", "OBSERVATION", 6, 26], ["titration range", "OBSERVATION", 321, 336]]], ["The probability of single curve \ue103t for independent assays or assay templates was determined by Akaike's Informative Criteria Test conducted on blinded sample data using GraphPad Prizm.", [["independent assays", "TEST", 39, 57], ["assay templates", "TEST", 61, 76], ["blinded sample data", "TEST", 143, 162], ["GraphPad Prizm", "TREATMENT", 169, 183]]], ["Diagnostic parameters were determined in accordance to Armbruster and Pry.", [["Diagnostic parameters", "TEST", 0, 21]]], ["76 Authors contributions S. A. M. conceived this research, selected with D. A. N. and D. E. the assays to be used herein and established with the assistance of D. A. N. and K. S. R. R. technology speci\ue103cation, standard operating procedure requirements and minimum acceptable performance criteria for system progression.", [["standard operating procedure requirements", "TREATMENT", 210, 251], ["system progression", "PROBLEM", 300, 318]]], ["S. A. M., D. E. and E. W. planned and oversaw execution of all BSL2 work presented herein, with K. S. R. R. overseeing all BSL4 work and M. L. consulting on EUA-grade assay development requirements.", [["M. L.", "SPECIES", 137, 142], ["K. S. R. R.", "SPECIES", 96, 107], ["M. L.", "SPECIES", 137, 142], ["EUA", "TEST", 157, 160], ["grade assay development requirements", "PROBLEM", 161, 197]]], ["K. S., D. E., K. S. R. R. and S. A. M. designed the recombinant virion assay target sites.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["recombinant virion assay target sites", "DNA", 52, 89], ["S. A. M.", "SPECIES", 30, 38], ["K", "TEST", 0, 1], ["the recombinant virion assay", "TREATMENT", 48, 76]]], ["S. A. M., D. E. and K. S. evaluated manually, computationally and biochemically the impact of assay template genetic dri\ue09d on assay performance.", [["assay performance", "TEST", 125, 142]]], ["K. S. undertook with the assistance of L. U. all BSL2 assay transfer, modi\ue103cation and validation work.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1]]], ["K. S., E. B. and E. W. constructed the recombinant HIV pseudotyped virions (BSL2 standards).", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["E. B.", "ORGANISM", 7, 12], ["E. W.", "ORGANISM", 17, 22], ["HIV", "ORGANISM", 51, 54], ["pseudotyped", "ORGANISM", 55, 66], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 51, 54], ["K", "TEST", 0, 1], ["the recombinant HIV pseudotyped virions (BSL2 standards", "TREATMENT", 35, 90]]], ["C. C. and D. L. performed all RT-qPCR in blood inhibition and bloodcompatible lyophilized assay development studies under the guidance of M. L., S. A. M., D. E. and N. N. S. A. M. and D. E. proposed the use of red dyes for blood-compatible RT-qPCR.", [["blood", "ANATOMY", 41, 46], ["blood", "ANATOMY", 223, 228], ["D. L.", "ORGANISM", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["red dyes", "SIMPLE_CHEMICAL", 210, 218], ["blood", "ORGANISM_SUBSTANCE", 223, 228], ["C. C.", "SPECIES", 0, 5], ["D. L.", "SPECIES", 10, 15], ["C. C.", "SPECIES", 0, 5], ["D. L.", "SPECIES", 10, 15], ["M. L.", "SPECIES", 138, 143], ["all RT", "TREATMENT", 26, 32], ["blood inhibition", "TEST", 41, 57], ["bloodcompatible lyophilized assay", "TEST", 62, 95], ["red dyes", "TREATMENT", 210, 218], ["blood", "TEST", 223, 228]]], ["D. E., A. T. and K. S. established the optimal conditions for bloodcompatible single-and multi-plexed RT-qPCR, with S. A. M. conducting multiplexing modelling.", [["K. S.", "ORGANISM", 17, 22], ["K. S.", "SPECIES", 17, 22], ["S. A. M.", "SPECIES", 116, 124], ["multi-plexed RT-qPCR", "TREATMENT", 89, 109]]], ["N. N. oversaw implementation by D. E. and A. T., of instrument/consumable engineering, so\ue09dware and standard operating procedure spec-i\ue103cations set by S. A. M. as advised for in-country requirements by K. R. and D. A. N. L. E., J. B., C. B. and K. S. R. R. performed all BSL4 procedures described herein.", [["A. T.", "SPECIES", 42, 47], ["S. A. M.", "SPECIES", 150, 158], ["K. S. R. R.", "SPECIES", 244, 255], ["all BSL4 procedures", "TREATMENT", 266, 285]]], ["S. A. M., K. S., K. S. R. R., D. E. and A. T. prepared this manuscript with equal support from all contributing authors.Conflicts of interestThe authors declare no competing \ue103nancial interests.", [["equal support", "TREATMENT", 76, 89]]]], "PMC7267801": [["Understanding large-scale effects of the corona crisis ::: What is the current situation?The psychological effects of pandemics such as the corona crisis are not yet well understood.", [["pandemics", "DISEASE", 118, 127], ["the corona crisis", "PROBLEM", 37, 54], ["pandemics", "TREATMENT", 118, 127], ["the corona crisis", "PROBLEM", 136, 153], ["large", "OBSERVATION_MODIFIER", 14, 19], ["-scale", "OBSERVATION_MODIFIER", 19, 25], ["corona crisis", "OBSERVATION", 41, 54]]], ["So far, there is only initial empirical evidence on the effects of the crisis on our psyche.", [["the crisis", "PROBLEM", 67, 77]]], ["In Germany, for example, the COSMO consortium has been collecting weekly waves of psychological responses since early March 2020 and finds increases in the perceived risk of the virus, concern about and fear of the virus, and concern about the economy and society as a whole (COSMO consortium, 2020).", [["the virus", "PROBLEM", 174, 183], ["the virus", "PROBLEM", 211, 220], ["virus", "OBSERVATION", 178, 183], ["virus", "OBSERVATION", 215, 220]]], ["Studies from China, which assessed the consequences of strict quarantine measures, revealed a wide range of psychological distress including panic disorder and post-traumatic stress disorder symptoms (Qiu et al., 2020).", [["psychological distress", "DISEASE", 108, 130], ["panic disorder", "DISEASE", 141, 155], ["post-traumatic stress disorder", "DISEASE", 160, 190], ["strict quarantine measures", "TREATMENT", 55, 81], ["psychological distress", "PROBLEM", 108, 130], ["panic disorder", "PROBLEM", 141, 155], ["post-traumatic stress disorder symptoms", "PROBLEM", 160, 199], ["wide range", "OBSERVATION_MODIFIER", 94, 104], ["post-traumatic", "OBSERVATION_MODIFIER", 160, 174]]], ["Other research suggests that various psychological processes and concepts predict the adherence to so-called physical distancing measures \u2013 currently the most promoted measures to slow down the spread of the virus.", [["various psychological processes", "PROBLEM", 29, 60], ["physical distancing measures", "TREATMENT", 109, 137], ["the virus", "PROBLEM", 204, 213]]], ["In a recently published overview, Van Bavel, Baicker, Boggio, and et al. (2020) have examined a plethora of relevant psychological predictors with the aim of addressing public health issues related to the corona crisis.", [["the corona crisis", "PROBLEM", 201, 218], ["corona crisis", "OBSERVATION", 205, 218]]], ["In summary, they suggest that \u2013 among other things \u2013 collective identities, cooperation behaviour, solidarity norms, but also preparing people to identify misleading communication (e.g., in terms of conspiracy theories) can motivate them to act for the common good.", [["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142]]], ["This resonates with other work compiled by Jetten, Haslam, Reicher & Cruwys (2020), who argue that explaining the collective processes involved in responses to the corona crises may benefit, in particular, from addressing social identity processes.", [["the corona crises", "PROBLEM", 160, 177]]], ["Such processes may become particularly relevant for a post-corona environmental psychology that addresses global crises.Differentiating the corona crisis from the climate crisis ::: What is the current situation?The main question of our analysis is whether and how the corona crisis \u2013 despite its devastating consequences \u2013 can be helpful for understanding and even supporting a social-ecological transformation.", [["global crises", "PROBLEM", 106, 119], ["the corona crisis", "PROBLEM", 136, 153], ["our analysis", "TEST", 233, 245], ["the corona crisis", "PROBLEM", 265, 282], ["corona crisis", "OBSERVATION", 140, 153], ["climate crisis", "OBSERVATION", 163, 177], ["main", "OBSERVATION_MODIFIER", 216, 220], ["corona crisis", "OBSERVATION", 269, 282]]], ["Large parts of the population \u2013 across manifold countries \u2013 accepted the strict corona mitigation measures taken, or demand(ed) even stricter regulations.", [["the strict corona mitigation measures", "TREATMENT", 69, 106], ["parts", "OBSERVATION_MODIFIER", 6, 11], ["population", "OBSERVATION_MODIFIER", 19, 29], ["corona", "OBSERVATION_MODIFIER", 80, 86]]], ["This is striking, given that similar restrictions would have been very unlikely before corona with regard to environmental crises that do share some characteristics.", [["environmental crises", "PROBLEM", 109, 129]]], ["For example, the climate crisis and the corona crisis have in common that certain indicators change with exponential growth and a large collective (if not all humans) is affected.", [["humans", "ORGANISM", 159, 165], ["humans", "SPECIES", 159, 165], ["humans", "SPECIES", 159, 165], ["the climate crisis", "PROBLEM", 13, 31], ["the corona crisis", "PROBLEM", 36, 53], ["exponential growth", "PROBLEM", 105, 123], ["climate crisis", "OBSERVATION", 17, 31], ["corona crisis", "OBSERVATION", 40, 53], ["exponential", "OBSERVATION_MODIFIER", 105, 116], ["growth", "OBSERVATION_MODIFIER", 117, 123], ["large", "OBSERVATION_MODIFIER", 130, 135], ["collective", "OBSERVATION", 136, 146]]], ["Both require drastic private and public measures, mitigation in terms of changing routines, and vulnerable groups are struck hardest.", [["drastic private", "TREATMENT", 13, 28], ["public measures", "TREATMENT", 33, 48], ["mitigation", "TREATMENT", 50, 60], ["drastic", "OBSERVATION_MODIFIER", 13, 20]]], ["For both, large parts of the scientific community call for action.Differentiating the corona crisis from the climate crisis ::: What is the current situation?Of course, there are important differences between the crises.", [["the corona crisis", "PROBLEM", 82, 99], ["the crises", "PROBLEM", 209, 219], ["large", "OBSERVATION_MODIFIER", 10, 15], ["corona crisis", "OBSERVATION", 86, 99], ["climate crisis", "OBSERVATION", 109, 123]]], ["Some would argue that the psychological distance to the climate crisis is much larger and, therefore, a lower (systemic) risk is perceived (Br\u00fcgger, 2020).", [["larger", "OBSERVATION_MODIFIER", 79, 85]]], ["Many people might also hold the opinion that corona-related restrictions are only temporary, while lifestyle changes for climate crisis mitigation may be seen as continuous.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["climate crisis mitigation", "TREATMENT", 121, 146]]], ["People may experience different emotions because the climate crisis appears less urgent.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["different emotions", "PROBLEM", 22, 40], ["the climate crisis", "PROBLEM", 49, 67]]], ["It is also likely that people feel more collectively efficacious towards the corona crisis, given that feedback about (successful) mitigation is communicated almost on a daily basis.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["the corona crisis", "PROBLEM", 73, 90], ["also likely", "UNCERTAINTY", 6, 17], ["corona crisis", "OBSERVATION", 77, 90]]], ["Finally, SARS-CoV-2 has very tangible consequences for individuals in risk groups (risk of death or severe illness among older people) and immediate implications such as collapsing health care systems in an uncontrolled outbreak.", [["SARS", "DISEASE", 9, 13], ["death", "DISEASE", 91, 96], ["illness", "DISEASE", 107, 114], ["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133], ["SARS-CoV", "SPECIES", 9, 17], ["death", "PROBLEM", 91, 96], ["severe illness", "PROBLEM", 100, 114], ["an uncontrolled outbreak", "PROBLEM", 204, 228], ["uncontrolled", "OBSERVATION_MODIFIER", 207, 219], ["outbreak", "OBSERVATION", 220, 228]]], ["The consequences of climate change, in turn, may not be perceived as tangible and urgent by many parts of the western society \u2013 unlike corona, which hit Western societies with force.Differentiating the corona crisis from the climate crisis ::: What is the current situation?At the peak of the corona crisis, the most important scientific and political task is to ensure a functioning public health system, namely, to save lives now.", [["climate change", "PROBLEM", 20, 34], ["the corona crisis", "PROBLEM", 198, 215], ["the corona crisis", "PROBLEM", 289, 306], ["corona", "OBSERVATION_MODIFIER", 135, 141], ["corona crisis", "OBSERVATION", 202, 215], ["climate crisis", "OBSERVATION", 225, 239], ["peak", "OBSERVATION_MODIFIER", 281, 285], ["corona crisis", "OBSERVATION", 293, 306]]], ["However, the long-term socio-political consequences of the pandemic require a research agenda that addresses how we as human beings cope with an altered socio-political environment.", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124]]], ["This requires a collective perspective on how people appraise and respond to climate change and other impending crises, following the massive societal changes brought about by the corona crisis.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["other impending crises", "PROBLEM", 96, 118], ["the massive societal changes", "PROBLEM", 130, 158], ["massive", "OBSERVATION_MODIFIER", 134, 141], ["societal", "OBSERVATION", 142, 150], ["corona crisis", "OBSERVATION", 180, 193]]], ["Within environmental psychology, the social roots of pro-environmental behaviour have been increasingly acknowledged in recent years (Amel, Manning, Scott, & Koger, 2017; Bamberg, Rees, & Seebauer, 2015; Fielding & Hornsey, 2016).", [["roots", "ANATOMY", 44, 49]]], ["We believe that the Social Identity Model of Pro-Environmental Action (SIMPEA, Fritsche, Barth, Jugert, Masson, & Reese, 2018) in particular provides an appropriate framework for generating a \u2018post-corona\u2019 research agenda for understanding pro-environmental behaviour for several reasons.", [["a \u2018post-corona\u2019 research agenda", "TREATMENT", 190, 221]]], ["In a nutshell, the SIMPEA assumes that people's response to a crisis is subject to social group processes (Fritsche et al., 2018): People perceive societal crises through the lens of their social identity.The Social Identity Model of Pro-environmental action (SIMPEA) ::: What is the current situation?More specifically, the SIMPEA predicts that the salience of social norms (i.e., rules that govern behaviour in groups and societies), collective efficacy beliefs (i.e., beliefs that we as a group can reach our goals), and identification with social groups (i.e., the emotional and cognitive bond to social groups) predict the appraisal of a crisis (i.e., is the crisis a relevant risk?) and the response to a crisis (e.g., supporting a policy, see Fig. 1).", [["people", "ORGANISM", 39, 45], ["People", "ORGANISM", 131, 137], ["SIMPEA", "DNA", 325, 331], ["people", "SPECIES", 39, 45], ["People", "SPECIES", 131, 137], ["a crisis", "PROBLEM", 60, 68], ["a crisis", "PROBLEM", 641, 649]]], ["The appraisal of the crisis, in turn, results in emotions and motivations that again affect the social components.", [["the crisis", "PROBLEM", 17, 27], ["crisis", "OBSERVATION", 21, 27]]], ["This cyclical conceptualisation of the model provides perhaps the first and most convincing argument for using the SIMPEA in order to understand how people will respond to and appraise climate change following the corona crisis.", [["people", "ORGANISM", 149, 155], ["people", "SPECIES", 149, 155], ["the SIMPEA", "TREATMENT", 111, 121], ["the corona crisis", "PROBLEM", 210, 227], ["corona crisis", "OBSERVATION", 214, 227]]], ["Second, the SIMPEA integrates individual and social responses to collective crises.", [["SIMPEA", "DNA", 12, 18], ["collective crises", "PROBLEM", 65, 82]]], ["It is deeply rooted in a strong social identity theory (SIT) tradition, and provides a comprehensive set of predictions for how group processes affect appraisals of and responses to collective crises.", [["collective crises", "PROBLEM", 182, 199]]], ["We will base our analysis primarily on an extended interpretation of the model that includes contextual and psychological factors that may emerge from the corona crisis.", [["base our analysis", "TEST", 8, 25], ["contextual and psychological factors", "PROBLEM", 93, 129], ["the corona crisis", "PROBLEM", 151, 168], ["corona crisis", "OBSERVATION", 155, 168]]], ["We will not reiterate all factors of the model that have been successfully tested earlier (Fritsche et al., 2018).The Social Identity Model of Pro-environmental action (SIMPEA) ::: What is the current situation?With regard to the corona crisis, the SIMPEA suggests that people perceive the crisis and appraise the situation as a risk, based on both individual and social factors, which results in certain emotions (e.g., fear, concern) and motivations (e.g., motivation to stockpile).", [["people", "ORGANISM", 270, 276], ["people", "SPECIES", 270, 276], ["the corona crisis", "PROBLEM", 226, 243], ["the crisis", "PROBLEM", 286, 296], ["corona crisis", "OBSERVATION", 230, 243]]], ["These emotions and motivations are assumed to affect people's group identification (e.g., identification with a neighbourhood or a \u201c#stayathome\u201d movement) and the salience of social norms (e.g., people should follow the government's new rules of staying at home).", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["people", "SPECIES", 195, 201]]], ["Identification, salience of social norms, and group efficacy beliefs (i.e., the belief that we as a group or society can tackle the corona crisis) should then, according to the model, predict actual behaviour (e.g., one's own physical distancing behaviour).The Social Identity Model of Pro-environmental action (SIMPEA) ::: What is the current situation?Most importantly, however, a response can also be how people react to and appraise other crises.", [["people", "ORGANISM", 408, 414], ["people", "SPECIES", 408, 414], ["other crises", "PROBLEM", 437, 449]]], ["This is one of the key arguments of our analysis.", [["our analysis", "TEST", 36, 48]]], ["The SIMPEA's cyclical nature allows to postulate that group processes as a function of the corona crisis may inform responses to other large scale crises \u2013 such as towards the climate crisis.", [["the corona crisis", "PROBLEM", 87, 104], ["other large scale crises", "PROBLEM", 129, 153]]], ["The current changes of normality might provide a wedge for societal and political debates on these changes in the future: Based on the collective experience of the corona crisis, people might, for example, have realised that some behaviour changes such as slower mobility or reduced consumption also satisfy psychological needs or motivations (e.g., a need for competence satisfied through gardening or working in home office; see lower right of the SIMPEA; Fig. 1).", [["people", "ORGANISM", 179, 185], ["people", "SPECIES", 179, 185], ["a wedge for societal", "TREATMENT", 47, 67], ["the corona crisis", "PROBLEM", 160, 177], ["some behaviour changes", "PROBLEM", 225, 247], ["slower mobility", "PROBLEM", 256, 271], ["corona crisis", "OBSERVATION", 164, 177], ["right", "ANATOMY_MODIFIER", 437, 442]]], ["The current situation might not only offer a window of opportunity for individual climate-change related behaviour change.", [["change related behaviour change", "PROBLEM", 90, 121]]], ["More specifically, it might open up windows for strong and collectively supported \u2013 and politically implemented \u2013 emission reductions.", [["\u2013 emission reductions", "TREATMENT", 112, 133]]], ["For example, if the corona crisis resulted in humanity working together more closely, climate negotiations could also benefit from a superordinate identity that encompasses different national groups (Batalha & Reynolds, 2012).The Social Identity Model of Pro-environmental action (SIMPEA) ::: What is the current situation?However, not only do we need to understand why people change their behaviour significantly or when people are open for corresponding policy measures.", [["people", "ORGANISM", 370, 376], ["people", "ORGANISM", 422, 428], ["people", "SPECIES", 370, 376], ["people", "SPECIES", 422, 428], ["the corona crisis", "PROBLEM", 16, 33], ["corona", "OBSERVATION_MODIFIER", 20, 26]]], ["We also need to understand how humans and their personal and collective well-being (cf. Roy, Riley, Sears, & Rula, 2018) in general might be affected by these changes.", [["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37]]], ["This could inform politicians and change-makers how to best implement policies that lead to high reductions in environmental degradation while simultaneously securing and promoting well-being of people and their communities.", [["people", "ORGANISM", 195, 201], ["people", "SPECIES", 195, 201], ["high reductions in environmental degradation", "PROBLEM", 92, 136]]], ["Given how strongly basic psychological need satisfaction determines human well-being and motivation (e.g., Deci & Ryan, 2000) and also relates to pro-environmental behaviour (e.g., Cooke, Fielding, & Louis, 2016; Kasser, 2009), focusing on basic psychological need satisfaction may be imperative.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73]]], ["The corona crisis might be a good starting point in researching psychological factors (such as basic psychological needs) that buffer against a drop in personal and collective well-being in times of dramatic behaviour change.The corona crisis highlights specific social identities ::: Extending the SIMPEA to understand the effects of the corona crisis ::: What is the current situation?", [["The corona crisis", "PROBLEM", 0, 17], ["dramatic behaviour change", "PROBLEM", 199, 224], ["The corona crisis", "PROBLEM", 225, 242], ["the corona crisis", "PROBLEM", 335, 352], ["corona", "OBSERVATION_MODIFIER", 4, 10], ["crisis", "OBSERVATION", 11, 17], ["corona crisis", "OBSERVATION", 229, 242], ["corona crisis", "OBSERVATION", 339, 352]]]], "62503f1644ab37642dbc887d28642c76c288bf09": [["BackgroundHealth harms are increasing among the estimated 200,000 people who inject drugs (PWID) in the United Kingdom (UK).", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["Since 2012, there has been a steady increase in hospitalisations for serious bacterial infections [1] , a doubling of opioid-related deaths [2] , and outbreaks of invasive and infectious diseases among PWID, particularly among those who are homeless [1] [2] [3] .", [["bacterial infections", "DISEASE", 77, 97], ["deaths", "DISEASE", 133, 139], ["invasive and infectious diseases", "DISEASE", 163, 195], ["serious bacterial infections", "PROBLEM", 69, 97], ["steady", "OBSERVATION_MODIFIER", 29, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["infectious", "OBSERVATION", 176, 186]]], ["The recent outbreak of coronavirus is of particular concern, given vulnerability to respiratory problems among PWID in the UK, many of whom also smoke (crack cocaine, heroin, tobacco) and have a much higher incidence of chronic obstructive pulmonary disease (COPD) than the general population [4] .", [["pulmonary", "ANATOMY", 240, 249], ["coronavirus", "DISEASE", 23, 34], ["respiratory problems", "DISEASE", 84, 104], ["cocaine", "CHEMICAL", 158, 165], ["heroin", "CHEMICAL", 167, 173], ["chronic obstructive pulmonary disease", "DISEASE", 220, 257], ["COPD", "DISEASE", 259, 263], ["cocaine", "CHEMICAL", 158, 165], ["heroin", "CHEMICAL", 167, 173], ["coronavirus", "ORGANISM", 23, 34], ["tobacco", "ORGANISM", 175, 182], ["pulmonary", "ORGAN", 240, 249], ["tobacco", "SPECIES", 175, 182], ["coronavirus", "PROBLEM", 23, 34], ["respiratory problems", "PROBLEM", 84, 104], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 220, 264], ["coronavirus", "OBSERVATION", 23, 34], ["chronic", "OBSERVATION_MODIFIER", 220, 227], ["obstructive", "OBSERVATION_MODIFIER", 228, 239], ["pulmonary", "ANATOMY", 240, 249], ["disease", "OBSERVATION", 250, 257], ["COPD", "OBSERVATION", 259, 263]]], ["Drugrelated deaths in the UK are higher than any European Union (EU) country; in the year before Britians exit they accounted for one third of all reported in the EU country and, in the year prior to Britain's exit, accounted for a third of all reported in the EU [5] .", [["deaths", "DISEASE", 12, 18]]], ["To do so effectively, it is essential that interventions are informed by an in-depth understanding of current constraints to safe injecting practices and how environments can be modified to facilitate or protect against health harms.BackgroundHomelessness and public injecting are interrelated and constitute part of the structural risk environment fostering health harms, such as bacterial and viral infections, among PWID [8] .", [["Homelessness", "DISEASE", 243, 255], ["bacterial and viral infections", "DISEASE", 381, 411], ["safe injecting practices", "TREATMENT", 125, 149], ["BackgroundHomelessness", "PROBLEM", 233, 255], ["bacterial and viral infections", "PROBLEM", 381, 411], ["Homelessness", "OBSERVATION", 243, 255], ["viral infections", "OBSERVATION", 395, 411]]], ["Skin and soft tissue infections (SSTI), such as abscesses and cellulitis, are a growing cause of hospitalisation among PWID [9] , with homeless PWID particularly susceptible to SSTI and related complications, such as septicaemia and endocarditis [10] .", [["Skin", "ANATOMY", 0, 4], ["soft tissue", "ANATOMY", 9, 20], ["abscesses", "ANATOMY", 48, 57], ["Skin and soft tissue infections", "DISEASE", 0, 31], ["SSTI", "DISEASE", 33, 37], ["abscesses", "DISEASE", 48, 57], ["cellulitis", "DISEASE", 62, 72], ["SSTI", "DISEASE", 177, 181], ["septicaemia", "DISEASE", 217, 228], ["endocarditis", "DISEASE", 233, 245], ["Skin", "ORGAN", 0, 4], ["soft tissue", "TISSUE", 9, 20], ["abscesses", "PATHOLOGICAL_FORMATION", 48, 57], ["Skin and soft tissue infections (SSTI)", "PROBLEM", 0, 38], ["abscesses", "PROBLEM", 48, 57], ["cellulitis", "PROBLEM", 62, 72], ["SSTI", "PROBLEM", 177, 181], ["related complications", "PROBLEM", 186, 207], ["septicaemia", "PROBLEM", 217, 228], ["endocarditis", "PROBLEM", 233, 245], ["soft tissue", "OBSERVATION_MODIFIER", 9, 20], ["infections", "OBSERVATION", 21, 31], ["SSTI", "OBSERVATION_MODIFIER", 33, 37], ["abscesses", "OBSERVATION", 48, 57], ["cellulitis", "OBSERVATION", 62, 72], ["septicaemia", "OBSERVATION", 217, 228], ["endocarditis", "OBSERVATION", 233, 245]]], ["This increased risk among the unstably housed may be a consequence of inability to maintain safe and hygienic injection practices when injecting in public places, where injections may be hurried, with a lack of clean surfaces, poor lighting and difficulties in accessing clean water to use as a drug solvent [11] [12] [13] [14] [15] .", [["[11] [12] [13] [14] [15]", "CHEMICAL", 308, 332], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 308, 332], ["safe and hygienic injection practices", "TREATMENT", 92, 129], ["a drug solvent", "TREATMENT", 293, 307]]], ["The use of water from toilets, cisterns, ditches and puddles has been noted [11, [15] [16] [17] [18] [19] [20] [21] [22] [23] , and these sources are likely to be contaminated with particulates and microorganisms.", [["[11, [15] [16] [17] [18] [19] [20] [21] [22] [23]", "CHEMICAL", 76, 125], ["[15] [16] [17] [18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 81, 125], ["microorganisms", "PROBLEM", 198, 212], ["cisterns", "ANATOMY", 31, 39], ["likely to be", "UNCERTAINTY", 150, 162], ["contaminated", "OBSERVATION", 163, 175]]], ["Although few studies have specifically explored the role of water used to prepare injections in relation to SSTI among PWID, there are indications that the use of puddle and toilet water is a risk [20, 21] .", [["SSTI", "DISEASE", 108, 112], ["few studies", "TEST", 9, 20], ["injections", "TREATMENT", 82, 92], ["SSTI", "PROBLEM", 108, 112], ["puddle and toilet water", "TREATMENT", 163, 186]]], ["Indications of difficulty accessing water among the most marginalised are of crucial concern also, given the potentially protective benefit hand washing can have against viral infections such as influenza and COVID-19.BackgroundWater is required to prepare street drugs such as heroin and crack cocaine into a solution for injection.", [["hand", "ANATOMY", 140, 144], ["viral infections", "DISEASE", 170, 186], ["influenza", "DISEASE", 195, 204], ["heroin", "CHEMICAL", 278, 284], ["cocaine", "CHEMICAL", 295, 302], ["heroin", "CHEMICAL", 278, 284], ["cocaine", "CHEMICAL", 295, 302], ["heroin", "SIMPLE_CHEMICAL", 278, 284], ["hand washing", "TREATMENT", 140, 152], ["viral infections", "PROBLEM", 170, 186], ["influenza", "PROBLEM", 195, 204], ["COVID", "TEST", 209, 214], ["street drugs", "TREATMENT", 257, 269]]], ["As a component of injection preparation, water is a concern due to its ability to carry micro-organisms, and as it might be shared when groups of people inject drugs together.", [["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["injection preparation", "TREATMENT", 18, 39], ["micro-organisms", "PROBLEM", 88, 103], ["drugs", "TREATMENT", 160, 165]]], ["In the UK, \"water for injection\" (WFI) is a sterile pharmaceutical product used to reconstitute medicinal injections.", [["a sterile pharmaceutical product", "TREATMENT", 42, 74], ["medicinal injections", "TREATMENT", 96, 116]]], ["It has to meet a range of quality standards including limits on particulate contamination and bacterial endotoxins [24] .", [["bacterial endotoxins", "PROBLEM", 94, 114]]], ["Prior to 2003, supply of WFI to PWID was prohibited in the UK under the 1971 Misuse of Drugs Act.", [["WFI", "CHEMICAL", 25, 28]]], ["In response to the increased evidence of hepatitis C (HCV) risk from sharing injecting paraphernalia (i.e. injecting equipment other than needles and syringes) [25, 26] , section 9A of the Act was amended in 2003 to decriminalise the supply of WFI and other paraphernalia by practitioners, pharmacists and people engaged in the \"lawful provision of drug treatment services\" [27] .", [["hepatitis C (HCV)", "DISEASE", 41, 58], ["hepatitis C", "ORGANISM", 41, 52], ["HCV", "ORGANISM", 54, 57], ["people", "ORGANISM", 306, 312], ["people", "SPECIES", 306, 312], ["HCV", "SPECIES", 54, 57], ["hepatitis C (HCV) risk", "PROBLEM", 41, 63], ["needles and syringes", "TREATMENT", 138, 158], ["hepatitis", "OBSERVATION", 41, 50]]], ["Under the Medicines Act 1968, however, all medicines for parenteral administration, including WFI, are classified as a prescription only medicine [28] .", [["all medicines", "TREATMENT", 39, 52], ["parenteral administration", "TREATMENT", 57, 82]]], ["This prevented needle and syringe programmes (NSP) effectively supplying WFI, despite the 2003 law change, unless it was issued under prescription.", [["This prevented needle and syringe programmes", "TREATMENT", 0, 44]]], ["Contraventions to the law during this time included the supply, by a social enterprise, of plastic 1.4 ml sterile water ampoules.", [["plastic 1.4 ml sterile water ampoules", "TREATMENT", 91, 128]]], ["A campaign ensued to change the status of WFI from prescription only medicine to enable its supply though NSP.", [["NSP", "PROBLEM", 106, 109]]], ["In June 2005, this was realised; with the regulations amended so that drug treatment services (including NSP) could supply WFI to PWID [30] .", [["drug treatment services", "TREATMENT", 70, 93]]], ["The status of WFI as a prescription only medicine remains however, with a prescription required for all other uses other than supply to PWID.BackgroundA maximum 2 ml volume restriction was initially placed on ampoules of WFI supplied to PWID, in order to reduce potential for water sharing [28] .", [["WFI", "CHEMICAL", 221, 224], ["BackgroundA maximum 2 ml volume restriction", "TREATMENT", 141, 184], ["ampoules of WFI", "TREATMENT", 209, 224]]], ["This concern was largely related to HCV risk, given evidence that HCV can survive for up to 3 weeks in bottled water and on water containers after use [25] .", [["HCV", "ORGANISM", 36, 39], ["HCV", "ORGANISM", 66, 69], ["HCV", "SPECIES", 36, 39], ["HCV", "SPECIES", 66, 69], ["HCV risk", "PROBLEM", 36, 44], ["HCV", "PROBLEM", 66, 69]]], ["There was a further amendment of the Medicines Act in 2012 to allow the supply of 5 ml water ampoules by drug workers to PWID, but with no public announcement to this effect, awareness of the change among injecting equipment manufacturers and providers was minimal [31] .", [["the Medicines", "TREATMENT", 33, 46], ["5 ml water ampoules", "TREATMENT", 82, 101]]], ["The only 2 ml licensed and marketed WFI available in the UK is in a glass ampoule.", [["WFI", "CHEMICAL", 36, 39], ["UK", "GENE_OR_GENE_PRODUCT", 57, 59]]], ["A \"safe snap\" ampoule snapper was made available in 2006 [23, 29] to reduce the risk of glass cuts and associated HCV transmission potential.", [["HCV", "SPECIES", 114, 117], ["A \"safe snap\" ampoule snapper", "TREATMENT", 0, 29], ["glass cuts", "PROBLEM", 88, 98], ["HCV", "OBSERVATION", 114, 117]]], ["Some NSP remained reluctant to provide glass ampoules due to concerns about ampoule cost or the percieved potential for glass cuts if opened without an ampoule snapper [23] .", [["Some NSP", "PROBLEM", 0, 8], ["glass ampoules", "TREATMENT", 39, 53], ["glass cuts", "TREATMENT", 120, 130]]], ["Distribution of 5 ml ampoules of water is limited again due to cost, and also ignorance of the change in the law, drug litter potential, and fears of HCV infection through shared ampoules.", [["HCV infection", "DISEASE", 150, 163], ["HCV", "ORGANISM", 150, 153], ["HCV", "SPECIES", 150, 153], ["5 ml ampoules of water", "TREATMENT", 16, 38], ["HCV infection", "PROBLEM", 150, 163], ["5 ml", "OBSERVATION_MODIFIER", 16, 20], ["change", "OBSERVATION_MODIFIER", 95, 101], ["HCV infection", "OBSERVATION", 150, 163]]], ["At present, in the UK, provision of WFI through NSP is limited, fragmented and inconsistent.", [["fragmented", "OBSERVATION", 64, 74]]], ["The majority of injecting supplies are now accessed through community pharmacies, which usually dispense standard issue injecting packs, and these rarely contain WFI.BackgroundThere is a need to interrogate current harm reduction messaging and injecting paraphernalia provision to ascertain whether it meets the needs of PWID who are rough sleeping or unstably housed.", [["WFI", "CANCER", 162, 165], ["current harm reduction messaging", "TREATMENT", 207, 239], ["paraphernalia provision", "TREATMENT", 254, 277], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["In the UK, this is a growing population, increasingly vulnerable to health harms.", [["a growing population", "PROBLEM", 19, 39], ["growing", "OBSERVATION_MODIFIER", 21, 28], ["population", "OBSERVATION", 29, 39]]], ["Relatively little research has focused on the use of water for illicit drug preparations, apart from assessing viral transmission risk.", [["illicit drug preparations", "TREATMENT", 63, 88]]], ["Current harm reduction advice advocates the use of WFI, with the \"next best\" alternative boiled and cooled potable (drinkable cold tap) water, and after this, cold tap water.", [["Current harm reduction advice", "TREATMENT", 0, 29], ["drinkable cold tap", "TREATMENT", 116, 134], ["cold tap water", "TREATMENT", 159, 173]]], ["Our research illustrates that while these hierarchies of best practice may be actionable by people living and injecting in homes, they are not necessarily feasible for people living or injecting on the streets.", [["people", "ORGANISM", 92, 98], ["people", "ORGANISM", 168, 174], ["people", "SPECIES", 92, 98], ["people", "SPECIES", 168, 174]]], ["We present mixed-method data generated with PWID in London to highlight the environmental constraints faced by people living and injecting drugs on the streets, with a focus here on reports of liquids used for drug preparation purposes.", [["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["liquids", "TREATMENT", 193, 200], ["drug preparation purposes", "TREATMENT", 210, 235]]], ["In doing so, we aim to inform pragmatic interventions to reduce drug, and other related, health harms among the most marginalised PWID in the UK.MethodsThis paper reports on data from the London-based, National Institute for Health Research funded, Care and Prevent Study.", [["pragmatic interventions", "TREATMENT", 30, 53], ["drug", "TREATMENT", 64, 68], ["Methods", "TREATMENT", 145, 152]]], ["This mixed method study generated questionnaire with urinalysis (n = 455) and qualitative interview (n = 32) data with PWID in London, UK, between October 2017 and March 2019.", [["This mixed method study", "TEST", 0, 23], ["urinalysis", "TEST", 53, 63]]], ["The aim of Care & Prevent is twofold: (1) to explore associations between SSTI and the renal disease, AA amyloidosis, including though risk screening and specialist referral and (2) to explore the risk factors and contexts related to SSTI among PWID.", [["renal", "ANATOMY", 87, 92], ["renal disease", "DISEASE", 87, 100], ["AA", "CHEMICAL", 102, 104], ["amyloidosis", "DISEASE", 105, 116], ["SSTI", "DISEASE", 234, 238], ["renal", "ORGAN", 87, 92], ["SSTI", "PROBLEM", 74, 78], ["the renal disease", "PROBLEM", 83, 100], ["AA amyloidosis", "PROBLEM", 102, 116], ["the risk factors", "PROBLEM", 193, 209], ["SSTI", "PROBLEM", 234, 238], ["renal", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 93, 100], ["amyloidosis", "OBSERVATION", 105, 116]]], ["This paper will present findings pertaining to the latter aim, primarily drawing on qualitative accounts of injection preparation practices.MethodsStudy methods have been published in detail [32] .", [["injection preparation practices", "TREATMENT", 108, 139]]], ["Participants were recruited through word of mouth and recruitment flyers at drug treatment services, homeless hostels and day centres across London.", [["mouth", "ANATOMY", 44, 49], ["mouth", "ORGANISM_SUBDIVISION", 44, 49], ["Participants", "SPECIES", 0, 12]]], ["Surveys, urinalysis and qualitative interviews primarily took place at private rooms in the recruiting services, with some qualitative interviews conducted in a caf\u00e9, on the street or in participants' homes.", [["participants", "SPECIES", 187, 199], ["urinalysis", "TEST", 9, 19], ["qualitative interviews", "TEST", 24, 46]]], ["All were reimbursed a \u00a310 voucher for the survey and urinalysis and \u00a320 for an interview.", [["the survey", "TEST", 38, 48], ["urinalysis", "TEST", 53, 63]]], ["The questionnaire was entered into Open Data Kit (ODK) software and researcher administered using the ODK Collect application on Android tablets [33] .", [["Android tablets", "TREATMENT", 129, 144]]], ["Participants provided information on their socio-demographics, drug use history, injection preparation and administration practices, equipment use and reuse, health care practices, lifetime experience of SSTI and other health conditions.", [["SSTI", "DISEASE", 204, 208], ["Participants", "SPECIES", 0, 12], ["injection preparation", "TREATMENT", 81, 102], ["administration practices", "TREATMENT", 107, 131], ["SSTI", "PROBLEM", 204, 208]]], ["Qualitative interviews sought detail on areas outlined above, were of 60-120 min duration, audio-recorded with consent and professionally transcribed verbatim.MethodsUsing Stata version 15.1, the characteristics of study population were described using numbers and percentages for categorical variables, means (standard deviations) for normally distributed continuous variables and median (95% CI) for non-normally distributed continuous variables.", [["Stata version", "TEST", 172, 185], ["study population", "TEST", 215, 231], ["categorical variables", "TEST", 281, 302], ["non-normally distributed continuous variables", "PROBLEM", 402, 447]]], ["No multivariate analyses were undertaken for this paper as the risk variable, water, was not measured.", [["multivariate analyses", "TEST", 3, 24]]], ["Qualitative analysis was informed by constructivist grounded theory methods [34] with data analysed as generated in order to inform the direction of subsequent interviews, coding, case selection, memo and theory generation.", [["Qualitative analysis", "TEST", 0, 20]]], ["Consolidation of these codes formed the basis of a coding frame, against which all transcripts were coded (first stageSurveyThree quarters of those participating the survey (75%, 341/455) identified as male and (74%, n = 336) as white or white British.", [["coding frame", "DNA", 51, 63]]], ["Participants' mean age was 46 years (range 21 to 68).", [["Participants", "SPECIES", 0, 12]]], ["Most (79%, n = 360) were currently receiving opioid agonist therapy, with two thirds (62%, n = 284) reporting drug injecting in the past 12 months.", [["opioid agonist therapy", "TREATMENT", 45, 67]]], ["Use of crack and heroin in combination, aka \"snowball\", was favoured, with 49% (n = 255) reporting this as their primary drug injected, risng to 58% among those who had injected in the past year (n = 164/284).", [["heroin", "CHEMICAL", 17, 23], ["heroin", "CHEMICAL", 17, 23], ["heroin", "SIMPLE_CHEMICAL", 17, 23], ["heroin", "TREATMENT", 17, 23]]], ["Of note, given the vulnerability to COVID-19 among those with respiratory problems, 61% (n = 278) of the sample reported current crack smoking, 47% (n = 214) current heroin smoking, and 91% (n = 414) current tobacco smoking, the latter for a median duration of 29 years.", [["respiratory problems", "DISEASE", 62, 82], ["smoking", "CHEMICAL", 135, 142], ["heroin", "CHEMICAL", 166, 172], ["smoking", "CHEMICAL", 216, 223], ["heroin", "CHEMICAL", 166, 172], ["tobacco", "ORGANISM", 208, 215], ["tobacco", "SPECIES", 208, 215], ["COVID", "TEST", 36, 41], ["respiratory problems", "PROBLEM", 62, 82]]], ["Sixty-four (14%) participants had received a diagnosis of COPD, with a number likely undiagnosed.", [["COPD", "DISEASE", 58, 62], ["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29], ["COPD", "PROBLEM", 58, 62], ["COPD", "OBSERVATION", 58, 62], ["likely", "UNCERTAINTY", 78, 84], ["undiagnosed", "OBSERVATION", 85, 96]]], ["Most participants (78%, n = 355) reported a lifetime history of street homelessness with a mean duration of four years (range < 1 to 30 years).", [["street homelessness", "DISEASE", 64, 83], ["participants", "SPECIES", 5, 17]]], ["Just over half (57%, n = 259) were unstably housed for all or most of the past 12 months, with 33% (n = 152) in hostels, 14% (n = 61) street homeless, 7% (n = 31) staying with friends or family and 3% (n = 15) in prison.", [["hostels", "TEST", 112, 119]]], ["Participants were asked about lifetime experience of abscesses, cellulitis, venous ulcers and venous disease.", [["abscesses", "ANATOMY", 53, 62], ["venous", "ANATOMY", 76, 82], ["venous", "ANATOMY", 94, 100], ["abscesses", "DISEASE", 53, 62], ["cellulitis", "DISEASE", 64, 74], ["venous ulcers", "DISEASE", 76, 89], ["venous disease", "DISEASE", 94, 108], ["abscesses", "PATHOLOGICAL_FORMATION", 53, 62], ["venous ulcers", "PATHOLOGICAL_FORMATION", 76, 89], ["venous", "MULTI-TISSUE_STRUCTURE", 94, 100], ["Participants", "SPECIES", 0, 12], ["abscesses", "PROBLEM", 53, 62], ["cellulitis", "PROBLEM", 64, 74], ["venous ulcers", "PROBLEM", 76, 89], ["venous disease", "PROBLEM", 94, 108], ["abscesses", "OBSERVATION", 53, 62], ["cellulitis", "OBSERVATION", 64, 74], ["venous", "ANATOMY", 76, 82], ["ulcers", "OBSERVATION", 83, 89], ["venous", "ANATOMY", 94, 100], ["disease", "OBSERVATION", 101, 108]]], ["The majority (65%, n = 296) had experienced at least one of these conditions, of whom 46% (n = 137) reported consequential hospitalisation.", [["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Notably, of the 291 participants (64%) reporting a bacterial infection (abscess or cellulitis), 27% (n = 80) reported a diagnosis of septicaemia and 7% (n = 21) endocarditis.Qualitative findingsQualitative interview participants (n = 32) had similar characteristics to the survey sample, with 69% (n = 22) male; 81% (n = 26) white or white British, average age of 43 years old and 94% (n = 30) had experienced homelessness.", [["abscess", "ANATOMY", 72, 79], ["bacterial infection", "DISEASE", 51, 70], ["abscess", "DISEASE", 72, 79], ["cellulitis", "DISEASE", 83, 93], ["septicaemia", "DISEASE", 133, 144], ["endocarditis", "DISEASE", 161, 173], ["homelessness", "DISEASE", 410, 422], ["abscess", "PATHOLOGICAL_FORMATION", 72, 79], ["participants", "SPECIES", 20, 32], ["participants", "SPECIES", 216, 228], ["a bacterial infection (abscess", "PROBLEM", 49, 79], ["cellulitis", "PROBLEM", 83, 93], ["septicaemia", "PROBLEM", 133, 144], ["endocarditis", "PROBLEM", 161, 173], ["Qualitative findings", "PROBLEM", 174, 194], ["homelessness", "PROBLEM", 410, 422], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["infection", "OBSERVATION", 61, 70], ["abscess", "OBSERVATION", 72, 79], ["cellulitis", "OBSERVATION", 83, 93], ["septicaemia", "OBSERVATION", 133, 144], ["endocarditis", "OBSERVATION", 161, 173]]], ["Qualitative accounts indicate how injecting preparation practices, and the environments in which they are situated, can facilitate risk for SSTI and serious sequelae.", [["SSTI", "DISEASE", 140, 144], ["SSTI", "PROBLEM", 140, 144], ["serious sequelae", "PROBLEM", 149, 165]]], ["Below, we present data pertaining to the injection preparation process with a focus on water source as an environmental constraint to safe practice and the strategies employed by participants to navigate this constraint.Qualitative findings\"Snowball\" injection preparation requires \"cooler\"Qualitative findingsParticipants were asked to describe in detail their process for preparing a \"typical injection\".", [["participants", "SPECIES", 179, 191], ["Participants", "SPECIES", 310, 322], ["the injection preparation process", "TREATMENT", 37, 70], ["safe practice", "TREATMENT", 134, 147], ["Snowball\" injection preparation", "TREATMENT", 241, 272], ["a \"typical injection\"", "TREATMENT", 384, 405]]], ["All participants followed a similar procedure for preparing heroin, with variation in relation to amount of acidifier used and the order in which acidifier, heroin and a solvent were combined in the spoon (for more information on this process, see [35] ).", [["heroin", "CHEMICAL", 60, 66], ["heroin", "CHEMICAL", 157, 163], ["heroin", "CHEMICAL", 60, 66], ["heroin", "CHEMICAL", 157, 163], ["acidifier", "SIMPLE_CHEMICAL", 146, 155], ["heroin", "SIMPLE_CHEMICAL", 157, 163], ["participants", "SPECIES", 4, 16], ["a similar procedure", "TREATMENT", 26, 45], ["acidifier", "TREATMENT", 108, 117], ["a solvent", "TREATMENT", 168, 177]]], ["This mixture was then heated, prior to drawing up through a filter ready for injection.", [["a filter", "TREATMENT", 58, 66], ["injection", "TREATMENT", 77, 86]]], ["Those who injected heroin and crack cocaine in combination all referred to the addition of cold water (or other cold solvent) prior to adding the crack.", [["heroin", "CHEMICAL", 19, 25], ["cocaine", "CHEMICAL", 36, 43], ["heroin", "CHEMICAL", 19, 25], ["cocaine", "CHEMICAL", 36, 43], ["heroin", "SIMPLE_CHEMICAL", 19, 25], ["other cold solvent", "TREATMENT", 106, 124]]], ["The proportion of cold water or \"cooler\" added to the heroin mix was detailed precisely and appeared remarkably uniform across accounts.", [["heroin", "CHEMICAL", 54, 60], ["heroin", "CHEMICAL", 54, 60], ["the heroin mix", "TREATMENT", 50, 64], ["uniform", "OBSERVATION_MODIFIER", 112, 119]]], ["Troy and Tim's accounts are indicative:Qualitative findingsThe citric goes into the spoon first, I always inject probably 100mls 1 of water, or like suck in 100mls water \u2026 I just put the brown in and cook up the brown, put 80mils of water in, then 20mils of cooler and then the crack, squash it up and use a filter.", [["citric", "CHEMICAL", 63, 69], ["citric", "SIMPLE_CHEMICAL", 63, 69], ["The citric", "TREATMENT", 59, 69], ["a filter", "TREATMENT", 306, 314], ["filter", "OBSERVATION", 308, 314]]], ["Ross' reference to \"quite shit\" is echoed by others interviewed, with a general perspective that the quality of the crack available through London street markets at the time of the study was poor.", [["the study", "TEST", 177, 186]]], ["When the end-point of preparation was judged by clarity of the injection solution, this could result in the addition of excessive acidifier to break down cutting agents and manufacturing by-products in the crack [35] .", [["the injection solution", "TREATMENT", 59, 81], ["excessive acidifier", "TREATMENT", 120, 139], ["cutting agents", "TREATMENT", 154, 168]]], ["What these accounts also highlight, however, is that a proportion of the drug injection solution has not been subjected to heat, with implications for health harms depending on the contamination present in the \"water\" sourced.Desperate constraints: sourcing water alternativesThe environments in which participants prepared injections posed multiple constraints to enacting \"best practice\" harm reduction advice.", [["participants", "SPECIES", 302, 314], ["the drug injection solution", "TREATMENT", 69, 96], ["health harms", "PROBLEM", 151, 163], ["the contamination", "PROBLEM", 177, 194], ["harm reduction advice", "TREATMENT", 390, 411]]], ["As noted above, nearly 80% of the survey sample reported a lifetime history of rough sleeping, rising to 94% of those providing qualitative accounts.", [["rough sleeping", "PROBLEM", 79, 93]]], ["Many interview participants spoke of their \"typical injection\" preparation processes occurring in public or semi-public settings such as public toilets, bin sheds, stairwells, car parks, parked cars and even moving buses.", [["participants", "SPECIES", 15, 27]]], ["As detailed in other qualitative studies [11, [13] [14] [15] , semipublic injecting is characterised by opportunity, urgency and constraint.", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 46, 60], ["other qualitative studies", "TEST", 15, 40], ["urgency", "PROBLEM", 117, 124]]], ["When asked how this can impact on the injection preparation practice he replies \"people might forget to put citric in or use puddle water\".", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["the injection preparation practice", "TREATMENT", 34, 68]]], ["While he is fearful to do this himself, he has seen others use puddle water \"a lot\".Desperate constraints: sourcing water alternativesWhen asking about injection preparation practices, the first author took care to elicit specific detail about type and amount of acidifier used, but did not think to lend the same scrutiny to water source and type.", [["injection preparation practices", "TREATMENT", 152, 183]]], ["Unelicited accounts of solvents used in the preparation process unsettled this lack of attention.", [["solvents", "TREATMENT", 23, 31]]], ["Jeff, for example, spoke at length about the embodied effects of using cola as a water alternative, of which this quote is an extract: Dean spoke of injections that \"sting like fuck\" when using \"neat lemon juice\" in place of water, acknowledging that he was \"destroying my veins\" by doing so.", [["juice", "ANATOMY", 206, 211], ["veins", "ANATOMY", 273, 278], ["cola", "ORGANISM_SUBDIVISION", 71, 75], ["lemon", "ORGANISM", 200, 205], ["juice", "ORGANISM_SUBSTANCE", 206, 211], ["my veins", "MULTI-TISSUE_STRUCTURE", 270, 278], ["veins", "ANATOMY", 273, 278]]], ["The use of alcohol in place of water was also frequently mentioned, and given that many rough sleeping participants were also heavy drinkers, this was likely to be a readily accessible liquid for injection preparation on the street: These practices were not spoken of lightly.", [["alcohol", "CHEMICAL", 11, 18], ["alcohol", "CHEMICAL", 11, 18], ["alcohol", "SIMPLE_CHEMICAL", 11, 18], ["participants", "SPECIES", 103, 115]]], ["The need to source an alternative to water was a desperate constraint in the context of injection preparation.", [["injection preparation", "TREATMENT", 88, 109]]], ["As Alex indicates: \"I've used alcohol or fucking, yeah, man, you do things when you're desperate, you know.\"Desperate constraints: sourcing water alternativesThe expression of desperation was most acute when participants spoke of using saliva as an alternative to water.", [["alcohol", "CHEMICAL", 30, 37], ["alcohol", "CHEMICAL", 30, 37], ["alcohol", "SIMPLE_CHEMICAL", 30, 37], ["saliva", "ORGANISM_SUBSTANCE", 236, 242], ["man", "SPECIES", 56, 59], ["participants", "SPECIES", 208, 220], ["saliva", "TREATMENT", 236, 242]]], ["Although he lost the hit he had been hoping for, he did not experience the health harms recounted by Dev in conversation with the first author:Desperate constraints: sourcing water alternativesYou said you've got a wicked scar on your groin, right?Desperate constraints: sourcing water alternativesIt's infection, it got infected.", [["scar", "ANATOMY", 222, 226], ["groin", "ANATOMY", 235, 240], ["infection", "DISEASE", 303, 312], ["scar", "PATHOLOGICAL_FORMATION", 222, 226], ["groin", "ORGANISM_SUBDIVISION", 235, 240], ["a wicked scar on your groin", "PROBLEM", 213, 240], ["It's infection", "PROBLEM", 298, 312], ["infected", "PROBLEM", 321, 329], ["scar", "OBSERVATION", 222, 226], ["groin", "ANATOMY", 235, 240], ["right", "ANATOMY_MODIFIER", 242, 247], ["infection", "OBSERVATION", 303, 312]]], ["What it was, there was no water actually and I had to use a bit of saliva.", [["saliva", "ORGANISM_SUBSTANCE", 67, 73], ["a bit of saliva", "TREATMENT", 58, 73]]], ["I had to use a bit of saliva, there was more gear, yeah.Desperate constraints: sourcing water alternativesThere was no water, so you used saliva?Desperate constraints: sourcing water alternativesYeah, thinking that could work and it didn't work, man.", [["saliva", "ORGANISM_SUBSTANCE", 22, 28], ["saliva", "ORGANISM_SUBSTANCE", 138, 144], ["man", "ORGANISM", 246, 249], ["man", "SPECIES", 246, 249], ["a bit of saliva", "TREATMENT", 13, 28]]], ["It worked, I still got my hit, but I also got the worst infection of my life, I nearly died \u2026 Yeah, I was in hospital for nearly 3 months.", [["infection", "DISEASE", 56, 65]]], ["Septicaemia.Desperate constraints: sourcing water alternativesWhere were you cooking up the hit?Desperate constraints: sourcing water alternativesIn the flats, bottom of the flats.", [["Septicaemia", "DISEASE", 0, 11], ["Septicaemia", "PROBLEM", 0, 11], ["flats", "OBSERVATION_MODIFIER", 153, 158], ["bottom", "OBSERVATION_MODIFIER", 160, 166], ["flats", "OBSERVATION", 174, 179]]], ["Yeah, I was homeless at this time, innit.Desperate constraints: sourcing water alternativesCan you tell me about it in detail, like walk me through what happened?Desperate constraints: sourcing water alternativesWhat I remember, I must have gone out, graft, scored, I didn't have enough fucking [water] \u2026 I didn't have no trouble getting my groin, I must have got it and then it, I had some sort of fever like fucking hell, fever come across me and it was bad so I had to go to hospital \u2026 after that I was knocked out then woke up in the hospital bed, I went for fucking surgery.", [["fever", "DISEASE", 399, 404], ["fever", "DISEASE", 424, 429], ["graft", "TISSUE", 251, 256], ["groin", "ORGANISM_SUBDIVISION", 341, 346], ["graft", "TREATMENT", 251, 256], ["trouble getting my groin", "PROBLEM", 322, 346], ["fever", "PROBLEM", 399, 404], ["fever", "PROBLEM", 424, 429], ["fucking surgery", "TREATMENT", 563, 578], ["graft", "OBSERVATION", 251, 256], ["groin", "ANATOMY", 341, 346]]], ["And then a second surgery after that because they didn't get all the infection out.Desperate constraints: sourcing water alternativesWhat did they say it was?", [["infection", "DISEASE", 69, 78], ["a second surgery", "TREATMENT", 9, 25], ["the infection", "PROBLEM", 65, 78], ["infection", "OBSERVATION", 69, 78]]], ["Like, how did it get that bad that quickly?Desperate constraints: sourcing water alternativesIt was an infection, an infection was found, a bug was found in the mouth \u2026 Yeah, in any mouth, in people's mouths.", [["mouth", "ANATOMY", 161, 166], ["mouth", "ANATOMY", 182, 187], ["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 117, 126], ["mouth", "ORGANISM_SUBDIVISION", 161, 166], ["mouth", "ORGANISM_SUBDIVISION", 182, 187], ["people", "ORGANISM", 192, 198], ["mouths", "ORGANISM_SUBDIVISION", 201, 207], ["people", "SPECIES", 192, 198], ["an infection", "PROBLEM", 100, 112], ["an infection", "PROBLEM", 114, 126], ["a bug", "PROBLEM", 138, 143], ["infection", "OBSERVATION", 103, 112], ["infection", "OBSERVATION", 117, 126], ["mouth", "ANATOMY", 161, 166], ["mouth", "ANATOMY", 182, 187]]], ["Just that bug and it's a nasty bug, a right nasty bug.", [["a right nasty bug", "PROBLEM", 36, 53], ["right", "ANATOMY_MODIFIER", 38, 43]]], ["And that's why I remember when I tried to put a bit of saliva in, know what I mean, so, it makes sense.Desperate constraints: sourcing water alternativesSo, was there was nowhere else you could get water from, or \u2026?Desperate constraints: sourcing water alternativesNo, no.Navigating constraint: trying to stay safeThe context of constraint for many was one where public access to water, for drinking, washing or other purposes was not guaranteed.", [["saliva", "ORGANISM_SUBSTANCE", 55, 61], ["washing", "TREATMENT", 401, 408], ["no", "UNCERTAINTY", 269, 271]]], ["And I was dehydrating, dehydrating, plus there's no toilet, no taps anywhere around, no rain, no nothing.", [["dehydrating", "PROBLEM", 10, 21], ["dehydrating", "PROBLEM", 23, 34], ["taps", "PROBLEM", 63, 67], ["no", "UNCERTAINTY", 85, 87]]], ["I was proper sick for a hit, in the end because I couldn't find no water and my spit wouldn't work and then I got another bag and I had to do it with a puddle of water and then like filter the water through the sterits [alcohol swab], filter it out that way.Through the alcohol swabs?Yeah, just to get the dirt of the water.Through the alcohol swabs?Of note in this excerpt are the lengths that Jeff went to, not only to have a hit, but to navigate the constraints of his environment.", [["alcohol", "CHEMICAL", 220, 227], ["alcohol", "CHEMICAL", 270, 277], ["alcohol", "CHEMICAL", 336, 343], ["alcohol", "CHEMICAL", 220, 227], ["alcohol", "CHEMICAL", 270, 277], ["alcohol", "CHEMICAL", 336, 343], ["alcohol swab", "TREATMENT", 220, 232], ["filter", "TREATMENT", 235, 241]]], ["Filtering puddle water through an alcohol swab (provided by NSP for wiping injecting sites) is a poignant example of self-care, also illustrating the short-sighted limitations of service provision where swabs are deemed essential but water ampoules are not.", [["alcohol", "CHEMICAL", 34, 41], ["alcohol", "CHEMICAL", 34, 41], ["an alcohol swab", "TREATMENT", 31, 46], ["self-care", "TREATMENT", 117, 126], ["service provision", "TREATMENT", 179, 196], ["swabs", "TREATMENT", 203, 208], ["water ampoules", "TREATMENT", 234, 248]]], ["As Sara says \"you don't get water with the [injecting] kit.\"Through the alcohol swabs?For Sara, and some other unstably housed participants, the answer is to carry bottled water.", [["alcohol", "CHEMICAL", 72, 79], ["alcohol", "CHEMICAL", 72, 79], ["participants", "SPECIES", 127, 139]]], ["Ben details his rationale for using bottled water and his strategy for obtaining it:Through the alcohol swabs?A lot of the time people would use puddle water.", [["alcohol", "CHEMICAL", 96, 103], ["alcohol", "CHEMICAL", 96, 103], ["alcohol", "ORGANISM", 96, 103], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["his strategy", "TREATMENT", 54, 66], ["puddle water", "TREATMENT", 145, 157]]], ["But I was always scared of that, so I always got scared in case there was like an animal and then you'd suck the animal in and then you'd put the animal inside yourself \u2026 I used to always get people to buy me bottles of Volvic water and then I'd pull up from the bottle.", [["people", "ORGANISM", 192, 198], ["people", "SPECIES", 192, 198]]], ["People would come and buy me drinks and food all the time.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["They always asked me, what do you want from the shop?Through the alcohol swabs?Okay, so like people walking by on the street?Yeah.Yeah.", [["alcohol", "CHEMICAL", 65, 72], ["alcohol", "CHEMICAL", 65, 72], ["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99]]], ["(Ben)Participants also spoke of carrying baby wipes and swabs with them, particularly useful to wipe hands and injecting sites in the absence of water to wash with.", [["hands", "ORGANISM_SUBDIVISION", 101, 106], ["Participants", "SPECIES", 5, 17], ["swabs", "TREATMENT", 56, 61]]], ["Neil, who had prepared injections with a variety of alcoholic beverages, spoke with pride of keeping his injecting sites clean on the streets, showing the first author his stash of alcohol swabs, always replenished in his coat pocket: \"I always have alcohol swabs and wipes and all that, just wee things like that, I always keep one \u2026 I'm just a survivor, love\".", [["alcohol", "CHEMICAL", 181, 188], ["alcohol", "CHEMICAL", 250, 257], ["alcohol", "CHEMICAL", 181, 188], ["alcohol", "CHEMICAL", 250, 257], ["Neil", "ORGANISM", 0, 4]]], ["He prioritised finding toilets to inject in that were \"clean\" and where he could wash his hands; however, bottled water (or an empty bottle) was often necessary, given the difficulty of obtaining water with a syringe from a public access sink when preparing and administering an injection in a closed toilet cubicle.DiscussionA well-established body of literature evidences health harms and health system burden associated with injecting drug use [36, 37] .", [["an empty bottle", "TREATMENT", 124, 139], ["a syringe", "TREATMENT", 207, 216], ["an injection", "TREATMENT", 276, 288], ["a closed toilet cubicle", "TREATMENT", 292, 315]]], ["UK surveillance data illustrate an increase in mortality and morbidity among PWID over the past decade [5, 38] particularly in areas of socioeconomic deprivation [38] and those hit hardest by local authority funding cuts [39] .", [["UK surveillance data", "TEST", 0, 20], ["an increase in mortality", "PROBLEM", 32, 56], ["morbidity", "PROBLEM", 61, 70], ["socioeconomic deprivation", "PROBLEM", 136, 161], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["In the decade since the implementation of UK government fiscal austerity policies (2010-2020), it is estimated that local authorities will have faced a core funding reduction of \u00a316 billion compared to the preceding decade [40] .", [["a core funding reduction", "TREATMENT", 150, 174]]], ["These cuts have impacted not only on housing and welfare provision but access to clean water on the city streets.", [["welfare provision", "TREATMENT", 49, 66], ["impacted", "OBSERVATION", 16, 24]]], ["As the homeless population has increased in the UK, most notably in London, 2 access to public amenities have decreased, with 673 public toilets closed by major councils since 2010 [42] .", [["increased", "OBSERVATION_MODIFIER", 31, 40], ["decreased", "OBSERVATION_MODIFIER", 110, 119]]], ["At the same time, drug treatment services, facing sustained budgets cuts of at least 18% [39] , have reduced costs where possible, impacting on the availability of water provision in NSP equipment packs.", [["drug treatment services", "TREATMENT", 18, 41], ["reduced costs", "PROBLEM", 101, 114], ["water provision", "TREATMENT", 164, 179], ["NSP equipment packs", "TREATMENT", 183, 202]]], ["The impact of these structural changes on injecting environments and practice is reflected in our qualitative accounts, with participants describing injection preparation with solvents ranging from puddle water to whisky to saliva when injecting in public and semi-public spaces.DiscussionThe risks or health harms associated with use of alternative solvents for injection has not, to date, been elucidated in the literature, apart from reference to bacterial infections arising from saliva contaminated injections.", [["infections", "DISEASE", 460, 470], ["saliva", "ORGANISM_SUBSTANCE", 224, 230], ["saliva", "ORGANISM_SUBSTANCE", 484, 490], ["participants", "SPECIES", 125, 137], ["injection preparation", "TREATMENT", 149, 170], ["solvents", "TREATMENT", 176, 184], ["alternative solvents", "TREATMENT", 338, 358], ["injection", "TREATMENT", 363, 372], ["bacterial infections", "PROBLEM", 450, 470], ["saliva contaminated injections", "TREATMENT", 484, 514], ["structural", "OBSERVATION_MODIFIER", 20, 30], ["changes", "OBSERVATION", 31, 38], ["semi-public spaces", "ANATOMY", 260, 278], ["bacterial", "OBSERVATION_MODIFIER", 450, 459], ["infections", "OBSERVATION", 460, 470]]], ["While some harms are proven, many are theoretical and not easily measured.", [["harms", "OBSERVATION", 11, 16]]], ["This is particularly the case in relation to use of alternatives to water.", [["alternatives", "TREATMENT", 52, 64]]], ["Alcohol for example, although an antibacterial and effective solvent for base drugs such as heroin, as an injection solvent may pose an overdose risk particularly in combination with heroin, methadone or other sedatives.", [["Alcohol", "CHEMICAL", 0, 7], ["heroin", "CHEMICAL", 92, 98], ["overdose", "DISEASE", 136, 144], ["heroin", "CHEMICAL", 183, 189], ["methadone", "CHEMICAL", 191, 200], ["Alcohol", "CHEMICAL", 0, 7], ["heroin", "CHEMICAL", 92, 98], ["heroin", "CHEMICAL", 183, 189], ["methadone", "CHEMICAL", 191, 200], ["Alcohol", "SIMPLE_CHEMICAL", 0, 7], ["heroin", "SIMPLE_CHEMICAL", 92, 98], ["heroin", "SIMPLE_CHEMICAL", 183, 189], ["methadone", "SIMPLE_CHEMICAL", 191, 200], ["an antibacterial", "TREATMENT", 30, 46], ["base drugs", "TREATMENT", 73, 83], ["heroin", "TREATMENT", 92, 98], ["an injection solvent", "TREATMENT", 103, 123], ["heroin", "TREATMENT", 183, 189], ["methadone", "TREATMENT", 191, 200], ["other sedatives", "TREATMENT", 204, 219]]], ["Although the amount of alcohol injected is small, when used intravenously, it does not go through the liver before the brain, as it would with oral (drinking) administration; therefore, it reaches the brain faster and in a more concentrated form.", [["liver", "ANATOMY", 102, 107], ["brain", "ANATOMY", 119, 124], ["oral", "ANATOMY", 143, 147], ["brain", "ANATOMY", 201, 206], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "SIMPLE_CHEMICAL", 23, 30], ["liver", "ORGAN", 102, 107], ["brain", "ORGAN", 119, 124], ["oral", "ORGANISM_SUBDIVISION", 143, 147], ["brain", "ORGAN", 201, 206], ["oral (drinking) administration", "TREATMENT", 143, 173], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["small", "OBSERVATION_MODIFIER", 43, 48], ["liver", "ANATOMY", 102, 107], ["brain", "ANATOMY", 119, 124], ["brain", "ANATOMY", 201, 206], ["faster", "OBSERVATION_MODIFIER", 207, 213]]], ["Puddle water may contain a range of organisms found in the environment, including the heat resistant spores of anaerobic bacteria including Clostridium species that cause tetanus and botulism [43] and Pseudomonas species, associated with multidrug resistance and sepsis [21] , as well as particulate matter and environmental chemicals.", [["tetanus", "DISEASE", 171, 178], ["botulism", "DISEASE", 183, 191], ["sepsis", "DISEASE", 263, 269], ["Clostridium species", "ORGANISM", 140, 159], ["Pseudomonas species", "ORGANISM", 201, 220], ["Puddle water", "TREATMENT", 0, 12], ["organisms", "PROBLEM", 36, 45], ["the heat resistant spores", "PROBLEM", 82, 107], ["anaerobic bacteria", "PROBLEM", 111, 129], ["Clostridium species", "PROBLEM", 140, 159], ["tetanus", "PROBLEM", 171, 178], ["botulism", "PROBLEM", 183, 191], ["Pseudomonas species", "PROBLEM", 201, 220], ["multidrug resistance", "PROBLEM", 238, 258], ["sepsis", "PROBLEM", 263, 269], ["anaerobic bacteria", "OBSERVATION", 111, 129], ["multidrug resistance", "OBSERVATION", 238, 258], ["sepsis", "OBSERVATION", 263, 269], ["environmental chemicals", "OBSERVATION", 311, 334]]], ["Saliva is a polymicrobial fluid.", [["polymicrobial fluid", "ANATOMY", 12, 31], ["polymicrobial", "DISEASE", 12, 25], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["a polymicrobial fluid", "PROBLEM", 10, 31], ["polymicrobial fluid", "OBSERVATION", 12, 31]]], ["While heating drug solutions containing saliva may inhibit bacterial growth, not all organisms are likely to die at the same temperature, the same solution acidity or in such a short duration of heating time.", [["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["heating drug solutions", "TREATMENT", 6, 28], ["bacterial growth", "PROBLEM", 59, 75], ["all organisms", "PROBLEM", 81, 94]]], ["Other components of saliva, such as proteins, may prompt an immune response if injected.", [["saliva", "ORGANISM_SUBSTANCE", 20, 26], ["saliva", "TREATMENT", 20, 26]]], ["The potential for infection from saliva injections is therefore highlighted as a concern.DiscussionOur study is the first to report, to our knowledge, purposeful use of saliva as an alternative to water in injection preparation.", [["infection", "DISEASE", 18, 27], ["saliva", "ORGANISM_SUBSTANCE", 33, 39], ["saliva", "ORGANISM_SUBSTANCE", 169, 175], ["infection", "PROBLEM", 18, 27], ["saliva injections", "TREATMENT", 33, 50], ["DiscussionOur study", "TEST", 89, 108], ["saliva", "TREATMENT", 169, 175], ["an alternative to water in injection preparation", "TREATMENT", 179, 227], ["potential for", "UNCERTAINTY", 4, 17], ["infection", "OBSERVATION", 18, 27]]], ["Bacterial infections attributed to salivacontaminated injections have been documented in the literature, however, only in relation to the licking of needles and/or injection sites.", [["infections", "DISEASE", 10, 20], ["Bacterial infections", "PROBLEM", 0, 20], ["salivacontaminated injections", "TREATMENT", 35, 64], ["injection sites", "PROBLEM", 164, 179], ["infections", "OBSERVATION", 10, 20]]], ["Binswanger et al. [44] found that of 169 community-recruited PWID in San Francisco, 28% (n = 46) reported licking their needles prior to injection.", [["injection", "TREATMENT", 137, 146]]], ["On examination, 32% (n = 54) presented with abscesses and/or cellulitis.", [["abscesses", "ANATOMY", 44, 53], ["abscesses", "DISEASE", 44, 53], ["cellulitis", "DISEASE", 61, 71], ["abscesses", "PATHOLOGICAL_FORMATION", 44, 53], ["cellulitis", "PATHOLOGICAL_FORMATION", 61, 71], ["examination", "TEST", 3, 14], ["abscesses", "PROBLEM", 44, 53], ["cellulitis", "PROBLEM", 61, 71], ["abscesses", "OBSERVATION", 44, 53], ["cellulitis", "OBSERVATION", 61, 71]]], ["After controlling for skin-popping and years of injection drug use, participants who licked their needles were more likely to have an abscess or cellulitis than those who did not.", [["skin", "ANATOMY", 22, 26], ["abscess", "ANATOMY", 134, 141], ["abscess", "DISEASE", 134, 141], ["cellulitis", "DISEASE", 145, 155], ["skin", "ORGAN", 22, 26], ["abscess", "PATHOLOGICAL_FORMATION", 134, 141], ["participants", "SPECIES", 68, 80], ["an abscess", "PROBLEM", 131, 141], ["cellulitis", "PROBLEM", 145, 155], ["skin", "ANATOMY", 22, 26], ["abscess", "OBSERVATION", 134, 141], ["cellulitis", "OBSERVATION", 145, 155]]], ["A study of 40 hospitalised PWID in New York found that 33% (n = 13) reported licking their needles prior to injection with three also licking their skin prior to injection to clean the site and 12 afterwards [45] .", [["skin", "ANATOMY", 148, 152], ["skin", "ORGAN", 148, 152], ["A study", "TEST", 0, 7], ["licking their needles", "PROBLEM", 77, 98], ["injection", "TREATMENT", 108, 117], ["skin", "ANATOMY", 148, 152]]], ["The majority 68% (n = 27) had been admitted to hospital for treatment of bacterial infections although no statistically significant association was found between needle licking and bacterial infection.", [["bacterial infections", "DISEASE", 73, 93], ["bacterial infection", "DISEASE", 181, 200], ["The majority", "TEST", 0, 12], ["treatment", "TREATMENT", 60, 69], ["bacterial infections", "PROBLEM", 73, 93], ["needle licking", "PROBLEM", 162, 176], ["bacterial infection", "PROBLEM", 181, 200], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["infections", "OBSERVATION", 83, 93], ["bacterial", "OBSERVATION_MODIFIER", 181, 190], ["infection", "OBSERVATION", 191, 200]]], ["Several case series and reports have documented infections (primarily endocarditis, but also femoral abscess) attributed to oral bacterial (oropharyngeal organisms) among PWID who report licking their needle and/or injection site prior to drug injection [46] [47] [48] [49] .DiscussionOf note, is the consistency of detail provided by qualitative participants about preparation of heroin and crack cocaine in combination for injection and that this differs from the only other study found to illustrate the steps taken in this process.", [["femoral abscess", "ANATOMY", 93, 108], ["oral", "ANATOMY", 124, 128], ["infections", "DISEASE", 48, 58], ["endocarditis", "DISEASE", 70, 82], ["femoral abscess", "DISEASE", 93, 108], ["heroin", "CHEMICAL", 381, 387], ["cocaine", "CHEMICAL", 398, 405], ["heroin", "CHEMICAL", 381, 387], ["cocaine", "CHEMICAL", 398, 405], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["oropharyngeal", "ORGANISM_SUBDIVISION", 140, 153], ["heroin", "SIMPLE_CHEMICAL", 381, 387], ["participants", "SPECIES", 347, 359], ["Several case series", "TEST", 0, 19], ["documented infections (primarily endocarditis", "PROBLEM", 37, 82], ["femoral abscess", "PROBLEM", 93, 108], ["oral bacterial (oropharyngeal organisms", "PROBLEM", 124, 163], ["heroin", "TREATMENT", 381, 387], ["injection", "TREATMENT", 425, 434], ["other study", "TEST", 471, 482], ["infections", "OBSERVATION", 48, 58], ["endocarditis", "OBSERVATION", 70, 82], ["femoral", "ANATOMY", 93, 100], ["abscess", "OBSERVATION", 101, 108]]], ["Ponton and Scott (2004) recreated typical injection preparation practices with 65 people recruited through three NSP sites in England.", [["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88], ["typical injection preparation practices", "TREATMENT", 34, 73]]], ["Injection preparation was demonstrated for the following: heroin (n = 47), crack cocaine (n = 8) and heroin and crack together (n = 10).", [["heroin", "CHEMICAL", 58, 64], ["cocaine", "CHEMICAL", 81, 88], ["heroin", "CHEMICAL", 101, 107], ["heroin", "CHEMICAL", 58, 64], ["cocaine", "CHEMICAL", 81, 88], ["heroin", "CHEMICAL", 101, 107], ["heroin", "SIMPLE_CHEMICAL", 58, 64], ["heroin", "SIMPLE_CHEMICAL", 101, 107], ["Injection preparation", "TREATMENT", 0, 21]]], ["In contrast to Ponton and Scott's findings that crack is added to the heroin mixture after heating, our participants all describe using cold water (or water alternative) to cool down the prepared heroin solution before crack addition.", [["heroin", "CHEMICAL", 70, 76], ["heroin", "CHEMICAL", 196, 202], ["heroin", "CHEMICAL", 70, 76], ["heroin", "CHEMICAL", 196, 202], ["heroin", "SIMPLE_CHEMICAL", 70, 76], ["heroin", "SIMPLE_CHEMICAL", 196, 202], ["participants", "SPECIES", 104, 116], ["the heroin mixture", "TREATMENT", 66, 84], ["cold water (or water alternative", "TREATMENT", 136, 168], ["the prepared heroin solution", "TREATMENT", 183, 211]]], ["This is undertaken to prevent the crack cocaine congealing in a high temperature solution but may also have implications for bacterial contamination and infection.", [["cocaine", "CHEMICAL", 40, 47], ["infection", "DISEASE", 153, 162], ["cocaine", "CHEMICAL", 40, 47], ["a high temperature solution", "TREATMENT", 62, 89], ["bacterial contamination", "PROBLEM", 125, 148], ["infection", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 153, 162]]], ["Heating drug solutions has been indicated to inactivate HIV [50] and prevent systemic candidal infections [51] .", [["candidal", "ANATOMY", 86, 94], ["candidal infections", "DISEASE", 86, 105], ["HIV", "ORGANISM", 56, 59], ["candidal", "PATHOLOGICAL_FORMATION", 86, 94], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 56, 59], ["Heating drug solutions", "TREATMENT", 0, 22], ["systemic candidal infections", "PROBLEM", 77, 105], ["systemic", "OBSERVATION_MODIFIER", 77, 85], ["candidal", "OBSERVATION_MODIFIER", 86, 94], ["infections", "OBSERVATION", 95, 105]]], ["Heroin solutions in the UK are prepared with acid to convert base heroin to a soluble salt.", [["Heroin", "CHEMICAL", 0, 6], ["heroin", "CHEMICAL", 66, 72], ["Heroin", "CHEMICAL", 0, 6], ["heroin", "CHEMICAL", 66, 72], ["UK", "GENE_OR_GENE_PRODUCT", 24, 26], ["heroin", "SIMPLE_CHEMICAL", 66, 72], ["salt", "SIMPLE_CHEMICAL", 86, 90], ["Heroin solutions", "TREATMENT", 0, 16], ["acid", "TREATMENT", 45, 49], ["a soluble salt", "TREATMENT", 76, 90]]], ["The excess use of acid is implicated in the causal chain to SSTI by precipitating venous sclerosis [35, 52] .", [["venous", "ANATOMY", 82, 88], ["SSTI", "DISEASE", 60, 64], ["venous sclerosis", "DISEASE", 82, 98], ["SSTI", "CANCER", 60, 64], ["venous", "PATHOLOGICAL_FORMATION", 82, 88], ["SSTI", "PROBLEM", 60, 64], ["precipitating venous sclerosis", "PROBLEM", 68, 98], ["venous", "ANATOMY", 82, 88], ["sclerosis", "OBSERVATION", 89, 98]]], ["Heating with acid can, however, also kill non-spore-forming bacteria, depending on the solution acidity and temperature reached.DiscussionIt is difficult to assess bacterial risks associated with the use of cold water for injection preparation or the use of alternative water sources, given that most literature mentioning water in the injection process does so in the context of HIV and HCV transmission potential.", [["HIV and HCV transmission", "DISEASE", 380, 404], ["HIV", "ORGANISM", 380, 383], ["HIV", "SPECIES", 380, 383], ["HIV", "SPECIES", 380, 383], ["HCV", "SPECIES", 388, 391], ["forming bacteria", "PROBLEM", 52, 68], ["the solution acidity", "TREATMENT", 83, 103], ["cold water", "TREATMENT", 207, 217], ["injection preparation", "TREATMENT", 222, 243], ["alternative water sources", "TREATMENT", 258, 283], ["the injection process", "TREATMENT", 332, 353], ["HIV", "PROBLEM", 380, 383], ["HIV", "OBSERVATION", 380, 383], ["HCV", "OBSERVATION", 388, 391]]], ["Ciccarone and Bourgois [53] present a hypothesis that cold water heroin solutions may have fostered HIV transmission in the early phases of the epidemic in the USA.", [["Ciccarone", "CHEMICAL", 0, 9], ["heroin", "CHEMICAL", 65, 71], ["HIV transmission", "DISEASE", 100, 116], ["Ciccarone", "CHEMICAL", 0, 9], ["heroin", "CHEMICAL", 65, 71], ["Ciccarone", "SIMPLE_CHEMICAL", 0, 9], ["HIV", "SPECIES", 100, 103], ["cold water heroin solutions", "TREATMENT", 54, 81], ["early phases", "OBSERVATION_MODIFIER", 124, 136]]], ["More recently, a model of HIV transmission examining heroin source-type (including cold water prepared solutions) supports this prior hypothesis [54] .", [["HIV transmission", "DISEASE", 26, 42], ["heroin", "CHEMICAL", 53, 59], ["heroin", "CHEMICAL", 53, 59], ["HIV", "ORGANISM", 26, 29], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 26, 29], ["cold water prepared solutions", "TREATMENT", 83, 112]]], ["Gaskin et al. [55] present one of the few studies with a HCV transmission remit to detail water source.", [["HCV", "ORGANISM", 57, 60], ["HCV", "SPECIES", 57, 60]]], ["Participants comprise 40 NSP clients based in Worcestershire, England.", [["Participants", "SPECIES", 0, 12]]], ["The majority (70%) reported using one water source only: for 72%, this was tap water, followed by 21% using boiled and cooled water.", [["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["While the majority used tap water for injection preparation, only 10% considered this to be an ideally hygienic source.", [["tap water", "TREATMENT", 24, 33], ["injection preparation", "TREATMENT", 38, 59]]], ["The authors make a strong recommendation for provision of sterile water for injection, in order to \"meet the basic needs of individuals and help facilitate behavioural change\" [55:429] .", [["sterile water for injection", "TREATMENT", 58, 85]]], ["They report that, subsequent to their study, the Worcestershire Community Drug Team commenced the low-threshold provision of sterile water in ampoules.", [["their study", "TEST", 32, 43], ["the low-threshold provision", "TREATMENT", 94, 121], ["sterile water in ampoules", "TREATMENT", 125, 150]]], ["Of the 57 participants demonstrating heroin preparation, with or without crack cocaine, 61% (n = 35) used tap water, with other sources including bottled water (18%, n = 10), boiled water (11%, n = 6) and sterile water from ampoules (2%, n = 1).", [["heroin", "CHEMICAL", 37, 43], ["cocaine", "CHEMICAL", 79, 86], ["heroin", "CHEMICAL", 37, 43], ["cocaine", "CHEMICAL", 79, 86], ["participants", "SPECIES", 10, 22], ["heroin preparation", "TREATMENT", 37, 55], ["tap water", "TREATMENT", 106, 115], ["sterile water from ampoules", "TREATMENT", 205, 232]]], ["The only group documented not to heat their solution were people preparing crack on its own, with three using tap water, one using \"boiled and cooled\" water from the kettle, one using bottled water and one using water obtained from a toilet.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["tap water", "TREATMENT", 110, 119]]], ["Despite the latter finding, no reflection is included on the bacterial or other health implications of this practice.", [["this practice", "TREATMENT", 103, 116]]], ["Interventions may be feasible in reducing risk.", [["Interventions", "TREATMENT", 0, 13]]], ["Campbell [23] reports on the pilot provision of 2 ml plastic water ampoules to PWID in Glasgow over 2 months in 2012.", [["the pilot provision", "TREATMENT", 25, 44]]], ["The plastic ampoules were supplied separately to the injecting packs, with PWID invited to take as many as they needed.", [["The plastic ampoules", "TREATMENT", 0, 20], ["the injecting packs", "TREATMENT", 49, 68], ["PWID", "TREATMENT", 75, 79], ["plastic ampoules", "OBSERVATION", 4, 20]]], ["Over the 2 months, at the three pilot sites, 31, 518 ampoules were distributed, with footfall at the sites increasing by 25% during this period compared to the preceding 2 months.", [["sites", "OBSERVATION_MODIFIER", 101, 106], ["increasing", "OBSERVATION_MODIFIER", 107, 117]]], ["Of 42 clients interviewed during this time, four (9%) identified using toilet water (from the bowl) or puddle water prior to the pilot-with none reporting use of these sources during the intervention.DiscussionConcerns around the potential for HCV transmission through sharing of water among PWID led to the legal framework for UK supply described in the introduction.DiscussionGiven the reluctance to provide glass ampules by some local authorities, it is timely to revisit this evidence and associated guidance.", [["HCV", "ORGANISM", 244, 247], ["UK", "GENE_OR_GENE_PRODUCT", 328, 330], ["HCV", "SPECIES", 244, 247], ["toilet water", "TREATMENT", 71, 83], ["puddle water", "TREATMENT", 103, 115], ["the intervention", "TREATMENT", 183, 199], ["HCV transmission", "TREATMENT", 244, 260], ["UK supply", "TREATMENT", 328, 337], ["glass ampules", "TREATMENT", 410, 423]]], ["Heimer and colleagues [56] report recent laboratory studies illustrating that HCV transmission occurs via the needles and syringes used in preparing and injecting drugs, not through shared paraphernalia.", [["HCV transmission", "DISEASE", 78, 94], ["HCV", "ORGANISM", 78, 81], ["HCV", "SPECIES", 78, 81], ["recent laboratory studies", "TEST", 34, 59], ["HCV transmission", "PROBLEM", 78, 94], ["the needles and syringes", "TREATMENT", 106, 130]]], ["They recommend, given these results, that NSP \"may want to reconsider expanding scarce resources to provide supplies that will do little or nothing to prevent HCV transmission\" [56:471] .", [["HCV", "DISEASE", 159, 162], ["HCV", "SPECIES", 159, 162]]], ["This view surprises in its blindness to risks other than viral transmission that could be obviated through the provision of sterile injecting paraphernalia.", [["blindness", "DISEASE", 27, 36], ["its blindness", "PROBLEM", 23, 36], ["viral transmission", "PROBLEM", 57, 75], ["blindness", "OBSERVATION", 27, 36]]], ["The reuse of stored filters for injecting, for example, is likely to pose a bacterial and fungal infection risk.", [["infection", "DISEASE", 97, 106], ["stored filters", "TREATMENT", 13, 27], ["a bacterial and fungal infection risk", "PROBLEM", 74, 111], ["bacterial", "OBSERVATION", 76, 85], ["fungal", "OBSERVATION_MODIFIER", 90, 96], ["infection", "OBSERVATION", 97, 106]]], ["Although bacterial risks from using non-sterile and alternative water sources are not well documented, our qualitative data in combination with the high prevalence of SSTI and related hospitalisation among the survey sample indicate a need for policy reform.", [["SSTI", "DISEASE", 167, 171], ["bacterial risks", "PROBLEM", 9, 24], ["non-sterile and alternative water sources", "TREATMENT", 36, 77], ["SSTI", "PROBLEM", 167, 171], ["bacterial risks", "OBSERVATION", 9, 24]]], ["We call for funding and increased supply of adequate quantities of WFI to people who do not have access to clean water.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80]]], ["Greater awareness of the legality of 5 ml WFI provision for PWID is likely to facilitate distribution, given that these are marketed at a similar cost to 2 ml glass ampoules.", [["PWID", "TREATMENT", 60, 64]]], ["Our study finding dissemination groups with PWID indicate that 5 ml WFI are desired, but that some sharing would take place.", [["Our study", "TEST", 0, 9]]], ["Despite evidence of reduced HCV transmission risk through water, provision of small volume (2 ml) plastic ampoules (licensed but not currently marketed, and therefore costly) would be ideal.", [["HCV", "SPECIES", 28, 31], ["reduced HCV transmission risk", "PROBLEM", 20, 49], ["small volume (2 ml) plastic ampoules", "TREATMENT", 78, 114], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["HCV", "OBSERVATION", 28, 31], ["small", "OBSERVATION_MODIFIER", 78, 83], ["volume", "OBSERVATION_MODIFIER", 84, 90]]], ["Relaxation of prescription only medicine regulations that prevent drug services and other nonpharmacy suppliers splitting WFI packs (10 ampules) into smaller units would remove an additional important barrier to adequate distribution.DiscussionThe use of unsafe alternatives to WFI potentiates high health risks and health system burden among an increasingly vulnerable population of unstably housed PWID.", [["WFI", "CHEMICAL", 278, 281], ["Relaxation of prescription", "TREATMENT", 0, 26], ["medicine regulations", "TREATMENT", 32, 52], ["drug services", "TREATMENT", 66, 79], ["other nonpharmacy suppliers", "TREATMENT", 84, 111], ["WFI packs", "TREATMENT", 122, 131], ["an additional important barrier", "TREATMENT", 177, 208]]], ["In a context whereby PWID report use of puddle water, alcohol and saliva to prepare drugs for injection, harm reduction messaging that enjoins people to \"wash their hands\" before injecting, alongside the provision of injecting kits without water, enacts a structural violence-shaming through a denial of the constraints faced by the most marginalised.", [["alcohol", "CHEMICAL", 54, 61], ["alcohol", "CHEMICAL", 54, 61], ["alcohol", "SIMPLE_CHEMICAL", 54, 61], ["saliva", "ORGANISM_SUBSTANCE", 66, 72], ["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["saliva", "TREATMENT", 66, 72], ["drugs", "TREATMENT", 84, 89], ["injection", "TREATMENT", 94, 103], ["harm reduction messaging", "TREATMENT", 105, 129]]], ["In response to the findings of the Care & Prevent study, Exchange Supplies (a social enterprise in the UK that provides harm reduction equipment and materials) has adapted its water risks poster for display in NSP (Fig. 1 ).", [["harm reduction equipment and materials", "TREATMENT", 120, 158]]], ["In addition, the wider environmental constraints placed on actioning such advice need to be considered.", [["the wider environmental constraints", "PROBLEM", 13, 48]]], ["More widespread distribution of WFI from NSP is required, alongside the wider provision of methods to clean hands and injecting sites.", [["WFI", "CANCER", 32, 35], ["hands", "ORGANISM_SUBDIVISION", 108, 113], ["WFI", "PROBLEM", 32, 35], ["NSP", "PROBLEM", 41, 44], ["methods", "TREATMENT", 91, 98], ["widespread", "OBSERVATION_MODIFIER", 5, 15], ["distribution", "OBSERVATION_MODIFIER", 16, 28]]], ["This is particularly crucial given the recent COVID-19 pandemic and constraints faced by the most marginalised to enacting protective practices.", [["the recent COVID", "TEST", 35, 51]]], ["Installation of public water fountains, alongside the provision of handheld water purifiers and similar devices to homeless people who inject drugs, could also be considered as an environmentally sound way to provide water for skin washing and injection preparation practices.DiscussionIn the time this paper has been in review, we have developed, in collaboration with Exchange Supplies, a prototype street injecting kit (Fig. 2) .", [["skin", "ANATOMY", 227, 231], ["people", "ORGANISM", 124, 130], ["skin", "ORGAN", 227, 231], ["people", "SPECIES", 124, 130], ["public water fountains", "TREATMENT", 16, 38], ["handheld water purifiers", "TREATMENT", 67, 91], ["drugs", "TREATMENT", 142, 147], ["skin washing", "TREATMENT", 227, 239], ["injection preparation practices", "TREATMENT", 244, 275], ["skin", "ANATOMY", 227, 231]]], ["This responds to cost constraints to widespread WFI provision and the need identified through our work specifically for people who prepare and inject drugs in public spaces for access to water.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126]]], ["The kit comes in a box that doubles as a stable safe injecting space with windbreak.", [["stable", "OBSERVATION_MODIFIER", 41, 47]]], ["Contents comprise two 30G syringes, four swabs, two Sterifilts, two vitamin C sachets, two spoons, two \"fitstick\" syringe disposal devices, two antimicrobial handwipes in a sachet and two 5 ml sterile water ampoules.", [["vitamin C", "CHEMICAL", 68, 77], ["vitamin C", "CHEMICAL", 68, 77], ["vitamin C sachets", "SIMPLE_CHEMICAL", 68, 85], ["30G syringes", "TREATMENT", 22, 34], ["two Sterifilts", "TREATMENT", 48, 62], ["two vitamin C sachets", "TREATMENT", 64, 85], ["two \"fitstick\" syringe disposal devices", "TREATMENT", 99, 138], ["two antimicrobial handwipes", "TREATMENT", 140, 167], ["a sachet", "TREATMENT", 171, 179], ["sterile water ampoules", "TREATMENT", 193, 215]]], ["The addition of antimicrobial handwipes attends to difficulties people have in accessing running water for washing hands and is of added value in relation to COVID-19 and other infection prevention for PWID-many of whom have compromised immune and respiratory systems.ConclusionOur study highlights the role of unsafe liquids used to prepare drug injection solutions.", [["COVID-19", "CHEMICAL", 158, 166], ["infection", "DISEASE", 177, 186], ["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70], ["antimicrobial handwipes", "TREATMENT", 16, 39], ["washing hands", "TREATMENT", 107, 120], ["COVID", "TEST", 158, 163], ["other infection prevention", "TREATMENT", 171, 197], ["compromised immune and respiratory systems", "PROBLEM", 225, 267], ["ConclusionOur study", "TEST", 268, 287], ["unsafe liquids", "TREATMENT", 311, 325], ["drug injection solutions", "TREATMENT", 342, 366], ["infection", "OBSERVATION", 177, 186], ["respiratory systems", "ANATOMY", 248, 267]]], ["Given the serious health harms associated with this practice, it is crucial that services engage with the everyday realities of people living on the streets and amend service provision accordingly.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["Current harm reduction messaging and injecting equipment provision in the UK is failing to meet the needs of the most marginalised.", [["Current harm reduction messaging", "TREATMENT", 0, 32]]], ["There is an urgent need to revisit the marketing and/or legal limits to the volume of WFI ampoules supplied to PWID, particularly given that concerns about sharing water increasing HCV transmission seem not to have been borne out in subsequent analysis.", [["HCV", "SPECIES", 181, 184], ["the volume of WFI ampoules", "TREATMENT", 72, 98], ["PWID", "TREATMENT", 111, 115], ["sharing water increasing HCV transmission", "PROBLEM", 156, 197], ["subsequent analysis", "TEST", 233, 252]]]], "PMC7195357": [["IntroductionThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has profoundly impacted the practice of urology in fundamental ways\u2014most elective surgeries are on hold, outpatient visits are shifting to telehealth, and protocols for in-person visits have been significantly modified.1 According to the Centers for Disease Control and Prevention COVID-NET data, 74.5% of hospitalized SARS-CoV-2 patients are 50 years or older and 54.4% are male.2 Given these demographics, patients hospitalized with SARS-CoV-2 are likely to have urologic conditions, previously diagnosed or undiagnosed.", [["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["SARS", "DISEASE", 396, 400], ["SARS", "DISEASE", 512, 516], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "ORGANISM", 396, 404], ["patients", "ORGANISM", 407, 415], ["patients", "ORGANISM", 485, 493], ["SARS-CoV-2", "ORGANISM", 512, 522], ["patients", "SPECIES", 407, 415], ["patients", "SPECIES", 485, 493], ["severe acute respiratory syndrome coronavirus-2 (SARS-CoV", "SPECIES", 16, 73], ["SARS-CoV", "SPECIES", 396, 404], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 61], ["elective surgeries", "TREATMENT", 150, 168], ["Disease Control", "TREATMENT", 327, 342], ["NET data", "TEST", 364, 372], ["SARS", "PROBLEM", 512, 516], ["urologic conditions", "PROBLEM", 542, 561], ["undiagnosed", "PROBLEM", 587, 598], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["impacted", "OBSERVATION_MODIFIER", 92, 100]]], ["In addition, 42% of patients in the intensive care unit require invasive mechanical ventilation, necessitating sedation and foley catheter insertion.3", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["invasive mechanical ventilation", "TREATMENT", 64, 95], ["sedation", "TREATMENT", 111, 119], ["foley catheter insertion", "TREATMENT", 124, 148], ["invasive", "OBSERVATION_MODIFIER", 64, 72], ["mechanical ventilation", "OBSERVATION", 73, 95], ["foley catheter", "OBSERVATION", 124, 138]]]], "PMC7122089": [["Box 1\u2002Defining Global Health Governance ::: Introduction: Global Transformation and Health\u201cGlobal governance for health describes the structures and processes through which the global health issues are addressed\u201d (European Perspectives on Global Health.", [["Global Transformation", "OBSERVATION", 58, 79]]], ["35).Box 1\u2002Defining Global Health Governance ::: Introduction: Global Transformation and HealthGHG is the \u201ctotality of collective regulations to deal with international and transnational interdependence in the context of health issues\u201d (Hein/Kohlmorgen 2008, p.", [["Global Transformation", "OBSERVATION", 62, 83]]], ["84).Box 1\u2002Defining Global Health Governance ::: Introduction: Global Transformation and HealthBox 1 (continued)\u201cFor us GHG is viewed as a contested space which is much broader and deeper than current scholarship acknowledges.", [["Global Transformation", "OBSERVATION", 62, 83]]], ["Instead of existing in a separate sphere to globalisation, we view GHG as immanent in the critical processes of globalisation and marked by sharp divisions in policy and competing worldviews of global health which have not yet settled or reached an identifiable conclusion\u201d (Kay and Williams 2009, p.", [["marked", "OBSERVATION_MODIFIER", 130, 136], ["sharp", "OBSERVATION_MODIFIER", 140, 145]]], ["3).Box 1\u2002Defining Global Health Governance ::: Introduction: Global Transformation and HealthWhat has led to this change and what does it mean for the future of global health?", [["HealthWhat", "CHEMICAL", 87, 97], ["Global Transformation", "OBSERVATION", 61, 82]]], ["The rise of GHG is closely linked to the process of globalization (Lee et al. 2002), understood as an intensification of cross-border flows of goods, services, finance, people, and ideas.", [["people", "SPECIES", 169, 175], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["GHG", "OBSERVATION", 12, 15]]], ["Globalization has been facilitated by new technologies and by changes in the institutional and policy regimes at the international and national levels, for example by the promotion of trade liberalization (Held et al. 1999).", [["policy regimes", "TREATMENT", 95, 109], ["new", "OBSERVATION_MODIFIER", 38, 41]]], ["It extends far beyond the economic realm to political, cultural, environmental, and security issues and implies an increasing transnational interconnectivity of people and communities, leading to a growing density of transnational social relations and the creation of common identities based on characteristics other than nationality\u2014for example among people in civil society networks fighting for justice in global health.", [["people", "ORGANISM", 161, 167], ["people", "ORGANISM", 352, 358], ["people", "SPECIES", 161, 167], ["people", "SPECIES", 352, 358], ["increasing", "OBSERVATION_MODIFIER", 115, 125], ["growing", "OBSERVATION_MODIFIER", 198, 205], ["density", "OBSERVATION", 206, 213]]], ["Globalization has increased the need for inter- and transnational cooperation to \u201cgovern\u201d the many global forces that can effect human health.", [["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["increased", "OBSERVATION_MODIFIER", 18, 27]]], ["Yet, in the absence of a central political authority beyond the nation state, there are multiple sets of often conflicting rules and norms.", [["central", "OBSERVATION_MODIFIER", 25, 32], ["multiple", "OBSERVATION_MODIFIER", 88, 96]]], ["How can relations of legitimacy and accountability be established when the demos is spilling over beyond the territorial foundations of democratic rule?Box 1\u2002Defining Global Health Governance ::: Introduction: Global Transformation and Health", [["territorial", "OBSERVATION_MODIFIER", 109, 120], ["Global Transformation", "OBSERVATION", 210, 231]]]]}